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Traditional plant medicines are plant-derived therapeutic products prepared and applied 
according to long-standing medical customs. Around the world they are widely used in 
primary and preventative healthcare and readily available over the counter. Currently their 
position in New Zealand’s regulatory system of healthcare is not adequately addressed. This 
health policy possibly impacts access, user-information, and fails to safeguard public health. 
In its Traditional Medicine Strategy 2014-2023, the World Health Organization (WHO) 
calls on Member States to provide a regulatory framework so that the formal and safe 
contribution of traditional therapeutics in national systems of healthcare can be advanced. 
The health policy question arising from this is how traditional plant medicines could be 
incorporated into a contemporary regulatory framework which is both evidence-based and 
appropriate for these long-standing therapeutic products. Evidence of effectiveness and 
safety of health interventions is paramount for regulatory integration of traditional plant 
medicines. Presumed lack of such evidence is one reason why New Zealand and other 
countries are yet to make progress in regulating these remedies. 
The objective of this thesis is twofold. First, it is to establish whether systematic collation of 
long-standing empirical evidence from the clinical knowledge base on medicinal plants can 
provide reliable and verifiable pharmacological data. Can it be used to substantiate 
traditional health claims and therefore contribute to a framework for evidence-based health 
policies? This empirical evidence is informed by observations in patient care, evaluated and 
transmitted inter-generationally by clinical experts. In written medical traditions, 
therapeutic uses of medicinal plants are historically recorded in medical and more recently 
in specialised phytotherapeutic textbooks. Second, it is to determine if the way the EU dealt 
with evidence and safety requirements could help shape New Zealand’s policy on 
traditional plant medicines. 
The research design of this interdisciplinary thesis spans across medical history, 
phytotherapy and health science. It employs a longitudinal, comparative textual analysis of 
European clinical textbooks from the early modern period onwards. It starts with the 
influential medical textbook New vollkommen Kräuter-Buch by the German physician, 
apothecary and botanist Tabernaemontanus (1522-1590) and concludes with present day 




divergence of pharmacological data recorded on two medicinal plants, Arnica (Arnica 
montana) and St. John’s Wort (Hypericum perforatum) over 400 years. As a research 
instrument and to organise a large amount of historical and contemporary pharmacological 
records, the Historical Assessment Tool was developed and tested as a systematic and 
reproducible method. Traditional clinical knowledge is triangulated with information on the 
exemplars listed in the official Prussian and German pharmacopoeias and their 
commentaries, as well as with several modern regulatory and authoritative herbal 
monographs (i.e. by Commission E, EMA, WHO, ESCOP, and HagerROM). This 
bibliographic evidence is further compared with evidence of efficacy for indications as 
investigated with randomised-controlled trials (RCTs), and scientific evidence from 
experimental laboratory research.  
Parallel findings of therapeutic indications on Arnica and St. John’s Wort across all 
qualitative and quantitative sources and time periods led to concluding that long-standing 
traditional clinical knowledge relating to the examined medicinal plants is a reliable and 
verifiable source of evidence. Evaluation of Arnica demonstrated an uninterrupted medical 
transmission of two clusters of indications over 400 years, relating to the treatment of 
consequences of injuries and accidents, and for pain related to the musculo-skeletal system 
and nerves. Analysis of data on St. John’s Wort showed congruency of medical 
transmission between three clusters of complaints relating, in modern terminology, to 
inflammation and catarrh of the gastro-intestinal system (gastro-enteritis, dyspeptic 
disorders), to burns and wounds, and to psychovegetative disorders (depressive moods, 
anxiety, nervous unrest, and hormonally driven dysphoria in relation to the female 
menstrual cycle). The validity of historical traditional indications was further supported 
when cross-checked with outcomes from clinical trials where undertaken. Data from 
experimental research provided insights into active constituents and possible mechanisms 
related to the empirically observed effects. The intergenerational professional literature on 
the materia medica represents the most comprehensive evidence source on the clinical 
scope of the medicinal plants investigated. 
Notwithstanding the small number of exemplars analysed, clinically orientated historical 
and contemporary authoritative textbooks within the European materia medica are 
recommended as a comprehensive and reliable source of empirical evidence for 




evidence is particularly important where modern scientific evidence is wanting or absent. 
The Historical Assessment Tool is proposed as a feasible method for the systematic 
collation and evaluation of bibliographic data for traditional health claims. This would be an 
additional pathway to make such data operational in an evidence-based policy framework. 
The complexity of regulating traditional plant medicines is further illustrated by an inquiry 
into the European Union’s approach to dealing with evidence and safety requirements for 
such therapeutics. This thesis concludes with health policy recommendations arising from 
these analyses. These relate to the regulation of traditional plant medicines as a distinct 
therapeutic product category: 
 to advance regulation on traditional plant medicine in New Zealand 
 to implement a systematic framework for the collation and evaluation of 
bibliographic empirical evidence 
 to develop a system for safety assessments that incorporates both historical safety 
observations and modern pharmacovigilance 
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1.1 Traditional plant medicine and its regulatory position in Western 
systems of healthcare 
Regulation is a prominent feature of Western healthcare systems. Its purpose is to safeguard 
public health by ensuring that therapeutic interventions are of high quality, safe, and 
effective (Kelber et al., 2014, p. 448). There are three key areas of regulation in healthcare: 
of professions, of products, and of procedures (Burton, Smith, & Falkenberg, 2015; World 
Health Organization, 2013, p. 13). This thesis addresses the regulation of products sold over 
the counter (OTCs), specifically traditional medicines prepared from medicinal plants 
which consumers use for self-care. Such products contain plant materials as active 
ingredients, being herbs, seeds, berries, roots, leaves, bark, flowers, algae, lichens, certain 
exudates, and macroscopic fungi. Typical traditional preparations are teas, tinctures, 
extracts, essential oils, expressed juices, and processed exudates (Knöss, 2018, p. 368). 
These preparations are variously termed plant medicines, herbal medicines, herbal 
remedies, herbal drugs, herbal drug preparations, botanical medicines, phytomedicines, 
phytotherapies, or traditional medicines (Iannitti, Morales-Medina, Bellavite, Rottigni, & 
Palmieri, 2016, p. 1; World Health Organization, 1999). In New Zealand, traditional plant 
medicines are categorised under Natural Health Products (NHPs) and are a widely used 
form of natural healthcare (Barnes, McLachlan, Sherwin, & Enioutina, 2016). Despite their 
prevalence and increasing popularity, current regulations for plant medicines neither 
adequately address their place in New Zealand’s healthcare system nor protect public 
health.  
Although the therapeutic effects of medicinal plants are well known in clinical practice, 
relatively few have been fully investigated with the modern scientific methodologies that 
form the basis of decisions in current health regulation. In contemporary clinical practice, 
plant-based medicines are predominantly prescribed according to empirical traditional 
knowledge which is concerned primarily with the observed effects on health (Evans, 2009; 
Wiese, 2016). Could, therefore, long-standing empirical knowledge as historically 
documented and transmitted in the clinical literature on plant medicines contribute to the 
validation of traditional remedies? In particular, could such bibliographic evidence of 




therefore a pathway for the registration of traditional medicines? If so, could such 
therapeutic products take their place in a contemporary regulatory framework that is 
informed by evidence-based policy?  
The long history of cross-cultural use of plant medicines demonstrates their ongoing 
importance and value to communities. The practice of using plants as medicines is universal 
and as old as human life itself. Plant medicines have been used for millennia with known 
therapeutic effects. While contemporary Western medicine predominantly makes use of 
chemically manufactured drugs, it is historically rooted in plant medicine. Many original 
synthetic drugs are derivatives from medicinal plants native or naturalised in Europe, such 
as morphine and codeine from Papaver somniferum, digoxin from Digitalis lanata or 
aspirin from Philipendula ulmaria. Medicinal plants have been empirically proven to 
regulate biological processes. The mechanisms that drive their wide-ranging effects across 
the human genome are increasingly explained via contemporary scientific methodologies 
(Sen & Samanta, 2015). Systems biology and network pharmacology offer novel 
explanations of their high safety, effectiveness and pleiotropic effects by examining the 
influence of traditional plant medicines on higher human regulatory and over-arching 
processes (Rezadoost, Karimi, & Jafari, 2016; Schwabel, Vennos, & Saller, 2014; van der 
Greef et al., 2010). The long-term use of judiciously selected plants by humans as a source 
of nutrition and medicine has confirmed that their bioactive compounds exert low toxicity 
for humans, maybe due to plants’ and humans’ millennia of co-evolution leading to 
morphogenetic and phylogenetic closeness (Douros et al., 2016; Lasek & de Smet, 1999; 
Loew, 2005, p. 123; Yarnell & Abascal, 2014).BJM 
The World Health Organization (WHO) states that traditional therapeutics that have been 
administered over a long period of time usually result in medicines where the dosage and 
formulation have empirically evolved to maximise their therapeutic effectiveness and 
minimise risk (World Health Organization, 2012, p. 17). Thus, their toxicity, formulation 
and dosage are seen to be established.  In contrast to traditional plant medicines, synthetic 
substances are a relatively recent form of therapy, becoming increasingly prevalent from the 
end of the 19th century and then widespread in the 20th century. Due to their novelty, they 
required stringent investigation to assess their safety and efficacy in relation to human 
physiology. Throughout the 20th century, regulations have been introduced, primarily to 




regulated under the Medicines Act 1981 but plant-based medicines are regulated separately 
from pharmaceutical drugs via the Dietary Supplements Regulations 1985. New Zealand 
regulations are different from international regulations in currently prohibiting statements 
about the therapeutic purposes of traditional remedies. This prohibition applies even when 
scientific research has determined a traditional product to be effective.  
The Dietary Supplement Regulations 1985 further complicate the matter by placing 
traditional plant medicines in the same category as modern and often synthetically derived 
nutritional supplements that were developed in the 20th century to address nutritional 
deficiencies. These contain vitamins, amino acids, antioxidants like β-carotene, taurine and 
lycopene, minerals, trace elements, and lipids. Traditional plant medicines are, however, 
distinct from nutrients in foods and dietary supplements, and from pharmaceutical drugs. It 
has thus been suggested that their different characteristics and purpose necessitate a 
separate regulatory framework that adequately reflects their natural, non-synthetic 
composition and their place in long-standing traditional systems of medicine (Abdel-Tawab, 
2018, pp. 387-388). Traditional medicines transcend nutritional purpose: they have 
pharmacological effects that are used to prevent and treat illnesses. While health claims are 
not permitted under the current New Zealand regulations, health claims are inferred by 
consumers who seek these medicines out for their attributed benefits. 
A WHO global survey has confirmed that many governments of its Member States, 
including New Zealand, do not recognise traditional medicine and their therapeutics as an 
integral part of their healthcare system and do not provide regulations, funding or access to 
them (Cordell, 2014, xxix). Through socio-economic and political-legal factors that shaped 
healthcare systems in Western and westernised countries since the 20th century, non-
biomedical treatment options are now commonly not taught in medical schools or 
universities lacking such schools, have only minimal access to research funding, 
laboratories, or general medical infrastructure, and are not provided in hospitals or covered 
by government health insurance systems (Willis & Coulter, 2007, p. 218). Moreover, the 
professions using traditional therapeutics do not obtain registration in many Western 
countries, and private educational institutions teaching traditional strategies for health 
usually do not receive educational funding, impeding their appearance of legitimacy. As 
Eskinazi (1998, p. 1622) explains in his policy perspective, Western academics who have 




discrimination, and career impediments. This indicates that non-scientific factors are 
shaping the current privileging of Western biomedicine. Such hegemony disallows multiple 
epistemologies and pluralism in medicine, marginalising many forms of discovery and 
knowledge (Holmes, Murray, Perron, & Rail, 2006, p. 181; Jagtenberg et al., 2006). Some 
researchers argue that science does not occur in a vacuum but is a social phenomenon, a 
practice that is embedded in wider cultural values and power relationships in society 
(Myers, Xue, Cohen, Phelps, & Lewith, 2012, p. 70). Anti-trust laws in the USA now make 
such economic and professional dominance and restrictions on competition illegal, even for 
medicine (Wardwell, 1994). If biomedicine, only a portion of the medical field, controls or 
limits access to non-biomedical services and non-pharmaceutical therapeutics, it results in a 
monopoly. This is not seen to be in the public interest (Bodeker, 2000, p. 5; Ho, 2013; 
Willis & Coulter, 2007, pp. 218-219). 
1.2 Challenges for integration 
The pertinent policy question therefore is how can traditional plant medicine be 
incorporated into a contemporary regulatory framework that is both evidence-based and 
appropriate for traditional therapies? Evidence-based policy subscribes to the notion that 
only those healthcare options which are based on scientific information about what works 
should be sanctioned (Rycroft‐Malone et al., 2004, p. 81). The evidence-based medicine 
(EBM) movement claims that such evidence should be drawn from clinical trials set up for 
the proof of efficacy, and that evidence requirements should be the same for all therapeutic 
interventions regardless of whether they are long-standing or novel (Angell & Kassirer, 
1998; Parker, 2007). Archie Cochrane, the forerunner of the EBM movement, strongly 
argued for the privileged use of randomised-controlled trials (RCTs) for determining the use 
of finite health resources (O'Donnell, Atkinson, Freebairn, & Rychetnik, 2017, p. 163). 
Consequently, EBM proceeded to hierarchically privilege RCTs above all other forms of 
knowledge generation (Daly et al., 2007; Howick, 2011; O'Donnell et al., 2017).  
Notably, there are numerous similar ‘hierarchies of evidence’ but there are marked 
inconsistencies and disparities between them. Such difference is one of the reasons why 
some policy advisors see evidence hierarchies as unsuitable replacements for more case-
specific judgements in public healthcare based on broader considerations (Rawlins, 2008, 
pp. 33-34; Sanderson, 2003). There is no finite answer to the question of which evidence 




Sanderson, 2003). Although EBM focuses on RCTs and systematic reviews—forcing health 
professions to notice the totality of published literature and to stop the perpetuation of 
ineffective or outdated practices (Epstein, 2017) —it is an insufficient method for 
establishing which evidence facilitates appropriate decision making in clinical practice 
(Rawlins, 2008). While biomedicine is based on a medical paradigm that is informed by 
natural science, the core of its evidence base persists in empirical form. Technology 
assessment reports and disease intervention analyses estimate that up to 80% of treatments 
in conventional Western biomedicine have not been subjected to EBM criteria (Imrie & 
Ramey, 2000; Smith, 1991; US Congress Office of Technology Assessment, 1978, 1983). 
Acquired skills and expertise passed on in the medical curriculum, in clinical practice, and 
in peer-reviewed professional education underpin this empirical body of medical 
knowledge. In this, the challenges of producing EBM evidence on efficacy through clinical 
trials are no different from the challenges faced in traditional plant medicine.  
Healthcare interventions in real life patients are inherently complex. No medical system 
could function in a clinically sound way if the currently acclaimed gold standard of 
medicine, RCTs, were the only means to validate interventions and achieve regulatory 
approvals. This is because RCTs establish internal validity of efficacy of interventions 
within a highly-selected, homogenous population under ideal conditions (Feinstein & 
Horwitz, 1997; Jackson & Waters, 2004; Rychetnik, Frommer, Hawe, & Shiell, 2002; 
Sanderson, 2003). Moreover, the assessment of efficacy in a clinical trial is not designed to 
inform the real-life effectiveness of an intervention, but rather to clear regulatory hurdles 
for product registration (Khan, Mar, & Brown, 2018, p. 247). These interventions may not 
show external validity when applied to a heterogeneous population of patients. Real life 
patients may suffer from co-morbidities or have individual variations that were not present 
in patients selected for the RCT. There is also a gap between the approach of evidence-
based medicine and the principle of patient-centred medicine (Bensing, 2000). The 
significance of this potential variability is illustrated in a regional review of family-practice 
patient records in Canada that confirmed multi-morbidity as the rule rather than the 
exception (Fortin, Bravo, Hudon, Vanasse, & Lapointe, 2005). It is therefore impossible to 
know if a therapy approved on EBM criteria is appropriate or effective for sub-populations 
that were not included in a trial (Coulter, 2012).  




genetic, individual, social, cultural, economic, and environmental factors that are not easily 
discernible from RCTs (O'Donnell et al., 2017, p. 205). Moreover, clinical efficacy is only 
one aspect of healthcare delivery. The preferences, concerns, and expectations that patients 
bring to clinical encounters need to be integrated in patient-centred and values-based 
healthcare systems where the therapeutic context and therapeutic relationship between 
patients and care providers make significant contributions to health outcomes (McCarthy & 
Rose, 2010; Saller, 2006b). In contrast, EBM approaches to healthcare by design cannot 
respond to individual patients’ health goals as they treat patients as impersonal subjects 
(Greenhalgh, Snow, Ryan, Rees, & Salisbury, 2015; Reuben & Tinetti, 2012). Although 
RCTs are convenient and have become synonymous with the scientific method, they are—
when taken as stand-alone evidence— limited in their knowledge base (Madjar & Walton, 
2001). This disconnect between research and real-life practice limits the usefulness of 
RCTs, not only for clinicians, but also for regulators. The substantial costs of RCTs in 
money, time, and energy, are further issues that hamper their practicality (Rawlins, 2008, 
pp. 18-19). In addition, in 2008 the revised Declaration of Helsinki elevated ethical 
considerations for research on humans. It restricted placebo-controlled trials to areas of 
research where no other effective treatment exists (World Medical Association, 2008). Even 
though these restrictions were revised in 2013, placebo-controlled studies continue to cause 
ethical issues by potentially violating the principle of beneficence (Batra & Howick, 2017). 
The regulatory systems in many Western countries that were established for the regulation 
of newly developed pharmaceutical drugs create legal and commercial disadvantages for 
traditional plant medicines, thus impeding patient access to them. The issues with scientific 
evidence that have been raised give currency to the proposition that RCTs should not be a 
prerequisite for the registration of established therapies. Such an exclusive pathway to their 
legitimacy would ignore the empirical evidence base of long-standing medicines (Clark-
Grill, 2007; Evans, 2009; Flatt, 2012, 2013; Holmes et al., 2006, p. 184; Jagtenberg et al., 
2006; K.A. Jobst, 1998; Schwager, 2012; Walach, 2009). Where data on effectiveness and 
innocuousness already exist, the compulsory establishment of these parameters via the 
pharmaceutical research model is not compelling. Moreover, such a regulatory prerequisite 
would financially prevent the reintegration of traditional plant medicines into a 
contemporary healthcare system: the Western healthcare model does not usually fund 
traditional plant medicines and data generation of scientific evidence on non-patentable 




(Eskinazi, 1998, p. 1622).  
The evidence base for traditional medicines is currently compromised by the persistent 
resistance of governmental and private research funding agencies to support the 
development of a comprehensive, modern evidence base for traditional plant medicines. 
Clearly, the call for evidence is not matched by resources to gather it (Coulter, 2004, p. 109; 
Lewith, Jonas, & Walach; Saller, 2006a, p. 113; Spencer & Jacobs, 2003). This 
underfunding of research contributes to a perpetual marginalisation of traditional plant 
medicines. At the same time the pharmaceutical-based healthcare model becomes more 
normative as governments use tax payer funds for biomedical schools, public hospitals, 
diagnostic testing and synthetic drugs, but not for traditional therapeutics. This is often 
justified on the grounds that there is a lack of modern scientific evidence for many such 
medicines. Yet an elevation of traditional empirical knowledge is in line with the WHO 
strategy on traditional medicines (World Health Organization, 2012). In this approach, 
RCTs become part of the mix of evidence but not as the gold standard for clinical practice, 
research, and policy (Jagtenberg et al., 2006, p. 323). Various researchers have proposed 
different models to replace EBM evidence-based pyramids, such as an evidence house 
(Jonas, 2005), a circular model of evidence (Walach, Falkenberg, Fønnebø, Lewith, & 
Jonas, 2006), or a matrix based approach, which emphasises the need to match research 
questions to specific types of research (Petticrew & Roberts, 2003). Given the long-
established practice of using plants as medicines and the sheer volume of such therapeutics 
in traditional medical systems worldwide, it is urgent to investigate ways to substantiate 
their effectiveness. Such exploration is the topic of this thesis. 
1.3 Seeking regulatory solutions for traditional medicines   
Given this context and the current dominant position that international regulators afford 
EBM, the New Zealand Government faces a difficult question: how can it best develop 
appropriate evidence-based policies for traditional plant medicines and its empirical 
knowledge base? As New Zealand has not yet implemented its own regulatory framework 
for traditional medicines, this study first seeks to understand the regulatory solutions that 
other governments have implemented, and to see whether such information could help 
shape New Zealand’s policy.  




medicines. Such regulations have been implemented in other countries such as Australia, 
Canada, Switzerland, and the USA. However, the greatest effort in the West to harmonise 
policies around this issue and the most complex attempt involving multi-cultural societies 
have occurred in Europe as part of the integrative process of the European Union (EU). The 
main regulatory body for medicines in this economic and political union is the European 
Medicines Agency (EMA), but each of the 28 Member States also has their own separate 
regulatory agency. The Economic and Social Committee of the European parliament 
mandated that the EU Member States harmonise their guidelines on registration of 
traditional medicines (Europäisches Parlament, 2004). This mandate resulted in the 
European Union Directive 2001/83/EC, later updated to 2004/24/EC. After an initial 
transition period it took full effect in 2014. Its purpose is to have established quality criteria, 
to protect the consumer, and to facilitate free movement of herbal products within Europe 
(Kroes, 2014; Sammons et al., 2016). Traditional medicines must now be licenced for sale, 
which can be achieved via a Marketing Authorisation (MA) or a Traditional Herbal 
Registration (THR). As each of the 28 Member States of Europe has a different approach to 
the regulation and integration of traditional medicines into their domestic healthcare 
systems, harmonising policy across the EU has presented multiple challenges. As a multi-
cultural society, New Zealand may therefore benefit from examining how the EU has dealt 
with the dilemma of integrating traditional medicines into a contemporary health system 
while subscribing to the principles of evidence-based health policy.  
1.4 Sources of evidence 
A key feature of this thesis will be the identification of sources of evidence that can 
substantiate the therapeutic use of traditional plant medicines. In traditional systems, 
knowledge is typically conveyed in two main ways: through oral and written transmission. 
This research will deal with written evidence only, as an investigation of evidence from oral 
transmission requires methodologies beyond the scope of this study. Traditional Māori 
healing, Rongoā Māori, is not suitable for an exploration of written documentary evidence 
about traditional medicines because its medical knowledge was and is transmitted orally 
(Boulton, Hudson, Ahuriri-Driscoll, & Stewart, 2014; Mark, 2012; Mark & Lyons, 2010). 
Consequently, this study turns to documentary evidence of another prevalent medical 
tradition practised in New Zealand, that of Traditional European Medicine (TEM). Pākehā 




New Zealand as per the 2013 Census. European plant medicines are commonly available 
over-the-counter in New Zealand pharmacies, health stores, supermarkets, and online. They 
are also key therapeutics prescribed by registered Medical Herbalists and Naturopaths 
(Leach, 2013). This tradition carries sufficient importance that there are NZQA approved 
colleges that teach traditional European plant medicine. Thus, documentary evidence on 
European plant medicines provides a suitable exemplar for this thesis. 
Rycroft-Malone (2004, p. 298) proposes that evidence in evidence-based practice should be 
considered to be “knowledge derived from a variety of sources that has been subjected to 
testing and has found to be credible”. Systematic historical research could play a part in 
establishing and validating data on the effectiveness and safety of medicinal plants thus 
informing regulations (Helmstädter & Staiger, 2014). There are various historical sources 
that help to establish whether long-standing traditional medical knowledge has been 
consistently and accurately transmitted textually. If so, these texts can now be used to 
support the evidence base of traditional plant medicines.  
1.5 Objective of the research 
The objective of this thesis is to establish whether judiciously selected historical and 
contemporary clinical sources on the European materia medica could provide a pathway to 
substantiate therapeutic claims for traditional plant indications and therefore contribute to a 
framework for New Zealand’s evidence-based polices on NHPs. Is this professionally 
documented medical knowledge about the effectiveness and safety of traditional European 
plant medicines a reliable and verifiable source of evidence that can be incorporated into a 
regulatory framework? Do such historical documentary sources adequately and accurately 
describe medicinal plants, their uses, therapeutic effects, and safety to support the 
regulatory acceptance of traditional medicines? 
To examine conformities and differences in the use of traditional plant medicine in the 
context of formal European healthcare delivery and regulation, this research takes an 
interdisciplinary approach across medical history, phytotherapy and health science. The 
research design employs a longitudinal, comparative textual analysis from the early modern 
period onwards to the present day, using two medicinal plants as exemplars, Arnica 
montana (Arnica) and Hypericum perforatum (St. John’s Wort). The results of this 




indications derived from RCTs, and results from experimental laboratory research. Such 
triangulation of data derived from both qualitative and quantitate methods aims to 
strengthen conclusions drawn from the research. 
This thesis will further examine how the EU dealt with evidence and safety requirements to 
substantiate traditional indications (Cranz, 2010; Gallagher, 2013; Peschel, 2014; Quintus & 
Schweim, 2012; Sammons et al., 2016). The aim is to determine whether such information 

















2.1 Historical and contemporary context of traditional plant medicine  
The first tangible evidence of humans using plants as medicines is in fossil discoveries 
dating back to the Middle Palaeolithic age some 60,000 years ago. An analysis of the soil 
around a discovered burial site revealed extraordinary quantities of plant pollen of eight 
species, seven of which were medicinal plants still used in traditional medicine today 
(Solecki, 1975). In Europe, the earliest evidence of prehistoric peoples’ use of plants as 
medicine stems back to a mummified body of a man who lived 5,300 years ago. ‘Oetzi’, the 
ice-age man, was discovered in a retreating alpine glacier in Tyrol at the Austrian-Italian 
border in 1991. He carried with him fine slices of Fungus chirugorum threaded on a leather 
band, presumably to treat abdominal problems caused by the infestation of whipworm 
(Trichuris trichiura) that was found in him (Heinrich, Barnes, Prieto-Garcia, Gibbons, & 
Williamson, 2017). This remedial fungal species was officially listed until the 6th edition of 
the German pharmacopeia (DAB EB6 1968) (Schneider, 2001, p. 242). Such ongoing use of 
plant medicines for communities around the world has been described by medical historian 
Crellin (2001) as “social validation”. The unabated popularity of plant medicines points 
both to their usefulness and their effectiveness. It is unlikely that their application would 
have persisted if no relief had been gained (Schneider, 2001).  
The consistently observed health effects of plant medicines were transmitted orally from 
generation to generation. In many literate societies, including those in Europe, Egypt, India, 
Tibet, and China, this medical knowledge was also codified in specialised written texts 
reflecting the authoritative scientific knowledge of a given time (Balick, 1994; Cox, 1994; 
Farnsworth, 1990, 1994; Müller-Jahncke & Friedrich, 1996; Touwaide, 1998, 2005; 
Tschirch, 1910, pp. 787-844). The European medical tradition provides a rich textual record 
of clinical applications of medicinal plants spanning more than two millennia (De Vos, 
2010; Tobyn, Denham, & Whitelegg, 2011). Over this period, plant-based therapeutics 
dominated European healthcare delivery, with remedies derived from animals and minerals 
playing only a minor role. The therapeutic effects of herbal drugs in patient care were 
extensively recorded in medical textbooks, formulatories, antidotaries, dispensatories, 
herbals, monographs, and official pharmacopoeias and their compendia. It was only in the 




were relegated in Western healthcare systems (Schmitz, 1998, pp. 405-406).  
The large body of information that underpins traditional medicine is referenced as 
traditional knowledge (TK). The International Council for Science defines TK as “a 
cumulative body of knowledge, know-how, practices and representations maintained and 
developed by peoples with extended histories of interaction with the natural environment” 
(International Council for Science, 2002, p. 2). This knowledge provided the historical 
foundation for all pharmacological medicines. There is now a schism between traditional 
medicine which is based on TK, and biomedicine which is based on more recent natural 
science methodologies, mainly chemistry, biology, and physics. Yet this distinction is a 
relatively new phenomenon driven by paradigmatic changes in Western medicine since the 
19th century. Today, there is a move to canvass TK once more for the development of 
contemporary medicines, including pharmaceutical drugs (Cordell, 2000; Cragg, Newman, 
& Snader, 1997; Farnsworth, 1994; Gurib-Fakim, 2006; Khazir, Mir, Pilcher, & Riley, 
2014; Lahlou, 2013; Mulzer & Bohlmann, 2013; Oubre, Carlson, King, & Reaven, 1997; 
Phillipson, 2007). This is because traditional medical knowledge has frequently uncovered 
verifiable botanical drugs (Atanasov et al., 2015; Bladt & Wagner, 2007; Buss & Butler, 
2010; Butler, 2004; Cox, 1994; Cragg et al., 1997; Duke, n.d.; Fabricant & Farnsworth, 
2001; Mustafa et al., 2015; Oubre et al., 1997; Patwardhan, 2005). Seventy-five percent of 
119 widely used modern drugs are either compounded from medicinal plants or synthesised 
based on plant structures and they have the same or similar use as in traditional medicine 
(Farnsworth, 1994, p. 43). Of 1355 small-molecule new chemical entities that were used as 
a source for disease treatment from 1981-2010, more than 71% were natural or ‘inspired’ by 
natural substances (Buss & Butler, 2010; Newman & Cragg, 2012). Of the anti-tumour 
drugs, almost half were based on natural substances. Overall, about 40% of all 
contemporary medicines are either natural products or their semi-synthetic derivates (John, 
2009). The 2015 award of the Nobel Prize in medicine to Tu Youyou for her research on 
Artemisia annua is a strong signal that plant medicine has once again become pertinent to 
the scientific community (Efferth et al., 2015).  
Plants continue to provide the largest and most economical collection of therapeutically 
active compounds. Over 35,000 species worldwide are used for the manufacture of plant 
medicines (Saller, Melzer, & Rostock, 2011, p. 204). They belong predominantly to 67 




be amongst the most important sources of new drugs in the future (Atanasov et al., 2015, p. 
1606; Fabricant & Farnsworth, 2001; Gilani & Rahman, 2005; Katiyar, Gupta, Kanjilal, & 
Katiyar, 2012; Mulzer & Bohlmann, 2013; Phillipson, 2001, 2003; Pieters & Vlietinck, 
2005). With global issues such as rapidly increasing antibiotic resistance to several common 
and serious bacterial infections now confirmed in over 500,000 patients (World Health 
Organization, 2018a), research teams increasingly look to nature for new leads. Apart from 
their therapeutic value, plant medicines are well-regarded as a cost-effective therapy since 
the development of a synthetic single compound into an approved drug takes an average 
time of 12-13 years at a cost of up to $800 million USD (Festel, Schicker, & Boutellier, 
2010). This cost is particularly striking when compared with the increasing number of low-
cost traditional plant medicines with proven equivalence to synthetic drugs, for example St. 
John’s Wort in mild to moderate depression (Schulz, 2002). 
2.1.1 Traditional systems of medicine as resources for solving health problems 
Access to and development of effective, safe, affordable, and acceptable medicines is an 
ongoing challenge for healthcare worldwide (World Health Organization, 2012). The WHO 
emphases traditional medicine systems and their therapeutics as key resources for solving 
the world’s unabated health problems. It defines traditional medicine as “the sum total of 
the knowledge, skill, and practice based on the theories, beliefs, and experiences indigenous 
to different cultures, whether explicable or not, used in the maintenance of health as well as 
in the prevention, diagnosis, improvement or treatment of physical and mental illness” 
(World Health Organization, 2013, p. 15). Systems of traditional medicine differ from more 
recent complementary and alternative medicine modalities through a medical paradigm with 
practices, strategies, and beliefs that were in existence well before the development and 
spread of modern scientific medicine, often for centuries if not millennia (Akerele, 1992). 
They represent congruent and complete medical paradigms that continue to be practised 
today such as TCM (traditional Chinese medicine), Ayurveda (traditional medicine of the 
Indian subcontinent), Unani-Tibb (traditional medicine of Arabic countries), and Traditional 
European Medicine (TEM). 
TEM is a relatively recent terminology (Bruchhausen & Schott, 2008, p. 18). It is applied to 
differentiate the principles of pre-modern European medicine from those of modern 
medicine in Europe. TEM refers to a treatment approach, both therapy and prevention, that 




rooted in antique Greek medicine (Uehleke, 2007, p. 203). Aristotelian philosophy was a 
key influence on this medical paradigm which gave rise to humoralism, vitalism, the 
treatment of the individual, and a focus on healthy lifestyle management. It is distinctly 
separate from biomedicine, also known as modern medicine, Western medicine, mainstream 
medicine, allopathic medicine, conventional medicine, or orthodox medicine which 
developed rapidly in Europe from the 19th century onwards. The philosophy and 
therapeutics underpinning TEM are sometimes referred to as classical naturopathy (Joos, 
Eicher, Musselmann, & Kadmon, 2008) or as the Western herbal tradition (Evans, 2009; 
Tobyn et al., 2011; Waddell, 2016). In contrast, the term naturopathy, without the adjective 
classical, is not a synonym for TEM. Naturopathy (Naturheilkunde) was developed in the 
second half of the 19th century as a counter-movement against the scientific revolution and 
its new chemical and technology-based medicine (Roth, 1991). The term includes more 
recent natural treatment approaches from the 19th century onwards (Jütte, 1996). This health 
movement laid the ground for what is termed today complementary and alternative 
medicine (CAM) (Gaboury, April, & Verhoef, 2012; Uehleke & Saller, 2011). 
It is estimated that today as much as 80% of the world’s population applies traditional 
medicine as a primary form of healthcare, either as part of an official healthcare system or 
in self-care (Saad & Said, 2011, p. 47). According to data published by Euromonitor, the 
global expenditure on herbal products in 2010 was around US$30 billion of an overall total 
of US$176 billion global consumer healthcare expenditure (Gallagher, 2013, p. 15). The EU 
market for medicinal herbal products is estimated at about 6 billion Euro (Cranz & Anquez-
Traxler, 2014, p. 495). Consumers worldwide are projected to spend US$140 billion on 
plant-based healthcare and wellness by 2024 (Paine & Roe, 2018, p. 410). Although this 
projection seems high compared with the US$30 billion global expenditure in 2010 and 
includes the wellness industry, it confirms an upwards trend. However, in markets such as 
Western Europe, where plant medicine is already well established, year-on-year growth 
rates are minimal (Gallagher, 2013, p. 14). 
The WHO data suggests that societies around the world take a pluralistic approach to 
medicine which includes their traditional medicines because pharmaceutical drugs cannot 
address all health needs, are not easily accessible to all, are too expensive and not always 
appropriate (World Health Organization, 2012). Moreover, the WHO recognises that 




cultural reasons” (World Health Organization, 1999, p. 1). For example, consumers of 
Western and Northern European countries such as France, Germany, Switzerland, Austria, 
UK, and Sweden use herbal medicines to complement contemporary pharmaceutical 
treatments. In contrast, difficult economic conditions in Eastern European countries limit 
access to expensive pharmaceutical medicines prompting the respective populations to seek 
more economically priced traditional herbal products for their primary healthcare needs 
(World Health Organization, 2010). This situation is also reflected in developing countries, 
where traditional medicines are often the only accessible form of healthcare (Cordell, 2011; 
International Bioethics Committee (IBC), 2013). 
From a public health perspective, Western pharmaceutical biomedicine has made its biggest 
contributions in emergency medicine, in the treatment of acute infectious diseases, and in 
surgical treatments. Higher survival rates in critical health events are significant 
achievements. Furthermore, advanced technology allows the screening of otherwise 
difficult to detect disease states, enabling intervention and treatment of such diseases. Yet 
according to the WHO, the biomedical approach is ill prepared for the public health 
challenges ahead. It has been unable to increase the overall health of the world’s population 
or reduce health expenditure since health problems worldwide have shifted from acute 
illnesses to often preventable chronic disease (World Health Organization, 2005). This has 
been most strikingly illustrated in the USA since the Flexner report (Flexner, 1910). That 
report prompted a transformation of the medical curriculum to a model exclusively built on 
basic science and pharmaceutical drug applications, and which eliminated non-
pharmaceutical methods of prevention and treatment of disease (Oubré, 1995, p. 47). 
Subsequently, the listings of plant drugs in the US pharmacopoeia fell from 59% in 1890, to 
28% in 1940 and to less than 2% by 1990 (Hughes, 2006). During these decades advances 
in hygiene, social measures, and targeted biomedical care lowered mortality rates of 
infectious diseases (Ackerknecht, 1992), but despite massive investment in biomedical 
health services, including the ‘war on cancer’, there was a steady rise in chronic ill-health 
by the end of the 20th century. According to regional US community health statistics, 
Americans experienced in the 1920s an average of 0.82 episodes of disabling illness a year 
compared to 2.21 by the 1980s (Barsky, 1988, p. 415). There may be many contributing 
reasons for the overall decline of health, such as an ageing population, changes in diet, 
prevalence of smoking, environmental toxicity, and a decrease in manual labour and 




kept chronic illnesses from increasing nor provided preventative solutions.  
Based on their persistent use by the population, some governments, for example in 
Switzerland, Japan and China, officially fund both traditional and modern synthetic 
medicines as part of their healthcare systems, but most consumers in Western countries 
must fund traditional plant medicines privately. This situation is an outcome of historical, 
political, economic, and epistemic factors that led to the privileging of biomedicine in 
Europe, and its dominance across the globe as a consequence of the European colonial 
encounter (Ijaz & Boon, 2018; Wartmann, 1993). Disparities are seen in regulations at 
national levels where plant medicines may be defined variously as a medicine, medical 
device, plant food supplement, natural health product (NHP), traditional herbal medicinal 
product (THMP), dietary supplement, food, or cosmetic. In some jurisdictions they are not 
regulated at all or even prohibited (International Bioethics Committee (IBC), 2013).  
2.1.2 The patient’s perspective 
The current public healthcare system in Western or westernised countries is problematic for 
two reasons. Firstly, the cost of biomedicine is prohibitive even for affluent countries and 
secondly it does not meet consumer expectations. The significant level of patient 
dissatisfaction with biomedicine first came to prominence with the Eisenberg report (1993) 
which sampled adults over 18-years-old from across the USA. It showed that the number of 
self-funded visits to practitioners of unconventional therapies that were neither taught 
widely in U.S. medical schools nor generally available in U.S. hospitals exceeded the 
number of visits to all U.S. conventional primary healthcare physicians. During the 1990s, 
expenditures for non-conventional medicine further increased. This was primarily attributed 
to a larger proportion of the population seeking alternative therapies, rather than to 
increased visits per patient (Eisenberg, Davis, Ettner, & et al., 1998). By the 1990s almost 
half of the public in most industrialised countries regularly used complementary forms of 
medicine (Astin, 1998; Eisenberg et al., 1998; Gardiner & Wornham, 2000; MacLennan, 
Wilson, & Taylor, 1996). Numerous surveys indicate that such high prevalence of use 
persists and that the use of complementary healthcare is here to stay (de Souza Silva et al., 
2014; Ducrest et al., 2017; Eardley et al., 2012; Euromonitor, 2011; Fennell, Liberato, & 
Zsembik, 2009; Gonzalez-Stuart, 2011; Green, Santoro, Allshouse, Neal-Perry, & Derby, 
2017; Hall & Jolly, 2014; Harris, Cooper, Relton, & Thomas, 2012; Hung, Kang, Bollom, 




Thomson, Jones, Browne, & Leslie, 2014). 
Disenchantment with biomedicine is reflected in numerous surveys into patient behaviour in 
several Western countries. While consumer behaviour is dynamic and influenced by local 
conditions, there are some common trends. Since the 1990s the pressure to shift from a sick 
care model to a more humanised well care model has been mounting (Micozzi, 1995). 
Dissatisfaction with the current Western drug model is apparent, particularly when 
treatments of chronic and terminal conditions are perceived inadequate, i.e. “doctor’s 
medicine not working” (Crellin, 2001, pp. 48-49), when pharmaceutical drugs have side 
effects or treatments are experienced as invasive, when doctors are insensitive to patients’ 
physical, emotional, and spiritual needs, when patients desire more personal control, when 
household health-care costs for a biomedical approach become prohibitive, when sufficient 
consultation time with a conventional physician is limited, or when patients prefer a more 
holistic health promotion (Mitchell, 2014; Thomson et al., 2014). Other surveys have 
identified that the rise in demand for CAM healthcare approaches, including plant 
medicines, is part of a wider social, mainly female-driven consumer movement that links 
with postmodernist values about nature, science, technology, health, authority, individual 
responsibility, and consumerism (Astin, 1998; Willis & Coulter, 2007, pp. 216-220). The 
holistic health movement from the late 1970s also resurrected many aspects of traditional 
medicine (Oubré, 1995, pp. 47, 51). Proponents of this movement reject the reductionist 
scientific view of humans and demand a shift back to Western medicine’s own tradition of 
personalised healthcare and Hippocratic principles such as “do no harm” (Wolpe, 1990, p. 
917). Undoubtably, the Western ecology movement (Drengson & Inoue, 1995) has also had 
a major influence on patient preference for natural medicines (Houghton, 1995, p. 136). 
Their starting point for decision-making is not Western science with its focus on clinical 
studies and scientific evidence on active constituents, mechanisms of action, and efficacy 
(Abdel-Tawab, 2018, p. 388; Bardia, Nisly, Zimmerman, Gryzlak, & Wallace, 2007). 
Instead, the popularity of traditional therapeutics suggests that many patients perceive value 
in these therapies even if they lack academic and scientific explanation (Bardia et al., 2007; 
Willis & Coulter, 2007). Their preferences are based on traditional healthcare that is 
familiar, has shown to be effective and non-harmful, and is local and affordable (Bodeker, 
2000, p. 3; Little, 2009, p. 300; Welz, Emberger-Klein, & Menrad, 2018, p. 6). 
Representative surveys of the German population suggest that patients appreciate the 




compared to conventional synthetic OTC products (Nieber, 2014, p. 207). Accordingly, 
many synthetic drugs are gradually becoming less attractive to consumers due to side-
effects, serious adverse effects, the risk of dependency, and the widespread resistance of 
microorganisms to modern antibiotics (Sen & Samanta, 2015, p. 66). That said, in countries 
with both well-established traditions of plant medicine and ready access to Western 
biomedicine, consumers are generally aware of the limitations of plant medicines in 
contexts where pharmaceutical drugs are deemed more appropriate (Institut für Demoskopie 
Allensbach, 2010).  
Patient attitudes are congruent with an analysis published by the British Medical Journal of 
evidence for 3000 medical treatments. It found that only 11% were definitively beneficial, 
23% were probably beneficial, and 51% were of unknown effectiveness (BMJ, 2012). The 
pharmaceutical industry itself estimates that 90% of Western drugs are ineffective for about 
60% of the patients using them (Petit-Zeman, 2003; "What happened to personalized 
medicine?," 2012). In addition, a review of the top 10 drugs in the USA further point to 
their limited usefulness for many patients, confirming that they work at best for one in four 
people and at worst for one in twenty-five—even though regulatory approvals for these 
drugs had been gained based on EBM evidence (RCTs) and mechanistic essays (Vergeres, 
2017, p. 42). In New Zealand the preparation for a new Medicines Strategy also highlighted 
issues with synthetic drugs. It discovered that 50% of New Zealand patients do not take 
their pharmaceutical medicines or do not take them as prescribed, and 9% of patients are 
given the wrong medicine or the wrong dose with harmful effects (Ministry of Health, 
2006). At the same time, NHPs for self-medication have steadily grown in this country over 
the past 20 years despite a lack of regulation (Barnes et al., 2016).  
2.2 Situation assessment in New Zealand 
Traditional systems of medicine are used by indigenous and migrant populations in New 
Zealand to address their primary healthcare needs, as broadly consistent with the majority 
of people around the world (Barnes et al., 2016; Fabricant & Farnsworth, 2001). Nationally 
representative population-based data on the prevalence of use of plant medicines are not 
available. However, there are some localised studies that explore the prevalence of use of 
NHPs in specific patient populations. These studies estimate that about 50% of adults and 
70% of children use therapies and preparations from sources outside conventional 




medication (Barnes et al., 2016, p. 909; Chrystal, Allan, Forgeson, & Isaacs, 2003; Wilson, 
Dowson, & Mangin, 2007). In recent decades there has been increased interest and use of 
NHPs in New Zealand, which is reflected in their industry value to the New Zealand 
economy of $1.4 billion NZD (Barnes et al., 2016, pp. 905-909; Natural Products New 
Zealand, 2017). Note that this sum contains non-herbal dietary supplements as well as 
infrastructure value. The frequent use of parallel health paradigms by the New Zealand 
population has implications for health policy. Patients’ choice of healthcare is protected in 
New Zealand under the Code of Health and Disability Services Consumers’ Rights 
Regulations 1996, which falls under the Health and Disability Commissioner Act 1994. 
Similarly, in Australia, a Position Statement of the Council of Australian Therapeutic 
Advisory Groups (CATAG) confirmed that in most instances Australian hospitals cannot 
legally prevent the use of complementary medicines by their in-patients (CATAG, 2015). 
2.2.1 WHO directives and policy support for the integration of traditional 
medicines into New Zealand’s healthcare system 
Despite being a signatory to the WHO—an organisation which requests that governments 
harness the contribution of traditional medicines to healthcare by promoting, regulating, 
researching, and integrating them into their healthcare systems (Burton et al., 2015, p. 13)—
successive New Zealand governments have not implemented key objectives of the WHO’s 
traditional medicines strategies. Forty years ago, the Declaration of Alma-Ata called for the 
inclusion of traditional medicine into primary healthcare (Wartmann, 1993; World Health 
Organization, 1978). Building on subsequent strategies (World Health Organization, 2002), 
the current global Traditional Medicine Strategy 2014-2023 (World Health Organization, 
2013) and the corresponding Regional Strategy for the Western Pacific (2011-2020) 
emphasise people’s rights to quality health services that are available, accessible, 
affordable, and culturally acceptable (World Health Organization, 2012, p. v). The Beijing 
Declaration, which informs the current WHO Traditional Medicine Strategy 2014-2023, 
recognises that “[g]overnments have a responsibility for the health of their people and 
should formulate national policies, regulations and standards, as part of comprehensive 
national health systems to ensure appropriate, safe and effective use of traditional medicine” 
(World Health Organization, 2008, p. 1). The 2018 Declaration of Astana, unanimously 
endorsed by all Member States, re-emphasises the critical role of primary health care 




including traditional medicines: 
We support broadening and extending access to a range of health care services 
through the use of high quality, safe, effective and affordable medicines, including, 
as appropriate, traditional medicines, vaccines, diagnostics and other technologies 
(emphasis added). (World Health Organization & United Nations Children's Fund 
(UNICEF), 2018, p. 9) 
 
Traditional medicines are also considered by other international regulations. The enduring 
use of medicinal plants is understood as intellectual heritage within a culture, which 
international organisations such as World Intellectual Property Organisation (WIPO), 
World Trade Organisation (WTO), and United Nations Educational, Scientific and Cultural 
Organization (UNESCO) formally acknowledge and aim to protect (Commission on 
Intellectual Property Rights, 2002, p. 73; Lenzerini, 2011). The International Bioethics 
Committee (IBC) of UNESCO links the promotion of traditional medicine with its mandate 
to promote cultural diversity. Under the Universal Declaration on Bioethics and Human 
rights (International Bioethics Committee (IBC), 2013, pp. 1, 17) freedom of choice in 
medicine is seen as consistent with obligations to respect cultural diversity and pluralism 
(Article 12) and respect for traditional knowledge (Article 17). There are various parameters 
within which traditional medicine and its knowledge base are understood and encouraged to 
be respectfully handled: The Universal Declaration on Cultural Diversity (2001), The 
Convention for the Safeguarding of the Intangible Cultural Heritage (2003), the Convention 
on Biological Diversity (2003), and the United Nations Declaration on the Rights of 
Indigenous Peoples (2007) (International Bioethics Committee of UNESCO, 2012).  
With its long-standing strategy for supporting systems of traditional medicine, the WHO 
provides practical policy support to Member States for integrating traditional medicine into 
their healthcare systems (World Health Organization, 2012, 2013). It also provides 
normative and standard-setting guidelines for the collection of medicinal plants through to 
their release as safe and efficacious medicines. Such guidelines relate to the assessment of 
herbal medicines (Akerele, 1992), to GMP quality control systems in their manufacturing 
(World Health Organization, 1994), to methodologies on research and evaluation of 
traditional medicine (World Health Organization, 2000), to good agriculture and collection 
practices (World Health Organization, 2003), to quality control methods for medicinal plant 




(World Health Organization, International Union for Conservation of Nature, & World 
Wildlife Fund, 1993). The need for stringent quality control methods from collection of 
medicinal plants to their commercial release as a therapeutic product is also understood by 
many regulators (Knöss, 2018). The WHO Monographs on selected medicinal plants 
(World Health Organization, 1999, 2004, 2009, 2010) summarise the scientific and 
traditional empirical knowledge identified at the time of their publication. Moreover, in line 
with its strategy to provide regulatory support for the integration of traditional medicines 
into contemporary healthcare, the WHO recently added a traditional medicine chapter to the 
International Classification of Disease (ICD) system ICD-11 for Mortality and Morbidity 
Statistics (2018) for non-biomedical, traditional disease classifications (chapter 26) (World 
Health Organization). This addition is an important recognition of traditional systems of 
medicine (Morris, Gomes, & Allen, 2012). In a first step, ICD-11 accommodates TCM 
classification of disease; sub-chapters to accommodate disease classifications from other 
medical traditions are pending. The WHO further offers a global platform for 
communications amongst regulatory agencies via the International Regulatory Conference 
on Herbals (IRCH).  
In addition to being a member of the WHO, New Zealand is also a member of the 
Commonwealth, which established in 1998 a Working Group on Traditional and 
Complementary Health Systems to address policy issues to reflect public healthcare 
demands and patterns of use (Commonwealth Secretariat, 2001, p. 472). The management 
of the integration of traditional and conventional medicine is named as a key point of the 
action plan (Bodeker, 2000, p. 3).  
2.2.2 Legislative and political impediments for the integration of traditional 
medicines 
Regardless of extensive policy resources provided by the WHO, New Zealand trails other 
signatories in introducing legislation on traditional medicines for several reasons. For the 
past 100 years, New Zealand’s regulatory system has been set up to regulate synthetically-
derived Western medicines. The colonisation of New Zealand had a significant impact on 
the pre-European traditional medical system with legislative consequences (Berghan et al., 
2017). The Tohunga Suppression Act 1907 was initially aimed at the elimination of 
improperly trained tohunga, Māori healers, but mainly drove all tohunga and their 




practice and deliberate deception (Te Ara. The encyclopedia of New Zealand, 2018). This 
Act in effect breached the second article of the Treaty of Waitangi 1840, the fundamental 
legal document that addresses for New Zealand the relationship between the Crown and the 
indigenous Māori population. The Tohunga Suppression Act 1907 was eventually repealed 
in 1962 (Te Ara. The encyclopedia of New Zealand, 2018). However, there was another Act 
that further impeded the use of traditional medicines. A year after the Tohunga Suppression 
Act 1907 was passed, the Quackery Prevention Act 1908 was passed to stop the sale of 
sham medicines (Duke, 2005, p. 11). It became a means to provide state sponsored 
legitimacy of Western biomedicines while marginalising those without ‘scientific proof’ to 
the medical fringe.  
With these two Acts, traditional medicines—whether the healing practises of Rongoā Māori 
or those of immigrant populations—were marginalised or outlawed. These actions resulted 
in significant loss of traditional medical knowledge in New Zealand during the 20th century. 
Despite these impediments for the public and for non-physician practitioners, specific plant-
based drugs were used in regular medicine at least until WW2 when sulphonamides and 
penicillin became prevalent (personal communication Dr. Marian Stewart (1909-2003), 
Graduate of Medical School, Otago University, February 24, 2000). This continuation 
explains why the First Schedule to the Medicines Regulations 1984, based on the Medicines 
Act 1981, contains several plant drugs that are listed as prescription medicines, restricted 
pharmacist-only medicines, or pharmacy-only medicines, as well as their synthetic 
analogues. Unlike in the UK, access to those medicinal plants is illegal in New Zealand for 
those who have not graduated as physicians or pharmacists even though New Zealand 
physicians and pharmacists are usually not trained in the appropriate clinical use of these 
medicines in patient care. 
The outlawing of traditional remedies during the 20th century as therapeutic substances in 
the context of traditional systems of medicine created obstacles for the co-existence of 
systems of traditional medicine alongside Western biomedical practices. In 2001, a 
Ministerial Advisory Committee on Complementary and Alternative Health was established 
under section 11 of the New Zealand Public Health and Disability Act 2000 to advise the 
Minister for Health on how to integrate traditional medicine and CAM into mainstream 
healthcare practice (Ministerial Advisory Committee on Complementary and Alternative 
Health, 2004). This mandate led to the formulation of the Māori Health Action Plan in 




Māori health statistics and inequalities (Fraser & Tilyard, May 2008; Mark, 2012), to the 
passing of the Health Practitioners Competence Assurance Act 2003 for enabling the 
legitimisation of CAM practices by statute (Duke, 2005, pp. 12-13), and to various attempts 
at regulating NHPs. However, there is still no tangible progress on these interrelated issues. 
There are at least three key reasons for this problem: the lack of political urgency in 
progressing a regulatory framework for NHPs and professions using them; the failed pursuit 
of a joint regulatory authority for medicines and other therapeutic products with Australia 
under the joint Australia New Zealand Therapeutic Products Act (Medsafe, 2012), and the 
withdrawal by the incoming Labour-led Government in October 2017 of the subsequently 
developed domestic Natural Health and Supplementary Products Bill. The proposed trans-
Tasman regulatory system met strong concerns from consumers and politicians for being 
overly restrictive and harmful to New Zealand consumers and the NHPs industry (Ellena, 
2005, p. 106). The much lighter and more appropriate New Zealand-only regime which 
reflected the low risks of NHPs enjoyed political cross-party and industry support with 
minor but vocal opposition (Natural Products New Zealand, 2017). The domestic bill was 
intended to protect consumer choice and to provide a low-cost access to NHPs that are safe, 
effective, and suitable for use in self-treatment (Ministry of Health, 2017). At the time of 
writing, the Health Minister is yet to announce how the Government will proceed with 
regulation of NHPs.  
This unresolved situation is particularly severe for the traditional healing system of New 
Zealand. The Waitangi Tribunal report on the Wai 262 claim notes that a lack of urgency of 
the Crown to redress the current lack of support and funding for Rongoā Māori in general 
and rākau rongoā (plant medicines) specifically may be driven by several reasons: political 
sensitivities towards claims raised in Parliament of a perceived lack of evidence of efficacy 
for such traditional therapeutics, continued lack of belief in the efficacy of Rongoā Māori 
by the Crown itself, and the lingering scepticism sown by the Tohunga Suppression Act 
1907 (Legislation Direct, 2011, p. 225-226). A recent report released by the Health Quality 
& Safety Commission has identified continued institutional racism against Māori, medical 
advice regularly being delivered in a culturally insensitive way, and a health system that 
delivers significant health inequity ("Racism in health 'killing and harming Maori'," 2019, 
July 29). This provides currency to the argument that regulations supportive of traditional 






From an international perspective, the current New Zealand legislative framework is out of 
step with the international regulatory landscape and does not align with WHO directives to 
integrate traditional and complementary medicine as a vital part of state-funded healthcare. 
From a domestic perspective, current regulations do not adequately support consumer 
choice. According to Peter Davis (1992, p. 15), emeritus professor in Population Health and 
Social Science at the University of Auckland, the current situation represents a problematic 
institutional and regulatory framework that supports corporate pharmaceutical power, 
raising basic policy issues of control and regulation. Under this framework, the scope of 
traditional, non-pharmaceutical medicines cannot be accurately stated under the Medicines 
Act 1981. Although the Dietary Supplement Regulations 1985 and the Food Act 1981 
provide some framework for quality requirements, they too disallow therapeutic claims on 
NHPs, even when a long-standing empirical knowledge base or scientific evidence is 
available. Such restrictions promote either underutilisation of these low or non-toxic health 
products or the inappropriate use of them due to a lack of valid consumer information. As 
NHPs are widely used in the community, recent initiatives to enhance their integration and 
quality such as the formerly proposed domestic Natural Health and Supplementary Products 
Bill are key for the future of New Zealand healthcare needs; they were created to help New 
Zealand achieve consistency in the principles of best practice regulation. 
Once introduced, new regulations for over-the-counter NHPs would be part of the overall 
regulatory framework of the New Zealand healthcare system. They should enable informed 
choice by consumers, meet standards for quality, provide evidence to support health claims, 
and address the legal requirements for therapeutic preparations that are safe, effective, and 
true to label. The introduction of such regulations should support the integration of 
traditional medicines into a more sustainable healthcare model and help align New Zealand 
with the policy goals of the WHO’s Traditional Medicine Strategy 2014-2023. They should 
also provide a regulatory framework that enables their inclusion in healthcare funding. 
NHPs are ideally placed to help prevent and treat chronic illnesses. New Zealand, like other 
countries around the world, grapples with complex public health problems associated with 
an ageing population and an exponential increase of degenerative diseases such as obesity, 
diabetes, and cancer. Chronic disease is increasing in Western countries not only because of 




social, economic, and environmental factors also contribute to this upsurge in chronic 
disease (O'Donnell et al., 2017). The associated pharmaceutical drug costs and medical 
interventions are spiralling. They account for a large portion of a nation’s health budget, 
hampering the ability to provide adequate healthcare across the entire population (Keene et 
al., 2016). Although biomedicine has alleviated suffering of millions of people, a Western 
healthcare system that uses high technology medicine with drugs and surgery as the first 
line of defence is not financially sustainable and can have long-term negative health 
consequences due to focusing on symptom management rather than healing. This approach 
is also out of step with patient preferences for pluralistic medicine. New Zealand’s need to 
focus on regulatory support of NHPs is urgent, given the strain on the public healthcare 
system and the WHO position on the prevention of illness, the promotion of self-care, and 
healthy lifestyle coaching as ways to combat the global epidemic of non-communicable 
chronic diseases. 
2.2.3 The urgent need to progress regulations on traditional plant medicines  
Despite the obvious gaps in New Zealand regulation to support the co-existence and 
integration of NHPs, there are bigger hidden pitfalls to avoid. Milio (1987, p. 264) reasoned 
that for health policies to fulfil their potential of promoting good health in communities, it is 
necessary to have high-level political leaders who understand that human health is in an 
ecological relationship with our natural and human-made habitats. In such an ecological 
perspective, people’s health cannot be simply approached by a disease model that tidily 
segments health needs into medical diagnosis, symptoms, and risk factors to be targeted and 
eliminated. Instead, Milio (1986) argues, health policies should set a framework within 
which individuals and communities are enabled to take control of their own health and 
wellbeing. Thus, health policies should take the interests of the public into account, 
recognising that they may be different from the interests of the mainstream medical sector 
or paradigmatic stances of policy makers (Milio, 1987, p. 264). Consequently, a 
government has a broad responsibility to provide a policy framework that not only targets 
the treatment of diseases, but also enables their prevention. Successfully applied, this 
strategy would translate into healthier childhoods, a more vigorous life in the middle 
decades, and a less debilitating old age, all of which have personal and economic value 
(Milio, 1986, pp. 217-218). This policy framework is also an attractive proposition from a 




enable patients to be proactive about staying healthy—whereas reactive approaches focus 
on remedial care of manifested diseases which may require expensive drugs and hospital 
stays once patients are already ill. Milio’s reasoning is in line with the WHO statement 
which argues that well-applied policies targeted at the prevention and control of chronic 
diseases are urgent (World Health Organization, 2005). The trend in chronic, debilitating, 
and mostly preventable diseases is reflected in global figures which reveal that chronic 
diseases represent double the number of deaths from all infectious diseases including: 
HIV/AIDS, tuberculosis, and malaria; maternal and perinatal conditions; and nutritional 
deficiencies combined (World Health Organization, 2005, p. 2). While the most recent New 
Zealand data for chronic diseases are not currently available, a recent Australian study 
reflects the global data, concluding that chronic diseases are amongst the most common, 
costly, and preventable of all health problems (O'Donnell et al., 2017, p. 205).  
Milio (1987, p. 266) also maintains that health policies sit in the cultural context of broadly 
shared and implicit expectations as derived from historical, socio-political, and 
organisational experience. Consequently, health policies must take into account the values 
and cultural framework within communities (Barnes et al., 2016, p. 906). This conclusion is 
particularly relevant for the drafting of a regulatory framework that is set up to support the 
use of traditional medicine. Health policies should make it easy for people to choose NHPs 
if they desire to do so. This is pressing given the high prevalence of their use in New 
Zealand to prevent chronic disease and the need to treat health complaints before they 
become more imperilling. Such policy support would support citizens to take greater care 
for their own health, promoting the concept of self-care. 
If a political decision is made in New Zealand to emphasise a preventative healthcare 
approach and provide a supportive framework for access to lower-cost and safer 
interventions, then traditional and complementary medicine can provide an important 
contribution to the current health crisis. Such medicines are shown to lead to positive 
healthcare cost savings and productivity gains. For example, an Australian study calculated 
productivity gains of ASD $7.38 per $1 spent on a treatment regime with St. John’s Wort 
for depression (Shanahan & de Lorimier, 2014, p. 78). Moreover, two economic evaluations 
comparing St. John’s Wort preparations with generic antidepressants for the treatment of 
mild to moderate depression confirmed the plant-based treatment to be more cost-effective, 
with reduced incidences of adverse effects and increased compliance and positive outcomes 




Adjusted Life Year) compared with synthetic antidepressants is particularly important from 
a patient perspective (Jeanning & Meier, 2014a, p. 191). A German study comparing a 
Passionflower preparation with benzodiazepine medication showed a reduction of health 
insurance costs of several millions of Euro per year, alongside an increase of quality of life 
for patients using the herbal drug (Michels, Gibbert, Kreimendahl, & Trompetter, 2016). 
Such trends are also observed in a dataset from a Dutch health insurer that points to lower 
costs from fewer hospital stays, fewer prescription drugs, and higher life expectancy in 
patients whose GP engage with non-biomedical treatment modalities (Kooreman & Baars, 
2012). A Swiss Health Technology Assessment report evaluating the suitability of 
phytotherapy for general health insurance funding concluded that the existing data indicate 
positive cost-effectiveness for individual plant medicines (Wolf, Maxion-Bergemann, 
Bornhöft, & Matthiessen, 2005). Publicly subsidised patient access to phytotherapy is now 
permanently guaranteed by the Swiss constitution (Eidgenössisches Departement des Innern 
2005; Jeanning & Meier, 2014b; Saller, 2009, p. 268; Schweizerischer Bundesrat, 2017). 
These results align with other cost-benefit analysis research on natural medicine 
interventions (Tais & Oberg, 2013). Accordingly, when Germany reduced the Social Health 
Insurance funding for herbal medicinal products, it did not reduce its overall drug 
expenditure, but increased it more sharply than ever before (Schulz, 2002, p. 193).  
In the face of unsustainable growth in medical spending, important objectives for health 
policy makers should be primary prevention that directly decreases the risk of initially 
developing a disease, and secondary prevention that helps to reduce the severity of a disease 
(Woolf, 2009; Woolf et al., 2009). Apart from increasing the quality of life for a population, 
targeted strategies in public health lead to positive healthcare cost savings and productivity 
gains (Shanahan & de Lorimier, 2014). The mainstream health system and the public would 
therefore benefit if policy-makers explored health strategies that promote good health, 
prevent and treat disease, and ease discomfort by integrating traditional medicines into 
official healthcare. Modern pharmaceutical medicine and traditional plant medicine each 
have their strengths, uniquely contributing to healthcare. It is well recognised that physical 
and mental illness are driven by multiple factors; it would be impossible for any one 
modality to deal with every single aspect of disease phenomenon (Lyng, 1990, p. 82). At 
present, the New Zealand healthcare system divides the two types of medical practices into 
traditional versus pharmaceutical for patients, perhaps raising its own expenses, but 




Given that such economic and individual benefits have been documented, the New Zealand 
government and its citizens would have an interest in progressing regulations on traditional 
medicine and integrating traditional medicine into the healthcare system. Policy-making 
activities are sensitive to the times, timing, and timeliness (Honari & Boleyn, 1999). Milio 
(1985, pp. 273-274) emphasises that timeliness is a key principle for policy success because 
improvements in health through primary healthcare interventions take time to become 
apparent. These principles have not been observed in New Zealand: regulations for NHPs 
remain unresolved for several decades. There are no data available that quantify the loss of 
quality of life or life expectancy when New Zealanders are prevented from fully practising 
their traditional medical customs, a gap of knowledge that also exists elsewhere 
(Helmstädter & Staiger, 2012, p. 96). The lack of progress on regulations for NHPs is 
compounded by the fact that in countries where regulations on NHPs and natural healthcare 
practitioners are lacking, physicians have been seen to be hesitant to recommend NHPs or 
to refer to natural health specialist highlighting the urgency for such regulations (Botting & 
Cook, 2000). 
2.2.4 Threshold of proof of scientific type efficacy as impediment for integration  
Why is the regulation of NHPs not gaining faster traction in New Zealand despite strong 
patient preference, potential therapeutic and economic benefits, and policy support from the 
WHO for the integration of traditional medicine into mainstream healthcare? A letter from 
the Minister of Health (6th of October 2014) may provide some insights into how the New 
Zealand government intended to implement the WHO Traditional Medicine Strategy 2014-
2023: “The Government supports people having choice about their personal health care, 
including choosing traditional and complementary therapies when these are safe. However, 
such therapies can only be considered for public funding when there is sufficient evidence of 
efficacy” (letter reference 14001516; emphasis added). According to this statement, New 
Zealand’s healthcare system embraces an evidence-based approach to its healthcare policies 
by requesting efficacy proof (RCTs) even for well-established therapies such as traditional 
plant medicines. While evidence-based policies aim to improve the efficiency and 
beneficial outcomes of healthcare (O'Donnell et al., 2017, p. 204), McQueen (2002, p. 83) 
argues that accurately defining “evidence-based” is difficult given the broad range of public 
health actions and the social and cultural contexts in which health interventions take place. 




and meta-analysis, are therefore problematic when dealing with what constitutes evidence 
in public health and how evidence should be evaluated given the complexities of clinical 
practice (Jackson & Waters, 2004; Rychetnik et al., 2002; Speller, Learmonth, & Harrison, 
1997). Other authors note that evidence-based policies may be employed to justify the 
argument for biomedical funding criteria in Western healthcare systems at the cost of other 
treatment options (Learmonth & Mackie, 2000; Traynor, 2002). In this context the 
relationship between contemporary Western biomedicine and traditional medicine, 
frequently mislabelled as alternative medicine, is often expressed in terms of dichotomies 
such as science versus anti-science or rationality versus irrationality. In this view, EBM is 
promoted as objective, quantifiable and the foundation of “real” knowledge creation while 
traditional knowledge is judged to be anecdotal, imprecise and irrelevant. 
As Cornelius Borck (2016, pp. 140-150), Director of the Institute for History of Medicine 
and Science at the University of Lübeck, Germany, identifies, the definition of ‘evidence’ is 
not value-free, being made legitimate by its cultural, socio-economical, and political 
context. The disciplines of social and political science, and medical anthropology provide 
many studies that illustrate the cultural underpinnings of medicine; as such therapeutic 
interventions are not neutral or devoid of moral and social colouring (Davis, 1992, p. 293; 
Hahn & Gaines, 2012; Whyte, van der Geest, & Hardon, 2002). Indeed, biomedicine and 
traditional medicine were both informed by evidence long before the arrival of EBM less 
than 30 years ago. It is therefore not a lack of evidence that is the topic of discussion here, 
but rather the privileging and legitimisation of one form of evidence over another. Disputes 
between medical empiricism and various scientific or paradigmatic theories are not new. As 
medical history from antiquity illustrates, Western medicine has embraced various different 
medical concepts that employ inductive or deductive approaches to the establishment of 
scientific knowledge (Diepgen, 1941, 1949, 1951, 1955; Rothschuh, 1953, 1978; 
Schipperges, 1999; Schmitz, 1998; Schmitz, Friedrich, & Müller-Jahncke, 2005; Stolberg, 
2011). Different explanatory models for illness are underpinned by different forms of 
evidence that justify the recommended treatment (Bauer, 1997; Pieringer, 2000; Wood, 
2006). Such debates link to the evaluation of competing therapeutic strategies and more 
recently to their eligibility for funding (Borck, 2016, pp. 150-151). Various therapeutic 
approaches with their related forms of evidence co-exist in the pluralistic landscape of 
contemporary Western healthcare —even though biomedicine receives almost exclusive 




Contemporary Western medicine is informed by three key forms of evidence (Borck, 2016, 
p. 142): firstly, evidence based on empiricism as a source of knowledge acquired by means 
of repeated and reflected empirical observation and evaluation of therapeutic use; secondly, 
evidence based on pathophysiological explanatory models relating to experimental science 
with laboratory-based evidence; and thirdly, evidence based on clinical studies such as 
RCTs conducted mainly under ideal conditions with selected patients. The first 
methodology of empiricism provides the backbone of all medical systems, including 
biomedicine (Sackett, 1997). It is a fundamental tool of scientific and medical research 
(Kosso, 1992) that provides evidence for decision making in healthcare (Fugh-Berman, 
1997). The term comes from the Greek word for experience, ἐμπειρία (empeiría). It is based 
on reproducible, real-world practice-based evidence which goes beyond anecdotal 
observations (Crellin & Philpott, 1990). In this thesis, this empiricist-based evidence is 
termed empirical evidence. In the context of traditional medicine, this term has also been 
equated with traditional knowledge (Evans, 2006; World Health Organization, 2013) or 
traditional evidence (Ministry of Health, 2015, p. 9). Traditional evidence is based on a 
natural experiment where practitioners have been prescribing and patients have been using 
therapeutics over a long period of time. There has been some confusion in the literature 
where authors have conflated the term empiricism with clinical trials (i.e. RCTs) (Wood, 
2006, p. 9). Yet, empiricism and experimentalism are two entirely different scientific 
methods that should not be conflated. Empiricism refers to observation and experience 
yielding open system data, whereas experimentation refers to designed experiments yielding 
statistically significant data within a closed system. Empirical evidence is the foundation of 
traditional plant knowledge, a foundation which is reflected in the German term 
Erfahrungsmedizin, Erfahrung being the German term for empiricism, as commonly used to 
describe traditional medicine.  
The second methodology is grounded in natural science and inspired a new medical 
paradigm from the 19th century onward, leading to a pathophysiological treatment model 
that became preferentially state-sponsored in Western countries in the 20th century. 
Pathophysiology and experimental laboratory-based research continue to feature strongly in 
biomedicine and are also applied in the research of plant medicines. This methodology is, 
however, increasingly challenged by EBM. Knowing the biological basis and mechanism of 
action of a therapy does not necessarily help the patient or the treatment provider in 




studies on the molecular mechanisms of action of medicinal plants may point to explanatory 
models but they cannot be automatically correlated to their therapeutic effects. Plant 
compounds may or may not be physiologically effective in vivo due to metabolic processes 
and issues with bioavailability and absorption (Gertsch, 2009, p. 181; Bast et al., 2002, p. 
204). 
The third methodology uses controlled clinical studies to generate evidence. RCTs were 
developed initially to establish evidence of efficacy and to a lesser degree safety for 
biomedical healthcare interventions. They are advocated by proponents of EBM as 
conclusive proof for inclusion or exclusion of an intervention in state-funded healthcare 
(Sackett, Rosenberg, Gray, Haynes, & Richardson, 1996; Sackett, Straus, Richardson, 
Rosenberg, & Haynes, 2000). EBM emphasises treatment outcomes and is less concerned 
about the underlying explanation for why treatments might work (Willis & Coulter, 2007, p. 
217). The EBM movement hierarchically privileges RCTs above other forms of knowledge 
generation (Howick, 2011; O'Donnell et al., 2017). Although it is debatable if EBM 
constitutes a new paradigm according to Kuhn (1970), it was announced as such by its 
proponents (Evidence-Based Medicine Working Group, 1992, p. 2420 ). Evidence-based 
medicine de-emphasises intuitive, un-systematic real-life clinical experience, and 
pathophysiological rationale as sufficient grounds for clinical decision making. It stresses 
the examination of evidence from clinical research for all clinical decisions, treatment 
guidelines, and regulations. Although RCTs can help establish internal validity of a selected 
treatment group under observation, difficulties arise when an attempt is made to privilege 
such evidence for clinical and policy decisions. This is because patients selected for clinical 
trials may not wholly reflect the features of populations who will undergo the treatment in 
real life, thus affecting the external validity of a trial (Loke, Price, & Herxheimer, 2007). 
Moreover, RCTs have been shown to be an inadequate tool for measuring safety, in 
particular in relation to infrequent and uncommon adverse effects as they are commonly 
limited in study size and observational period (Chou et al., 2010, p. 503; Vandenbroucke, 
2004, p. 2).  
These three key forms of evidence are not mutually exclusive. They drive different research 
questions. However, evidence-based policies in healthcare are increasingly taking the lead 
from the principles of EBM despite limitations in the usefulness of RCTs in real world 




not the ultimate tool for establishing evidence (Sackett et al., 2000). Within a very short 
period, EBM has become the major political and philosophical approach in the development 
of clinical guidelines and in healthcare regulations (Churchill & McGuire, 1998; Holmes et 
al., 2006; O'Donnell et al., 2017). Although EBM privileges knowledge derived from RCTs 
over other forms of knowledge, it has not been shown as actually superior to other forms of 
knowledge generation (Borck, 2016, p. 148). It is currently unknown if this relatively new 
approach to healthcare has led to better health outcomes in patients. Only scarce evidence to 
substantiate this assumption could be found (Djulbegovic, Morris, & Lyman, 2000; 
Emparanza, Cabello, & Burls, 2015, p. 101; Fakhry, Trask, Waller, & Watts, 2004). There 
is, however, evidence that it takes a long time to adopt outcomes from clinical trials into 
standard care even when treatments have shown to be unnecessary, harmful, or unhelpful 
(Epstein, 2017). 
There is a move towards Comparative Effectiveness Research (CER) and pragmatic trials to 
provide research outcomes that better reflect proof of effectiveness and safety under normal 
practice conditions (Coulter, 2011). Such research is now mandatory in some countries, for 
example in the USA, and it replicates more closely the type of evidence that underpins 
traditional medicine (Coulter & Khorsan, 2011, p. 173). Even though this is a positive move 
for traditional medicine systems, there are equally important and immediately available 
sources of evidence to support the use of traditional plant medicines. These sources of 





3 LITERATURE REVIEW 
3.1 Context to the literature search 
The importance of bibliographic evidence of systematically appraised pharmacological data 
was already highlighted almost 20 years ago (Benedum, Loew, Schilcher, Nicolai, & 
Steinhoff, 2000). The 2004 EU Directive that governs the registration of Traditional Herbal 
Medicinal Products (THMPs) recognises bibliographic proof of an ingredient’s or a 
product’s recorded traditional use as central evidence for the designated tradition use 
category. Directive 2004/24/EU builds on the previous pan-European guideline 
65/65/EWG, article 4.8 a (ii), which provided a pathway for market approvals of known 
substances based on bibliographic evidence (Nicolai & Steinhoff, 2001, p. 4). However, 
experience with the implementation of Directive 2004/24/EU has shown that bibliographic 
evidence of historical indications, modes of application, efficacy, product safety and 
innocuousness has not been comprehensively considered for traditional uses (Jütte et al., 
2017).  
Bibliographic evidence on traditional plant medicines has been found in the literature of 
three key disciplines, namely medicine, pharmacy, and botany. Until the end of the 19th 
century, botany and pharmaceutical compounding were integral sciences for the 
professional development of physicians (Freyer, 1995). A database search strategy was 
constructed to find relevant papers on the therapeutic uses of traditional plant medicines 
from these disciplines (see Appendix 1). It returned 2,026 articles of which 1991 were 
unique hits. The electronic database search was further complemented by a physical 
literature search undertaken at libraries and archives in Germany and Switzerland. 
Appendix 2 provides the preliminary list of historical and contemporary medical textbooks 
and pharmacopoeias selected in this manual search. Those texts were vetted as potential 
bibliographic evidence sources for regulatory purposes. The selection criteria that were 
developed as part of the research method and the final selection of medical texts evaluated 
for this research project will be discussed in the Materials and Methods chapter (Chapter 
4.4.2).  




research into the traditional materia medica 1 of continental Europe. In line with the focus 
of this thesis, the review will examine research into the German language medical literature 
only. It will not examine research on linguistics, literary structure, or artistic aspects of 
illustrations printed in historical medical textbooks. Moreover, the large body of 
experimental research into plant drugs, as discussed in specialised magazines such as Planta 
Medica, is not examined as it is not the topic of this thesis. 
Despite a large body of literature on medicinal plants, as exemplified by the high hit rate of 
articles from the search strategy, the phytotherapeutic evaluation of historical medical data 
for regulatory purposes is only a recently emerging field. For this, a further manual search 
had to be executed. There exists, however, a good body of academic research into related 
domains: pre-modern medical theories, the central place of medicinal plants in the history 
of European medicine, and their lasting cultural significance (Baader, 1987; Baumann, 
1998; Benedum et al., 2000; Bergdolt & Keil, 1980; Diepgen, 1949; Dressendörfer, 2003; 
Eckart, 2009; Fahrig, 1992; Feldmann, 1996; Freyer, 1996; Friedrich & Müller-Jahnke, 
2005; Giesecke, 2006; Helmstädter, Hermann, & Wolf, 2001; Isphording, 2008; Keil, 1982, 
1985; Keil & Dilg, 1991; Kusche, 1990; Mägdefrau, 1992; Martin, 1991; Müller-Jahncke & 
Friedrich, 1996; Pavord, 2005; Rohland, 1982; Rothschuh, 1978; Rüsen, 1986; Schipperges, 
1999; Schmid, 1939; Schmitz, 1998; Stille, 2004; Stolberg, 2011; Telle, 1982a; Tillmann, 
1988; Wulle, 1999; Zander, 2000). This historical and cultural background to the European 
materia medica helps frame research on evidence of long-standing pharmacological 
knowledge for regulatory purposes. A further body of literature, which will be discussed in 
more detail in the Materials and Methods chapter, provides linguistic and conceptual 
translation aids for the systematic appraisal of the pharmaceutical content recorded in 
historical medical books. 
The deficit of research into the regulatory relevance of historical medical textbooks may be 
because the effectiveness of traditional therapeutics has been questioned in academic circles 
despite their longevity (Riddle, 1985, pp. xx-xxii; Watkins, Pendry, Corcoran, & Sanchez-
 
1 Note: when materia medica is spelled in lower case, the term refers to the body of remedial 
substances used in the practice of medicine; when the initial letters are capitalised (either Materia 





Medina, 2011, p. 1070). Many historians of medicine and pharmacy did not consider 
indications documented in early modern European pharmacopoeias and textbooks to be 
clinically relevant for today’s regulatory environment or medical practice (Dressendörfer, 
2003). Academia frequently resists the notion that historically prescribed plant medicines 
are valid treatments. This is despite the fact that physicians of the early modern period listed 
about 80% of the European plant species positively assessed in the regulatory monographs 
by the German Commission E (Heide, 2001). Even in 1993, the Deutsche Gesellschaft für 
Pharmakologie und Toxikologie (German Association for Pharmacology and Toxicology) 
described phytotherapy as a ‘scientifically retarded, historical form of pharmacology’ 
(Benedum, 2001, p. 13). It is therefore unsurprising that a method to evaluate systematically 
the transmission of historically documented pharmacological knowledge for regulatory 
purposes has yet to be formalised. Thousands of unstudied Latin, Greek, Arabic, and early 
modern German herbal texts and recipe books across Europe, northern Africa, and the 
Middle East await such an exploration (Buenz et al., 2004, p. 495). Schanz (2009) is one of 
the few authors who focused his historical research on the regulatory potential of historical 
medical texts, thus demonstrating the relevance of such research. His investigation on 
clinical indications of Hawthorn (Crataegus spp., Rosaceae) and Motherwort (Leonurus 
cardiaca, Labiatae) recorded over 2000 years of European medical history provides a 
comprehensive, detailed, and evaluated assessment of their pharmacological uses up to the 
present day. Remarkably, he was the first applicant to receive a registration in Germany 
under the 2004 EU Directive for a mono-preparation, a medicinal Hawthorn tea, by 
submitting his historical longitudinal comparative research (Schanz, 2009, p. 144). The 
investigation by Kazemekaitis (2010) into plant medicines primarily used in Lithuania, but 
also in Latvia, Estonia, and parts of Poland, identifies dozens of medicinal plant species that 
have been used in Eastern European healthcare for at least 100 years but are not currently 
officially recognised in the EU. The author of this study concludes that these plant species 
could qualify for positive traditional use monographs under Directive 2004/24/EU and 
could thus become available as traditional medicines for all EU Member States 
(Kazemekaitis, 2010, p. 5). The studies of Schanz and Kazemekaitis demonstrate how 
historical research can support traditional medicine in the registration of its therapeutics.  
Lichtenthaeler (1987, pp. 395-398) argues that the reluctance to acknowledge historical 
medical knowledge stems from the subconscious metaphysical attitude that derived from 




Age of Enlightenment. Much of the 19th and 20th century literature on medical history has 
focused on an alleged post-Hellenistic decline of medicine following a highpoint of 
Western medicine as represented by illustrious Graeco-Roman physicians. This decline was 
said to have continued throughout the Middle Ages when political and religious 
developments unfavourably influenced science in general and medicine in particular. Since 
the Age of Enlightenment, new medical and biochemical insights are claimed to have 
enabled the “triumphal march” (De Vos, 2010, p. 2) of scientific Western medicine in the 
modern era (Diepgen, 1914, pp. 7-10; Touwaide, 2005). The notion of history as continuous 
progress since the Age of Enlightenment contrasts with the concept of oscillation of medical 
insights and practices, including radical changes in some centuries. For example, the 
paranoia elicited during the European witch hunts led to the discontinuation of long-
established but hallucinogenic pain-relieving and anaesthetic medication from the late 16th 
century until the 19th when such drugs were re-introduced, albeit in a different format 
(Schmitz, 1998, pp. 413-414). Significant shifts in medicine were illustrated by medical 
historian Tsouyopoulos (2008), drawing on Michel Foucault’s (1973) notion of 
discontinuities in history. In contrast, the otherwise informative Chronik der Medizin 
(Chronicle of Medicine) edited by Schott (2000) illustrates inept historiography as new 
breakthrough discoveries being implied to have heroically superseded established therapies 
for the prevention, treatment, and healing of many illnesses. In this view, traditional 
medicines are framed at best as a source of precursors for synthesizing phytochemicals into 
drugs (Huwer, 2008; Müller-Jahncke & Friedrich, 1996) and at worst as a retrograde, 
inferior, and romantically-influenced form of knowledge compared with cutting-edge 
bioscientific knowledge (Tobyn et al., 2011, p. ix). The regulatory environment is not 
immune to such views as is evident in New Zealand legislation. The exclusion of traditional 
medical practices from mainstream medicine and funding was—as already mentioned—
solidified by several Acts, namely the Tohunga Suppression Act 1907, the Quackery 
Prevention Act 1908, the Medicines Act 1981, and the Dietary Supplements Regulations 
1985.  
The following literature review summarises first the current state of research into 
pharmacological data documented in historical European medical textbooks, beginning with 
Tabernaemontanus’ influential work New vollkommen Kräuter-Buch. This medical 
textbook, first published in 1588, is selected as pars pro toto to represent the body of 




Europe. It incorporates local, foreign and experientially-gained knowledge covering the 
pharmacological effects of medicinal plants spanning back to medical schools of antique 
Greece, Byzantine and medieval Europe while integrating contemporaneous insights from 
the early modern era. The review then gives an overview of research on other historical 
medical texts, where methods of medical history alone or in combination with 
ethnopharmacology were applied to ascertain their pharmacological data. Lastly, it 
discusses historical research into empirical knowledge on medicinal plants used as 
bibliographic evidence for regulatory purposes. 
3.2 Tabernaemontanus and the New vollkommen Kräuter-Buch: current 
state of research  
In the 1980s, Tillmann observed that Tabernaemontanus 
and his encyclopaedic medical textbook New vollkommen 
Kräuter-Buch is an influential but insufficiently 
researched resource of the European botanical pharmacy 
(1988, p. 4). Whereas Tabernaemontanus’ biography is 
now reasonably well understood (Bofinger, 2004; Clair, 
2011), a comprehensive transcription and translation of 
pharmacological data from his body of work are lacking. 
Some plant monographs of the 1625 edition 
(Tabernaemontanus, 1625) have been transcribed by a lay 
historian, albeit without pharmacological evaluation (Neü 
vollkommen Kräuter-Buch, n.d.). Thus, gaps of 
understanding remain about Tabernaemontanus’ 
pharmaceutical and pharmacological information 
(Tillmann, 1988, pp. 4,5) and about how this data could be 
canvassed for regulatory purposes. Consequently, the New 
vollkommen Kräuter-Buch awaits a comprehensive appraisal of its body of knowledge. 
Recent scientific investigations into selected indications listed in this medical textbook 
point to the reliability of its data (Adams, Alther, Kessler, Kluge, & Hamburger, 2011; 
Adams, Berset, Kessler, & Hamburger, 2009; Adams, Gmünder, & Hamburger, 2007; 
Adams, Gschwind, Zimmermann, Kaiser, & Hamburger, 2011; Adams, Kessler, Kluge, & 
Hamburger, 2010; Adams, Schneider, Kluge, Kessler, & Hamburger, 2012).  
Figure 1. Jacobus Theodorus 
Tabernaemontanus. Reprinted 






Although scholarship has yet to evaluate systematically all therapeutic information 
documented in Tabernaemontanus’ New vollkommen Kräuter-Buch, a few researchers have 
begun work on certain sections. The two main researchers are Baumann (1998), who 
investigates the therapeutic uses of medicinal plants in the Umbelliferae family recorded in 
the New vollkommen Kräuter-Buch, and Bofinger (2004), who compares clinical 
recommendations relating to medicinal plants of the Solanaceae and Lamiaceae family with 
current known active constituents and pharmacological actions. Both studies confirm the 
rationale behind many traditional applications. Bofinger highlights the logical structure of 
Tabernaemontanus’ plant monographs by using the exemplar of Tormentil (Potentilla 
erecta, Rosaceae; Potentilla tormentilla Neck, Rosaceae), confirming that this medical 
textbook is an accessible and suitable source for regulatory purposes.  
3.3 Studies relating to the therapeutic history of medicinal plants 
Some scholars apply a different research approach to Baumann and Bofinger by exploring 
Tabernaemontanus’ clinical information and that of other medical authors longitudinally, 
attempting to cross-validate modern scientific research with historical indications for 
specific plants as recorded across medical history. In Germany and Switzerland, many of 
these explorations were undertaken as doctoral dissertations in medicine, pharmacy, or 
natural science. The following synopsis highlights exemplars of research relating to 
consistently transmitted historical uses of medicinal plants compared with contemporary 
knowledge. 
Wulle’s study of the European materia medica recognises that over 1,000 drugs from plants 
(vegetabilia), animals (animalia), and minerals (mineralia) have been recorded since 
antiquity (Wulle, 1999, p. 8). He reviews the pharmacological actions of several of them, 
comparing the actions with contemporary use. Notably, based on their empirical 
observations, historical authors discuss both the therapeutic benefits and the safety concerns 
of quick-acting and potent drugs such as Papaver somniferum, Hyoscyamus niger, Atropa 
belladonna and Mandragora officinarum. They examine how such drugs can be safely 
administered through correct dosage, careful preparation, and appropriate combination with 
moderating plants (Wulle, 1999, pp. 34-44).  
Putscher (1968) tracks the therapeutic history of one of the oldest healing plants, Licorice 




how traditional indications have been recorded consistently, and their congruence with 
modern biochemical and pharmacological data. The interdisciplinary research group Fiore, 
Eisenhut, Ragazzi, Zanchin, and Armanini (2005) expand on these data with a study on the 
independent medicinal uses of Licorice in several unrelated ancient cultures. They claim 
that consistent indications for Licorice across different ethnic groups with different cultural 
backgrounds, and its universally reproducible therapeutic effects, are unequivocally beyond 
a placebo response. Li, Myers, Leach, Lin, and Leach (2003) have also noted such cross-
validation of indications from other medicinal plants across different traditional systems of 
medicine (Australian aboriginal medicine and TCM). 
Kreutzer (1988) longitudinally compares European pharmaceutical applications of native 
Orchids (Orchis spp., Orchidaceae) from antiquity to the end of the 20th century, with an 
emphasis on 16th century herbals. In his investigation, Kreutzer identifies 
Tabernaemontanus’ New vollkommen Kräuter-Buch as a precursor to contemporary official 
pharmacopoeias. Kreutzer confirms that the native Orchid disappeared as a botanical drug 
from the German Pharmacopoeia in the 1960s—even though it had been used medically for 
over two millennia and its therapeutic active constituents have long been validated. Freyer 
(1998) recognises that medicinal plants have been used since pre-historic times and that 
written pharmacological data have been transmitted in European medical literature for more 
than two millennia. He compares several plants used throughout the European medical 
history with contemporary knowledge on their active principles and with registered 
consumer products in today’s European market place. He usefully catalogues historical 
synonyms for medicinal plants. Richter (1998), in turn, undertakes a comparative 
longitudinal study of the medical history of Lemon balm (Melissa officinalis, Labiatae). He 
observes that Tabernaemontanus’ indications are very close to the scientific appraisals of 
Melissa officinalis recorded in today’s official pharmacopoeias, recognising that 
Tabernaemontanus accurately described the pharmacognosy of the plant, its 
phytopharmacology and related pharmaceutical compounding techniques (Richter, p.234).  
Other longitudinal studies briefly discuss Tabernaemontanus’ work in the context of the 
pharmaceutical and pharmacological characteristics of medicinal plants. Tschupp (1998) 
provides a longitudinal medicinal plant study on St. John’s Wort (Hypericum perforatum, 
Hypericaceae), focusing on the wealth of recorded historical recipes and pharmaceutical 




constituents and pharmacokinetics and pharmacodynamics properties. Tschupp additionally 
appraises scientific trials and highlights validation of several traditional uses. Pollio, De 
Natale, Appetiti, Aliotta, and Touwaide (2008) investigate continuity and changes in the 
Mediterranean medical tradition by tracing the therapeutic indications of Rue (Ruta spp., 
Rutaceae) prescribed in Hippocratic medicine, and comparing them with contemporary 
practices in countries along the Mediterranean Sea. Their study gives insights into the 
correlation of humoral and modern medical concepts. Rue was credited in humoralism as 
having hot and dry properties. According to the ‘principle of contraries’ (contraria 
contrariis) that aimed at restoring the right balance of all physiological components of the 
body, Rue was used historically to reduce any excess of fluid in the body through heat 
against moisture or cold and was frequently administered to cure pulmonary and ocular 
infections, menstrual ailments, and aches. It was also used as an antidote against poisons 
and various venomous bites. Notably, humoralism at times used other therapeutic strategies, 
such as the ‘principle of similarity’ (similia similibus). Thus, Rue was further recommended 
to treat inflammation through heat against heat, similar to today’s strategies in chronic 
inflammations (Pollio et al., 2008, p. 473). In contemporary Mediterranean practice, Rue 
continues to be prescribed to cure menstrual and digestive disorders, as an anthelmintic and 
vermifuge, as an anti-rheumatic, and illegally as an abortifacient —all medical issues that 
were historically seen to benefit from accelerated ‘flow’. Anti-inflammatory and analgesic 
properties are, as in antiquity, also applied, but secondarily to the previously mentioned 
applications (Pollio et al., 2008, p. 479). These modern applications mean that while in 
today’s phytotherapy practice the explanatory humoral concepts have fallen away, the key 
historical applications stayed on in clinical practice. 
As already noted, Schanz (2009) investigates Hawthorn (Crataegus spp., Rosaceae) and 
Motherwort (Leonurus cardiaca, Labiatae) in the context of over 2000 years of medical 
history and comprehensively assesses their pharmacological uses up to the present day. He 
determines that the extraction medium and dosage requirements listed in Bock’s early 
modern period herbal from 1577 are almost identical with today’s official guidelines for 
preparation and dosage as determined by the Commission E monograph on Hawthorn 
(Schanz, 2009, pp. 142-143). Mersi (2011) provides an overview of the medical uses of 
Ginger (Zingiber officinale, Zingiberaceae) and Lesser Galangal (Alpinia officinarum, 
Zingiberaceae) in the history of European phytotherapy. Mersi compares almost 90 




monographs. Unlike other researchers, Mersi investigates not only authoritative textbooks, 
but also previously unknown medical, folkloristic, and popular science texts. In her 
appraisal of Tabernaemontanus’ New vollkommen Kräuter-Buch she notes that this medical 
text provided recipes for the tropical plant Lesser Galangal but not for the equally exotic 
Ginger, because Tabernaemontanus preferentially recommended European medicinal plant 
species where an equivalent to an exotic or imported plant was available. Many of the 
historic indications of Lesser Galangal and Ginger have remained stable over the centuries, 
especially in the treatment recommendations for the gastrointestinal tract, a feature also 
noted with other oriental spices (Fabre, 2003). Many of Ginger’s and Lesser Galangal’s 
indications are now confirmed with modern scientific research methodologies. Mersi further 
explores how the humoral qualities of medicinal plants relate to disease targets. This 
qualitative analysis of phytotherapeutic information contained in historical medical 
textbooks had not been undertaken to this extent by other researchers and is therefore useful 
for future studies into botanical drugs and historical treatment strategies. 
Zorn (2013) examines the therapeutic significance of Hyssop (Hyssopus officinalis, 
Laminaceae) in European healthcare, investigating humoral nosology and contrasting it 
with scientific studies. The author focuses on clinical applications for patient care and 
excludes pharmacopoeias and regulatory monographs. His study demonstrates that most 
antique therapeutic indications remained stable over time and only a few were added, for 
example by Tabernaemontanus in the early modern period. Similarly, Anagnostou (2005) 
offers a longitudinal study on the therapeutic tradition of Passionflower in the history of 
medicine and pharmacy in America and Europe. While the consistency of indications across 
time and in separate continents suggests its therapeutic benefit, the author highlights that 
contemporary scientific methodology and the decoding of its active constituents now 
provide an additional scientific rationale to traditional uses. 
Verhoeven (2012) applies both a qualitative and quantitative method to his historical 
research on medicinal uses of Wood Betony (Stachys officinalis, Laminaceae). The author 
states that it was a dominant botanical drug from antiquity to the early modern period, rated 
by physicians for over 1800 years as an effective medicine; yet, its official importance in 
line with many other medicinal plants started to decrease by the early 19th century when the 
new natural science based medical paradigm emerged. It ultimately led Wood Betony to 




exclusively used as a traditional medicine or in homeopathy. Verhoeven’s study is 
particularly useful for regulatory purposes as it evaluates the historic indications with 
current pharmaceutical knowledge as recorded in Hagers Enzyklopädie der Drogen und 
Arzneistoffe (HagerROM, 2005). As a novelty in this line of research, he further 
incorporates into the comparison Dr. Duke's Phytochemical and Ethnobotanical Databases 
(Duke, n.d.), which list the transmission of indications documented in European healthcare 
after immigration of European physicians to the Americas. In the quantitative section of his 
study, Verhoeven statistically analyses the plausibility of the thirteen main historical 
pharmaceutical indications of Wood Betony as well as its use as an analgesic; all these 
indications can now be explained with current pharmacological knowledge (Verhoeven, 
2012, pp. 184-186). The study further concluded that the 16th century medical authors Pietro 
Andreae Matthioli and Tabernaemontanus have high level of convergence with indications 
listed in Hagers Enzyklopädie der Drogen und Arzneistoffe and Dr. Duke’s Phytochemical 
and Ethnobotanical Databases at 84% and 74% respectively (Verhoeven, 2012, pp. 187-
189). Verhoeven’s study illustrates that now-dismissed historical indications by regulatory 
monographs can be validated with the scientific methodology. 
Verhoeven’s results are echoed by other authors, such as Piwowarski, Granica, and Kiss 
(2015) whose systematic review of historical sources from antiquity to the 20th century 
confirm the benefits of Purple Loosestrife (Lythrum salicaria, Lythraceae) as an effective 
remedy for the  treatment of gastrointestinal tract ailments and complaints of the skin and 
mucous membranes. Phytochemical studies confirm high levels of polyphenols and 
heteropolysaccharides. The whole plant extract, as well as isolated compounds, has 
demonstrated antidiarrheal, antimicrobial, anti-oxidant, anti-inflammatory, and anti-diabetic 
properties. Piwowarski et al. claim that Purple Loosestrife was unjustifiably relegated to 
history by the introduction of synthetic corticosteroids and sulfasalazine drugs in the 1950s. 
Purple Loosestrife lacks the significant adverse effects that the long-term use of synthetic 
anti-inflammatory drugs cause when used for treating severe gastrointestinal diseases 
(Piwowarski et al., 2015, p. 247). Another series of essays on the therapeutic history of 
medicinal plants similarly confirms that now obsolete traditional uses of medicinal plants 
could be reconsidered in the light of scientific insights, such as for Gentian (Gentiana lutea, 
Gentianaceae) (Seitz, Lange, & Franz, 2005), Tormentilla (Potentilla erecta, Rosaceae) 
(Latté, 2006; Tomczyk & Latté, 2009), leaves of Red Vine (Vitis vinifera, Vitaceae ) 





Although all these studies comprise a substantial body of research into traditional plant 
indications, these explorations would benefit from a summary of which historical 
indications have been consistently transmitted, which have been discontinued and why if 
known, and which are underpinned by scientific trials and pharmacological studies. Such a 
critical appraisal of documented evidence on the effectiveness and safety of medicinal 
plants would enhance the usefulness of historical research for a bibliographic approval 
process as for example required by European regulations. In conclusion, the results from the 
aforementioned studies support the assessment that pre-modern medicine with its millennia-
old humoral paradigm provided an independent practical therapeutic framework that was 
coherent and logical in itself. Where traditional indications are investigated with modern 
scientific methodologies, they are usually validated. 
3.4 Statistical analysis of herbals  
Quantitative methods can further help verify if historical medical books provide reliable 
bibliographic sources of evidence for the registration of traditional plant medicine 
applications. The analyses into the medical textbooks of Hieronymus Brunschwig, 
Hildegard von Bingen and Leonhart Fuchs are exemplars of this type of analysis. 
3.4.1 Hieronymus Brunschwig 
The Liber de Arte Distillandi de Simplicibus (Small Book of Distillation) was written by the 
German surgeon Hieronymus Brunschwig (circa 1450 - 1512/13) and was first published in 
1500. It describes the distillation of drugs predominantly of plant origin and their 
therapeutic applications. It became one of the most popular medical and botanical textbooks 
of the 16th century and served as a technological reference encyclopaedia for professional 
distillers. Will’s (2009) study investigates humoral indications of the historical distillates 
with folk medicine and current official indications listed in Hagers Handbuch der Drogen 
und Arzneistoffe (HagerROM, 2005). The statistical analysis on accordance and divergence 
of traditional indications with contemporary medical use confirmed a 65% average of 
convergence to a 100% convergence in the case of bitters (Will, 2009, p. 47). In contrast to 
saponins where the lowest convergence was noted, bitter substances are particularly well 




3.4.2 Hildegard von Bingen and Leonhart Fuchs  
The study of Mayer-Nicolai (2009) investigates the medical textbooks of Hildegard von 
Bingen (1098–1179) and Leonhart Fuchs (1501–1566). Mayer-Nicolai compares the 
historical indications assigned to botanical drugs with their scientifically accepted 
contemporary use. A statistical analysis was developed to validate whether the recorded 
historical indications were randomly assigned or if there is an empirical basis for these 
indications. This study showed that both historical authors awarded indications with a 
higher accuracy than random distribution of indications. The statistical findings served as 
evidence that traditional indications were not assigned haphazardly but based on clinical 
knowledge. Mayer-Nicolai concluded that the probability of beneficial clinical effects of 
medicinal plants historically recorded in medical textbooks, but since relegated to history, is 
high (Mayer-Nicolai, 2009, p. 74).  
Apart from the statistical analyses employed by Will and Mayer-Nicolai, there are further 
examples of statistical approaches for quantifying convergence of traditional and modern 
knowledge (Leonti, Cabras, Castellanos, & Weckerle, 2012; Leonti, Cabras, Weckerle, 
Solinas, & Casu, 2010; Uehleke, Hopfenmueller, Stange, & Saller, 2012). Such statistical 
comparisons between traditional and modern approaches to phytotherapy showed that there 
is a high convergence between the main traditional indications and contemporary 
indications of a medicinal plant. Yet a difference is that modern official monographs tend to 
restrict applications to one or only a few indications for each medicinal plant whereas 
medieval and early modern medicine reflect more comprehensively the complex nature of 
plants that leads to their broad clinical uses (Uehleke et al., 2012, p. 189). This may explain 
why modern European phytotherapy, which is influenced by the biomedical approach to the 
human body, is narrower in its applications than is traditional plant medicine, which was 
practised in the context of humoralism and its holistic, personalised healthcare approach. 
The differences in traditional and contemporary medical approaches should be taken into 
consideration in a regulatory framework that genuinely aims to support the practice of 
traditional plant medicine. Otherwise, many traditional indications might be excluded from 
regulatory approvals despite their longevity and probability of effectiveness based on 
empirical evidence.  
3.5 Historical materia medica researched via ethnopharmacology  




the historical European materia medica received a boost with the attention paid by  
ethnopharmacology and ethnobotany to this written source of knowledge as exemplified by 
numerous research projects (Adams et al., 2010; De Vos, 2010; Heinrich, Edwards, 
Moerman, & Leonti, 2009; Heinrich, Kufer, & Leonti, 2005; Heinrich, Kufer, Leonti, & 
Pardo-de-Santayana, 2006; Helmstädter, 2016; Katiyar et al., 2012; Leonti, 2011; Leonti et 
al., 2010; Leonti, Casu, Sanna, & Bonsignore, 2009; Leonti et al., 2017; Leonti & 
Verpoorte, 2017; Moore, Hamza, Berke, & Umar, 2017; Piwowarski et al., 2015; Santic, 
Pravdic, Bevanda, & Galic, 2017; Staub, Casu, & Leonti, 2016; Valiakos, Marselos, 
Sakellaridis, Constantinidis, & Skaltsa, 2015; Waldstein, 2006, 2014). Ethnopharmacology 
has a good track record of uncovering verifiable botanical drugs from indigenous plant 
knowledge for public health interventions (Etkin, 1993, 1994; Etkin & Elisabetsky, 2005). 
It is important to note that indigenous plant medicines are not only used for health 
maintenance or the treatment of self-limiting ailments, but also for serious, life-threatening 
events such as venomous snake bites (de Moura et al., 2018). In Western healthcare 
systems, the current limitations imposed on traditional plant medicines to the treatment of 
minor, self-limiting ailments are due to regulatory restrictions which do not take into 
account the original scope of historical uses and the therapeutic potential of traditional plant 
medicines. 
There are many links amongst ethnopharmacy, ethnopharmacology, and phytotherapy, in 
particular the acknowledgment that empirical observations recorded in traditional systems 
of medicine are verifiable with contemporary scientific research (Etkin, 2001). 
Ethnopharmacology has begun to focus on ‘bioprospecting’ historical herbals for three 
reasons: generational loss of traditional medicinal plant knowledge; intellectual property 
issues related to botanical drugs developed and patented with the exploitative use of 
indigenous knowledge; and the desire to discover new drug leads (Buenz et al., 2006; 
Buenz, Johnson, Beekman, Motley, & Bauer, 2005; Buenz et al., 2004). This emerging 
discipline has been coined by French researchers as “archeo-pharmacology” (Staub, Geck, 
Weckerle, Casu, & Leonti, 2015), but as this term has not been taken up by other 
researchers, a widely accepted term remains to be determined for this method.  
The ethnopharmacological research to date confirms that medicinal information held in 
historical medical textbooks represents the ethnobotanical reports of that time (Touwaide, 




pragmatic and empirical approach to the botanical environment (Leonti et al., 2012; Leonti 
et al., 2010). Truly irrational uses of herbal medicines or individual opinions are filtered out 
in this method. To be considered, the herbal medicines need to have been well-established 
through generations of practice or they must have identical uses in two or more 
independent, geographically-separated cultures. Such recorded medicinal plant uses provide 
a high likelihood of universally reproducible therapeutic effects beyond placebo responses 
that might arise from expectations or from the therapeutic encounter itself (Fiore et al., 
2005; Li et al., 2003).  
The ethnopharmacological approach to historical medical texts has produced significant 
results. Perhaps the most reported example of successful ‘bioprospecting’ of herbals came 
with the award of the Nobel Prize in Physiology or Medicine in 2015 to Youyou Tu, who 
studied medicinal plants prescribed in TCM to treat fever and chills caused by malaria 
(Efferth et al., 2015). The breakthrough for the isolation of artemisinin came when the 
scientist followed the precise and reproducible ancient extraction technique noted in an over 
1700-year-old textbook authored by the ancient Chinese physician Ge Hong. Rather than 
the standard hot decoction process applied for the extraction of most other medicinal plants, 
the ancient text prescribed a low-temperature extraction of pressed juice from the plant 
Artemisia annua. This extraction led to the most active drug against malaria, an isolated 
sesquiterpene lactone containing an unusual peroxide bridge (Su & Miller, 2015). 
Antimicrobial assays by researchers at Nottingham University on a thousand-year-old 
recipe found in Bald’s Leechbook against eye infections also headlined worldwide when 
they proved to be effective against antibiotic resistant Gram-positive Staphylococcus 
aureus. The topical solution prepared with two species of Allium, Garlic, and Onion or 
Leek, together with wine, and oxgall bile from a cow’s stomach was most efficacious when 
prepared precisely according to its historical brewing instructions (Harrison et al., 2015). 
The discovery was made possible with the collaboration of an Anglo-Saxon scholar and a 
microbiologist, highlighting the importance of interdisciplinary collaboration in this 
emerging field of research.  Further, antimicrobial studies into medieval Anglo-Saxon and 
Welsh recipes for wound healing also confirmed antimicrobial activity against common 
wound pathogens (Wagner et al., 2017; Watkins, Pendry, Sanchez-Medina, & Corcoran, 
2012). Over two decades earlier, a recipe from an 8th century monastic medical textbook 
(Lorscher Arzneibuch) was attested, at least theoretically via a simulated reproduction of the 




An ethnopharmacological examination of a 13th century recipe book spotlights the historical 
pharmacological knowledge of plant synergy; for example, when Saffron and Poppy are 
combined, they have been scientifically proven to enhance the analgesic effects of opium 
alkaloids (Tamaddonfard & Hamzeh-Gooshchi, 2010; Valiakos et al., 2015). This 
combination is recorded in the early modern period by Tabernaemontanus in his monograph 
on Poppy (Tabernaemontanus, 1664, pp. 961A-965K). Furthermore, historical Greco-
Roman pharmacology was well aware of the dangers of using strongly and immediately 
acting drugs such as Papaver somniferum, such as addiction and death, and the benefits in 
analgesic and anaesthetic effect (Scarborough, 1995; Valiakos et al., 2015, p. 80). 
Therapeutic effects were demonstrated by the recreation of a popular medieval opiate drug 
called the ‘Great Rest’, recorded in the 12th century Italian medical recipe book 
Antidotarum Nicolai that was influential well into the early modern period. An 
interdisciplinary research team at the University of Toronto calculated the effective (ED50), 
toxic (TD50), and lethal (LD50) dose rates for the ingestion of raw opium from Poppy in 
combination with Henbane and Mandrake. Notwithstanding some judicious assumptions in 
the simulation of the recipe, the researchers established that the optimum dose of the Great 
Rest would have proved beneficial for most patients while the lethal dose was double the 
efficacious dose, providing a substantial safety margin. A modern pharmacological review 
on the synergistic combination of morphine, hyoscyamine, and scopolamine confirmed that 
tropane alkaloids which are present in Henbane with morphine which is present in Poppy 
are beneficial in combination because they increase sedative effects, deter the user from 
self-administration of multiple doses in a short period of time, and diminish opiate addiction 
(Everett & Gabra, 2014, p. 448; Kentala, Scheinin, Kaila, Seppälä, & Kanto, 1998). 
Although the plausibility of effectiveness and safety of historical recipes must be vetted on 
a case-by-case basis, their dosage and instructions evidently demonstrate clinical 
judgement. Where they have been tested the results to date indicate that traditional 
directions for use stand up well against contemporary knowledge.  
Ethnopharmacological approaches to historical herbals have also been applied to the 
investigation of historically prescribed medicinal plants for specific illnesses. A research 
team at the Institute of Pharmaceutical Biology of the University of Basel investigated five 
of the most important European herbals of the 16th and 17th century, including 
Tabernaemontanus’s New vollkommen Kräuter-Buch, for phytochemical activity in relation 




Adams et al., 2009; Adams et al., 2007; Adams, Gschwind, et al., 2011; Adams et al., 
2012). Their research demonstrates that Renaissance botanical medicines containing Great 
Water Plantain (Alisma plantago-aquatica L., Alismataceae) show anti-malarial activity 
against Plasmodium falciparum K1 strain with 77% growth inhibition (Adams, Gschwind, 
et al., 2011). Likewise, over 60% of medicinal plants traditionally recommended for the 
treatment of rheumatic disorders show activity in relevant assays and some are still used 
today for the same indications (Adams et al., 2009, p. 356). These results support the 
authors’ assessment that Renaissance-inspired herbals from the early modern period are a 
promising source of medical knowledge for the rediscovery of effective plant medicines.  
Similarly, Iranian researchers have been examining the main pharmaceutical manuscripts of 
Traditional Persian Medicine (TPM), comparing their historical medicines with evidence-
based clinical aspects and phytochemistry. Because antique Greek medicine is the historical 
root of both Arabic and European medicine, TPM shares many common therapeutics also 
recorded in the traditional European medical literature. Examples of ethnopharmacological 
research into historical medical textbooks relate to cardio-vascular diseases (Siddiqui & 
Aziz, 1963; Zarshenas, Jamshidi, & Zargaran, 2016), metastatic breast cancer (Zarshenas & 
Mohammadi-Bardbori, 2017), abnormal uterine bleeding (Mobli et al., 2015), and plant-
based diuretics (Shoja et al., 2015). Although not all medicinal plants or their indications 
have survived the arrival of biomedicine, none of these cross-validated studies suggest that 
the pharmacological treatment strategies described in the examined historical medical 
literature were random or irrational. 
As most of the medicinal plants listed in historical medical textbooks have not yet been 
clinically tested against disease-relevant targets or receptors, they could provide potentially 
useful botanical leads for drug discovery (Adams et al., 2012, p. 11). The authors rightfully 
caution, however, not to restrict research into traditional plant indications to biomedical 
principles of known or assumed molecular pathways involved in modern aetiology, thus to 
avoid the ‘magic bullet’ approach. Instead it is the hallmark of traditional medical systems 
that they approach health in a holistic way and emphasise health maintenance, disease 
prevention, and personalised curative treatments; applications of plant remedies play an 
important role in all three of these healthcare areas (Adams et al., 2007, p. 378). Therefore, 
an ethnopharmacological approach to the investigation of historical herbals will need to be 




as exemplified in the research by Teiten, Gaascht, Dicato, and Diederich (2013). 
Conversely, when the traditional medical paradigm that generated the empirical body of 
knowledge in the first place is considered in the research design, the likelihood of creating a 
meaningful body of evidence to support traditional applications of medicinal plants is not 
only enhanced but also safer (Etkin, 1993). Such an approach to the historical materia 
medica might provide outcomes that integrate cultural aspects and patient preferences 
alongside bioscientific knowledge so that sustainable, respectful and effective primary 
healthcare options can be achieved (Evans, 2006; Yaniv & Bachrach, 2005, pp. 459-462). 
Otherwise, ‘bioprospecting’ of herbals for the sole purpose of discovering patentable single-
entity drugs does not make use of the full potential of traditional medicines nor provide 
necessary information to advance a regulatory pathway model for them. Dal Cero (2016) 
demonstrates how a meaningful body of evidence can be created to support traditional 
applications of medicinal plants through her systematic analysis of the knowledge 
transmission of the Swiss medicinal flora over the last two millennia.  
3.6 Historical materia medica informing modern phytotherapy  
An emerging branch of research explores clinical applications recorded in historical 
textbooks for clinical uses by modern phytotherapists. For example, Tobyn et al. (2011) 
elucidate the depth of pharmacological knowledge contained in medical scripts from 
antiquity onwards and assess it against the background of applied modern phytotherapy and 
scientific research. Their critical exploration of the Western herbal tradition across 
millennia is aimed at inspiring the current generation of herbal experts in prescribing plant-
based medicines. In an earlier work on the British physician Culpepper (1616-1654), Tobyn 
(1997, 2013) explores historical concepts of humoral medical diagnosis for today’s holistic 
healthcare, emphasising the ongoing therapeutic relevance of such concepts. Francia and 
Stobart (2014) deliver a critical approach to the history of Western Herbal Medicine from 
classical antiquity to the early modern period. They contribute practical insights and 
linguistic tools to support historical research into pharmacological data contained in 
historical medical textbooks. Mayer, Uehleke, and Saum (2002) in turn appraise monastic 
and early Renaissance medicine alongside current phytotherapy and scientifically 
researched applications. This text is written for the lay person interested in the use of 
medicinal plants for self-care. Investigations into Anglo-Saxon (Thomas, 2011; Watkins et 




historical research for contemporary phytotherapy. The historical body of non-German 
medical literature pertaining to Great Britain or other systems of traditional medicine is, 
however, not the topic of this thesis and therefore will not be explored further.  
3.7 Research of the historical materia medica for regulatory purposes 
The literature reviewed above suggests that historical research into traditional plant 
applications can support modern scientific methodologies and inform an evidence-based 
approach to healthcare. The current regulatory framework in the EU permits bibliographic 
evidence of traditional plant applications. Such historical evidence must be prepared 
explicitly to fulfil regulatory criteria that govern the registration of Traditional Herbal 
Medicinal Products; in particular, it must document consistent transmission of medicinal 
plant applications. To date, systematic research of historical textbooks prepared as 
bibliographic evidence for regulatory purposes remains minimal, as most historical or 
ethnopharmacological studies have not focused on this outcome. However, a discussion has 
been initiated on a pathway forward that would provide such outcomes (Anton, Serafini, & 
Delmulle, 2012a, 2012b; Benedum et al., 2000; Helmstädter & Staiger, 2012, 2014; 
Kazemekaitis, 2010; Müller, 2001; Neely et al., 2011; Saad & Said, 2011; Schanz, 2009; 
Tims, 2016). This area of research is vital to ensure that verified traditional plant indications 
continue to be available under today’s regulations. The next chapter describes how such 
traditional evidence might be generated in the era of contemporary evidence-based health 




4 MATERIALS AND METHODS 
4.1 The research questions 
Historical medical textbooks have not been methodically scrutinised and evaluated for 
regulatory purposes, despite their significance as medical documents of literate European 
societies. This chapter will outline a method for exploring the systematisation of medical 
knowledge on the effectiveness and safety of traditional European plant medicines, 
knowledge that was transmitted professionally through key historical sources. The study 
seeks to determine if such historical documentary evidence consistently and accurately 
describes medicinal plants, their uses, and their therapeutic effects such that it could be 
admitted to substantiate therapeutic claims. Hence the question of interest is: does 
systematic bibliographic evidence of traditional medical use provide a pathway for 
registration of traditional medicines for countries that are yet to regulate traditional plant 
medicines? And, if so, what method and selection criteria would need to be applied to the 
selection of historical and contemporary sources so as to have representative sources of 
evidence on traditional plant medicines and their indications of use, including health 
claims?  
Such an analysis is pertinent. The WHO states that traditional preparations which have been 
clinically administered in patient care over a long period of time have empirically evolved 
to maximise their therapeutic effectiveness and minimise risk (World Health Organization, 
2012, p. 17). By implication, their toxicity, formulation and dosage are seen to be 
established. The premise of this thesis is that medical information that was consistently 
recorded by independent official or authoritative sources and employed to guide regular 
medical practice and education, represents legitimate information. The European materia 
medica as recorded in medical textbooks represents the accumulated, inter-generational 
knowledge of benefits and risks of medicinal plants used for healing. This repository of 
knowledge is the basis of current phytotherapeutic teachings, clinical use in patient care, 
and OTC remedies. Long-standing traditional medicines have been carefully evaluated and 
re-evaluated by many generations of professionally trained clinicians. This thesis proceeds 
under the assumption that such knowledge is not the anecdotal accounts of a few 
practitioners but represents a cumulative body of clinical data and expert consensus 




A consultation document relating to the former New Zealand Natural Health and 
Supplementary Products Bill suggested that health claims for natural health products 
(NHPs) could be made based on evidence of traditional use (Ministry of Health, 2015, p. 9). 
This Bill proposed to establish several sources of traditional evidence: repositories on 
traditional plant knowledge such as the Encyclopaedia of New Zealand, pharmacopoeias, 
monographs, treatises and other undefined medical texts. For oral traditions it was 
anticipated that testimony of individuals within a specific culture who have the authority to 
speak on such matters would be recognised (Ministry of Health, 2015, p. 10). There was a 
proposed list of 11 pre-approved bibliographic sources that could be used as evidence for 
health claims. The pre-approved list did not, however, include any textbooks on the 
traditional materia medica used in traditional systems of medicine practiced in New 
Zealand, yet these are the most important repository of traditional knowledge for 
contemporary clinical use.  
Medical text sources on the traditional materia medica are also underrepresented as sources 
of bibliographic evidence in other jurisdictions. In 2004, the EU Traditional Herbal 
Medicine Products Directive (THMPD) recognised traditional evidence to substantiate 
traditional claims for the registration of traditional herbal preparations (Europäisches 
Parlament, 2004). To qualify for this alternative proof of effectiveness, data from credible 
sources had to confirm a consistent line of transmission of medical uses (Müller, 2001, p. 
256). In theory a systematic evaluation of historical textbooks could therefore provide 
bibliographic tradition-of-use (TOU) data for regulatory purposes. Such evaluation could 
provide critically evaluated information on botanical species identification, therapeutically 
active parts, specific preparations, and therapeutic applications (Müller, 2001, p. 254). 
Systematic collection of empirical observations on safety from long-standing traditional use 
of a plant part or a plant preparation may also contribute to safety data relating to long-term 
use in a large population (Anton et al., 2012a). Nonetheless, such TOU data has not been 
systematically appraised for the establishment of the official EU monographs (Jütte et al., 
2017), and possible reasons for this are investigated as part of this thesis. 
4.2 Challenges of research into historical medical texts  
Until recently academia has given little focus to systematic appraisal of historical evidence 
on the effectiveness and safety of traditional plant medicines for regulatory purposes, as 




require an interdisciplinary approach because there are substantial conceptual, linguistic, 
and taxonomical challenges to overcome, making explorations into such sources complex. 
Furthermore, many of the older historical herbal textbooks are rare and hard to access, 
being preserved in libraries, museums, archives, and monasteries in wide-ranging locations, 
often with limited or no public access. There are now efforts in place to digitise such texts, 
as with the digitisation of the pharmaceutical-historical library of Dr. Vester at the 
Universitäts- und Landesbibliothek Düsseldorf, Germany, but much remains to be done to 
make them more readily accessible.  
In addition, since the privileging of a natural science approach to patient care from the late 
19th century onwards—an approach secured by socio-economic and political-legal 
dynamics—, traditional medicine has become increasingly marginalised (Borck, 2016; 
Coulter, 2007; Stolberg, 1998). Consequently, the usefulness of traditional therapeutics has 
often been questioned in academic circles or met with outright opposition and denigration, 
despite their longevity (Bruchhausen & Schott, 2008, p. 11; Coulter, 2004; Riddle, 1985, 
pp. xx-xxii). From the viewpoint of orthodox science, therapeutic claims for traditional 
medicines have no validity, and any healing effect that patients may have experienced from 
traditional medicines are seen as the result of a psychological ‘placebo effect’ or 
superstition (Holloway, 2000; Parker, 2007; Shapiro, 1959; Sneader, 2005). Cassidy, 
however, claims that such divergent views on the effectiveness of traditional medicine and 
its empirical knowledge base, which in literate societies was extensively codified in text, 
have more to do with paradigmatic preferences that they have to do with rules of science 
(Cassidy, 1995, p. 19). Existing research on European medical textbooks points to the 
likelihood that historically used taxa of medicinal plants exert a pharmacological activity 
beyond a placebo response (Leonti, 2011, p. 552; Moerman & Jonas, 2002). Therefore, this 
thesis aims to establish whether historical medical sources can provide sufficiently reliable 
pharmacological information that could be drawn on for regulatory purposes. It does so by 
comparing the transmission of pharmacological data over several hundred years and 
compares these data, where available, with evidence of efficacy from RCTs and data from 
experiential research. Historical data are further juxtaposed with approved health claims in 
contemporary official monographs as well as authoritative monographs by current experts 




4.3 Research design 
In formal European healthcare, there are five key bibliographic sources that document the 
medicinal uses of plants. These key sources are historical medical textbooks and their 
contemporary equivalents, regulatory pharmacopoeias, their commentaries, and official and 
authoritative herbal monographs: 
 Historical medical textbooks on the botanical materia medica represent the body of 
knowledge on remedial substances as used and recommended by clinicians. 
Historically, medical textbooks were written by university-educated physicians and 
apothecaries. These clinicians possessed the formal professional education, 
expertise, and resources required for such an undertaking. Authoritative historical 
medical textbooks reflect formal medical care and represent the standard scientific 
knowledge of their times (Anton et al., 2012b). They progressed in the 20th century 
into normative textbooks on phytotherapy.  
 Pharmacopoeias provide guidelines on essential medicines used in regular 
healthcare. Their drug specifications became legally binding in many European 
countries from the late 18th century onwards although official municipal 
pharmacopoeias already existed in the 16th and 17th century (Schmitz et al., 2005, 
pp. 195-196, 573-582; Vogelenzang, 1967, p. 348). Only the broad acceptance of a 
medicinal substance by a pharmacopoeia committee leads to its listing, a principle 
that is upheld today (Schanz, 2009, p. 44). Pharmacopoeias are important 
bibliographic sources for regulatory purposes because they confirm official use and 
provide conclusive botanical identification for a medicinal plant species and its 
official plant part(s). Over many centuries, pharmacopoeias also served as 
guidelines on therapeutic applications in patient care. In contrast to such earlier 
pharmacopoeias, those from the end of the 18th century onwards omit therapeutic 
information on clinical uses. Thus, pharmacopoeias transformed into official 
guidelines for medicine making only, focusing solely on the mandatory rules of 
quality control, drug identification, storage, and nomenclature of the medicines. 
Subsequently, commentaries took up the role of providing advice on clinical 
applications, and this body of bibliographic evidence will be included in this 
analysis. 
 Herbal monographs systematically document therapeutic information on a plant 




documents or as a series of monographs on several medicinal plants. Monographs 
can be official if released by a government, or non-official but authoritative and 
normative if released by experts. Monographs fulfil the role of official or 
authoritative therapeutic guidelines.  
For this study, selected texts from these distinct categories are systematically investigated as 
potential sources of historical documentary evidence concerning empirically evaluated 
traditional plant medicines and their indications of use.  
4.4 Research methods  
To be considered admissible in the registration of a traditional herbal product, the 
assessment of historical data and evidence requires a critique. The research methods of this 
thesis are grounded in a historical research design (Saucier Lundy, 2008, p. 396). The study 
employs a longitudinal, comparative analysis of selected texts from the early modern 
period, defined as from the end of the 15th century (Richter, 1998, p. 302) to the 21st 
century. Arnica montana (Arnica) and Hypericum perforatum (St. John’s Wort) are used as 
exemplars to identify the consistency of therapeutic information recorded in historical 
medical textbooks. In a first step, their tradition-of-use data will be extracted from selected 
medical textbooks according to criteria outlined below, and systematically recorded in 
tables using a pre-established therapeutic use-categories concept for coding as also 
explained below. In the juxtaposition of 400 years of clinical use, consistencies and 
differences can easily be recognised. This thesis terms this method as the “Historical 
Assessment Tool”. It will assist in the systematic collation and organisation of data on 
treatments that were deemed as effective in patient care over time. In addition, this tool will 
provide a framework for the collation of safety observations recorded in the literature. 
Observations of safety or adverse events documented from long-standing use in patient care 
might provide useful safety data. 
4.4.1 Process Map of the Historical Assessment Tool 
Following is the process map used for the systematic collation and analysis of raw data 
retrieved from historical sources. Particulars of the Historical Assessment Tool will be 
explained in further detail in subsequent sections. 




2) Establish therapeutic use-categories for the coding of therapeutic information;  
3) Translate therapeutic indications of a plant exemplar from German to English; 
For pre-modern texts: translate early modern German terminology into modern 
German before translating into English2; 
4) Code: attribute each therapeutic indication of a plant exemplar from a selected 
medical textbook to a therapeutic use-category and record in a table as well as a 
designated Historic Data Excel spreadsheet (for independent validation); repeat for 
each selected medical textbook; and 
5) Analyse the consistency of medical endorsement of indications over the analysed       
period, their reputed effectiveness, and assessments on safety. 
Use of multiple sources of data collection or multiple methods of analysis have been 
recommended in various disciplines. Such an approach provides different angles for looking 
at the same phenomenon and adds credibility by strengthening confidence in conclusions 
drawn (Patton, 2014, p. 661). This method has been termed triangulation (Jick, 1979). The 
most robust approach is to integrate both qualitative and quantitative methods in mixed-
method triangulation (Patton, 2014, p. 663). This thesis will first triangulate text sources 
from five key categories; medical textbooks, regulatory pharmacopoeias, their 
commentaries, regulatory monographs, and authoritative monographs. It will investigate 
consistencies and differences in various data sources at different time points within the 
same qualitative method. It will then analyse the data retrieved from this qualitative method 
with data from clinical and experimental research. Scientific trials of Arnica and St. John’s 
Wort are retrieved via a systematic database research in Medline, Embase, AMED, 
Cochrane Library, Web of Science and Cinhal (to June 2014). Search strategies are 
recorded in Appendix 1. Evaluation of experimental research will help to explain possible 
mechanisms underpinning traditional therapeutic uses. Comparing qualitative and 
quantitative data elucidates complementary aspects of the same phenomenon (Patton, 2014, 
p. 663). Triangulation of data will assist the objective of this research to establish whether 
judiciously selected historical sources on the European material medica provide a pathway 
to substantiate therapeutic claims for traditional plant indications. The main purpose of the 
 
2 The author is fluent in modern German and English and commands university entrance level of Latin. For 
the translation of text from early modern German to German, Dr. Heike Will, pharmacist and expert of the 
early modern period, University of Würzburg, provided linguistic expertise. The translations were further 





triangulation is therefore to determine the extent to which traditional indications and safety 
aspects are documented in historical medical textbooks compared with contemporaneous 
regulatory pharmacopoeias, their commentaries, and herbal monographs. 
4.4.2 Libraries, archives and collections accessed  
Thousands of medical textbooks and pharmacopoeias await scientific exploration. First this 
study considered key historical sources that were reviewed by Verhoeven (2012), Mersi 
(2011), Schanz (2009), Freyer (1998), and Richter (1998). It then reviewed medical 
textbooks from the Universitäts- und Landesbibliothek Düsseldorf (University and State 
Library of Düsseldorf, Germany); the Julius-Maximilians Universität Würzburg (University 
of Würzburg); the Germanisches Nationalmuseum (German National Museum, Nürnberg, 
Germany); the museum of the township Bad Bergzabern, birthplace of Tabernaemontanus, 
Germany); the Deutsches Apotheken-Museum (German Museum of Pharmacy, Heidelberg, 
Germany); the Medizinhistorisches Institut Universität Bern (Institute of Medical History, 
University of Bern, Switzerland); the Swiss National Library; Swissmedic, Berne, 
Switzerland; the private library of Reinhard Saller, emeritus Professor and Director of the 
Institute of Complementary Medicine, University Hospital Zürich; and the private library of 
the author. Electronic copies of several historical textbooks were accessed via the History of 
Medicine division of the U.S. National Library of Medicine, via the Biodiversity Heritage 
Library, via Internet Archive, and via Google books. After key texts were preliminarily 
screened, a selection of the most salient texts was collated as displayed in Appendix 2. Of 
those texts a final selection was taken based on the criteria below. 
4.4.3 Selection criteria of medical textbooks 
Both historical and contemporary primary sources were selected according to the following 
three criteria:  
1. Authors needed to be university-educated and qualified practitioners in the 
professional use of plant medicines with long-standing clinical experience treating 
patients. Experienced mainstream practitioners were selected because their written 
works reflect contemporaneous, medical practice at the time of publication of their 
textbook. As such they likely represent observed treatment outcomes as evaluated 
by formally educated clinicians made over the course of their professional careers. 




than data in textbooks copied down without the benefit of clinical evaluation from 
patient care. This selection criterion further aims at minimising idiosyncrasies. A 
body of medical literature authored by formally trained physicians may also be 
better accepted in the current regulatory environment than textbooks written by non-
academic phytotherapists or texts categorised as advice literature for lay people or 
folk medicine, even though these may display the same clinical data and may be 
equally valid if they represent a clinically evaluated source. 
2. The selected textbooks needed to reflect authoritative medical reference books. For 
the purpose of this thesis, an ‘authoritative’ book means one being used in 
conventional academic teaching, having been printed in multiple editions, or being 
referenced regularly as an authoritative source in subsequent medical textbooks. 
Such professional peer recognition suggests currency of the information presented. 
3. A selected textbook needed to represent an authoritative source for a selected 25-
year period, resulting in approximately four medical textbooks per century. This 
criterion helps to ensure that there are data for each successive generation of 
formally trained clinicians.  
The starting point of this study is the 4th edition of New vollkommen Kräuter-Buch authored 
by the German physician, apothecary and botanist Tabernaemontanus (1664), originally 
published in 1588. It is the medical textbook recognised as the most comprehensive German 
language repository of clinical plant knowledge in early modern Europe (Bofinger, 2004). 
As it is written in early modern German, the succeeding selected texts are also in German 
language so that the comparative contextual analysis reflects transmission of medical 
knowledge in the same cultural area. Consequently, the contemporaneous medical literature 
published in English is not considered (apart from cross-checking of some information). 
4.4.4 Selection of pharmacopoeias 
This thesis selected two pharmacopoeias from the same cultural area and periods as the 
selected medical literature, namely the German pharmacopoeia and its predecessor, the 
Prussian pharmacopoeia, which was the legal and structural foundation of the German 
pharmacopoeia. The examination includes the supplements to this official body of literature 
as well as commentaries which provide normative guidelines on therapeutic uses. This 
inclusion is necessary because from the end of the 18th century onwards, pharmacopoeias 




4.4.5 Selection of official monographs  
Official monographs published by a regulatory authority provide official guidelines on a 
medicinal plant’s formally accepted indications, information on dosage, and preparations. 
When a preparation fulfils the criteria laid out in an official monograph, it is granted market 
access in the associated territory. 
Two official sets of monographs were selected for this study. One set was published by the 
German Ministry of Health during the 1980s and 1990s (Commission E Monographs) and 
one was published by the European Medicine Agency (EU Herbal Monographs) based on 
the EU Directive 2001/83/E. The latter represent the most recent regulatory monographs 
published in Europe. The two selected sets of regulatory monographs serve as a benchmark 
to contrast officially endorsed health claims with clinical uses contemporaneously published 
in the selected medical textbooks. 
4.4.6 Selection of authoritative expert monographs  
Professional bodies and international organisations also publish herbal monographs. They 
are not official, but they may be referenced in some jurisdictions as authoritative 
bibliographical sources when applying for regulatory approval of a herbal product.  
This thesis chose three collections of monographs for analysis: the monographs published 
by the European Scientific Cooperation on Phytotherapy (ESCOP), the professional body 
that represents national herbal medicine organisations across Europe (edition 2013); the 
German pharmaceutical reference work HagerROM. Hagers Enzyklopädie der Arzneistoffe 
und Drogen (edition 2012); and the collection of herbal monographs of the WHO. The first 
two are authoritative expert monographs in Europe, and the third is a collection of 
monographs that the WHO offers to the international community as an authoritative source 
of scientific and traditional information on medicinal plants.  
4.5 Organisation and processing of data  
The analysis of historical texts poses several methodological challenges relating to the 
conceptualisation and management of a large volume of data, to linguistic barriers, to the 
modern interpretation of historical nosologies, and to the identification of pre-Linnean plant 
taxonomy. These challenges are encountered predominantly in texts published before the 




applications can be coded for analysis. Thus, the primary data recorded in the 4th edition of 
Tabernaemontanus (1664) are first translated into contemporary language before being 
tabulated. The data from all other text sources are transferred directly into their respective 
data tables as well as the Historic Data Excel spreadsheet. 
4.5.1 Translation of pre-modern texts 
Translating pre-modern textbooks into modern terminology with exactitude is problematic 
because pre-modern concepts of health and illness differ from contemporary biomedical 
views (Stolberg, 2011). Translations may therefore contain interpretative elements. As 
widely discussed in medical anthropology, explanatory models of health and illness 
constitute a set of beliefs related to aetiology, symptoms, pathophysiology, course of 
sickness, and treatment strategies. They are cultural models of reality that are also 
influenced by political-legal and socio-economic factors which may transform over time 
(Hahn & Gaines, 2012; Kleinman, 1978, 1980; Oubré, 1995, p. 45; Whyte et al., 2002). 
Until the 19th century, the scientific framework of European medicine was principally the 
natural philosophy (Naturphilosophie) of Hippocratic medicine with its key feature of 
humoralism, also termed humoral pathology or humoral theory. This medical concept stated 
that the human body can self-regulate, heal and restore (vis medicatrix naturae), and thus 
approached healthcare not only with medicines but also with guidelines on healthy living. 
Ill health was understood as a failure to adapt to the internal or external environment. Even 
though certain aspects of humoralism started to be questioned by findings from dissections 
in gross anatomy in the early modern era, it was not until the middle of the 19th century 
when natural sciences such as chemistry, physics, and biology seriously challenged the 
humoral explanatory model of illness (Bruchhausen & Schott, 2008, pp. 11-15). The 
vitalistic Hippocratic medicine principles that underpinned European medicine over the past 
millennia were eventually replaced by cellular pathology as the paradigmatic foundation of 
Western biomedicine. The new medical paradigm primarily focused on cells, body tissues, 
external germs, receptors, and man-made synthetic drugs. Biomedicine became the 
dominant form of mainstream medicine in Europe. Despite this reorientation, plant 
medicines, the focus of this thesis, continued to exist alongside their synthetic analogues.  
The shift in medical theories from humoralism to biomedicine causes some difficulties 




and nosologies. Leven (1998) and Karenberg (2009) have drawn attention to the 
complexities of identifying diseases in pre-modern texts. Such challenges arise because, as 
already mentioned, medical descriptions for illnesses are not ahistorical, independent 
elements; rather, they are an expression of a given culture at a given time and therefore will 
change as culture and its expressions evolve (Rothschuh, 1978). Despite these difficulties, 
the translation of herbal monographs from the early modern period onwards is aided by the 
fact that medical textbooks during pre-modern times are focused less on categorising 
specific diseases and more on the treatment of signs and symptoms based on observed 
pharmacological actions of plants. Moreover, during the early modern period, some 
physicians started to depart from Galen’s classification of medicinal plants, which since 
antiquity guided the choice of drugs according to their attributed primary humoral qualities 
of warming, cooling, drying, and moistening (Goehl, 1984). Instead, in the spirit of 
humanism, physicians complemented and sometimes corrected the information in antique 
Greek and medieval Arabic herbals with their own clinical observations (Klerk, 2014). Such 
empirical observations on therapeutic effects of drugs formed the practical basis of 
physicians, particularly since the Renaissance, to describe the remedial actions of medicinal 
plants on human physiology. In their pragmatic approach, they used organoleptic 
information, colour, smell, taste, and sensation (termed ‘secondary plant qualities’) as well 
observed pharmacological actions such as pain relieving, wound healing, or laxative effects 
(termed ‘tertiary plant qualities’) to inform their treatment approach (Crellin & Philpott, 
1990; Stille, 2004, pp. 19-20; Van Asseldonk, 2007, October). Whereas the concept of 
primary humoral qualities is intrinsically linked with medical theory, documented empirical 
observations can be more easily attributed for this research project. It is interesting to note 
that organoleptic observations continue to inform therapeutic uses of medicinal plants in 
indigenous communities where archetypical chemosensory cues have shown to correlate 
with nosological units (Geck, Cabras, Casu, Reyes Garcia, & Leonti, 2017). Recently, an 
analysis of historically attributed humoral qualities to medicinal plants has suggested that 
such attribution may be less foreign than thought and may have a pharmacological basis. 
Plants that have been historically classified as cold and wet have relatively high levels of 
water or mucilage with an emollient effect. Cold and dry plants have astringent compounds 
like tannins and parasympatholytic alkaloids. Hot and wet plants commonly have 
compounds like fatty oils, sugar, and starch. Hot and dry plants contain aromatic 
compounds like essential oils or glycosylates, sometimes combined with tannins (Van 




mucilage are archetypal phytochemicals; their humoral classifications are also found in 
diverse medical traditions (Bao, Li, Zheng, & Li, 2015; Chen, 1995; de la Cruz, Malpartida, 
Santiago, Jullian, & Bourdy, 2014; Messer, 1987; Rezadoost et al., 2016). 
4.5.2 Translation resources 
As detailed in the Process Map of the Historical Assessment Tool, the translation of 
indications from early modern German to contemporary German and subsequently to 
English requires a three-step process. After the botanical exemplars are correctly identified, 
the text passages will be first electronically transcribed from the original source and then 
translated into contemporary German. The resulting approximation will be subsequently 
translated into English before the pharmaceutical and pharmacological data will be 
tabulated.  
The following etymological and medical reference resources were used to overcome 
linguistic barriers encountered in the translation of the 17th century source: 
 Ein Neuwes Arzney Buch by German physician and anatomist Christoph Wirsung 
(1500-1571) is one of the most detailed early modern texts on human pathology in 
German language. The attached ‘dictionary on incomprehensible words’ 
(dictionario der unverständlichen Wörter) is particularly useful. The text was first 
published in 1568 and used by the medical profession as an authoritative medical 
encyclopaedia. It was later translated into English (Wirsung & Mosan, 1654). 
Tabernaemontanus revised and edited the edition published in 1577 (Wirsung & 
Tabernaemontanus, 1577). This pathology textbook is a fitting compendium to 
Tabernaemontanus’ New vollkommen Kräuter-Buch (Tabernaemontanus, 1664) for 
elucidating medical terminology. 
 Höfler (1899), Metzke and Heydemann-Metzke (1995), Genaust (1996), 
Mildenberger (1997), Kluge (2002), and Haubrich (2003) provide extensive 
etymological references for the translation of early modern medical terms. 
 Francia and Stobart (2014) and Goehl (1984) offer translation aids on humoral 
concepts of pathologies. 
 Ten glossaries further facilitated translation: 





o Novum Glossarium Latino-Germanicum Mediae et Infimae Aetatis (Dfng) 
(Diefenbach, 1867) 
o Deutsches Wörterbuch von Jacob und Wilhelm Grimm (DWB) (DWB, 1854-
1960) 
o Enzyklopädie Medizingeschichte (EnzMedGesch) (Gerabek, Haage, Keil, & 
Wegner, 2005) 
o Frühneuhochdeutsches Wörterbuch (FrnhdWb) (Goebel & Reichmann, 
1989-2013) 
o Handwörterbuch des Deutschen Aberglaubens (HWdAgl) (Hoffmann-
Krayer & Bächtold-Stäubli, 1927-1942) 
o Lexikon des Mittelalters (LexMA) (Keil, 1980-1998)  
o Mittelhochdeutsches Handwörterbuch (LEXER) (Lexer, 1872-1878) 
o Reallexikon der Germanischen Altertumskunde (RGA) (Reallexikon der 
Germanischen Altertumskunde, 1973-2008) 
o Die Deutsche Literatur des Mittelalters: Verfasserlexikon (VL) (Keil, Ruh, 
Schröder, Wachinger, & Worstbrock, 1978-2008). 
4.5.3 Selection of exemplars 
In an initial step, 13 medicinal plants were selected from the 4th edition of 
Tabernaemontanus (1664) and translated into modern German. This selection helped to 
gauge both the level of therapeutic information on medicinal plants presented in this early 
modern period text as well as the appropriateness of the early modern period as a starting 
point for this longitudinal, comparative textual analysis. The 13 medicinal plants were 
chosen from the viewpoint of contemporary use where they provide key therapeutics in the 
treatment of 12 body systems (as listed at the end of this subsection). 
The vetting of these preliminary 13 plant monographs pointed to consistencies between 
therapeutic uses of medicinal plants in the early modern period and contemporary 
phytotherapy in the main areas of use, but also to some differences where early modern 
applications tended to be broader than those of contemporary phytotherapy for most but not 
all exemplars. The early modern period was confirmed as a fruitful starting point for this 
research based on the comprehensive clinical information presented in the selected text. 
Accordingly, Arnica and St. John’s Wort were selected as the two exemplars for the final 




remedies in New Zealand (Nicholson, 2006, p. 5), a popularity which is mirrored in Europe 
(Dal Cero, 2016, p. 22). They therefore hold contemporary relevance. St. John’s Wort 
reflects a rich medical tradition that spans millennia. Today it is also one of the most 
scientifically researched medicinal plants. Arnica is a ubiquitous medicinal plant in 
European healthcare for the treatment of musculo-skeletal injuries and ailments. It had a 
wider range of applications in the past than today, and so provides a useful case study. 
12 body systems Medicinal plant Tabernaemontanus  
4th edition 1664 
bones Symphytum officinalis (Comfrey) pp. 949-951  2nd volume 
digestion Achillea millefolium (Yarrow) pp. 371-379  1st  volume 
gynaecology Alchemilla vulgaris (Lady’s mantle) pp. 248-251  1st  volume 
cardio-vascular system Crataegus spp. (Hawthorn) pp. 1448-1449 3rd  volume 
kidneys Solidago virgaurea (Goldenrod) pp. 1259-1260 2nd volume 
liver / gallbladder Silybum marianum (St. Mary’s Thistle) pp. 1078-1079 2nd volume 
lungs Thymus vulgaris (Thyme) pp. 741-744  2nd volume 
muscles Arnica montana (Arnica) pp. 714-715  2nd volume 
nerves (restoration) Hypericum perforatum (St. John’s Wort) pp. 1249-1252 2nd volume 
nerves (pain)  Papaver somniferum (Poppy) pp. 961-968 2nd volume 
skin / mucous membranes Calendula officinalis (Calendula) pp. 710-714  2nd volume 
stomach Matricaria chamomilla (Chamomile) pp. 58-68   1st  volume 
uro-genital tract (andrology) Urtica dioica / Urtica urens (Nettle) pp. 920-924 2nd volume 
4.5.4 Definition of use-categories 
The attribution of indications from historical texts to biomedical disease categories requires 
the development of a coding framework that can capture the varied therapeutic uses of 
medicinal plants in historical medical texts. The therapeutic use-category concepts of 
Heinrich et al. (2006, p. 158), Will (2009, p. 20), Dal Cero (2016, p. 25), and Staub et al. 
(2016, p. 1045) provided a fitting starting point. The use-categories defined in this study 
refer to body systems and to anatomical sites, except for the use-categories cancer and 
infection, and for two use-categories that reference a therapeutic action, apotropaic and 
tonic. A tonic is understood here as an agent that is able to support, restore, or maintain the 
physiological functioning of an organ system, leading to the subjective feeling of well-being 











antidote, against poisons, against external threats, talisman 
Cancer 
cancer 
malignant growths and knots, cancer 
Cardio-vascular system 
card-vasc 
heart, arteries, veins, and vessels, circulation, shock 
Digestion 
gastro-intest 
stomach and intestines: weak digestion, diarrhoea, constipation, parasites, 
worms, gastro-intestinal infection 
Endocrine system  
hormonal 
glands, hormones, metabolism 
Gynaecology  
gyn 








systemic infections: malaria, blood poisoning / septicaemia, fever 
Liver / Gallbladder / 
Spleen  
liver-spleen 
liver and gall bladder complaints: gallstones, nausea, dyspepsia, liver 
detoxification; blood building (in humoralism) 
spleen: digestive issues, humoral detoxification 
Musculo-skeletal system 
musc-skel 
muscles, bones, tendons, ligaments, joints 
Nervous system  
nerve 
pain, neuralgia, headache, injuries, sleep, dreams 
Respiratory tract 
respiratory 
upper respiratory tract: nose, sinuses, throat 
lower respiratory tract: bronchi, lungs 
Sexual function  
sex 
sexual function, sexual dysfunction, aphrodisiac, anaphrodisiac 
Skin / mucous membranes 
skin-mucous 
wounds, burns, ulcers, skin inflammation, mucous membranes of the mouth 
and gastro-intestinal tract 
Skin / mucous membranes 
skin-mucous cleanse 
topical drainage, cleansing of tissues 
Somatoform disorders 
somatoform 




systemic effects: invigoration, euphoria, to alleviate exhaustion 
Urinary tract  
uro 
kidney and bladder complaints, oedema, gravel and stones, infection, voiding 
disorders, enuresis (bed wetting) 
4.5.5 Explanatory notes to the use-categories 
 Spleen disorders are attributed to the liver-spleen category and not to a separate 
lymphatic category because in ancient Greek medicine the spleen was co-
responsible for humoral balance of digestive processes (Staub et al., 2016, p. 1045).  




melancholy (Francia & Stobart, 2014, p. 301; Wirsung & Tabernaemontanus, 1577, 
p. 297). Therefore, the attribution of a complaint to either the liver-spleen category 
or to the somatoform disorders category can only be interpreted through context. For 
example, the indication to chase excess black (bile) as discussed by 
Tabernaemontanus references a humoral concept and relates to the elimination of 
melancholy; melas is Greek for black and kholē is Greek for bile. In humoralism, 
fear, sadness, gloom, and fright were seen as typical symptoms of ‘melan-cholic’ 
illnesses (Zimmermann, 1975, pp. 91-96). Such mental and emotional afflictions are 
today commonly referenced as depression (Tschupp, 1998, pp. 44-47). 
Consequently, this indication is attributed to the somatoform category. In contrast, 
when Tabernaemontanus describes the liver cleansing benefit of reiniget Leber, this 
phrase probably relates not only to the liver as an organ but also to its humoral blood 
building function (Stolberg, 2003, p. 121). Liver indications are attributed to the 
liver-spleen category. 
 The term Ader references strangförmiges Gebilde (strand-like formation) 
(Mildenberger, 1997, p. 38). Ader, Sehnader, Sennader or Geäder may include 
ligaments, tendons, facia, nerves, and muscles (DWB, 1854-1960, pp. Band 16, Sp. 
148; Mildenberger, 1997, pp. 38-40, 665). By extension, the term Nerven could 
possibly have had a wider application than the contemporary biomedical definition 
of ‘nerves’ and could have included tendons and ligaments depending on context 
(Haubrich, 2003, p. 156). 
4.5.6 Attribution of historical indications to use-categories 
For the purpose of this thesis, the German term Anwendungsnennung is translated as 
‘indication of use’ or ‘indication’ for short. This translation aligns with the terminology 
used in other research projects (Mayer-Nicolai, 2009; Tobyn et al., 2011, p. ix; Will, 2009), 
and reflects the term ‘therapeutic indication’ used in herbal monographs authored by the 
EU. An ‘indication’ covers the reason for or situation in which a medicinal plant is used. 
Therefore, the term is interchangeable with ‘use report’. In this thesis, the word ‘indication’ 
does not imply its contemporary biomedical meaning which refers to the use of a specific 
drug for treating of a biomedical disease as approved by a regulatory authority; although it 
may relate to such a specific biomedically defined indication when an indication is used in 




As noted, the attributions of historical indications to use-categories predominantly reflect 
the anatomical site of the discussed complaint or, alternatively, the affected body system. 
Although most indications are attributed to one use-category only, an indication may in 
some instances span over two or more categories. For example, if an author explains the 
anatomical site of a complaint as well as the pharmacological action of the plant chosen for 
treatment, this pharmacological action is additionally noted under the corresponding use-
category. The following are some explanatory examples of attributions made in this way: 
 Muscle pain is attributed to the musculo-skeletal use-category (musc-skel) as the 
anatomical site of complaint as well as to the nervous system (nerve) use-category 
since the plant is discussed as a pain-relieving remedy.  
 Bleeding is categorised under the respiratory tract use-category (respiratory) if the 
indication references spewing blood from the chest, under the muscular-skeletal 
system use-category (musc-skel) if the text references an anti-ecchymotic action 
(reabsorption of blood in bruises), to the skin-mucous membrane use-category (skin-
mucous) if a styptic action on an externally bleeding wound is discussed, or to the 
gynaecology use-category (gyn) if the reference is to menstrual bleeding. Bleeding 
of the eye or brain is referenced to the anatomical location (head) as well as to the 
cardiovascular (card-vasc) use-category to reflect systemic styptic action.  
 Headaches can span across two or more use-categories. The anatomical site is the 
head (head). If an explanation is given (e.g. headaches due to menstruation), the 
indication is also noted under gynaecology (gyn). If nervous tension is described as 
the cause, the indication is also noted under nervous system use-category (nerve). 
 If the text discusses infections of a specific body system, the indication is listed 
under that use-category. For example, the treatment of an infection of the digestive 
tract is listed under gastro-intest or the treatment of an infection of the respiratory 
tract under respiratory. If an infection is referenced as systemic in nature without a 
reference to a specific body part or system, its indication is allocated to the generic 
category of infections (infection), as is the case with malaria. 
 Strokes are attributed to the cardio-vascular use-category (card-vasc) if the author 
discusses a plant’s circulatory effect, to the nervous system use-category if the 
stroke was said to have been caused by nerve injuries, and/or to the head use-




4.5.7 Botanical nomenclature 
The establishment of the scientific nomenclature of a medicinal plant is a prerequisite for 
valid research outcomes (Bennett & Balick, 2014; Heinrich & Verpoorte, 2014; Rivera et 
al., 2014). To avoid ambiguities and errors, and so that related information on indications 
and safety can qualify for regulatory purposes, the botanical nomenclature of medicinal 
plants described in historical medical textbooks must therefore be established 
unequivocally.  
The following resources were selected to validate and check botanical nomenclature. This 
selection was based on and expands previous research that successfully identified historical 
plant species with a similar approach (Will, 2009, pp. 13-14): 
a) the plant can be identified with reference to the historic plant dictionaries of Marzell 
and Wißmann (2000) and Mildenberger (1997) 
b) synonyms listed in Tabernaemontanus, together with the plant illustration, can be 
identified via Marzell and Wißmann (2000) or (Mildenberger, 1997)  
c) the plant has been conclusively identified by Marzell and Wißmann (2000) in other 
medical textbooks of the same historical period such as in Fuchs (1543), Bock 
(1577), Brunfels (1532) 
d) the plant has been conclusively identified by Baumann in Fuchs under reference to 
Linnaeus, Schinz, Sprengler, Dierbach, Kirschleger, Hatton, Sprague & Nelmes, 
Rytz, Marzell and Meyer (Baumann, Baumann, & Baumann-Schleifhauf, 2001, pp. 
51-56) 
e) the plant has been conclusively identified by Will in Brunschwig (Will, 2009) 
f) the historical plant name conclusively corresponds with the botanical name 
mentioned in a contemporaneous German or English language medical textbook 
such as in Fuchs (1543), Bock (1577), Brunfels (1532), Gerard (1633), or Turner 
(1562) 
g) the historic plant name conclusively corresponds with the contemporary name 
h) the plant name can be identified via deductive reasoning, but 
i) a plant name that can only be guessed by deductive reasoning must be discounted. 
In a further step, a plant name is cross-referenced with a botanical nomenclature database, 
the International Plant Names Index (IPNI), to align the historical name with the most up-




Royal Botanic Gardens, Kew, The Harvard University Herbaria, and The Australian 
National Herbarium. 
4.5.8 Organisation of Historic Data Excel spreadsheet 
The primary data were collated into the Historic Data Excel spreadsheet as a reference for 
independent verification. They underpin the tables constructed via the Historical 
Assessment Tool. Each indication was recorded by year of listing, author, type of textbook, 
page number, botanical identity (taxon, species name in German, English, Latin, vernacular 
or foreign plant names), plant part used, harvest advice, cautions, preparation (mode of 
administration), method of plant preparation (fresh or dry), application (topical and/or 
systemic), dosage, use-category, type of medical system where applied (regular, traditional 
or folk medicine), and original text (for independent cross-reference). The following 
sections establish the labels used for the recording of this primary data. 
4.5.8.1 Labels for plant parts  
Plant parts parts corresponding to the descriptions in the sources:  
flores folium radix 
flores con receptaculis folium, flores rhizome 
flores sine receptaculis herba semen 
flores (summitates) herba, folium  





4.5.8.2 Labels for plant preparations 
Pharmaceutical preparations corresponding to the descriptions in the sources, as translated 
from German to English: 
ash (salt) extract – wine poultice 
bath food powder 
capsules/tablets fumigation rub 
compress gargle rub with fresh plants 
cream / ointment / gel honey preparation smoking 
distillate hydrosol snuff 
drug injection spiritus/schnapps 
electuary juice of fresh plants steam bath (inhalation) 
enema mead syrup 
essential oil oil tincture 
extract paper/charta wash 
extract – beer pessary water extract/tea 
4.5.8.3 Labels for source type 
Types of bibliographic sources used for the analysis:  
Advice 
Literature 
Practical health advice written by physicians or non-physician herbal experts for lay 
people (not in the final selection) 
Medical 
Textbook 
A medical text written by a university-educated practising physician or apothecary 
(authoritative) 
Com Ph An academic commentary to a pharmacopoeia (authoritative) 
Monograph A comprehensive text on a single medicinal plant (official or authoritative) 
Ph Pharmacopoeia (official) 
Ph - Hom 
Pharmacopoeia for homeopathic, traditional, and anthroposophical preparations 
(official) 
Ph Supplement Pharmacopoeia supplement (authoritative) 
4.5.8.4 Conversion of weights 
The selected text from the early modern period, New vollkommen Kräuter-Buch 
(Tabernaemontanus, 1664), was printed at a time before measurements and weights were 
standardised across central Europe and when regions, cities, and even different professions 




conversion of weights is based on the official apothecary weights of the city of Basel, 
Switzerland, where the New vollkommen Kräuter-Buch was printed (Mildenberger, 1997). 
4.6 Background and selection of medical textbooks as sources of evidence  
Medicines derived from plants have dominated the medical landscape for most of human 
history and are also a vital part of European medical and cultural history (Kyrou et al., 
2017; Stille, 2004; Tshongo Muhindo, Ahn, Rousseau, Dierckxsens, & Hermans, 2017). To 
understand the regulatory situation in Europe, it is necessary to appreciate the central role of 
professional transmission of empirical knowledge on medicinal plants in regular European 
healthcare. This section first contextualises the historical significance of the botanical 
materia medica literature and then provides a summary of each of the textbooks selected for 
this study of the period from the 16th to the 21st century. The following short synopsis 
focuses on written transmission, but this thesis recognises that such written transmission co-
existed alongside various forms of oral traditions and that those traditions influenced each 
other (Touwaide & Appetiti, 2015). The oral transmission of knowledge is, however, 
outside of the scope of this thesis. 
Documentary evidence on the therapeutics used by European physicians confirms that 
medical, pharmaceutical, and botanical knowledge of therapeutic substances has been 
consistently recorded for more than 2500 years. Medicinal plants provided mainstream 
medicines well into the middle of the 20th century (De Vos, 2010; Schmitz, 1998; Schmitz 
et al., 2005). Influences on the European medical tradition can be traced back to 
Mesopotamia and later to Egypt with its pharmacopoeia of Ebers Papyrus (1500 BC). 
However, the basis of European medicine was laid down in classical Greece and during the 
Roman Empire, being grounded in the natural philosophy of Aristotle. Influential 
physicians and philosophers started to build written consensus about what was considered 
efficacious medicine (Leonti & Verpoorte, 2017, p. 162). Pharmacological and pharmaco-
botanical knowledge was presented in monographs and transmitted over the following 
millennia (Heinrich & Anagnostou, 2017). The most eminent classical authors were 
Hippocrates of Kos (ca. 460-370 BC) and his successors who wrote the Corpus 
Hippocraticum, a collection of medical treatises (Uehleke & Kraft, 2001, p. 246). The 
ensuing medical texts by the Roman army physician Pedanios Dioscorides (1st century AD) 
and those authored about a century later by the Greek physician Galen of Pergamon became 




medicine through their continuous dissemination of empirical knowledge on medicinal 
plants until the end of the 18th century (Leonti & Verpoorte, 2017, p. 162). Dioscorides, 
who systematically described in his De Materia Medica around 500 medical plant species 
as well as 90 mineral and 35 animal drugs, documented the medical, pharmaceutical, and 
botanical knowledge in the style of a medical encyclopaedia (Dal Cero, Saller, & Weckerle, 
2014, p. 255; Riddle, 1985). From then on, the term materia medica was applied to all 
medical textbooks where medical experts systematically authored in-depth monographs on 
therapeutic substances. 
Over the centuries educated physicians integrated local, foreign, or experientially-gained 
knowledge on the pharmacological effects of medicinal plants into a formal scientific 
framework of explanation, which reflected the theoretical understanding of their time 
(Touwaide, 2005, pp. 169-170). Translations of this Greek and Byzantine medical 
knowledge into Syriac, a dialect of Middle Aramaic, facilitated the transmission of the 
classical body of knowledge into Arabic and thus into the medieval Islamic world where it 
was not only preserved but developed further and transmitted back to the West through the 
pioneering work of Avicenna (1000 AD), the School of Salerno (ca. 1000-1300 AD), and 
the body of work created during the period of al-Andalus (711-1492 AD) (Russell, 2009). 
During the Middle-ages, Benedictine monks were directed by monastic rule to duplicate 
herbals, thus preserving the European tradition. The invention of a mechanised printing 
press in the 15th century by the German goldsmith Johannes Gutenberg (ca. 1400-1468) 
enabled the mass production of medical textbooks and their wide dissemination. From the 
16th century onwards, such texts were predominantly authored by university-educated 
physicians (Pugliano, 2017, p. 238).  
The early modern period marks a new approach to the documentation of medical knowledge 
and healthcare. Practitioners no longer relied solely on written texts or library medicine, a 
common feature of medieval medicine; rather, they moved towards systematic, clinical 
observation such as bedside medicine and epidemiology (Ackerknecht, 1992, pp. 96, 146). 
The spirit of the Renaissance fostered empirical science and rekindled interest in classical 
scholarship and ancient Graeco-Roman medical knowledge under the motto ad fontes (Dilg, 
2001; Porter, 2003, p. 171). Thus, Renaissance-inspired authors of medical compendiums 
and pharmacopoeias presented themselves as both reenactors of the ‘true’, classical 




From the end of the Middle Ages and beginning of the early modern period, the European 
materia medica was recorded in opulent, elaborate, and magnificently illustrated herbals. 
The medical information was systematically presented following scientific rules similar to 
those displayed in today’s textbooks. The logical, systematic framework provides an 
alphabetical index of medicinal plants, their botanical description and synonyms for 
identification, clinical indications, and ailments in humans and animals (Clair, 2011; 
Schmitz, 1998, pp. 403-418). The era is regarded as the pinnacle of clinical plant 
knowledge. Medical texts from the early modern period incorporated empirical scholarship 
of ancient Greek, Roman, Byzantine, medieval Islamic, and European oral and written 
medical tradition alongside new insights and plant monographs from central and northern 
European medicine, complementing the Mediterranean flora discussed in the antique Greek 
herbals. They added new genera and species from newly discovered territories (Adams, 
Alther, et al., 2011; Adams et al., 2009; Adams, Gschwind, et al., 2011; Adams et al., 2010; 
Bofinger, 2004; Dal Cero, Saller, & Weckerle, 2013). For example, the medical 
commentary to Dioscorides’ De Materia Medica (1544) by Andrea Matthioli (1501-1578) 
described an additional 600 medicinal plant species (Leonti & Verpoorte, 2017, p. 164). 
The influential New Kreüterbuch (1543) by the German professor of medicine and botany 
Leonhart Fuchs (1501-1566) lists around 100 new medicinal plants not previously described 
in Germany (Heide, 2001). These comprehensive herbals from the early modern period 
became the predecessors of today’s official pharmacopoeias and modern herbal 
monographs. They are rooted in the Graeco-Roman and Arabic tradition. Consequently, this 
analysis starts with a text from that period. The therapeutic applications recorded in the 
ensuing medical textbooks reflect the ongoing transmission of clinical knowledge on 
medicinal plants across the paradigmatic, socio-economic and political-legal changes of 
over 400 years. This body of literature falls under the WHO description of a codified 
system of traditional medicine. It has been disclosed in writing in ancient scriptures, is fully 
in the public domain, and has been passed on from generation to generation 
(Intergovernmental Committee on Intellectual Property and Genetic Resources Traditional 
Knowledge and Folklore, 2010, Annex, p.7).   
4.6.1 17th century: Tabernaemontanus New vollkommen Kräuter-Buch (1664) 
Humanism, the intellectual exploration of human nature freely and critically, laid the 




medicine and botany Theodorus Jacobus Tabernaemontanus, born Jakob Theodor (1520-
1590), and his systematic vetting of the European materia medica with clinical observation 
(Clair, 2011). Despite his lasting influence, Tabernaemontanus received relatively late 
historical attention (Schanz, 2009, p. 42). Medical historians and archivists, namely 
Sprengel (1817), Sachs (1875), Leyser (1881), Roth (1898), Buttmann (1898),  Hoffmann 
(1940),  Figala (1974), Becker (1984), Carlé (1964a, 1964b), and Künkle and Lorenz (1988) 
recovered fragments of original data about his life and work, but it was not until the 
research of Müller-Jahncke (1982), Reiser (1989), Bergdolt (1990, 1992), and most 
importantly Bofinger (2004; Müller-Jahncke & Bofinger, 2003) that more comprehensive 
insights into his impact in the transmission of the European materia medica emerged (Clair, 
2011). His lasting influence on medicine and botany is not only evident in central Europe 
(Sachs, 1875; Sprengel, 1817; Tillmann, 1988; Übel, 1990; Volz, 1990) but also in Great 
Britain via his professional and personal exchanges with the English physicians, botanists 
and medical authors William Turner (1508-1568) (Turner, Chapman, Tweddle, & 
McCombie, 1995) and John Gerard (1545-1612). Gerard made liberal use of information 
published in Tabernaemontanus’ New vollkommen Kräuter-Buch and of his illustrations 
from Icones stirpium (1590) (Gerard, 1633; Schanz, 2009, p. 43). 18th century Swedish 
botanist Carl von Linné (Linnaeus) named the pan-tropical genus Tabernaemontana with its 
exquisitely flowering shrubs and small trees in his honour. The English literature on early 
modern herbals is yet to acknowledge his contribution to botanical pharmacy, as 
exemplified in Arber’s incomplete appraisal of early modern herbals or Pavord’s selective 
cultural history of botany (Arber, 1912/1938, p. 76; Pavord, 2005).  
Tabernaemontanus’ opus magnum, the Neuw Kreuterbuch, later called New vollkommen 
Kräuter-Buch, was first published in 1588 (vol 1), with volumes 2 and 3 posthumously 
published in 1591 in Frankfurt, Germany. After further editions in 1613 and 1625, the 
tomes were subsequently edited and published in Basel, Switzerland (Tabernaemontanus, 
1588, 1591, 1613, 1625, 1664, 1687, 1731). The updated edition of 1664, which includes 
addenda by two physicians and botanists from the University of Basel, was re-printed 
unchanged until 1731 and is selected as pars pro toto for medical practice in the early 
modern period. This textbook fulfils all selection criteria as laid out.  
While humoral concepts still influenced Tabernaemontanus, his medical textbooks 




experienced physician, detailed botanical information including precise graphic plant 
representations, and guidelines on pharmaceutical compounding. Comparing the first 
volume solely authored by Tabernaemontanus with the second and third volumes that the 
German professor of medicine Nikolaus Braun (1558-1639) completed after the author’s 
death using printing blocks and notes left behind, it is evident that Tabernaemontanus added 
more detailed observations than contemporaries who continued to follow more closely the 
medical paradigm formalised by Galen (Baumann, 1998, pp. 105-108, 175, 237). With his 
practical medical, pharmaceutical and botanical experience, Tabernaemontanus documented 
insightful observations in great detail. In this respect, his approach to medicine was closer 
to Dioscorides who, unlike Galen, wrote his influential medical text De Materia Medica as 
a practical pharmacopoeia without linkage to transitory medical theories (Riddle, 1985, p. 
xix). This practical approach to the European materia medica, the clinical vetting of what 
works and what does not, may explain why, despite fluctuations in medical concepts over 
time, plant indications have enjoyed remarkable longevity, as validated by modern science. 
Tabernaemontanus advocated the use of local medicinal plants instead of exotic ones and 
described local species not described by Dioscorides (Tschirch, 1909a, p. 21). His interest 
in local plants did not preclude him from writing extensive monographs on imported drugs 
such as Cinnamon, Cardamom, and Nigella. As a student of two of the three ‘fathers of 
modern botany’ (Bergdolt, 1992)—the German physicians Otto Brunfels (1488-1535) and 
Hieronymus Bock (1498- 1554)—, Tabernaemontanus  also advanced the classification of 
plants, thus contributing in crucial aspects to the development of the botanical binary 
nomenclature formalised later by the Swedish physician and botanist Carl von Linné (1707-
1778) (Bofinger, 2004). The scientific approach and systematic arrangement of 
monographs, the comprehensive register of medicinal plants in 10 languages, and the 
register for ailments and preparations allow a logical way to navigate the large tome that 
incorporates the description of over 3000 medicinal plants over 1500 pages. The preface 
references 111 ancient, medieval, and contemporary authors, and more authors are 
referenced in the text itself. The materia medica expands on ancient Greek, Arabic, and 
European medieval sources. It includes customary medicinal plants from central Europe and 
florae that are largely absent in Dioscorides’ classical De Materia Medica and subsequent 
European herbals (Adams et al., 2012, p. 11). Tabernaemontanus’ description of Arnica 
montana is such an instance. Furthermore, he provides descriptions of galenic preparations 




His medical encyclopaedia on European therapeutics became recognised by both physicians 
and lay practitioners as the most comprehensive and reliable summary of medical 
knowledge of the preceding two millennia (Steinke & Meier, 2003, pp. 31-32). It surpasses 
earlier and later herbal treatises regarding the number of medicinal plants discussed, 
precision of indications, and practical advice (Heilmann, 1973, p. 35). Written and 
published shortly before the Thirty Years War (1618-1648) devastated much of Europe’s 
bibliographic reference collections, it remains the most comprehensive repository of 
European botanical therapeutics (Bofinger, 2004).  
The author’s clinical approach to the materia medica influenced the academic medical 
education and practice of European physicians for the next 200 years (Friedrich & Müller-
Jahnke, 2005, p. 115). Additionally, the plant monographs in New vollkommen Kräuter-
Buch were integrated in Johann Heinrich Zedler’s Grosses, vollständiges Universal-Lexicon 
(universal dictionary) (Zedler, 1732-1754), the largest German language encyclopaedia of 
the 18th century. It served as a clinical guide for priests extending their spiritual care to the 
physical health of their parish such as the Bavarian pastor Sebastian Kneipp or Swiss pastor 
Johann Künzle. Additionally, it was used as a reference for lay self-care (Bergdolt, 1990, 
1992; Clair, 2011; Mägdefrau, 1992; Schmid, 1939). Apart from its multiple editions, the 
popularity of this medical textbook is demonstrated, for instance, by the Vester Sammlung, 
a large repository of significant historical-pharmaceutical textbooks hosted at the 
Universitäts- und Landesbibliothek Düsseldorf that has 108 medical textbooks and 
encyclopaedias referencing Tabernaemontanus. Most quotations are recorded in 18th and 
19th century sources with some also in 20th century texts.  
4.6.2 18th century: Löseke and Plenck 
Tabernaemontanus’ textbook was last printed in 1731 so this data analysis continues with a 
subsequent text from the late 18th century: the 6th and last edition of the teaching textbook of 
Johann Ludwig Leberecht Löseke’s Materia medica (Löseke & Gmelin, 1790). This 
textbook aligns with the publication of the 1st edition of the Prussian pharmacopoeia which 
will be explored in a later section. 
4.6.2.1 Löseke (1724-1757) 
Johann Ludwig Leberecht Löseke was a practising physician and lecturer at the Prussian 




Halle (1694), such as Georg Ernst Stahl (1660-1734) and Löseke, defended the vitalistic 
principles said to underpin human physiology against the upcoming speculative theories of 
iatrochemists and iatrophysics (Ackerknecht, 1992, pp. 128-129). The first edition of 
Löseke’s Materia medica oder Abhandlung von den auserlesenen Arzneymitteln: Nach 
derselben Ursprung, Güte, Bestandtheilen, Maße und Art zu wirken nebst Vorschriften wie 
dieselben aus der Apotheke zu verordnen sind was printed in Berlin in 1754. By the 4th 
edition published in 1776, it is said to have become an important reference text for surgeons 
and physicians. It was also used as a lecture script at several universities (Löseke & 
Zückert, 1776, p. Vorwort). After Löseke’s early death, the textbook continued to be 
published by medical colleagues, initially by Johann Friedrich Zückert, and later by Johann 
Friedrich Gmelin, who in addition to practising medicine was also a chemist. Löseke’s 
Materia medica was extensively quoted for the next 100 years, including in the English 
medical literature (D.V., 1829; Pereira, 1854). 
Löseke emphasises the importance of empirical knowledge for science. This approach 
aligns with other influential contemporaries such as the German physician Friedrich 
Hoffmann (1660-1742), who proclaimed the slogan “reasoning plus experience” 
(Ackerknecht, 1992, p. 129). Löseke is not concerned with why a drug works, being 
satisfied with repeated clinical observation that it did in fact work, as for example with 
opium for pain relief or Cinchona bark for the treatment of malaria (Löseke & Zückert, 
1776, Vorbericht des Verfassers). The author references a wide-ranging collection of 
medical literature and experimental and academic research, mainly by authors from the 16th 
to the 18th century. Tabernaemontanus and Matthioli are two of his key medical references, 
and Linnaeus (1707-1778) provides the ultimate compendia for ensuring botanical accuracy 
in Löseke’s Materia medica.  
Löseke expresses fascination towards the chemical discoveries made during his lifetime and 
lauds the endeavours of chemists in discovering presumed active principles and modes of 
actions of medicinal plants. Yet the main therapeutics in his Materia medica remain whole 
plant medicines, reflecting mainstream medical practice of his time (Löseke & Gmelin, 
1790, p. 5; Schmitz, 1998, pp. 403-406). Each plant monograph provides information on 
therapeutic actions as well as contraindications where required. In a time when Paracelsus 
inspired heroic drug therapies with toxic heavy metals such as mercury, lead, and arsenic—




to be seen as modern scientists (Wulle, 1999, pp. 94-95), the author warns colleagues 
against the use of “heftige und neuerfundene Arzneyen” (violent and invented medicines) 
(Löseke & Zückert, 1776, p. Vorbericht des Verfassers). Both his fascination with and 
concern about the influence of chemistry on medicine illustrate the interplay between old 
medical paradigms of that time such as humoralism, and the emerging natural science-based 
ones. 18th century physicians faced many uncertainties with the rapid changes in medical 
theory and pharmaceutical practice that led European medicine to the era of chemical 
laboratory medicine (Ackerknecht, 1992). 
4.6.2.2 Plenck (1735-1807) 
For the analysis of St. John’s Wort, it was necessary to include one extra text from the late 
18th century. A cross-validation with other medical textbooks revealed that the shortness of 
Löseke’s Hypericum perforatum entry is not mirrored in other contemporaneous medical 
textbooks which originate from warmer climate zones of Europe where St. John’s Wort 
grows more prolifically, for example in Switzerland or Austria. This highlights the fact that 
traditions may also be defined across the 12 global climate zones with their various habitats 
and those may influence the selection of medicinal plants discussed in regional medical 
textbooks. For example, the influential Swiss physician, botanist, anatomist, and natural 
scientist Albrecht von Haller (1708-1777) (Steinke, Boschung, & Pross, 2009) references 
St. John’s Wort in his seminal but unofficial first edition of the Pharmacopoeia Helvetica 
on no less than 24 different pages (Haller, 1771, pp. 85-86, (II) 38-40, 67, 106-108, 110-
111, 150-151, 155, 201, 203, 235, 274-275, 280-281, 306, 315, 334). This quantity of 
references on medical uses highlights the continued significance of St. John’s Wort in some 
regions of Europe, even when under the experimental scrutiny of natural science during the 
Age of Enlightenment. Likewise, the Icones Plantarum Medicinalium by Josephus Andreas 
Jacobus Plenck (1735-1807), an Austrian physician, surgeon, obstetrician pharmacologist, 
chemist, and lecturer at the University of Tyrnau correspondingly lists multiple medical 
uses of St. John’s Wort (1794, p. 57). Plenck was an influential medical authority of the 18th 
century, and his clinical teaching textbook was widely used and quoted (De Santo, Aliotta, 
De Santo, & Aliotta, 2002). It fulfils the selection criteria established in 4.4.3 and is thus 
selected for this analysis. Plenck’s medical writing highlights how the therapeutic 
indications of this period were informed both by tradition and by novel natural science 




4.6.3 19th century: Richter, Strumpf, and Hager 
The first quarter of the 19th century exhibits the widening paradigmatic divide in medical 
theory. There were now numerous divergent approaches to clinical medicine and its materia 
medica, all grounded in different methodologies influenced by historical, theoretical, 
philosophical, empirical, and experimental considerations (von Engelhardt, 2000, pp. 144-
145).  
4.6.3.1 Richter (1778-1832) 
Georg August Richter (1778-1832), physician and professor of Praktische Heilkunde 
(practical medical science) at the Prussian University of Königsberg, authored the 
influential teaching series for clinicians Ausführliche Arzneimittellehre. Handbuch für 
praktische Aerzte in 6 volumes (Richter, 1826, 1827, 1828, 1829, 1830, 1832). Richter 
based his textbook series on a synthesis of clinical notes from his surgeon father, on 
influential physicians such as Christoph Wilhelm Hufeland (1762-1836), on his own 
repeated empirical observations, and on his collection of scientific research that he 
systematically recorded from 1812 onwards. His academic teaching text stands out for the 
detailed explanations of pharmacodynamic properties of medical plants on the human 
organism, providing a deeper understanding about how physicians at that time saw the 
actions of plant drugs beyond specific medical indications. 
Richter highlights the “Verwirrung” (confusion) and “Widersprüche“ (contradictions) 
amongst opposing medical theories and movements at the time (Richter, 1826, pp. V-XII). 
His stated motivation for the textbook series is to synthesise medical information for 
practising physicians as an aid during a time of paradigmatic upheaval, where ‘passions, 
authorities, egotism, blind empiricism, speculative philosophies and hair-splitting 
dogmatism’ caused significant confusion in medicine (Richter, 1826, pp. V-VI). In this 
period, long-standing whole plant drugs increasingly competed with isolated actives such as 
morphine, emetine, quinine, piperine, gentianin, lupulin, and atropine (Richter, 1998, p. 
308). Like Löseke before him, Richter defends the inclusion of traditional medicines and 
states that the proposed exclusions of such well-established drugs by some have more to do 
with individual preferences than with the actual usefulness of a drug.  
4.6.3.2 Strumpf (no biographical dates) 




equivalent to privy councillor) and town physician of Strassfurt before working in private 
practice in Berlin, produced the two-volume pharmacology textbook Systematisches 
Handbuch der Arzneimittellehre (Strumpf, 1848, 1855). These volumes continue to 
highlight efforts during the middle of the 19th century to hold onto a complete and 
trustworthy materia medica while also being open to new chemical discoveries. The 
scholarly structured academic teaching text is dedicated to Karl Gustav Mitscherlich, 
professor of pharmacology at the Friedrich-Wilhelm University in Berlin, and claims to 
comprehensively reflect contemporaneous pharmacology (Strumpf, 1848, p. VIII). Its aim 
is to provide physicians with a wide choice of medicines and rehabilitate what the author 
sees as the unjustifiable dismissal of traditional medicines by illustrating their therapeutic 
worth in practical patient care (Strumpf, 1848, p. VII). Strumpf’s clinical observations and 
case reports provide insight into the dynamics of a mid-19th century clinical practice. 
The textbook includes all official medicinal substances listed in the Prussian 
pharmacopoeia, as well as recently classified ‘obsolete’ medicines, alongside a small 
number of newly synthesised chemical drugs. It provides an extensive scientific literature 
review and information on historical medical uses, taxonomy, botany, chemical properties, 
preparations, pharmacodynamics effects, indications, clinical observations, and side effects. 
The author quotes Tabernaemontanus in the historical section, confirming the lasting 
influence of his medical authority (Strumpf, 1855, p. 47).  
4.6.3.3 Hager (1816-1897) 
Hermann Hager’s three-volume pharmacology textbook Handbuch der pharmaceutischen 
Praxis. Für Apotheker, Ärzte, Drogisten und Medicinalbeamte is selected to represent the 
last third of the 19th century (Hager, 1876, 1878, 1883c). The Prussian author (1816-1897) 
was a prominent practising apothecary, pharmacologist, and chemist. He was also one of 
the most prolific and influential authors of pharmaceutical and botanical works in the 19th 
century (Kerstein, 1966, pp. 470-471). Apart from his serial translations and commentaries 
on the Prussian and German pharmacopoeias (Hager, 1865, 1873, 1874, 1883a, 1883b, 
1884, 1892; Hager, Fischer, & Hartwich, 1891, 1892, 1895), his standard textbook Hagers 
Handbuch der pharmaceutischen Praxis left a legacy that reaches into the 21st century. This 
pharmaceutical reference text has been continuously updated and is available electronically 




The wide selection of chemical drugs discussed alongside traditional plant medicines in 
Hager’s textbooks makes evident that the natural science-based medical paradigm is 
becoming strongly present for the first time. Trade in medicinal plants declined by the end 
of the industrial revolution when industrially mass produced synthetic drugs became 
widespread (Richter, 1998, p. 362). Natural science orientated physicians now exhibited 
strong scepticism against traditionally endorsed medicinal plants if their effectiveness could 
not be experimentally explained—to the extreme that this attitude lead to therapeutic 
nihilism by some medical schools (Richter, 1998, p. 362; Schott, 2000). Nonetheless, Hager 
discusses numerous traditionally used medicinal plants in line with their listings in official 
pharmacopoeias and their demand in apothecaries, albeit in an abbreviated fashion. 
4.6.4 20th century: Schulz, Madaus, Kroeber, Weiss, and Saller et al. 
While at the beginning of the 20th century medicinal plants still provided the majority of 
drugs in European medicine, they became rapidly displaced by synthetic drugs, despite 
some increased use during war times. The textbooks selected for this period illustrate the 
effects of the modern natural science paradigm and its regulatory framework on the 
traditional materia medica. 
4.6.4.1 Schulz (1853-1932) 
Hugo Paul Friedrich Schulz (1853-1932), professor of chemistry and pharmacology at the 
Prussian University of Greifswald, north-eastern Germany, published his university lecture 
notes on the therapeutic effects and applications of German medicinal plants under the title 
Vorlesungen über Wirkungen und Anwendung der deutschen Arnzneipflanzen. Für Ärzte 
und Studierende (Schulz, 1919). This work achieved ‘great recognition’ (Madaus, 1938b, p. 
56) and became a reference text on the pharmacological actions of medicinal plants 
(Kroeber, 1948; Saller, Reichling, & Hellenbrecht, 1995). The teaching text by Schulz 
(1919, p. Vorwort) was aimed at educating physicians and medical students on official plant 
drugs listed in pharmacopoeias and on plant-based therapeutics commonly used by diverse 
medical training institutes and by patients. Even though academic medicine at the turn of 
the century was now moving fast towards the adoption of synthetic drugs as its key 
therapeutics, Schulz endorses the use of medicinal plants in healthcare by physicians and 
patients. He claims that this is justified even when a plant’s mechanism of action and 




defence of folk medicine indicates a widening gap between physicians who were 
academically grounded in new medical theories and the use of synthetic drugs and many of 
their patients who adhered to customary medical practices. This division became 
increasingly obvious after the last quarter of the 19th century (Steinke & Meier, 2003, p. 31). 
4.6.4.2 Madaus (1890-1942) 
Leading up to WW2, the German physician, mathematician, scientist, and drug company 
owner from Lower Saxony, Gerhard Madaus (1890-1942), wrote the comprehensive and 
thoroughly researched three-volume textbook Lehrbuch der Biologischen Heilmittel 
(Madaus, 1938a, 1938b, 1938c). It is still in print today. The aim of his research was to 
translate extensive traditional knowledge into modern science by drawing from the 
disciplines of botany, chemistry, pharmacy, pharmacology, and toxicology. This 
encyclopaedic medical resource aimed to improve the knowledge of his fellow physicians 
on the effects and applications of 444 local and imported medicinal plants. Based on an 
ethnomedical approach, on surveys of physicians working in clinics, hospitals, and private 
practice, on modern scientific research, and on historical appraisals including 
Tabernaemontanus, he presents systematically collated evidence on medicinal plants of 
Europe and, to a lesser degree, of other continents (Madaus, 1938b).  
The context of Madaus’ textbook is the experience of pressures on the medical system in 
WW1 and the scarcities of synthetic drugs experienced in the period leading up to WW2, 
which prompted a renewed official focus on plant drugs for mainstream healthcare (Richter, 
1998, pp. 350-351). This situation coincided with the realisation that synthetic ‘wonder 
drugs’ such as aspirin were linked to serious side effects such as gastritis, gastric bleeding, 
and Reye syndrome in children (Desborough & Keeling, 2017), hurting the reputation of 
newly-developed pharmaceutical drugs. Modern medicine was experiencing somewhat of a 
crisis, prompting cohorts of medical doctors to defer to a natural, constitutional, and neo-
Hippocratic approach to patient care (Aschner, 1931, 1937).  
4.6.4.3 Kroeber (1872-1951) 
The analysis of how plant medicine was clinically applied in the post-war period focuses on 
the seminal phyto-pharmacological textbook by the leading German pharmacist Ludwig 
Kroeber (1872-1951) Das neuzeitliche Kräuterbuch. Die Arnzeipflanzen Deutschlands in 




Although the selection of this text means that there are only 10 years between Madaus’ 
textbook and this one, Kroeber’s work was chosen for two reasons: firstly, it can indicate if 
the consequences of war impacted the way medicinal plants were used in patient care; and 
secondly, it endured as an important text for decades and thus merits evaluation. Until the 
1970s this three-volume medical compendium (Kroeber, 1947, 1948, 1949b) was consulted 
as an academic reference for phytotherapeutic courses that were offered as complementary 
courses alongside academic medical education at some German universities (Professor Dr. 
med. Reinhard Saller, personal communication, 26.08.2014).  
Kroeber was director of the large hospital pharmacy in München Schwabing and a member 
of the German pharmacopoeia committee. He collaborated with clinicians, chemists, and 
pharmacologists to write a comprehensive phytotherapeutic textbook aimed at practising 
physicians, apothecaries, and ‘friends of natural healing’ (Kroeber, 1949b, p. 477). In this 
textbook, Kroeber discusses 298 plants and provides a wide range of clinical, experimental, 
and historical information. Kroeber references Tabernaemontanus and other 16th century 
‘physician-botanists’ for their precise and detailed observations, which he says were 
continuing to ‘fertilise’ modern medical practice (Kroeber, 1948, p. 21). It is evident that 
healthcare in the immediate post-war period remained pluralistic and provided a variety of 
therapies and preparations, including traditional plant medicines, their modern isolates, 
synthetic drugs, homoeopathic remedies, and other medicines (Flamm, Kroeber, & Seel, 
1948, p. 20).  
4.6.4.4 Weiss (1885-1991) 
The medical textbook Lehrbuch der Phytotherapie (1974) authored by Rudolf Fritz Weiss 
(1895-1991) heralds a new era of phytotherapy (Weiss, 1974). Weiss was a prominent 
lecturer on phytotherapy in German postgraduate medical curricula for natural therapies at 
the Berliner Akademie für ärztliche Fortbildung (Berlin Academy for post-graduate medical 
education), and later in life an honorary professor for the same subject at the University of 
Tübingen. His academic teaching text is written from the perspective and experience of a 
practising physician and was initially published in 1944 under the title Die 
Pflanzenheilkunde in der ärztlichen Praxis. Vorlesungen an der Berliner Akademie für 
ärztliche Fortbildung (Weiss, 1944). From the beginning of his clinical teaching career in 
1937, Weiss approached phytotherapy as a scientific and specialised branch of medicine. 




lag behind other specialised branches of medicine, and he promoted its permanent inclusion 
in the medical curriculum (Weiss, 1985, p. 8). His goal was to formulate a modernised 
representation of traditional plant medicine—phytotherapy—that fits into the context of 
contemporary mainstream pharmaceutical medicine. Unlike the medical textbooks of his 
predecessors who presented clinical data in the context of individual plant monographs, 
Weiss organised the information around organ systems and conditions, thus allowing 
conventional medical doctors to easily integrate plant-based medicines into their treatment 
plans. Weiss’ distilled clinical experience is highly practical, drawing on his decade-long 
grounding as an internist. 
The 3rd edition of Weiss’ textbook reflects the position of plant medicine in the 1970s. The 
6th and last edition Weiss updated and released as the sole author (1985) was translated into 
English (Weiss, 2001) and continues to be used in academic phytotherapeutic training of 
English speaking countries, including New Zealand and Australia as witnessed by the 
author. The ensuing editions, heavily revised and rewritten by the internist Volker 
Fintelmann, were less well received by clinicians because they lacked some of the previous 
practical usefulness. Subsequently, it is the 6th edition, now referred to as the classic edition, 
that continues to be reprinted. 
4.6.4.5 Saller (1947- ), Reichling (1943- ), and Hellenbrecht (1939-1994) 
Twenty years later, the Phytotherapie. Klinische, pharmakologische und pharmazeutische 
Grundlagen meets the challenge of delivering a rounded picture of scientific evaluation 
alongside traditional, historical, and regulatory endorsed plant medicine applications in the 
context of a modern healthcare system (Saller et al., 1995). The three authors bring to this 
textbook pharmacological and pharmaceutical academic rigor, as well as long-standing 
expertise with clinical patient work. Reinhard Saller (1947-) is a practising physician and 
emeritus Professor and Director of the Institute of Complementary Medicine, Department of 
Internal Medicine, University Hospital Zürich. Jürgen Reichling (1943-) is a practising 
pharmacist, pharmacologist, and emeritus Professor at the Institute of Pharmacy and 
Molecular Biotechnology, University of Heidelberg. Dieter Hellenbrecht (1939-1994) was a 
practising physician and Professor at the Institute of Pharmacology at the Goethe University 
of Frankfurt, Main. Their comprehensive introduction to phytotherapy for students and 
health professionals is an original synthesis of the philosophical underpinning of traditional 





With their firm foundation in patient care, the authors emphasise that the use of traditionally 
grounded phytotherapy is a paradigmatic decision where evidence from the newly 
developed RCTs plays an ancillary rather than a leading role in the clinical decision making 
process (Saller et al., 1995, p. 9). They emphasise that cultural aspects, individual 
requirements, spiritual needs, and symbolism may play as much a role in a patient’s desire 
for traditional medicines as might the pharmacological effect of the medicinal plant itself 
(Saller et al., 1995, p. 9). In the authors’ view, phytotherapy is particularly well suited for a 
constitutionally-orientated, personalised medicine that addresses the pathophysiology of a 
disease as well as the individual situation or terrain that is at the core of the patient’s health 
and illness (Saller et al., 1995, pp. 22-24). As such, the use of plant medicines is not an 
alternative to conventional, biological science-based medicine, but a distinct-yet-regular 
part of it. They claim that plant medicines address gaps of care and complement 
biomedicine in the prevention and treatment of acute and chronic illness (Saller et al., 1995, 
p. 11). 
4.6.5 21st century medical textbook: Bäumler (no biographical dates) 
The analysis on clinical uses of plant medicines by practising physicians closes with the 
textbook Heilpflanzen Praxis heute. Porträts, Rezepturen, Anwendungen (Bäumler, 2007), a 
medicinal plant compendium that was reprinted in quick succession in 2010, 2012 and 
2013. Siegfried Bäumler is a senior internist and clinician in both conventional and natural 
medicine who practises at the Kneippianum, Bad Wörishofen (Munich), a well-frequented 
German hospital and health resort specialising in natural healing. This textbook aims to 
provide a practical plant medicine compendium by expanding a science-focused 
phytotherapy with ‘empirical phytotherapy’, incorporating repeated observations by 
generations of practising physicians and long-standing therapeutic uses in folk medicine 
(Bäumler, 2007, p. VII). The author deems this approach necessary since some medicinal 
plants have not yet been investigated with contemporary scientific methodologies but have 
been validated in clinical practice. Bäumler’s textbook provides data on botany, 
pharmacology, and pharmacy, as well as information on traditional, historical, social, 
philosophical, and mythological context. There are practical treatment recommendations, 
formulas, and a comprehensive list of indications for easy reference, as well as caveats 




4.7 Pharmacopoeias and their compendiums as sources of evidence: The 
examples of the Prussian and German pharmacopoeias 
Exemplifying the official representation of medicinal plants and attributed indications from 
the end of the 18th century onwards, this thesis investigates all editions, supplements, and 
commentaries of the Pharmacopoea Borussica (the forerunner and most influential 
pharmacopoeia in pre-unified Germany), the ensuing Pharmacopoea Germanica (the 
official pharmacopoeia of Germany), and the current Deutsches Arzneibuch (the German 
pharmacopoeia named so since 1910). The Ergänzungsbuch (supplement) and Kommentar 
(commentary) were two additional necessary texts to support practising physicians and 
apothecaries because since the end of the 18th century pharmacopoeias became reference 
works for pharmaceutical drug specifications only. This situation reflects the rapidly 
increasing influence of academically-orientated pharmacists in defining this novel purpose 
of pharmacopoeias during this time (Tschirch, 1915, p. 497). The section below expands on 
the Prussian and German pharmacopoeias, their commentaries and supplements. 
4.7.1 Context of the Prussian pharmacopoeia 
The Prussian pharmacopoeia (Ph. Borussica) is a regulatory text which exemplifies the 
official position on plant medicine in northern Germany some 200 years after the first 
publication of Tabernaemontanus’ New vollkommen Kräuter-Buch (Tabernaemontanus, 
1588). It was the committee of the 1st edition of the Ph. Borussica which made the far-
reaching decision to transform this legal text into a reference work for pharmaceutical drug 
specifications and manufacturing only. This new structure, which now excluded therapeutic 
information, became the prototype of all Central European pharmacopoeias up to the 
present day (Schmitz et al., 2005, pp. 573-574). The preface to the 1st Prussian 
Pharmacopoeia (Pharmacopoea Borussica, 1799) reveals that the text is the expert 
consensus of a group of seven authors, which represents a relatively small-but-influential 
committee dealing with drug appraisals. The size of the committee appears limited in 
comparison to the large body of therapeutic substances used in clinical practice up to the 
end of the 18th century. Earlier pharmacopoeias were predominantly written by physicians, 
but the 1st edition of the Prussian pharmacopoeia is co-authored by three apothecaries who 
significantly shaped this new type of pharmacopoeia (Schmitz et al., 2005, pp. 573-574). 
For the first time, the influence of natural science becomes apparent not only in the new 




chemical medicines and the vigorous elimination of traditional therapeutics (Schröder, 
1960, p. 11). The committee considered many of them as “überflüssig” (redundant) 
(Preussische Pharmacopöe: aus der lateinischen Urschrift übersetzt, 1813, p. VII). As a 
result, over 300 medicines were removed from the preceding reference text Dispensatorium 
Regium Electorale Borusso-Brandenburgicum (1781), which only 18 years earlier had 
listed over 1,000 medicines (Schmitz et al., 2005, pp. 574-576). The elimination of long-
established medicines reflects the rapid developments in chemistry which led to a desire to 
‘modernise’ medicine to align this field with what the authors perceived as the peak of 
modern science (Tschupp, 1998, pp. 121-122).  
All seven editions of the Ph. Borussica (1799, 1804, 1813, 1827, 1829, 1847 and 1862) are 
written in Latin. Subsequently, these editions were translated into German and annotated by 
commentators to make them more linguistically and technically accessible to the 
professionals who were mandated to follow these guidelines (Straberoh, 1829, pp. VI-VII). 
From its 1st edition in 1799 to its 7th and last edition in 1862, the Prussian pharmacopoeia 
fundamentally influenced the development of other regional German pharmacopoeias and 
asserted its dominance by serving as the foundational text for the German pharmacopoeia of 
the unified Germany. The 7th edition of the Ph. Borussica was adopted ahead of the 
unification by most of German States except for Hannover, Bayern, and Württemberg, 
which maintained their own regional pharmacopoeias until the publication of the Ph. 
Germanica (1872) that superseded all regional German pharmacopoeias. 
4.7.2 Context of the German pharmacopoeia / Deutsches Arzneibuch 
The German pharmacopoeia exemplifies the official position of plant medicine in Germany 
after the unification of the German States in 1871, almost 300 years after the first 
publication of Tabernaemontanus’ New vollkommen Kräuter-Buch (Tabernaemontanus, 
1588). The Pharmacopoeia Germanica (1865) was the first attempt at forming a national 
German pharmacopoeia that harmonised the independent regional equivalents of the 
German States (Schneider, 1966, pp. 195-196). However, it was not until the political 
unification of Germany in 1871 that a common, legally-binding pharmacopoeia was 
introduced on June 1, 1872, to replace all regional variants. It was modelled on the 1867 
update of the German pharmacopoeia from 1865, which in turn was modelled on the 




The need to prepare a unified pharmacopoeia for the German Empire suggests that regional 
medical customs were widespread in 19th century German States. Despite efforts to 
integrate such diversity—as highlighted in the preface of the first edition of Ph. Germanica 
(Hager, 1872)—the preceding Prussian pharmacopoeia had a decisive influence on the 
content of the unified German pharmacopoeia and significantly reduced the listings of 
customary medicines used in other regions. The preface clarifies that even though the listed 
medicines were compulsory pharmacy stock items, neither were individual states precluded 
from adding further medicines to it, nor were local pharmacies hindered in the 
manufacturing and selling of local medical specialities (Hager, 1872, p. VII).  
In the latter part of the 20th century the position of the German pharmacopoeia as the sole 
reference standard for drug specifications in Germany changed. Binding agreements 
amongst EU Member States to develop a common European pharmacopoeia meant that 
national pharmacopoeias lost their place as the primary reference source for drug standards 
(Böhme & Hartke, 1981, p. VII). The 1st European pharmacopoeia was published in 1974 
and was initially binding in eight European countries (Schanz, 2009, p. 45). The integration 
of the Deutsches Arzneibuch with the Europäisches Arzneibuch into one German language 
edition was concluded by 1986 with the publication of DAB 9 (DAB 9, 1986, p. 3). 
Consequently, medicines are regulated in Germany by three complementing standard 
reference texts: the Deutsches Arzneibuch DAB (German pharmacopoeia), the 
Homöopathisches Arzneibuch HAB (Homoeopathic pharmacopoeia for homeopathic, 
traditional, and anthroposophical medicines), and the Europäisches Arzneibuch or Ph. 
Europea (European pharmacopoeia). All three pharmacopoeias are legally binding. 
4.7.3 Commentaries 
Commentaries to the Prussian and German pharmacopoeias were printed as authoritative 
repertories for practising physicians and apothecaries, but were not officially ratified 
(Schmitz et al., 2005, pp. 582-584). They are included in this study as academic appraisals 
of the traditional materia medica. Their endorsement of indications will be analysed and 
compared with indications recorded in contemporaneous clinical textbooks. This 
comparison is to establish how comprehensively commentaries reflected contemporaneous 
medical praxis. Commentaries were popular reference works for clinicians and 
compounding pharmacists. At the turn of the 20th century, thousands of copies were sold, 




1902, pp. V-VI). The last commentary to the Deutsches Arzneibuch (DAB) was printed in 
1993 (Hartke, 1993). Since the harmonisation with the European pharmacopoeia there are 
now ongoing commentaries to this pan-European legislative text. 
4.7.4 Supplements 
As did the Prussian pharmacopoeia beforehand, the German pharmacopoeia significantly 
reduced the list of essential medicines, in particular plant-based medicines. Consequently, 
the supplements to the German pharmacopoeia released by the Deutscher Apotheker-Verein 
(the professional organisation of German apothecaries) became important reference texts 
from the 1870s onwards. These supplements aimed to provide authoritative drug standards 
on those medicinal plants, plant parts, and preparations that were absent in the official 
German pharmacopoeia but required for clinical practice, as trade items between 
pharmacies, and to meet patient demand. Just how many traditional medicines were 
removed from the German pharmacopeia becomes obvious when considering that the 
Deutscher Apotheker-Verein evaluated for its first supplement 2400 medicines, of which 
800 were selected for a monograph entry (Deutscher Apotheker-Verein, 1891, pp. III-IV). 
The monographs in these supplements set quality standards and mirror the structure of 
official pharmacopoeias; they too do not provide guidance on therapeutic use. Their 
practical usefulness to compounding apothecaries and pharmacists meant that they quickly 
went out of print. Updated editions were reprinted in quick succession (Deutscher 
Apotheker-Verein, 1891, 1897, 1906, 1916, 1930a, 1930b). The last supplement was 
printed in 1948, which was a reprint of the 6th supplementary text from 1941 [Erg.-B. 6] 
(Deutscher Apotheker-Verein, 1948). Subsequently, many of their listings became formally 
integrated into the main body of the German pharmacopoeia. Supplements are included in 
this analysis because they reflect contemporaneous use of medicinal plants in regular 
German healthcare.  
4.8 Official monographs as sources of evidence  
Official herbal monographs on legally sanctioned indications of use became necessary once 
such information was absent from pharmacopoeias. This study evaluates the Kommission E 
Monografien (Commission E Monographs), which were authored in the 1980s and 1990s by 
the Kommission E (Commission E), the scientific advisory board of the former 




Health). In addition, it evaluates the European Union Herbal Monographs (EU Herbal 
Monographs) authored by the Committee on Herbal Medicinal Products (HMPC) of the 
European Medicines Agency (EMA). They provide the regulatory guidelines in EU 
Member States for registering herbal medicinal products for self-medication. 
4.8.1  Commission E monographs 
The Commission E was formed in 1978 as part of the enactment of the updated Second 
Medicines Act 1976 (Arzneimittelgesetz 1976 or AMG 76) which provided a framework for 
registering the non-pharmaceutical medicines of phytotherapy, anthroposophical medicine, 
and homoeopathy (Hügel, Fischer, & Kohm, 1995). The new law mandated the explicit 
acknowledgement of pluralism in medicine in order to prevent a monopoly of natural 
science modalities as the exclusive benchmark for decisions on the registration of medicines 
(Deutscher Bundestag, 1976, p. 7). By law, empirical evidence and unique features of plant 
medicines were thus required to be permissible. These stipulations were informed by 
European guidelines for the harmonisation of medicines in the EU market (EWG 
Richtlinien 65/65, 75/318 and 75/319) that authorised alternative evidence for all categories 
of medicines (Müller, 2001, pp. 252-253). Consequently, the remit of the Commission E 
was to evaluate scientific and empirical knowledge on plant drugs. It pioneered the assured 
regulatory acceptance of plant medicines in conventional healthcare. 
The work of Commission E became known beyond Germany for publishing 380 
monographs that evaluated the safety and effectiveness of plant medicines (pflanzliche 
Arzneimittel) so that they could be licensed and medically prescribed in Germany 
(Bundesinstitut für Arzneimittel und Medizinprodukte, 2002). The monographs were 
published between 1984 and 1994 in the German Bundesanzeiger (Federal Gazette). They 
are accepted as supporting evidence for the registration of plant medicines in many 
jurisdictions, including Australia and Canada. The Commission E Monographs were listed 
in the formerly proposed New Zealand Natural Products Bill in New Zealand as a permitted 
source of evidence for therapeutic claims. 
4.8.2 European Union herbal monographs 
The objectives of the Directive 2001/83/EC of the European legislative framework are to 
allow European citizens access to medicines of their choice by ensuring the continued 




characteristics are considered when assessing their quality, efficacy, and safety (Knöss, 
2014a, p. 30; Knöss & Chinou, 2012). The regulations pertain to plant-based drugs only. 
The addition of drug material of animal origin including honey and propolis, chemical 
compounds, isolated plant constituents such as menthol, or amino acids are not permitted, 
although vitamins and minerals are if they are ancillary to the herbal formula (Keller, n.d., 
p. 12). The indications must be appropriate to the traditional herbal medicinal product with 
minor, self-limiting conditions only, and suitable for use without supervision. Such 
remedies must be of a specific strength and posology (dosage), and used orally, externally, 
or through inhalation. The main meaning of external use relates to topical applications to 
the skin; however, if the traditional use of a herbal medicinal product relates to oral, nasal, 
rectal, vaginal mucosae, ocular, or auricular delivery, such delivery is accepted if no safety 
concerns exist (Keller, n.d., p. 14). The simplified registration procedure (Acceptance 
Criteria Article 16a) applies if there is sufficient data on traditional use of the product to 
prove safety and plausible pharmacological effects based on long-standing use and 
experience (Keller, n.d., p. 14).  
There are two different types of monographs: one for “well-established medicinal use” and 
one for “traditional use” (European Medicine Agency, n.d.-a). As per Directive 2001/83/EC 
of the European Parliament and of the European Council, monographs on well-established 
medicinal use are based on scientific literature that embed two criteria: first that there are 
sufficient safety and efficacy data available for its registration, and second that the active 
substance of the medicinal product has been used within the EU for a minimum of 10 years. 
Efficacy is established with at least one RCT or a well-documented observational study. A 
monograph based on traditional use provides a pathway for a simplified registration where 
empirical data, but no clinical trials exist. Claims are accepted on the basis of plausible 
effectiveness and sufficient safety data (Europäisches Parlament, 2004). However, before 
product registration is granted, a product must demonstrate that it has been used for at least 
30 years including at least 15 years within the EU, is intended to be used without 
supervision of a medical practitioner, and is not administered by injection.  
The quality requirements for herbal medicinal products on the European market are 
contained in the EU pharmaceutical legislation and are the same for all herbal medicinal 
product licences in both traditional or well-established use categories (Kroes, 2014). They 




31 December 2016, 1719 traditional use and 859 well-established use registrations have 
been granted across the 28 Member States (European Medicines Agency, 2017, p. 2). 
Regarding monographic assessment, the EMA states on its official website (European 
Medicine Agency, n.d.-a) that “[a] European Union (EU) herbal monograph (formerly 
known as Community herbal monograph) contains the scientific opinion of the Committee 
on Herbal Medicinal Products (HMPC) on safety and efficacy data about a herbal substance 
and its preparations intended for medicinal use. The HMPC evaluates all available 
information, including non-clinical and clinical data, but also documented long-standing use 
and experience in the EU.” Accepted sources of evidence for a traditional use monograph 
include medicine, pharmacy, pharmacology, phytotherapy, and herbal medicine textbooks; 
pharmacopoeia entries; and official expert committee reports (Fan et al., 2012, p. 570). 
Specifically, ESCOP, WHO, and Commission E monographs are accepted as bibliographic 
evidence by HMPC, as are national formularies and compendia. Additionally, a listing in a 
pharmacopoeia can be used as proof of medicinal use of a plant and its preparations during 
the years a monograph has been valid (Committee on Herbal Medicinal Products (HMPC), 
2016, lines 273-281). A product dossier additionally requires any records that reflect the 
existence of a product in the market place over a period of 30 years, although a definite 
template for a simplified application via bibliographic proof is not available due to the 
varied nature of herbal medicinal products in the market place (Stolte & Knöss, 2014, pp. 
64-65). 
EU herbal monographs provide all information necessary for the registration of a product 
for sale, namely approved indications, suitability of use, and safety information, such as 
information regarding undesirable effects and interactions with other medicines. These EU 
monographs aim to support the harmonisation of the European herbal market by enabling 
national competent authorities to refer to one unique set of information on a herbal 
substance or preparation when evaluating marketing applications (Knöss, 2014a, p. 30). 
EMA states that even though Member States are not obliged to follow the monographs, any 
decision by a Member State not to accept the content of a monograph as adopted by the 
HMPC is seen as contradicting that Member State’s role in harmonising a simplified 
registration procedure (Commission of the European Communities, 2008, p. 3). The Mutual 
Recognition Procedure (MRP) which is based on Article 16d of the EU Directive 




(THMPs) to be registered and sold across Europe (Fan et al., 2012, pp. 570-571). According 
to Directive 2001/83/EC of the European legislative framework, all traditional herbal 
medicinal products require pre-marketing authorisation, including documentation of quality, 
safety, and efficacy before gaining access to the market (Steinhoff, 2002, p. 572). Thus, the 
EU herbal monographs provide a regulatory starting point towards the integration of 
THMPs into mainstream medicine across the EU. They afford the regulatory assurance that 
preparations adhering exactly to these monographs fulfil the quality, safety, and efficacy 
requirements for registration. Conversely, EMA does not prohibit other types of 
preparations or indications; however, for those preparations or indications, additional proof 
of effectiveness and safety must be provided before they are accepted for registration.  
References for medicinal plants that are published as a List Entry by the European 
Commission and not by the European Medicine Agency via HMPC provide another 
pathway for harmonisation of the European herbal market. These entries are legally binding 
for all Member States and a safety summary to support a product application is removed 
(Quintus & Schweim, 2012, p. 379). By April 2018, HMPC has published 154 monographs 
of which 13 are for well-established use; the European Commission published 12 List 
Entries. Only two List Entries relate to a combination formula of medicinal plants (Knöss & 
Wiesner, 2017, p. 13). The low number of List Entries predominantly relates to the lack of 
modern genotoxicity data on medicinal plants rather than actual risk concerns (Knöss, 2018, 
p. 374). 
4.9 Authoritative expert monographs as sources of evidence 
This section discusses three key authoritative monographs as sources of evidence for plant 
medicines, two published in Europe (the ESCOP Monographs and HagerROM. Hagers 
Handbuch der Pharmazeutischen Praxis) and one published by the WHO for its Member 
States and the international community. 
4.9.1 ESCOP monographs 
The ESCOP Monographs represent authoritative texts on herbal medicinal products. They 
are permissible references for numerous regulatory authorities, such as the European 
Medicines Evaluation Agency, the Australian TGA, and Health Canada. They were also 
listed as approved evidence in the proposed New Zealand Natural Health and 




work of Commission E which concluded in the mid-1990s. The initial funding for the 
enterprise was provided by the European Commission.  
ESCOP was founded in 1989 and represents national phytotherapy associations from fifteen 
European countries in their discussions with European medicines regulators. Their aim is 
“to advance the scientific status of herbal medicinal products and to assist with the 
harmonisation of their regulatory status at the European level (Kemper & Bruhn, 2005, p. 
702). The organisation collaborates with external herbal medicine experts and with a board 
of supervising editors who contribute to the writing of ESCOP Monographs. From 1997-
2010, this umbrella organisation published 108 authoritative monographs on medicinal 
plants which are continuously updated (Calvo & Cavero). Since 2011, new and revised 
monographs are published electronically (Krenn, Steinhoff, & Escop, 2014, A1). ESCOP 
Monographs list indications, dosage, contra-indications, interactions, and undesirable 
effects together with summaries of pharmacological, clinical, and toxicological data. These 
monographs claim to be a step in the development of harmonised scientific standards for 
herbal medicinal products in Europe (ESCOP, 2003b, p. VII).  
4.9.2 The HagerRom. Hagers Handbuch der Drogen und Arzneistoffe  
HagerROM. Hagers Handbuch der Drogen und Arzneistoffe (until recently known as 
Hagers Enzyklopädie der Arzneistoffe und Drogen) is the continuation of the 
pharmaceutical encyclopaedia authored by Hermann Hager who wrote the seminal 19th 
century text series Handbuch der pharmaceutischen Praxis. Für Apotheker, Ärzte, 
Drogisten und Medicinalbeamte (Hager, 1876). It has been continuously updated over the 
past 130 years and is now electronically published with regular updates (HagerROM, 2016). 
The text integrates the Commission E Monographs, several European pharmacopoeias, and 
the HAB compendium. It further provides information from scientific research, enduring 
clinical textbooks, and folk medicine. Recent editions of this pharmaceutical reference 
textbook reflect the exponential increase in experimental and clinical research into plant 
medicine. Of the five selected legal and authoritative monographs, this monograph contains 
the most comprehensive body of knowledge and has the advantage that it is continuously 
updated. It provides a comprehensive evaluation of existing clinical knowledge combined 




4.9.3 WHO monographs 
The internationally authoritative WHO Monographs are published in the context of the 
WHO’s long-standing strategy to support systems of traditional medicine that have global 
importance in serving an estimated 80% of the world population for their primary health 
needs (World Health Organization, 2012, 2013). From the 1990s onwards the WHO 
developed monographs to support the “assurance of the safety, quality and efficacy of 
medicinal plants and herbal products” (World Health Organization, 1999, p. 1). The WHO 
Monographs provide Member States with expertise and quality standards for the 
incorporation of traditional medicines into their regular healthcare systems and may be 
considered by a national authority on this basis (World Health Organization, 1999, p. 4).  
Over a period of 11 years, the WHO published 116 medicinal plant monographs in four 
volumes (1999, 2004, 2007 and 2009), plus an additional regional volume published in 
Russian (World Health Organization, 2010). This additional volume was specifically 
authored for the Newly Independent States (NIS) and Countries of Central and Eastern 
Europe (CCEE). It comprises monographs on medicinal plants commonly used in that 
region. As the national drug regulatory authorities were fully involved in the development 
of these monographs, they serve as official guidelines. 
WHO (1999, p. 2) states that the purpose of the monographs is to: 
 provide scientific information on the safety, efficacy, and quality control/quality 
assurance of widely used medicinal plants, to facilitate their appropriate use in 
Member States; 
 provide models to assist Member States in developing their own monographs or 
formularies for these or other herbal medicines; and 
 facilitate information exchange among Member States. 
Much work remains to develop further monographs on key medicinal plants from diverse 
biospheres and to update existing monographs with new research. All WHO Monographs 
are freely available on the official WHO website. 
4.10 Summary 
This chapter discussed the methods applied in this thesis and introduced the Historical 




pharmacological data on medicinal plants recorded in historical and contemporary 
textbooks. It further explained the purpose of the triangulation of such data across both 
qualitative and quantitative sources to strengthen conclusions drawn from the data analysed. 
It then proceeded to contextualise the historical significance of the botanical materia 
medica literature in European healthcare before providing a summary of each of the 
selected medical textbooks of the period from the 16th to the 21st century. The purpose of 
this was to provide the rationale for and context of the selected textbooks. This chapter also 
briefly described the historical background of the selected pharmacopoeias, their 
commentaries, and their supplements before explaining the selection of the official and 
authoritative monographs analysed in this study. The next two chapters of this thesis will 
now apply the described methods to cross-analyse pharmacological data on Arnica and St. 




5 ARNICA: THERAPEUTIC INDICATIONS FROM THE 
EARLY MODERN PERIOD (1588/1664) TO 
CONTEMPORARY PHYTOTHERAPY (2007) 
This chapter discusses the therapeutic significance of Arnica montana in European 
healthcare. A botanical, etymological, and historical introduction is followed by a 
longitudinal textual analysis of Arnica’s medicinal uses as recorded in medical textbooks, 
pharmacopoeias and their compendia, and monographs over the past 400 years. An 
additional review of scientific research provides contemporary clinical and experimental 
evidence on Arnica montana.  
The research questions under investigation are twofold. Is this professionally documented 
medical knowledge about the effectiveness and safety of traditional European plant 
medicines a reliable and verifiable source of evidence that can be incorporated into a 
regulatory framework? Secondly, do such historical documentary sources adequately and 
accurately describe medicinal plants, their uses, therapeutic effects, and safety to support 
the regulatory acceptance of traditional medicines? In other words, could these sources 
contribute to an evidence-based framework for New Zealand’s evidence-based polices on 
NHPs?  
5.1 Introduction to Arnica montana in European healthcare 
5.1.1 Botanical profile 
 Arnica montana is an alpine herbaceous perennial herb in the 
daisy family (Asteraceae). It belongs to the genus Arnica, a genus 
which includes about 30 different species (Mabberley, 2017). 
Native to Europe, it grows in alpine meadows and open coniferous 
forests 600-2800 meters above sea level from Scandinavia to the 
Balkans, and from Spain across central Europe to the Ukraine and 
central Asia (Engels & Brinckmann, 2015, p. 1). It can also grow 
in sandy, humic, or peaty lowlands (Info Flora, n.d.), resulting in 
different active constituent profiles (Willuhn, 1972b). Arnica 
reaches a height of about 30-60 cm with a horizontally growing 
Figure 2. Arnica 
montana in Kroeber, 




rhizome and bright yellow-orange tubular flowers. It establishes best in moist swampy areas 
with slightly acidic soil deficient in lime. It disappears quickly in areas that have been 
fertilised for farming purposes.  
Since the 18th century Arnica grew markedly in popularity, owing to traditional use, positive 
experimental research (Stirnadel, 1959), and literary praise in works such as Ode sur les 
Alpes (1773) by the Swiss physician Albrecht von Haller, and by the German poet, 
statesman, and natural scientist Johann Wolfgang von Goethe (Faber, 1953b, p. 179; 
Pelikan, 1975 (1958), pp. 247-249). In the 19th century it became increasingly sought after 
but subsequently endangered (Mayer & Czygan, 2000). In the 20th century, Arnica became 
subject to various regional and EU policies, habitat directives, and wildlife trade regulations 
(Allen et al., 2014; Bundesamt für Naturschutz, p. 3; Engels & Brinckmann, 2015, p. 5; 
May, 2013, p. 2). Romania is currently the main provider of wildcrafted Arnica, which is 
predominantly used for medicinal and cosmetic purposes (Engels & Brinckmann, 2015, p. 
4). Due to its high demand and endangered status, some European phytotherapy companies 
undertake their own cultivations. 
5.1.2 Historical and etymological profile 
Arnica is an old folk remedy prevalent in alpine areas of German speaking countries. It 
holds both medical and cultural significance (Zörnig, 1909, p. 111). Its unique applications 
made it an important remedy in both professional and folk medicine (Tschirch, 1909a, pp. 
1174-1184). Arnica first appears in European medical textbooks during the Middle Ages. It 
was not known by classical Greek physicians, including Hippocrates, Theophrastus, and 
Plinius, who commonly did not describe alpine flora (Faber, 1953b, p. 181; Kreitmair, 
1952, p. 441). The “Alisma” of Dioscorides, which was interpreted by Mattioli as “Arnica”, 
was more convincingly Alisma plantago since Dioscorides describes “Alisma” as 
displaying plantago like leaves with white, not yellow, flowers (Faber, 1953b, p. 181). 
Apart from its role in healthcare, Arnica in alpine areas of German speaking areas was one 
of nine sacred herbs selected to celebrate summer solstice and other regional customs 
(Faber, 1953b, p. 180). 
The German name Arnika may be derived from the Greek arnakis (lamb fur), in reference 
to the plant’s soft, hairy leaves, or ptarmika (sneeze herb), which relates to the unique 
property of Arnica dust to induce sneezing (Zörnig, 1909). Other authors speculate on its 




during the medieval period when the names Arcinca, Arnica, Artinca, and Arnich first 
appeared (Faber, 1953b, p. 179). In the 17th century, Arnica established such a phenomenal 
reputation that it was bestowed the name Panacea lapsorum (Willuhn, 1991), referring to 
Panazee, the goddess of the universal remedy and daughter of the Greek god of medicine, 
Asclepius. The old German name Wohlverlei or Wolferlei may refer to its use in the 
treatment of Intertrigo perinealis, colloquially called wulf (wolf) (Wijnsma, Woerdenbag, 
& Busse, 1995, p. 51). The species’ epithet montana relates to its endemic presence in 
alpine regions.  
Obon recognises that it is common in traditional medicine to refer to medicinal plants of 
different species with shared vernacular names when they have shared morphological and 
aromatic characteristics (Obon et al., 2012). This makes the positive botanical identification 
of medicinal plants discussed in historical medical textbooks both challenging and a high 
priority, being the prerequisite for a sound analysis. It is unclear when Arnica was 
unequivocally cited for the first time, because the plant had various Latin and vernacular 
names in pre-Linnaean times. The German apothecary and pharmaceutical author Heinrich 
Zörnig claims that Arnica was first referenced in Hildegard von Bingen’s 12th century 
medical textbook Physica where it is said to have gone under the name of 
“Wolvisgelegena” (Zörnig, 1909, p. 111). The first unequivocal citation, however, is in the 
14th century medical encyclopaedia by Mathaeus Sylvaticus, who referred to Arnica as 
“arnic” (Mayer & Czygan, 2000). 
The term “arnic” did not immediately have universal currency; 15th and 16th century 
physician-botanists continued to use varied Latin nomenclature such as Doronicum, Caltha 
alpina, Calendula alpina, Nardus celtica altera, Chrysanthemum latifolium, and 
Damasonium primum Dioscoridis, or German terms such as Lucianskraut, Mutterwurz, and 
Fallkraut (Geiger, Nees von Esenbeck, & Dierbach, 1839, p. 808; Saller et al., 1995, p. 50; 
Tschirch, 1909a, p. 34). There are several other regional names, such as Johannisblume or 
Johanniskraut (not to be confused with the other Johanniskraut which refers to St. John’s 
Wort), Stichkraut, Wolferley or Wohlverleih, Bergwegebreit, and Bergwohlverlei (Tschirch, 
1909a, pp. 1174-1175).  
Tabernaemontanus (1664) confirmed that “Wolferley” is the “Arnica” of the medici 
(medical doctors), thus creating a definite link between the noted vernacular and Latin 




montana is also known under various vernacular names such as mountain daisy, mountain 
tobacco, leopard’s bane (Mayer & Czygan, 2000), or mountain marigold (Gerard, 1633, pp. 
740-741). Only since the establishment of the classical binominal taxonomy introduced by 
Swedish physician and botanist Carl von Linné (1707-1778) has Arnica consistently been 
identified in medical textbooks as Arnica montana. 
5.1.3 Official status  
Arnica montana is currently the only officially approved species of the genus Arnica in the 
European pharmacopoeia, regulations that are legally binding for European Member States. 
Arnica chamissonis LESS. ssp. foliosa, an Arnica species native to North America, was 
official in the German pharmacopoeia for a short time from 1987 (DAB 9) to 1993 (DAB 
10) to provide an alternative crop to Arnica montana, a plant which is difficult to cultivate. 
Historically, other species from the genus Arnica were also used in medicine (Obon et al., 
2012). For example, Arnica alpina, Arnica foliosa, Arnica longifolia, and Arnica 
sachalinensis (REGL.) have all been used for therapeutic purposes (Willuhn, 1972b; 1981, 
p. 3). Arnica fulgens, Arnica sororia, and Arnica cordifolia were official in the US National 
Formulary VIII (Willuhn, 1972b), but did not achieve official status in Europe. It is 
plausible that these species also have medicinal properties. 
5.2 Arnica montana in medical textbooks 
The longitudinal textual comparison of medicinal uses of Arnica montana as recorded in 
authoritative medical textbooks from the 17th to the 21st century highlights that despite 
changes in paradigmatic explanatory models of health and illness, key indications remained 
remarkably consistent. Table 1 (below) provides an overview of the use-categories 
addressed by the listed indications. Indications relating to the use-categories musc-skel, 
nerve, skin-mucous, and tonic were consistently cited over the past 400 years, whilst 
indications relating to card-vasc and respiratory use-category were consistently endorsed 





































































































card-vasc 0 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
gastro-
intest ✓ ✓ ✓ ✓ ✓ 0 ✓ ✓ 0 0 0 
gyn ✓ ✓ ✓ ✓ 0 (✓) ✓ 0 0 (✓) (✓) 
head 0 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 0 0 
infection 0 ✓ ✓ ✓ ✓ 0 ✓ 0 0 (✓) ✓ 
liver-spleen ✓ ✓ 0 0 0 0 0 0 0 0 0 
musc-skel ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
nerve ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
respiratory 0 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
skin-
mucous ✓ 0 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
tonic ✓ ✓ ✓ ✓ (✓) ✓ ✓ ✓ ✓ (✓) ✓ 
uro ✓ ✓ ✓ 0 ✓ 0 ✓ 0 0 0 0 
Dark green rows refer to continued use 
Light green rows refer to intermittent but present-day use 
White rows refer to present-day discontinuation 
Brackets (✓) reference historical medicinal uses or folk medicine use 
 
The prefaces to the evaluated medical textbooks reveal that Arnica was a plant drug highly 
esteemed by the medical profession until the 1850s, after which time its fame, in contrast to 
folk medicine, started to wane. During WW1 and WW2, it was extensively employed again 
in injury recovery, which boosted its medical status (Stirnadel, 1959, p. 1518). Today, 
Arnica is mainly applied in complementary healthcare and in self-medication. Conventional 
healthcare relies predominantly on synthetic drugs and advances in trauma care to deal with 
issues traditionally addressed with Arnica. The most striking change in medicinal use of 
Arnica over the past 400 years, however, is its documented systemic and topical use until 
the mid-1980s, when European regulators approved topical use of Arnica only, taking a 
more conservative approach to benefit-risk ratios for plant medicines.  
The following sections discuss the pharmacological and pharmaceutical profile of Arnica in 
the European medical literature in more detail. When historical indications are summarised 




an analysis would not be required. However, in the context of this thesis, observations on 
medical trends provide supplementary insights on continuities and discontinuities of plant 
indications. The analysis of this first exemplar delivers therefore some explanatory context 
on plant applications over the past 400 years in addition to the tabulated data on recorded 
historical and contemporary indications.  
5.2.1 Arnica montana in Tabernaemontanus (edition 1664) 
Tabernaemontanus (1664, pp. 714E-715A ) discusses Arnica and its therapeutic 
applications under Chalta [Caltha] alpina, in German termed “Mutterkraut” and 
“Mutterwurz”, which the author identifies as the ‘Arnica of the physicians’. This passage is 
a reprint of the original Arnica manuscript from the 1st edition (1588) of the Neuw 
Kreuterbuch, where Tabernaemontanus accurately refers to the Arnica taxonomy of 
Rembert Dodoens (1516 – 1585), Dutch imperial physician and botanist, and that of Conrad 
Gessner (1516-1565), Swiss physician and botanist. The approximation of the translation is 
provided in Appendix 3, and the English translation of the pharmaceutical and 
pharmacological data is tabulated in Appendix 4.  
5.2.1.1 Annotations to the 1664 edition 
The 4th edition of New vollkommen Kräuter-Buch, which is used in this analysis, contains 
annotations by the Bauhin editors Caspar and Hieronymus Bauhin, both physicians, 
botanists, and successive professors at the University of Basel, Switzerland. All annotations 
attributed to Arnica itself are included in this analysis. As noted in Appendix 4, the Bauhin 
annotations relate to general uterine complaints, to inducing menstruation, to stopping 
diarrhoea, and to detoxifying animals. A cross-reference check with Gerard’s The Herbal or 
General History of Plants (Gerard, 1633, pp. 740-741) confirms a contemporaneous 
documentation of Arnica’s therapeutic uses in gynaecological issues, in infections, and for 
detoxification. This matches the Arnica annotations by the Bauhin editors to the 1664 
Tabernaemontanus edition. Thus, Gerard’s monograph on Arnica validates the inclusion of 
the Bauhin editors’ addendums to the Arnica monograph from 1664. The annotated list of 
indications recorded in the 4th edition of the Neu vollkommen Kräuter-Buch for Arnica 
therefore addresses eight use-categories: gastro-intest, gyn, liver-spleen, musc-skel, nerve, 




It is surprising that gynaecological indications were initially left out of Tabernaemontanus’ 
1588 edition, as the vernacular name for Arnica, “Mutterkraut” and “Mutterwurz”, refers to 
the uterus. Records for Arnica in gynaecology were known at least since medieval times. 
For example, Italian physician and botanist Matthaeus Sylvaticus (c. 1280- c. 1342) listed 
Arnica for abortive purposes in his influential medical encyclopaedia (Mayer & Czygan, 
2000). Tabernaemontanus was well aware of the usage of Arnica for gynaecological 
purposes since he had edited Wirsung’s pathology book (Wirsung & Tabernaemontanus, 
1577). Here, Arnica is listed as “Mutterwurz” to be used for infertility due to amenorrhoea 
(p. 239), for inducing menstruation (p. 382), and for unspecific complaints of the uterus (p. 
380, 382). Tabernaemontanus may have distinguished between information suitable for the 
medical profession only (Wirsung’s pathology book), and what was appropriate for an 
encyclopaedia also used in lay healthcare (Neuw Kreuterbuch).   
The editors of the 4th edition of Tabernaemontanus’ Neu vollkommen Kräuter-Buch, 
mistakenly attribute further indications to Arnica that relate to a different species. This 
mistaken botanical attribution was caused by the Dioscorides commentary of Pietro Andrea 
Mattioli (Matthiolus, 1501-1577), an influential Italian physician and botanist who claimed 
the “Groß Lucians Kraut” to be the same plant as the “Mutterkraut” thus combining the 
therapeutic uses of two distinctly different plants (Tabernaemontanus, 1664, p. 1116). This 
conflation was an incorrect (pre-Linnean) attribution as already noted by Dodoens in his 
Cruydt-boek from 1554 (Mayer & Czygan, 2000). In contrast to Mattioli, the German 
physician Adam Lonitzer (1528-1586) attributes in 1573 “Groß Lucians Kraut” to 
“Wasserwegerich” or “Froschlöffel” (Alisma plantago). This is plausible as they share 
identical botanical characteristics (Mayer & Czygan, 2000). Therefore, all indications of 
“Groß Lucians Kraut” that the Bauhin editors claim for Arnica are excluded in this analysis 
and only those that genuinely pertain to Arnica are listed.  
5.2.1.2 The understanding of heart and circulation in the early modern period 
Neither the original 1st edition (1588) nor the 4th edition (1664) of Tabernaemontanus’ Neu 
vollkommen Kräuter-Buch refer to the use of Arnica in heart conditions or as a circulatory 
stimulant. These indications were, however, acknowledged by later authors, for instance the 
English physician John Gerard, who translated and copied significant portions of the text. In 
reference to the monograph of Caltha, Gerard describes the plant “Mountaine Marigold” 




The floure of the Marigold is of temperature hot, almost in the second degree, 
especially when it is dry: it is thought to strengthen and comfort the heart very 
much, and also to withstand poyson, as also to be good against pestilent Agues, 
being taken any way. Fuchsius hath written, That being drunke with wine it bringeth 
downe the termes, and that the fume thereof expelleth the fecondine or after-
birth…Conserue [conserve] made of the flouers [flowers] and sugar taken in the 
morning fasting, cureth the trembling of the heart, and is also given in time of 
plague, or pestilence, or corruption of the aire. (Gerard, 1633, pp. 740-741). 
Gerard’s reference to Arnica’s indication as a heart tonic may have owed to his early 
exposure to William Harvey’s experimental confirmation of the circulation of blood 
(Harvey, 1628), a physiological fact which was not yet known when Tabernaemontanus 
first published his Arnica monograph (1588). The discovery of Arnica as a heart tonic 
illustrates that a medical tradition is not static but can expand with new medical insights. 
5.2.2 Arnica montana in medical textbooks from 1790 to 2007 
This section analyses the pharmacological and pharmaceutical profile of Arnica recorded in 
authoritative medical reference textbooks from the late 18th century to current 
phytotherapeutic textbooks by practising physicians in the 21st century. Appendix 5 
provides an overview of all therapeutic indications listed for Arnica in these sources over 
this period. 
5.2.2.1 Arnica in Löseke (1790) 
The 6th edition of the medical textbook Materia Medica, authored by Löseke and annotated 
by Gremlin (Löseke & Gmelin, 1790), reveals that Arnica was used more expansively in 
patient care than in the early modern period. From the 1700s onwards, a significant amount 
of experimental research into the pharmacology of Arnica expanded its medicinal 
applications (Stirnadel, 1959) as did new insights into human anatomy and pathophysiology 
(Erley, 1965, p. 232). 
The Arnica monograph published in the Materia Medica covers indications belonging to 12 
use-categories (see Appendix 5). Eight therapeutic actions align with actions already 







 bitter tonic  
 detoxifying 
 diuretic 
 emmenagogue / uterine tonic 
 tissue healing. 
In contrast to Tabernaemontanus’ Neu vollkommen Kräuter-Buch, the 18th century text 
notes three new treatment areas: indications relating to the cardio-vascular system, based on 
insights from experimental research into the circulatory stimulant actions of Arnica; the 
treatment of eyes, an anatomical area previously not specifically mentioned; and infection, 
specifically the treatment of malaria. These indications expand on the traditional medicinal 
uses of Arnica. 
The Materia Medica lists three different extraction methods, all accomplished with fresh 
Arnica flowers. The water and beer extracts were already noted by Tabernaemontanus, 
while the wine extract is newly noted in relation to Arnica (Löseke & Gmelin, 1790, p. 
171). The 18th century textbook lists for the first time an enema preparation, compounded 
with Arnica and mucilage drugs for those who cannot tolerate Arnica preparations per oral 
(Löseke & Gmelin, 1790, p. 171). Arnica enema is subsequently listed in Richter (1827) 
and Strumpf (1855); it is last mentioned in the 4th edition of the commentary to the German 
pharmacopoeia by Schneider & Süss (1902, pp. 421-422). Other preparations noted in 
Löseke were not found elsewhere and were therefore considered speciality preparation of an 
individual practitioner. They were discounted as traditional preparations.  
5.2.2.2 Arnica in Richter (1827) 
The second volume of Richter’s Ausführliche Arzneimittellehre. Handbuch für praktische 
Aerzte (Richter, 1827, pp. 140-153) classifies Arnica under Scharfe Mittel, a term which 
refers to acrid remedies. Richter (1827, p. 141) describes Arnica as an ‘extremely important 
remedy’ which cannot be replaced by another drug. As displayed in Appendix 5 the 
indications match Löseke’s indications to a very high degree, meaning that the 
recommended clinical applications of Arnica did not significantly change despite increasing 




Richter more precisely describes the beneficial circulatory actions of Arnica on the brain, 
and he introduces its cleansing effect on wounds and infected ulcers. At the same time, he 
discontinues the indication of urinary gravel, whilst still listing Arnica as a diuretic (uro 
use-category), and its use as a bitter tonic (liver-spleen category). This illustrates that 
physicians in clinical practice did not simply copy other peer’s recommendations but 
evaluated them with their own empirical observations. 
Richter (1827, p. 141) explains that Arnica activates the veins, arteries, lymph vessels, and 
nerves, and also primes their ‘irritability’ (Irritabilität) and ‘sensibility’ (Sensibilität). The 
author references capillaries, mucous membranes and connective tissues, sinews, tendons 
and ligaments, synovial skin, the periosteum, pleura and peritoneum, and outer skin as areas 
where actions are noted. The author also highlights Arnica’s therapeutic effect against 
processes of putrefaction. In addition, he describes Arnica’s invigoration of nerves, 
muscles, and vessels, all of which are beneficial to congestion of the brain and abdomen. He 
notes that in small doses Arnica increases the ability of the skin, lungs, and kidneys to both 
reabsorb and secrete fluid. 
Richter (1827, p. 148) argues that Arnica is best used immediately after an injury and states 
that in the treatment of after-effects of stroke it may only be effective in the first six weeks. 
The author summarises the following therapeutic effects of Arnica: 
 anti-ecchymotic 
 anti-haemorrhagic (after an injury or in passive bleeding from various organs) 
 anti-inflammatory (in rheumatism) 
 tissue healing. 
Richter (1827, pp. 141-143) cautions that excessive doses can cause inner agitation, heart 
pressure, stomach and digestive troubles, vomiting, diarrhoea, colic, tightening of the chest, 
and issues with urination. The documentation of safety warnings shows that the medical 
profession was aware of the dose-dependent side-effects of Arnica. 
5.2.2.3 Arnica in Strumpf (1855) 
The Arnica entry by Strumpf (1855, pp. 46-56) is detailed and it highlights the continued 
importance of Arnica in medical care. The emerging divergent value judgments on 
medicinal plants in the context of a shifting medical theory had little effect on Strumpf’s 




5). One difference is that the author no longer recommends the use Arnica as a diuretic (uro 
use-category). Strumpf demonstrates his clinical expertise and pharmacodynamic 
understanding of Arnica by including mucous membrane soothing plants such as Licorice in 
a recipe to counteract Arnica’s potential acrid effects, and by offering various organ-
specific recipes where Arnica is used as a synergist to support circulatory stimulation.  
5.2.2.4 Arnica in Hager (1876) 
Despite shifts in medical theory now clearly evident by the end of the 19th century, the 
evaluation by Hager (1876, pp. 462-467) of Arnica’s therapeutic applications in patient care 
does not reveal fundamental changes. Except for discontinuing indications relating to 
gynaecology, rheumatism, and to the stopping of passive bleeding, the author lists 
complaints belonging to all use-categories recorded twenty years earlier by Strumpf 
(Strumpf, 1855, pp. 46-56). Hager focuses, however, on the most important clinical uses, all 
of which reflect long-standing clinical practice. He restores Arnica’s indication for the 
promotion of diuresis after Strumpf de-listed it 20 years earlier. 
Hager (1876, p. 463) describes the stimulant effects of Arnica on nerves, blood vessels, 
respiration, blood circulation, and the excretion of urine and sweat. The listed systemic uses 
are as follows: 
 circulatory stimulant 
 paralysis from brain and spinal illnesses 
 cerebral concussion 
 infections affecting the gastro-intestinal system 
 infections causing putrefaction (Nerven- und Faulfieber) 
 external and internal trauma 
 epilepsy 
 acceleration of respiration. 
The listed topical uses are as follows: 
 sprains and strains 
 haematoma 
 wounds 




The author lists several commercial preparations containing Arnica for the treatment of 
chest ailments, wounds, eye issues, sciatica, nerve injuries, and cancer.  
Unlike Richter and Strumpf, Hager no longer groups plants with the same pharmacological 
actions under the same class and order but organises his textbook into alphabetically 
sequenced monographs. This aligns with the presentation of the materia medica in the 
German and its preceding Prussian pharmacopoeia. Hager also does not reference antique or 
medical authorities from the early modern period. For the first time, a medical textbook 
recounts a case report of accidental poisoning with Arnica tincture (Hager, 1883c, p. 115). 
The tincture was not unequivocally identified, but if it was indeed an Arnica tincture, the 
dose of 60-80g of a 1:3 tincture (the extraction ratio of Arnica flower extract listed in 
Hager) would have represented 20-26g of drug material compared to the 0.3-1g 
therapeutically recommended. This case report served as an important warning against 
overdosing with Arnica. 
5.2.2.5 Arnica in Schulz (1919) 
Schulz (1919, pp. 293-299) also discusses Arnica at length, listing indications belonging to 
seven use-categories (card-vasc, head, musc-skel, nerve, respiratory, skin-mucous, tonic 
(Appendix 5). His listings reflect the same use-categories as the previous authors. The 
majority of indications are discussed in the card-vasc, musc-skel, and skin-mucous use-
categories. 
Indications noticeably decrease in Schulz’s (1919) text compared with indications listed in 
medical textbooks up until the latter part of the 19th century. This points to a decline in 
importance of Arnica in regular medicine during this period. The omitted indications relate 
to the gastro-intestinal tract (diarrhoea and infections), to gynaecology (to promote 
menstruation and to cleanse the uterus after birth), to the head (concussion and its after 
effects), to the musculo-skeletal system (gout and rheumatism), to the head (epilepsy), and 
to the urinary tract (diuresis). The de-listing of Arnica in the treatment of rheumatism and 
gout may be linked to the 3rd commentary to the Ph. Germanica which also discontinued 
these indications (Hager et al., 1891). Schulz still mentions, however, previous medicinal 
uses of Arnica to reabsorb cerebral bleeding in strokes and as a strengthening stimulant, 




The author also reports that in the previous century Arnica was still an important wound, 
heart, and circulatory remedy. He notes the medical profession’s increasing lack of interest 
in the therapeutic use of Arnica owing to perceived overuse, and a shift in benefit-risk 
considerations. Schulz (1919, pp. 293-295) highlights, however, that Arnica remained a 
popular remedy in German households, where Arnica tincture was said to be commonly 
stocked in first aid cabinets for self-medication. He discusses the contemporaneous use of 
Arnica in veterinary clinics to treat sprains in animals from overexertion, to treat 
overworked vocal cords in singers, and to induce abortion (an illegal folk medicine 
application). He elaborates both on the therapeutic benefits of Arnica and on its side-effects 
when the plant drug is not used appropriately. As a pharmacologist, he emphasises that as a 
matter of course all strongly acting drugs must be taken with safety considerations in mind.  
5.2.2.6 Arnica in Madaus (1938) 
Madaus (1938b) reverses the trend towards reduction of clinical uses documented in 
medical textbooks and presents a more comprehensive list of indications for Arnica 
montana than was common in the previous 60 years. Published before WW2, this 
monograph re-lists ailments that became absent in medical textbooks from the last quarter 
of the 19th century onwards (see Appendix 5). Madaus’ Arnica monograph is significant 
because it is informed by a survey of therapeutic plant uses by German medical 
practitioners. This textbook covers indications in 11 use-categories and complements the 
monograph by Schulz (1919), published 20 years earlier, with traditional indications 
belonging to three use-categories (gastro-intest, infection, and uro). All were listed 
previously by Hager in the last third of the 19th century. Madaus further lists coronary 
insufficiency, specifically Angina pectoris, atherosclerosis Adipositas cordis, and cyanosis 
as modern indications. 
Two novel preparations are discussed in this text; an injection of Arnica solution and 
Madaus’ innovative “Teep” (a trituration of fresh plants in a milk sugar base). While the 
latter continues to be listed as an official preparation in the compendium to the German 
pharmacopoeia (the Homöopatisches Arzneibuch), these preparations are not listed in the 




5.2.2.7 Arnica in Kroeber (1948) 
The Arnica monograph by Kroeber (1948, pp. 37-42) published in his seminal textbook Das 
neuzeitliche Kräuterbuch. Die Arnzeipflanzen Deutschlands in alter und neuer Betrachtung 
records indications across eight use-categories (card-vasc, gastro-intest, head, musc-skel, 
nerve, respiratory, skin-mucous, and tonic). Apart from specific discussions of injury 
treatments which were more prevalent during war times, this clinical textbook closely 
reflects the main indications for Arnica as recorded by Madaus before WW2. Kroeber’s 
text, however, streamlines indications relating to the same cluster of complaints, and did not 
continue with the re-uptake of traditional pre-WW2 indications relating to gynaecology, 
infections, and urinary tract issues (see Appendix 5). 
In response to the necessities of war, Kroeber (1948, p. 40) focuses on the use of Arnica in 
the treatment of war injuries and wounds; for example, he recommends Arnica to stop 
bleeding in cerebral concussions and in the eye. These treatments are consistent with the 
usage of Arnica during WW1 when it had reclaimed its place in restorative care for injuries 
and bleeding wounds (Spaich, 1978, p. 87). Not least because of the scarcity of other drugs 
during times of war, Arnica remained an important plant in European healthcare with an 
estimated yearly harvest by the general population of around 50,000kg of dried Arnica 
(Faber, 1953b, p. 187).  
5.2.2.8 Arnica in Weiss (1974) 
In his Lehrbuch der Phytotherapie, Weiss (1974) lists therapeutic uses of Arnica under 
different body systems and medical problems rather than under a dedicated plant 
monograph as presented by previous authors. He streamlines the indications previously 
recorded by Kroeber to the most frequent clinical problems. They relate to six use-
categories (cardio-vasc, musc-skel, nerve, respiratory, skin-mucous, and tonic) (see 
Appendix 5). He expands on the internal uses of Arnica for coronary and general blood 
circulation, for Angina pectoris, and for the ageing heart. He de-lists, however, the long-
standing usage of Arnica for the treatment of gastro-intestinal infections, perhaps due to the 
availability of effective antibiotic treatments, and for head injuries, an area where trauma 
treatment had exponentially developed since WW2 (gastro-intest and head use-categories). 
While there was little change in clinical usage of Arnica before and after WW2, there was a 





5.2.2.9 Arnica in Saller, Reichling, and Hellenbrecht (1995) 
The Arnica monograph by Saller, Reichling, and Hellenbrecht (Saller et al., 1995) is based 
on long-standing medicinal uses, clinical experience, and scientific evaluation of clinical 
studies and experimental research. All sources are clearly referenced with the pertinent 
literature for independent cross-validation. Indications are discussed across three areas of 
therapeutic usage: traditional, clinical and official as approved by the regulatory 
Commission E Monograph Arnicae flos. The scientifically endorsed indications relate to 
five use-categories; card-vasc, musc-skel, nerve, respiratory, and skin-mucous. These are 
consistent with those of previous authors who based their texts predominantly on empirical 
evidence (see Appendix 5). The biggest distinction between this medical textbook and 
previous textbooks is in the card-vasc use-category. Until Weiss (1974, p. 177), internal 
uses of Arnica to support heart function and blood circulation were clinically discussed and 
endorsed, but Saller et al. (1995, p. 50) newly list them under folk medicine. This 
distinction may have arisen from changes in German regulations during the 1980s which 
implemented a new approach to healthcare based on preventative measures of health and 
safety. These regulations restrict the use of Arnica to external use only.  
The Arnica monograph by Saller et al. (1995, pp. 49-55, 405) incorporates all approved 
claims of the Commission E Monograph, a monograph which confirms Arnica’s anti-
inflammatory, analgesic, and antiseptic properties (Kommission E, 1984a). The authors 
quote experimental and rodent research. It points to Arnica’s antiseptic, antibiotic, anti-
bacterial, anti-fungal, anti-inflammatory, anti-rheumatic, lipid- and cholesterol-reducing, 
anti-sclerotic, blood-pressure lowering, immune stimulant, cytotoxic, antitumor, diuretic, 
cholagogue, and granulopoiesis stimulant actions (Saller et al., 1995, p. 52). These 
interpretations, deduced from basic science methodologies, may elucidate the empirical use 
of Arnica preparations in TEM. 
In contrast to the Commission E Monograph (1984a) which exclusively refers to Arnica 
flowers, the authors list both officially and traditionally recognised active parts of Arnica, as 
folk medicine continues to use Arnica herb (aerial parts of the plant) and root (rhizome). 
These are the same plant parts that were officially sanctioned in the German pharmacopoeia 
until the end of the 19th century. It is noteworthy that in 1978 the supplementary text to the 
German pharmacopoeia, the Homöopathisches Arzneibuch (HAB) (1978, p. 205) restored 
Arnica rhizome as an officially endorsed plant part. Saller et al. (1995, p. 54) state that 




oil which must be made with dry flowers. Formally approved preparations are tincture, 
infusion, and oil of Arnica, as well as topical creams. 
5.2.2.10 Arnica in Bäumler (2007) 
In Bäumler’s (2007) clinical textbook the therapeutic applications of Arnica come full 
circle. Grounded in the experiences of a seasoned physician of both conventional and 
natural medicine, the Arnica monograph in Heilpflanzenpraxis heute: Porträts, Rezepturen, 
Anwendung reflects traditional indications based on repeated clinical observations 
complemented with insights from newer scientific methodologies. Bäumler (2007, pp. 61-
63) recommends therapeutic preparations of Arnica in seven use-categories; card-vasc, 
infection, musc-skel, nerve, respiratory, skin-mucous, and tonic (see Appendix 5). In line 
with previous medical authors pre-1980, he describes the internal use of Arnica at low doses 
of 3-10 drops (1:10 tincture) for weakness of the heart, for Angina pectoris, and as a tonic in 
exhaustion from overexertion (Bäumler, 2007, pp. 63, 646). Bäumler notes that allergic 
reactions are rare and further states that when Arnica is taken correctly side-effects in 
patients are minimal (Bäumler, 2007, pp. 640-641).  
5.2.3 Summary results of empirically endorsed medicinal uses of Arnica montana 
listed in the medical literature: What remained, what changed 
The following section provides the results from triangulating qualitative data recorded in 
independent medical textbooks on the medicinal uses of Arnica montana over a period of 
400 years. The data show several indications that were consistently endorsed over this 
period. When comparing historic with present-day therapeutic uses of Arnica, the results 
displayed in Appendix 5 demonstrate uninterrupted consistency of empirical evidence on 
two clusters of therapeutic indications.  
Based on repeated and professionally evaluated clinical observations, practising physicians 
over this period considered Arnica to be beneficial for complaints of the musculo-skeletal 
and nervous systems. Clinical usage over several centuries means that these treatments fulfil 
the tradition-of-use criteria well beyond the suggested definition of tradition by the WHO of 




Table 2. Empirically endorsed medicinal uses of Arnica montana listed in medical 
textbooks over at least 400 years. 
Use-category Indications 
musc-skel injuries, sprains and strains, torn muscles and ligaments; bruises, oedema, haematoma 
nerve pain related to musculo-skeletal system and nerves 
 
In the 18th and 19th centuries, insights from experimental research expanded prior use of 
Arnica thus demonstrating that tradition is not static. The following are additional 
therapeutic indications noted over the past 200 years; they relate to four use-categories: 
Table 3. Medicinal uses of Arnica montana listed in medical textbooks since the end 
of 18th century.  
Use-category Indications 
card-vasc circulatory insufficiency (since Löseke 1790) 
varicose veins, phlebitis (topical) (since Kroeber 1948) 
respiratory breathing difficulties / catarrh (since Löseke 1790 until Weiss 1974) 
sore throat (infection) (since Madaus 1938) 
skin-mucous ulcers, wounds (since Richter 1827) 
boils (since Schulz 1919) 
mouth and throat inflammation (since Strumpf 1855) 
tonic heart tonic in exhaustion and debility (since Schulz 1919) 
 
The indications of Arnica for circulatory insufficiency, varicose veins, phlebitis, sore throat, 
ulcers, wounds, boils, mouth and throat inflammation, and as a heart tonic in exhaustion and 
debility, meet the EU tradition-of-use criteria of 30 years of continued medicinal use. 
However, the therapeutic claims for Arnica as an internal tonic and as a circulatory and 
coronary stimulant, including for the improvement of breathing, pose a regulatory 
challenge. These indications fulfilled the tradition-of-use criteria until the 1980s when the 
Commission E departed from tradition and exclusively authorised external uses of Arnica. 
Internal uses became re-classified as historical uses, causing a gap in the legal transmission 
of medicinal knowledge about the correct internal uses of Arnica. Remarkably, despite 
regulatory cautions since the 1980s, Arnica tinctures and infusions continue to be discussed 
for internal use in some medical textbooks, for instance in Bäumler (2007, pp. 63, 646). 
Traditional internal uses of Arnica are also noted in textbooks by European phytotherapists 




26-27; Willfort, 1975, pp. 53-54; Zizmann, 1996, pp. 218-220). Similarly, such low dose 
application is evident in customary practice (Mességué, 1977, pp. 31-32). Based on this 
continued internal use of Arnica in clinical practice, the indications ‘tonic’ and ‘circulatory 
stimulant’ would benefit from a renewed regulatory benefit-risk assessment to determine 
their regulatory status since toxicity concerns of Arnica are dose-dependent.  
A detailed discussion on indications recorded in the evaluated medical textbooks is 
provided in Appendix 6. This deeper data analysis serves the purpose of illustrating the 
initial steps undertaken in the development of the Historical Assessment Tool as a method 
for the systematic organisation of tradition-of-use data of medicinal plants. It is conducted 
for the first exemplar (Arnica) only. 
5.2.3.1 Dosage range recorded in medical textbooks 
Physicians noted a dosage regime between 200mg and 2g of dried flowers or roots, 
commonly prepared as a medicinal tea taken 3x per day. The lower end of the dosage lines 
up with the commentary to DAB 8  (Böhme & Hartke, 1981, p. 165) that recommends an 
infusion of 200mg of flowers in 200ml hot water, taken by tablespoon full 10ml at a time. 
Most medical textbooks (see Historic Data Excel spreadsheet), limited the maximum 
recommended dosage to 1g of flower or root, as exemplified in Hager (1876, pp. 463, 465). 
Regarding extracts, medical textbooks recommend a dosage range of a 1:10 tincture 
between 0.12ml and 1.2ml (10 to 30 drops) taken 3 times per day. This dosage also lines up 
with the recommended safe dosage range listed in the commentary to DAB 8, which is 0.3-
0.5g (20-30 drops) of tincture (Böhme & Hartke, 1981, p. 165). Since the 19th century, 
medical textbooks caution against overdoses with Arnica due to toxic side-effects. 
5.2.4 Arnica montana in the Prussian and German pharmacopoeias 
This section examines official guidelines on Arnica montana listed in the Prussian and 
German Pharmacopoeias and their unofficial but normative compendiums. The purpose of 
analysing this body of literature is twofold; firstly, to triangulate their data with the data of 
the evaluated medical textbooks, and secondly to investigate their suitability as 
bibliographic evidence to substantiate claims on traditional uses of medicinal plants. It does 
so by contrasting the data recorded in this body of literature with data recorded in the 




5.2.5 The Prussian pharmacopoeia 
Analysis of the Prussian pharmacopoeia, published in seven editions between 1799 and 
1862, reveals a fundamental change in the regulatory approach to the European materia 
medica. As said before, up to the end of the 18th century guidelines on pharmaceutical 
preparations and their related therapeutic applications appeared together, but the committee 
of the 1st edition of the Ph. Borussica transformed the pharmacopoeia structure into a 
reference work for drug specifications and pharmaceutical manufacturing only. 
Consequently, the sole purpose of the Prussian pharmacopoeia was to provide regulatory 
guidelines on which plant parts were mandatory pharmacy stock items, their preparations, 
and quality standards.  
The preface to the 4th edition of the Ph. Borussica (Staberoh, 1827, p. IX) highlights the 
emerging competing interest between pharmacists and practising physicians. Whilst the 
authors state that a pharmacopoeia must meet the wishes of both healthcare professions, it is 
interesting to note that physicians are reprimanded for expecting too many customary 
medicines to be available. No doubt, in the context of pharmacopoeias, the trend towards 
emphasising technical over clinical viewpoints was made easier with the separation of 
technical manufacturing guidelines from therapeutic considerations for patient care. This 
increasing influence of natural science on the medical repertoire available to European 
physicians proved to have long-lasting consequences (Tschirch, 1909b, p. 4). The 7th and 
last edition of the Ph. Borussica (1862) confirms the upsurge of industrially mass-produced 
pharmaceutical drugs in place of traditional plants and their applications (Völcker, 1862).  
The regulatory separation between drug standards and therapeutic applications remains in 
Europe and other Western countries to this day. It is also reflected in New Zealand where 
Medsafe3, a business unit of the Ministry of Health, is the authority responsible for the 
regulation of technical aspects of therapeutic products, while PHARMAC and ACC are 
responsible for judging their therapeutic suitability for funding (Ministry of Health). 
5.2.5.1 Official plant parts in the Prussian pharmacopoeia 
The Arnica montana monograph published in the 1st edition of the Prussian Pharmacopoeia 
lists flower, herb, leaf, root, and whole plant as mandatory official plant parts (1799, pp. 21, 
 





29, 49). They were deemed essential drugs until the 5th edition published in 1829 (Dulk, 
1847). The 6th edition removed the mandatory availability of Arnica leaves and Arnica herb. 
Arnica flowers without receptacle became the official drug from the 6th edition onwards. 
The 7th edition removed the mandatory availability of Arnica root. Therefore, by 1862 
Arnica flowers without receptacle remained the only official drug (Völcker, 1862, p. 80). 
Commentaries to the 2nd (Juch, 1808), 3rd (Juch, 1817), and 4rd (Juch & Raab, 1830) 
editions of the Ph. Borussica provide some insights into the rationale for changing the 
official plant drug from Arnica flower with receptacle to Arnica flower without receptacle. 
It is noteworthy that the commentator is from southern Germany which highlights the far 
reach of the Prussian pharmacopoeia. Carl Wilhelm Juch, Bavarian Professor of Chemistry, 
Natural Science and Nutrition, notes that the receptacles of Arnica flowers are commonly 
contaminated with eggs or larvae of the Arnica fly (Tephritis arnica) when harvested well 
past flowering (Juch, 1817, p. 246). So that the Arnica flowers avoid contamination, he 
recommends harvesting them just as they open. However, in line with other commentators 
he points out that such contaminations are not the real reason for potential irritation in the 
gastro-intestinal tract; rather, the cause can be found in the acrid active constituents of the 
plant itself (Dulk, 1833c, pp. 109-112; Juch & Raab, 1830, pp. 24-25). Nonetheless, the 6th 
(1847) and 7th (1862) editions of the Prussian pharmacopoeia mandate the use of Arnica 
flowers without receptacle (Hager, 1865; Mohr, 1849). 
5.2.5.2 Official preparations in the Prussian pharmacopoeia 
The Prussian pharmacopoeia endorses three Arnica preparations; hot water infusion, 
ethanol-water extract, and powder. The 4th edition discontinues the ethanol-water extract 
made with the whole Arnica plant and replaces it with an extract made with Arnica flowers 
only (Juch & Raab, 1830; Straberoh, 1829, p. 244). Whilst there are no specific references 
as to how to manufacture an Arnica tincture or extract from its drug, there are general 
directions on the manufacturing of tinctures (Völcker, 1862, p. 199), extracts, and powders 
(Völcker, 1862, pp. 57-58). It is noteworthy that with each pharmacopoeia edition and 
related commentaries, the analytical section expands with reports on new discoveries of 





5.2.5.3 Listed therapeutic indications in commentaries to the Prussian 
pharmacopoeia 
Analysis of commentaries to the Prussian pharmacopoeias reveals that different 
commentators provide different therapeutic appraisals, or none at all. Friedrich Mohr, an 
apothecary and pharmaceutical assessor at the Royal Prussian Medical Association, omits 
all information relating to therapeutic applications of Arnica preparations and thus limits the 
clinical usefulness of his annotations (Mohr, 1848, p. 443; 1849, pp. 245, 411). In contrast, 
the commentary of the Prussian apothecary and pharmaceutical author Hermann Hager 
(1816-1897) comprehensively discusses therapeutic applications, making his a useful 
clinical text (Hager, 1865). Unlike other commentators, this author also includes 
information from pharmacopoeias of two other German states, the kingdom of Hannover 
and the electorate of Hessen, providing an expanded picture of the regulatory status of 
Arnica in German states at the time. 
Table 4. Use-categories of Arnica montana addressed in the commentaries to the 





























































































































































card-vasc 0 0 0 0 0  ✓ 
gastro-intest ✓ ✓ ✓ ✓ ✓  0 
gyn ✓ 0 0 0 0  0 
head 0 0 0 0 0  ✓ 
infection 0 ✓ ✓ ✓ ✓  ✓ 
liver-spleen ✓ 0 0 0 0  0 
musc-skel ✓ ✓ ✓ ✓ ✓  ✓ 
nerve ✓ ✓ ✓ ✓ ✓  ✓ 
respiratory 0 0 0 0 0  ✓ 
skin-mucous ✓ ✓ ✓ ✓ ✓  ✓ 
tonic ✓ ✓ ✓ ✓ ✓  (✓) 
uro ✓ 0 0 0 0  ✓ 
Dark green rows refer to continued use 
Light green rows refer to intermittent but present-day use 
White rows refer to discontinuation 
Brackets (✓) reference historical medicinal uses or folk medicine use 
 
Discrepancies in annotations on recommended therapeutic uses of official plant drugs 




therapeutic applications opened room for divergent assessments. Commentaries therefore 
need to be analysed in conjunction with clinical textbooks to understand how 
comprehensively they reflect contemporaneous medical practice. The two main 
commentators of the Prussian pharmacopoeia are Friedrich Philipp Dulk (1788-1851) (on 
the 2nd to 5th edition) and the aforementioned Hager (on the 7th edition). Dulk, like Hager, 
was a pharmacist. He also lectured in chemistry at the influential Albertus University, 
Königsberg, and was a practising apothecary in that same East Prussian city.  
Table 4 (above) provides an overview of the use-categories covered by the therapeutic 
indications of Arnica montana endorsed by Dulk and Hager in their commentaries to the 
Prussian pharmacopoeia in comparison to use-categories covered by Tabernaemontanus in 
the 17th century.  
5.2.5.4 Dulk’s series of commentaries (1808 – 1829) 
Dulk's series of commentaries (1808, 1813, 1828, and 1829) endorses Arnica preparations 
in treating injuries, bruises, and rheumatism (musc-skel), for activating nerves in instances 
of paralysis (nerve), and for diarrhoea (gastro-intest). Moreover, the powder with 
comminute Arnica flowers is recommended as a snuff for sneezing (tonic and skin-mucous 
cleansing action) (Dulk, 1828, pp. 89-94; 1833a, pp. 106-107; 1833b, pp. 109-112; 1847, 
pp. 716-718). The author recommends Arnica leaves for the same indications but 
recognizes that they are less potent than the flowers. The indications listed by Dulk belong 
to the same use-categories as those by Tabernaemontanus, but he expands traditional uses 
by additionally listing Arnica for the treatment of bruises and in rheumatism. Moreover, he 
expands on tradition by listing Arnica as an antiseptic remedy and as a care for wounds 
(infection and skin-mucous category). Such applications became prevalent in the 19th 
century on the back of experimental research that was not available when 
Tabernaemontanus wrote the Neuw Kreuterbuch. In contrast to Tabernaemontanus, Dulk 
discontinues the listing of Arnica as a bitter for humoral detoxification in poisoning (liver-
spleen category). This is the only indication in the first half of the 19th century where a 
change in medical theory from humoralism to natural science led to the discontinuation of 
an indication in the use of Arnica. 
Dulk lauds Arnica root for its antiseptic properties, which he attributes to tannins. He claims 
it to be a more potent antiseptic than other remedies, having the ability to combat sepsis in 




(Cinchonae cortex). Due to its antibacterial properties, he recommends Arnica root over 
Arnica flowers to stem diarrhoea. Research in the 1970s confirmed that Arnica rhizome and 
root contain higher levels of essential oils than Arnica flower and petals, thus having a 
stronger antiseptic action than the above ground plant parts (Willuhn, 1972b, pp. 225-226). 
Aromatic hydrocarbons are the main group of essential oil constituents in Arnica root; they 
are thymol derivates (Pljevljakušić et al., 2012, p. 177). 
5.2.5.5 Hager’s commentary (1865) 
Hager’s (1865, pp. 582-583, 691-692, 1133-1134) commentary discusses therapeutic 
indications relating to eight use-categories. That is, he expands Dulks’s (1828) commentary 
with indications relating to an additional three use-categories; card-vasc, head, and uro. The 
use of Arnica to activate diuresis was already discussed by Tabernaemontanus. However, 
the use of Arnica as a circulatory stimulant, diaphoretic, and treatment for cerebral 
concussions is an expansion of traditional medical use based on experimental 
investigations. Like Dulk, Hager recommends Arnica’s stimulating and antiseptic effects in 
the treatment of septicaemia (atonische Nerven- und Faulfieber), for the external treatment 
of bruises due to falls and blows, and for watery ulcers of the skin. These three areas of 
treatment are also an expansion on traditional indications listed by Tabernaemontanus. 
5.2.5.6 Summary results of medicinal uses of Arnica montana listed in 
commentaries to the Prussian pharmacopoeia  
This section analysed commentaries to the Prussian pharmacopoeia as an independent 
qualitative data source on indications of Arnica montana endorsed for regular patient care. 
The results of this evaluation were used to cross-validate indications listed in the 
contemporaneous medical literature. Appendix 7 provides the tabulated summary of 
indications listed in the commentaries to the Prussian pharmacopoeia. A comparison 
amongst Tabernaemontanus (1664), Dulk (1828), and Hager (1865) shows that all three 
authors list indications belonging to the musc-skel, nerve, and tonic use-categories; 
although Hager references the tonic use of Arnica snuffs and tobacco for the first time as a 
customary rather than regular medicinal application (Hager, 1865, p. 692). Unlike Hager, 
both Tabernaemontanus and Dulk record the treatment of diarrhoea with Arnica (gastro-
intest use-category). Hager’s de-listing of this indication is due to the discontinuation of 




pharmacopoeia, the plant part traditionally used for the treatment of gastro-intestinal 
ailments (Hager, 1865). Hager disagrees with this regulatory de-listing. He remarks that 
Arnica flower and root have distinctly different medicinal properties since the root is said to 
contain high levels of tannins which are not present in the flowers. For this reason, he 
argues that preparations made from these two different plant parts cannot be interchanged. 
The distinct properties of Arnica root may be why the contemporaneous Ph. Hannoverana 
and Ph. Hassia continue to list Arnica root (Hager, 1865, p. 583). Consequently, Hager 
(1876, p. 465) lists the use of Arnica radix for the treatment of gastro-intestinal complaints 
in his separate clinical textbook Handbuch der pharmaceutischen Praxis.  
Comparison of Hager’s and Dulk’s commentaries with the medical literature of the first half 
of the 19th century (Appendices 5 and 7) reveals that Hager’s commentary more closely 
mirrors clinical applications of Arnica in patient care. Apart from indications relating to the 
gastro-intest and gyn use-categories, nine use-categories listed by Hager are congruent with 
those listed in the contemporaneous medical textbooks. As already mentioned, the 
discontinuation of the indication ‘diarrhoea’ is due to the removal of Arnica radix from the 
list of essential drugs. Why Hager stopped recommending the use of Arnica to promote 
menstruation and to cleanse the uterus during the puerperium is unknown. 
In conclusion, analysis of the Prussian pharmacopoeia shows that this body of literature 
provides evidence of how official plant parts and their preparations were officially 
permitted in a European country in the first half of the 19th century. It is a legal source of 
bibliographic evidence concerning an officially endorsed medicinal plant and its 
preparations. The corresponding authoritative commentaries independently validate the 
main indications of Arnica recorded in the contemporaneous medical literature. In contrast 
to medical textbooks, this body of evidence does not, however, encompass the broader 
long-standing applications recorded in the medical literature. The usefulness of 
commentaries as a sole body of evidence for therapeutic claims is complicated by the fact 
that there are several different commentators, each providing a slightly different appraisal of 
endorsed therapeutic applications for patient care. Therefore, this thesis recommends that 
commentaries to the Prussian pharmacopoeia are used as complementary sources of 
evidence for therapeutic claims alongside judiciously selected authoritative medical 
textbooks. These have been shown to represent more comprehensively long-standing 
clinical uses of Arnica, raising the possibility that they represent more comprehensively 




5.2.6 The German pharmacopoeia 
This section discusses Arnica montana in the regulatory context of the German 
pharmacopoeia (Ph. Germanica), starting with its 1st official edition published in 1872 after 
the formation of the Deutsches Reich (German Empire) and continuing to its renamed 
present-day equivalent Deutsches Arzneibuch (DAB) (named so since 1926). The first two 
sections below discuss the official plant parts and official preparations as listed from the 1st 
edition of the Ph. Germanica to the 10th edition of the DAB 2012 (1926; 1968; 1978; 1986; 
1993; 2012; 1999; 1910; Hager, 1872; 1890, 1900; 1882). The third section discusses the 
indications listed in the commentaries to the German pharmacopoeia. The results exemplify 
consistency in official guidelines on some plant parts and preparations over a 140-year 
period, but also significant changes in the official scope of Arnica from the turn of the 20th 
century, and then again from the 1980s.  
5.2.6.1 Official Arnica plant parts in the German pharmacopoeia 
Arnica montana is listed consistently in the German pharmacopoeia since its 1st edition 
(Hager, 1872), reflecting Arnica’s ongoing significance in professionally delivered 
healthcare. An analysis of official plant parts reveals consistencies in the recommendation 
of Arnica flower as an official drug as well as an elimination of all other initially official 
plant parts until their reuptake at the end of the 20th century. Their temporary omission over 
the course of the 19th and 20th century contrasts with the full range of plant parts used by 
Tabernaemontanus (aerial parts, flowers, and root) as well as the plant parts referenced in 
the medical literature published parallel to the German pharmacopoeia. The reduction of 
official plant parts in the Ph. Germanica influenced the recommended indications for 
Arnica in the corresponding commentaries. 
Arnica flower is the official plant part listed in all editions of the German pharmacopoeia; 
however, until the 7th edition the Deutsches Arzneibuch (1968, p. 343), this listing related to 
Arnica flower without receptacle only. This requirement was to help avoid potential 
contamination issues of Arnica receptacles with eggs and larvae from the Arnica fly, a 
constraint questioned by commentators ever since its adoption by the German regulator 
(Anselmino & Gilg, 1911c, pp. 537-539; 1928, pp. 604-607; Bernhard Fischer & C. 
Hartwich, 1901, pp. 290-291; Hager, 1872, p. 22; 1883a, pp. 750-752; Hager et al., 1891, 
pp. 663-664; Hirsch & Schneider, 1891, p. 306; Schlickum, 1883, pp. 178-179; Schneider 




receptacle of Arnica contains higher levels of essential oils than the flower, justifying the 
clinical request for including the receptacle as part of the official drug (Willuhn, 1972b, pp. 
225-226).  
Arnica root is listed in the inaugural edition of the Ph. Germanica (1872) but was 
discontinued as an essential pharmacy item from the 2nd edition onwards (1882). This 
discontinuation contrasts with nine other European pharmacopoeias, all of which retained 
the listing of Arnica root, including those of Austria, England, Italy, and Spain (Tschirch, 
1909a, p. 1174). The supplements to the German pharmacopoeia, published by the 
Deutscher Apotheker-Verein (German Apothecary Association), also list Arnica root as a 
drug commonly requested by physicians, traded between pharmacies, or purchased directly 
by patients for self-medication (Deutscher Apotheker-Verein, 1891, pp. VI, 219; 1906, p. 
300). The reason for discontinuing Arnica root as an essential medicine is not discussed in 
the 2nd edition of the German pharmacopoeia, but it may have been due to conservation 
issues or a re-assessment of various treatment options for diarrhoea and gastro-intestinal 
infections, the key indications for Arnica root. By de-listing Arnica root, indications relating 
to the gastro-intestinal tract also became de-listed in the commentaries to the 2nd edition of 
the German pharmacopoeia (Hager, 1883a). Almost one hundred years later, Arnica root 
was re-introduced as an official plant part in the 1st edition of the compendium to the 
German pharmacopoeia, HAB 1 (1978). Advances in plant science now enable the 
cultivation of Arnica montana for commercial use, mitigating conservation issues 
associated with Arnica (Jurkiewicz et al., 2010; Pljevljakušić et al., 2014). 
From DAB 9 (1986) to DAB 1999, the German regulator permitted a second interchangeable 
subspecies, Arnica chamissonis Less. spp. foliosa (Nutt.), with similar active constituents. 
However, when the German pharmacopoeia harmonised with the European pharmacopoeia, 
only Arnica montana remained as the official species. 
5.2.6.2 Official preparations in the German pharmacopoeia 
The Arnica flower as a drug and two preparations derived from it, water infusion and 
tincture, have consistently been official from the 1st edition of the German pharmacopoeia 
(Hager, 1872) to the 10th edition (DAB 10, 1993). Arnica preparations were either 
recommended for internal use or as an external compress. From 1999 onwards, the 1:10 
strength tincture prepared from dry flower of Arnica remained the only official extract listed 




DAB 7 lists for the first time a modern 20-25% Arnica cream prepared with a 1:10 dry plant 
Arnica tincture, and thus this preparation expands traditional preparations (DAB 7, 1968). 
In addition, HAB 1, the official compendium to the German pharmacopoeia, reintroduces 
preparations that were omitted in the German pharmacopoeia from the end of the 19th 
century. They are mother tinctures prepared with either fresh whole plant or with dry root 
and rhizome (1:10 extraction ratio) (HAB 1, 1978, pp. 198-210). In parallel to DAB, the 
HAB compendium also lists a mother tincture with dry Arnica inflorescence. Mother 
tinctures can be used directly as traditional phytotherapeutic preparations or as a starting 
preparation for homeopathic compounding (Leivers, 2005). Furthermore, HAB 1 lists an oil 
preparation with dry Arnica inflorescence (extraction ratio 1:10) (1978, pp. 202-205). 
5.2.6.3 Preparations in the commentaries to the German pharmacopoeia  
Analysis of the commentaries and supplements to the consecutive editions of the German 
pharmacopoeia reveals that the official drug and its extracts were applied in a variety of 
ways, including the tincture for bath preparations. The drug as a 5-20% water infusion 
could be applied either as a compress or as an enema, the diluted tincture for a compress, a 
bath preparation or as a rub, and the drug prepared as a powder or pill for internal use (0.3g 
- 1g per dose) (Schlickum, 1883; Jehn & Crato, 1901; Schneider & Süss, 1902). However, 
such preparations were de-listed in the 20th century. For example, the medicinal use of 
compresses was last recommended in the commentary to the 10th edition of the DAB 
(1991). 
Up to the 4th commentary of the German Pharmacopoeia published in 1902, commentators 
describe two formerly official but by then customary preparations, Arnica snuff and tobacco 
(Schneider & Süss, 1902). They were commonly applied for their stimulating, toning, and 
mucous membranes cleansing effects. This custom is reflected in Arnica’s Bavarian 
vernacular name Schnupftabaksbleum (Sneeze wort) (Tschirch, 1909a, p. 1175). A 
preparation that is also absent in the German pharmacopoeias and its commentaries, but 
listed in its supplementary text, is a charta, a medicated paper saturated with Arnica tincture 
then air dried (Deutscher Apotheker-Verein, 1891, 1897, 1906). These were ready-made 
stock items stored in pharmacies and hospitals for the swift topical treatment of injuries. 
They were replaced during the 20th century with more convenient topical preparations such 
as medicated creams and gels. A further unofficial but professionally dispensed preparation 




as an internal tonic at a dose of 0.5g (Deutscher Apotheker-Verein, 1930b, 1948). Even 
though this preparation was dropped as a pharmacy item after WW2, Arnica distillate (or 
Schnapps) remains a customary home preparation in alpine areas of Switzerland, Austria, 
France, and Germany.  
In contrast to these de-listings, the commentary to DAB 7 newly records a gargle with the 
official 1:10 dry-plant tincture in a 5-10x dilution (1969, p. 512). This preparation was 
previously described in medical textbooks for the treatment of strained, inflamed, or 
infected vocal cords of professional singers (Fischer, 1941, p. 59; Schulz, 1919, p. 298). It 
is last listed in the commentary to DAB 8 (1981). In contrast to DAB, the Commission E 
Monograph on Arnica (Kommission E, 1984a), a monograph that more closely reflects 
clinical applications in patient care compared to pharmacopoeia listings and commentaries, 
approves mouthwash as an officially sanctioned Arnica preparation. This official 
endorsement enabled the release of such preparations into the market place.  
5.2.6.4 Summary results of medicinal uses of Arnica montana listed in the 
commentaries to the German pharmacopoeia 
This section analysed commentaries to the German pharmacopoeia as an independent 
qualitative data source on indications of Arnica montana endorsed for regular patient care. 
The data was used to cross-validate indications listed in the contemporaneous medical 
literature. Table 5 below presents the synopsis of all use-categories addressed by indications 
recorded in the commentaries to the German pharmacopoeia or Deutsches Arzneibuch 
(DAB). This summary shows that indications relating to the musc-skel and nerve use-
categories were consistently cited in all commentaries. Indications relating to the tonic use-
category (excitant action and in shock) and uro use-category (diuresis) were listed until the 
beginning of the 20th century when the first major reduction on endorsed indications 
becomes apparent (Anselmino & Gilg, 1911a, 1911b, 1928). Indications relating to the 
card-vasc and skin-mucous use-categories were referenced until the 8th commentary 
(Böhme & Hartke, 1983), but de-listed thereafter when the second major reduction on 
endorsed indications occurred. The remainder of use-categories show intermittent listings 
based on divergent views of the commentators.  
The deletion of indications pertaining to the gastro-intest use-category is connected to the 
de-listing of the plant part responsible for the therapeutic action in gastro-intestinal 




was discontinued as an essential pharmacy item from the 2nd edition onwards (1882). 
Consequently, the listing of the treatment of diarrhoea with Arnica root was also omitted 
from then on. All indications recorded in the commentaries to the German pharmacopoeia 
are tabulated in Appendix 8.  
Appendix 9 provides an additional appraisal of these indications. The purpose of this in-
depth evaluation was to additionally gauge the potential of commentaries as a bibliographic 
body of evidence for health claims. For this, Appendix 9 provides a comprehensive 
evaluation of indications endorsed by these commentaries and the context in which they 




























































































































































































































































card-vasc 0 ✓ ✓ ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 0 
gastro-
intest ✓ ✓ 0 0 0  0 0 0 0 0 0 0 0 0 
gyn ✓ 0 0 0 0  0 0 0 0 0 0 (✓) 0 0 
head 0 ✓ ✓ 0 ✓  ✓ 0 ✓ 0 0 0 0 0 0 
infection 0 ✓ ✓ 0 ✓  ✓ 0 ✓ 0 0 0 0 0 0 
liver-
spleen ✓ 0 0 0 0  0 0 0 0 0 0 0 0 0 
musc-skel ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
nerve ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
respiratory 0 ✓ ✓ 0 ✓  ✓ 0 0 0 0 0 0 0 0 
skin-
mucous 
✓ ✓ ✓ 0 ✓  ✓ 0 ✓ ✓ ✓ ✓ ✓ 0 0 
tonic ✓ ✓ ✓ 0 ✓  ✓ 0 ✓ ✓ ✓ 0 0 0 0 
uro ✓ ✓ ✓ 0 ✓  ✓ 0 ✓ 0 0 0 0 0 0 
 
Dark green rows refer to continued use 
Light green rows refer to intermittent but present-day use 
White rows refer to present-day discontinuation  








The most consistently endorsed indications in scholarly commentaries to the German 
pharmacopoeia from 1874 until 1981, as listed either in all commentaries (card-vasc, musc-
skel, and nerve use-categories) or in most commentaries (skin-mucous use-category), are as 
follows: 
Table 6. Endorsed indications for Arnica montana in the commentaries to the 
German pharmacopoeia 1874-1981. 
Use-category Indications 
card-vasc circulatory insufficiency 
musc-skel blunt injuries, sprains, strains; bruises, oedema, haematoma  
nerve nerve and muscle pain 
skin-mucous ulcers / wounds 
 
Commentaries after the mid-1980s departed from a favourable benefit-risk assessment for 
internal uses of Arnica as a cardio-vascular stimulant and as a topical disinfectant in wound 
care (1993; Hartke, Bertram, Mutschler, & Althoff, 1987). This assessment was in line with 
regulatory guidelines that permitted external uses of Arnica only. However, it contrasted 
with the Austrian pharmacopoeia ÖAB 90 and HAB which permit the internal use of Arnica 
preparations at a low dose (Blaschek et al., 2012, pp. 12, 16). This recent regulatory-driven 
reduction in the scope of Arnica montana is the biggest shift of Arnica’s regular medicinal 
uses in Germany over the past 400 years. The 1980s were a watershed in Europe for the risk 
assessment of medicinal plants. This period now stands out for its noticeable regulatory low 
tolerance for any potential risks in relation to plant derived medicines (Zepernick, 
Langhammer, & Lüdcke, 1983). It is a context in which endorsement of internal and topical 
disinfectant applications of Arnica was omitted from DAB 9 and its commentaries onwards; 
no information could be found in the German pharmacopeia itself or in its commentary on a 
dose-dependent risk assessment in relation to these changes. This new regulatory approach 
to plant medicines coincided with emerging themes of danger and risk, which became 
prominent features of the biomedical discourse on herbal medicine (Lewis, 2011). DAB 9 
(1986) and its commentary (1987) exemplify this shift by displaying an increased focus on 
plant toxicology, potential risks, and side-effects. While this shift was aimed at protecting 
the public, it is significant that very few clinical herbal experts were selected to co-author 
the more recent monographs in DAB, as evident in the author list of the preface to DAB 9. It 




fewer indications than were legally permitted by the Commission E Monograph on Arnica 
(Kommission E, 1984a). In this official monograph, Arnica was additionally approved as a 
topical disinfectant to treat boils, inflammation of mucous membranes in the mouth and 
throat, and inflammation caused by insect bites.  
By the end of the 20th century, the remaining entries in the commentary to DAB 10 (1993, p. 
190), compared with entries in medical textbooks, are as follows: 
Table 7. Indications for Arnica montana endorsed in the commentary to DAB 10 
(1993) compared with indications listed in the medical literature.  
Use-
category 
Indications listed in the 
10th commentaries to the 
German pharmacopoeia 
Indications consistently 
listed in medical literature 
>30 years 
Indications consistently 
listed in medical literature 
>150 years: 
musc-skel 
blunt injuries, sprains, 
strains; bruises, oedema, 
haematoma 
injuries, sprains and strains, 
torn muscles and ligaments; 
bruises, oedema, haematoma 
injuries, sprains and strains, 
torn muscles and ligaments; 
bruises, oedema, 
haematoma  
nerve muscle and joint pain  
pain related to musculo-
skeletal system and nerves 
pain related to musculo-
skeletal system and nerves  
tonic  








respiratory  sore throat (infection) 
breathing difficulties / 




mouth and throat 
(inflammation); boils 
ulcers, wounds (since 
Richter 1827) 
 
These remaining indications recorded in the commentaries to the German pharmacopoeia 
are in line with the main indications consistently listed in the evaluated medical literature 
over the past 400 years. Yet indications relating to the cardio-vascular and respiratory 
systems, and those relating to the skin and mucous membranes, became de-listed despite 
consistent clinical use.  
In conclusion, Pharmacopoeias provide a legal source of bibliographic evidence on an 
officially endorsed plant drug and its preparations and should be permitted as a verified 
reference. The corresponding authoritative commentaries independently validate all main 
indications of Arnica applied in regular medicine during this time as recorded in the 
medical literature. A comparison of commentaries to the German pharmacopoeia and 




on actual clinical use of medicinal plants than contemporaneous medical textbooks. As with 
the commentaries to the Prussian pharmacopoeia, the usefulness of commentaries as a body 
of evidence for claims is complicated by the fact that there were at times several different 
commentators to a pharmacopoeia edition, each providing a slightly different appraisal of 
recommended therapeutic applications for patient care. This thesis proposes that 
commentaries to the German pharmacopoeia could be used as complementary sources of 
evidence for therapeutic claims alongside judiciously selected authoritative medical 
textbooks. The evaluated medical textbooks have shown to represent more comprehensively 
long-standing clinical uses of Arnica compared to those listed in the contemporaneous 
commentaries to the German pharmacopoeia. This raises the possibility that they represent 
more comprehensively long-standing clinical uses of other medicinal plants too. 
5.2.7 Arnica montana in regulatory and authoritative expert monographs 
The following section investigates how 20th century official and authoritative herbal 
monographs represent Arnica. It then triangulates the endorsed therapeutic indications listed 
in those monographs with therapeutic indications listed in medical textbooks. 
This study analyses the following two official Arnica monographs: 
 The Kommission E Monografie (Commission E Monograph) Arnicae flos by the 
German Ministry of Health (1984) 
 The European Union (EU) Herbal Monograph Arnicae flos by the European 
Medicine Agency (2014).  
These assess and sanction officially the therapeutic scope and safety of Arnica, therefore 
creating a regulatory pathway for Arnica products to be sold in the marketplace if those 
products adhere to the monograph’s approved claims and guidelines.  
Additionally, this study evaluates three authoritative expert monographs on Arnica: 
 The ESCOP Monograph Arnica flos (2003)  
 The WHO Monograph Flos Arnicae by the World Health Organisation (2007) 
 The Arnica monograph in the pharmaceutical reference work HargerROM. Hagers 
Enzyklopädie der Arzneistoffe und Drogen (2012).  
These latter three have no legal status but represent expert evaluations; they may be used as 




of a plant-based medicine, for example in the EU (Anagnostou, 2017, pp. 8-9; Steinhoff, 
2017, p. 18). 
Table 8 gives an overview of the use-categories covered by indications discussed in these 
five monographs.  






































































































































card-vasc 0 ✓ ✓ 0 (✓) ✓ ✓ 
gastro-
intest 
intermittent 0 0 0 0 ✓ 0 
gyn intermittent 0 0 0 0 ✓ (✓) 
head intermittent 0 0 0 0 0 0 
infection intermittent 0 0 0 0 0 (✓) 
liver-spleen pre-modern 0 0 0 0 0 0 
musc-skel ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
nerve ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
respiratory intermittent ✓ ✓ 0 0 ✓ ✓ 
skin-
mucous 
intermittent ✓ ✓ 0 ✓ ✓ ✓ 
tonic ✓ ✓ 0 0 0 0 (✓) 
uro intermittent 0 0 0 0 0 0 
Dark green rows refer to continued use 
Light green rows refer to intermittent but present-day use 
White rows refer to present-day discontinuation  
Brackets (✓) reference historical medicinal uses or folk medicine use 
 
The Kommission E Monografie (Commission E Monograph) is a regulatory monograph by the former 
German Bundesgesundheitsamt (BGA) (German Ministry of Health) that provided approved claims for 
sale of plant-based medicines based on empirical and scientific evidence. 
 
The European Union Herbal Monograph is a regulatory monograph authored by the Committee on Herbal 
Medicinal Products (HMPC) of the European Medicines Agency (EMA) based on consensus of 28 EU 
Member States. The Arnica monograph evaluated was a “traditional use” monograph. 
 
The ESCOP, WHO and HagerROM monographs are expert monographs and provide broader perspectives 





Appendix 10 tabulates all indications listed for Arnica montana in official and authoritative 
monographs, comparing them with indications listed in medical textbooks over the past 400 
years. It is striking that indications listed for the treatment of musculo-skeletal ailments due 
to injuries and accidents, and pain associated with the musculo-skeletal system and nerves 
are listed across all independent sources and data points. The EU Herbal Monograph 
Arnicae flos 2014 is the only monograph that does not list indications relating to the skin-
mucous category. In addition, all sources except the EU Herbal Monograph Arnicae flos 
2014 and ESCOP Monograph Arnica flos (2003) also list indications correlating to the 
cardio-vasc and respiratory use-categories. The five evaluated monographs are now 
discussed further below. 
5.2.8 Regulatory monographs 
The following sections evaluate two official monographs, the Commission E Monograph 
Arnicae flos (1984) and the EU Herbal Monograph Arnicae flos (2014) as independent 
qualitative sources to cross-validate therapeutic information recorded in authoritative 
medical textbooks.  
5.2.8.1 The Commission E Monograph Arnicae flos (1984)  
The Commission E Monograph Arnicae flos of the former German Bundesgesundheitsamt 
(BAG) (the German Ministry of Health) was published in 1984 (Kommission E, 1984a) and 
provided the legal basis for the registration of Arnica preparations in the German market as 
mandated by the Second Medicines Act 1976 (Arzneimittelgesetz 1976 or AMG 76). It 
specifies that the composition of the drug consists of the fresh or dry inflorescence of 
Arnica montana L. or A. chamissonis Less. subsp. foliosa (Nutt.) Maguiere [Fam. 
Asteraceae]. Its endorsed preparations consist of cut herb or powder, tinctures, creams, and 
oils. The dosage range is as follows: 
Infusion: 
 2 g of herb per 100 ml of water.   
Tincture for cataplasm: 
 Tincture in 3 - 10 times dilution.   
For mouth rinses: 





 Not more than 20 - 25 percent tincture.   
Arnica oil: 
 Extract of 1 part herb and 5 parts fatty oil.  
 Ointments with not more than 15 percent of Arnica oil. 
The monograph describes the anti-inflammatory, analgesic and antiseptic activities of 
Arnica and permits claims for the following external indications (translated from German): 
 injury and consequences of accidents, e.g., haematoma, dislocations, contusions, and 
oedema due to fracture 
 rheumatic muscle and joint problems  
 inflammation of the oral and throat region 
 furunculosis (boils) 
 inflammation caused by insect bites 
 superficial phlebitis.   
The approved therapeutic claims of Arnica in the treatment of injuries and effects of 
accidents (musc-skel and nerve use-categories) are congruent with the therapeutic uses of 
Arnica listed in the 4th edition of Tabernaemontanus’ medical textbook published in 1664. 
The indication of rheumatic muscle and joint problems has been noted in the European 
medical repertoire of Arnica since the end of the 18th century (Löseke 1799), whilst the 
indications of inflammation of the oral and throat region (respiratory use-category), 
furunculosis, insect bites (skin-mucous use-category), and surface phlebitis (skin-
mucous/card-vasc use-categories) are modern nosologies of the 20th century (see Appendix 
5). Thus, the Commission E Monograph Arnicae flos covers indications relating to five of 
the six use-categories consistently endorsed in clinical medical textbooks (the tonic use-
category is missing). It provides a rounded reflection of external clinical uses of Arnica in 
European healthcare.  
Since the Commission E Monograph Arnicae flos recommends Arnica for external use only, 
there are no endorsed indications relating to the internal use of Arnica for supporting the 
cardio-vascular system and for achieving a tonic effect. This lack of endorsement of internal 
uses contrasts with medicinal uses of Arnica over the previous 400 years. As already noted, 
the 1980s were a watershed for risk assessments of medicinal plants, with a new 
preventative approach to public health and safety resulting in a low tolerance for any risk 




committee about the official negative safety assessment of Arnica for internal use. Whilst 
some members took a cautionary approach and won the argument, others claimed that this 
monograph incorporates a modern overestimation of Arnica’s toxicity relative to the long-
standing clinical experiences of its safety when prescribed within the appropriate 
therapeutic range (Weiss & Fintelmann, 1997, p. 163).  
The Commission E Monograph Arnicae flos states that interactions with pharmaceutical 
drugs are unknown. It warns, however, of potential detrimental effects of Arnica 
preparations in prolonged treatment of damaged skin, such as in injuries or Ulcus cruris 
(indolent leg ulcers), which may cause oedematous dermatitis with the formation of 
pustules and eczema. Additionally, treatments involving high concentrations of Arnica are 
noted to cause primary toxic skin reactions with the formation of vesicles or even necrosis 
(Kommission E, 1984a, para. Nebenwirkungen). Nonetheless, the monograph permits the 
use of Arnica on small areas of broken skin when applied appropriately. This approval 
aligns with the traditional use of Arnica as a wound disinfectant on small surfaces. 
5.2.8.2 The EU Herbal Monograph Arnicae flos (2014)  
The EU Herbal Monograph Arnicae flos (Committee on Herbal Medicinal Products 
(HMPC), 2014b) is a monograph based on traditional clinical usage. Claims in the 
traditional use category are accepted on the basis of sufficient safety data and plausible 
effectiveness (Europäisches Parlament, 2004). Its relative brevity compared to the 
monograph on Arnica authored by the German Commission E derives from a multi-national 
process mandating that permitted indications, modes of application, proof of effectiveness, 
and safety (innocuousness) must be agreed upon by majority consensus of all 28 EU 
Member States (Committee on Herbal Medicinal Products (HMPC), 2013). Accordingly, 
Member States where Arnica does not have traditional clinical significance could veto long-
standing national acceptance by others. Thus, the EU Herbal Monograph Arnicae flos 
reflects a pragmatic political compromise. It had to consider other factors than clinical 
evaluations. Similar difficulties in harmonising local medical customs across many nations 
became apparent during the writing of the first German pharmacopoeia in the 1870s (as 
discussed in the Materials and Methods chapter). 
The EU Herbal Monograph Arnicae flos (Committee on Herbal Medicinal Products 
(HMPC), 2014b, p. 3) permits external use of Arnica flower preparations for the following 




 relief of bruises 
 sprains 
 localised muscular pain.  
The pre-approved preparations with Arnica flower are: 
 tincture (1:10), extraction solvent ethanol 60% or 70% 
 tincture (1:5), extraction solvent: ethanol 60% 
 liquid extracts of fresh flowers (1:20), extraction solvent: ethanol 50%. 
The dosage regime for semi-solid or liquid preparations for cutaneous (topical) is prescribed 
as follows: 
 semi-solid dosage form: 20-25% tincture in base to apply on the affected area two to 
three times daily 
 liquid dosage form: 2.5 ml of tincture as an impregnated dressing to apply on the 
affected area three to four times daily 
 semi-solid dosage form: 20% tincture in base to apply on the affected area two to 
three times daily 
 semi-solid dosage form: 50% liquid extract in base to apply a thin layer on the 
affected area two to four times daily. 
The pre-approved indications relate to the musculo-skeletal and nervous systems, reflecting 
the main indications for Arnica as continuously documented over the past 400 years. Thus, 
these indications accurately capture long-established traditional uses in regular European 
healthcare. However, the monograph also makes it obvious that the current regulatory 
approach does not make full use of further available empirical evidence on traditional uses 
as methodically coded in historical sources. Since the end of the 18th century, additional 
traditional indications have been consistently documented in the German medical literature, 
and those traditional indications of Arnica could have been considered in this traditional use 
monograph (see Appendix 5): 
 as a circulatory stimulant  
 in varicose veins /phlebitis 
 in rheumatic muscle and joint problems 




 in wounds 
 in boils 
 in inflammation of the mouth and throat. 
The long-standing clinical indications listed above, despite being consistently recorded in 
medical textbooks and also legally permitted in one of its Member States, Germany, were 
not considered by the HMPC for the final monograph on Arnica. The omission of these 
indications is surprising. The Assessment Report (Committee on Herbal Medicinal Products 
(HMPC), 2014a) recognises that Arnica’s wound-healing effects were already documented 
in the early modern period by Tabernaemontanus. It further emphasises medieval uses of 
Arnica for haematoma, injuries, varicose issues, phlebitis, gout, rheumatism, indigestion, 
and cardiovascular disease. Moreover, the Assessment Report states that Arnica has been 
used in Germany at least since 1957 as an official remedy for recovery from injury; for the 
effects of trauma such as haematoma, distortions (dislocation and sprains), contusions 
(bruises), and oedema due to fracture; for the systemic treatment of rheumatic muscle and 
joint complaints, furunculosis, inflammations caused by insect bites, and superficial 
phlebitis; and for the treatment of inflammations of the oral and throat region, such as 
gingivitis and aphthous ulcers. Notwithstanding this reference to the officially approved 
uses in the German healthcare system, a systematic appraisal of historical evidence on 
traditional use could not be found in this Assessment Report on Arnica and the 
aforementioned additional long-standing indications were not officially listed in the final, 
approved monograph. 
The relative paucity of indications in the EU Herbal Monograph Arnicae flos thus exposes 
some challenges in the execution of the EU Directive 2004/24/EC for traditional use since 
the Directive stipulates that a medicinal product containing a herbal substance must have 
proof of tradition for 30 years. The problematic nature of this time frame is noted in the 
Assessment Report on Arnica itself, stating that only herbal preparations evidenced over the 
preceding 30 years at a specific posology could be included in the final monograph 
(Committee on Herbal Medicinal Products (HMPC), 2014a, p. 3). It then excludes 
traditional water and oil extracts of Arnica despite their consistent listings in the German 
pharmacopoeia and official compendia (HAB), their long-standing documented use in the 
medical literature, and their official approval by the German Ministry of Health in 1984 




There are different concepts of “tradition” (Dal Cero, 2016, pp. 8-13). A regulator will 
consider indications depending on the approach to its concept of “tradition”. In the 
anthropological sense, “tradition” is seen as the transfer of knowledge over three 
generations (Shils, 1981), but Helmstädter and Staiger argue that the life span of a 
generation may vary widely depending on context (Helmstädter & Staiger, 2012, pp. 94-
95). In a medical tradition, two steps of transmission are achieved in a period of 21-30 years 
since it takes between seven and 10 years to train a physician. This timeframe is similar to 
the guidelines in the EU Directive 2004/24/EG which requests a tradition-of-use proof of a 
herbal medicinal product for 30 years, of which 15 must be in the EU. The stipulation of 30 
years of proof of tradition is, however, a regulatory construct for the purpose of 
harmonising traditional medicinal products in the European market (Jütte et al., 2017, p. 
220). If applied rigidly, this timeframe does not reflect the dynamic nature of medicine and 
how it evolves in order to stay relevant (Patwardhan, Vaidya, Chorghade, & Joshi, 2008; 
Shils, 1981; Staub et al., 2016).  
Traditional recipes are commonly adapted over time to reflect local conditions, the 
availability of raw materials, and the therapeutic situation (Schwabl & Vennos, 2015, p. 
113). Technical advances, market conditions, customer preferences, and regulatory 
mandates may all influence the type of preparations sold, while the use of specific plant 
parts may change due to availability and conservation issues. The World Intellectual 
Property Organization (WIPO), an international body concerned with the protection of 
traditional knowledge (TK), also underlines that TK refers to knowledge systems, creations, 
and innovations which are constantly evolving in response to changing environments. As 
such, TK is not just continuous reproduction; it is also about innovating and creating within 
the traditional framework (Intergovernmental Committee on Intellectual Property and 
Genetic Resources Traditional Knowledge and Folklore, 2010, Appendix, p.14). A rigid 
requirement of proof of tradition for 30 years may therefore be too short or too long. Such a 
requirement might also fail to consider that tradition is preserved—even when some 
modifications in preparations and their applications take place over the years (Helmstädter 
& Staiger, 2014, p. 5). Accordingly, the use of medicinal plants at a given time is dependent 
on cognitive features such as perception and assessment, ecological factors, and cultural 
history; they all contribute to the evolution of a tradition (Leonti, 2011). Thus, the stipulated 




hindering broader representation of Arnica’s medical tradition or regional medical diversity 
in European countries.  
Traditional use registrations are accepted in the EU on the basis of sufficient safety data and 
plausible efficacy. The EU Herbal Monograph Arnicae flos cautions against the internal use 
of Arnica without referencing dose-dependent effects. It lists a raft of cautions, most 
remarkably ones against topical applications of Arnica in children under 12 years of age or 
in pregnancy. These are not due to actual safety concerns but a lack of contemporary 
scientific safety data (Committee on Herbal Medicinal Products (HMPC), 2014b, p. 4). 
EMA’s safety statement on the limitations for topical use significantly departs from that of 
the preceding German Commission E Monograph Arnicae flos which did not limit external 
use of Arnica to non-pregnant adolescents and adults. It further sits at odds with long-
standing traditional uses of Arnica as noted in the medical literature.  
5.2.9 Authoritative expert monographs 
The following section triangulates three independent authoritative expert monographs on 
Arnica montana and compares them with the two official European monographs as well as 
the Arnica monographs recorded in the medical literature.  
5.2.9.1 The ESCOP Monograph Arnica flos (2003) 
The ESCOP Monograph Arnica flos (ESCOP, 2003a, pp. 43-47), is an authoritative 
monograph published by the professional body representing national phytotherapy 
organisations across Europe. It specifies the whole or partially broken fresh or dried 
flowerheads of Arnica montana as the official drug which must comply with European 
pharmacopoeia quality standards (ESCOP, 2003a, p. 43). Endorsed preparations are 
ointments, creams, gels or compresses made with 5-25% V/V tinctures or fluid extract, or 
with diluted tinctures (1:3 or 1:10 extraction ratio), or diluted fluid extracts, or a decoction 
of 2.0g of dried Arnica flower extracted in 100ml of water. There is no guideline on how 
often they are to be applied, but the monograph states that overdoses are not expected with 
external use (ESCOP, 2003a, pp. 43-44). 
The ESCOP Monograph Arnica flos confirms the anti-inflammatory, antimicrobial, and 
cytotoxic actions of Arnica based on in vitro and in vivo experiments. It recommends 
Arnica preparations for six different indications, all as external applications (ESCOP, 






 inflammation caused by insect bites 
 gingivitis 
 aphthous ulcers 
 symptomatic treatment of rheumatic complaints. 
Compared with the approved indications listed in the Commission E Monograph Arnicae 
flos, the ESCOP Monograph Arnica flos lists fewer recommendations, since indications of 
superficial phlebitis, boils (furunculosis) and inflammation of the oral and throat region are 
absent. Indications noted in the ESCOP Monograph Arnica flos therefore exclusively cover 
the musc-skel, nerve and skin-mucous use-categories. Indications relating to the musculo-
skeletal and nervous systems have been consistently recorded in the medical literature over 
the past 400 years. Indications relating to the skin and mucous membranes have been 
consistently recorded since the first quarter of the 19th century (Richter 1827). This latter 
use-category is supported by in vitro tests demonstrating antimicrobial activity of Arnica 
constituents on infections localised on skin and mucous membrane surfaces (ESCOP, 
2003a, p. 44).  
In contrast to the Commission E Monograph Arnicae flos (1984) which endorses superficial 
phlebitis as an approved claim, the ESCOP Monograph Arnica flos lists no indications 
related to the card-vasc use-category. The ESCOP monograph Arnica flos discusses, 
however, two randomised, double-blind, placebo-controlled studies with patients suffering 
from chronic venous insufficiency (primary varicosis) in the legs, where swelling and pain 
were significantly more relieved after the verum treatment with an Arnica gel or ointment in 
one study, while comparable improvements but no difference between groups were shown 
in the other (ESCOP, 2003a, p. 45). Nonetheless, the indication ‘varicose veins’ is not listed 
in the ‘Therapeutic Indications’ list (ESCOP, 2003a, p. 43); therefore these indications are 
referenced in Table 8 above and Appendix 10 in brackets and italics only.  
The ESCOP Monograph Arnica flos highlights the analgesic activity of Arnica in muscle 
ache which was confirmed in a small clinical trial (ESCOP, 2003a, p. 45). Even so, the 
indication ‘muscle ache’ is also not listed as a ‘Therapeutic Indication’. This is surprising as 
a cross-check with the medical literature confirms that the therapeutic action of Arnica to 




at least since the early modern period (see Tabernaemontanus Appendix 5). Rheumatic 
muscle and joint problems were also official claims in the Commission E Monograph 
Arnicae flos but are not recorded in the ESCOP monograph. 
The ESCOP Monograph Arnica flos lists the following contra-indications and warnings: 
 contra-indicated in allergy to Arnica or other members of the Compositae family 
 for external use only 
 not to be used on open wounds. 
The monograph notes that skin irritations have been reported and that dermatitis from 
Arnica may occur in susceptible individuals. The contra-indication for Arnica on any open 
wounds is noteworthy as the use of Arnica in boils (furunculosis) and insect bites was 
permitted in the Commission E Monograph Arnicae flos.  
5.2.9.2 The WHO Monograph Flos Arnicae (2007) 
The WHO Monograph Flos Arnicae (World Health Organization, 2007, pp. 77-87) covers a 
wide range of detailed expert information on traditional uses and scientific research. As 
Arnica is harvested, cultivated and used across many countries, the monograph begins with 
detailed information on the correct identification of this medicinal plant. It provides a 
botanical and microscopic description for drug identification, including its organoleptic 
properties which are described as aromatic in odour and bitter and acrid in taste. This aligns 
with the organoleptic description of Arnica in Tabernaemontanus (see Appendix 4).  
The thorough botanical identification methods provided in the WHO Monograph Flos 
Arnicae are essential. Plant substitution, accidental or deliberate adulteration, and the use of 
non-therapeutic plant fillers are widely recognised as problematic and potentially hazardous 
(Bennett & Balick, 2014; Heinrich & Verpoorte, 2014, p. 385; Rivera et al., 2014). For 
example, Arnica montana is quite frequently adulterated with Mexican Arnica (Heterotheca 
inulides), Arnica chamissionis ssp., and Calendula officinalis which are sold as substitutes 
(Engels & Brinckmann, 2015, p. 6). Additionally, local replacements of one species with 
another that has similar therapeutic effects is common. A recent investigation of products 
sold under the name of “Arnica” showed that they did not contain Arnica montana but 
Trixis inula, Heterotheca subaxillaris, Grindelia spp., and Pseudogynoxys spp. (Aguilar, 
2015, p. iv). While these plants have similar properties to Arnica montana and have been 




similar complaints, these cases highlight that the vernacular name “Arnica” does not 
conclusively refer to Arnica montana but can refer to other local plant species, much as was 
the case in pre-Linnean times. Therefore, the WHO Monograph Flos Arnicae provides 
important botanical identification tools to the international community. The unequivocal 
botanical identification of Arnica montana is essential for an accurate vetting of traditional 
uses for regulatory purposes.  
The WHO Monograph Flos Arnicae (2007, pp. 77-87) defines the dried flowerheads 
(capitula) of Arnica montana as the desired herbal drug part. Other parts of Arnica 
traditionally used in European countries, namely the herb, root or whole plant, are not 
listed. Unlike the Commission E Monograph Arnicae flos, the ESCOP Monograph Arnicae 
flos, and the evaluated European medical literature, the WHO Monograph Flos Arnicae 
does not reference the fresh flowerhead as starting material for preparations.  
The WHO Monograph Flos Arnicae recommends the external use of Arnica as an undiluted 
tincture, a compress with either a water infusion or a tincture, a mouth rinse with a 10-fold 
dilution of a 1:10 tincture, or an ointment with tincture or essential oil of Arnica. There is 
no posology available for internal use, although internal use is referenced under traditional 
medicine. 
The monograph is divided into three sections; “Uses described in pharmacopoeias and well 
established documents”, “Uses described in traditional medicine” and “Medicinal Uses” 
(World Health Organization, 2007, pp. 80-81). It cites experimental pharmacology based on 
in vitro and animal studies to support the analgesic, anti-inflammatory, antioxidant, anti-
tumour, cardiovascular, choleretic and uterine stimulant effects of Arnica. 
Under “Uses described in pharmacopoeias and well established documents” the WHO 
Monograph Flos Arnicae (World Health Organization, 2007, pp. 80-81) lists Arnica flower 
preparations as topical counterirritants for the treatment of pain and inflammation resulting 
from: 
 minor injuries and accidents, including bruises, ecchymosis, haematomas 
and petechiae 
 inflammation of the oral mucous membranes 
 insect bites 




Therefore, this section lists indications belonging to the musc-skel and nerve use-categories, 
both of which have been consistently referenced over the past 400 years. The inflammation 
of the oral mucous membranes indication (skin-mucous use-category) was first listed in 
Strumpf (1855), while the insect bites and superficial phlebitis indications are 20th century 
nosologies. These mirror the indications listed in the Commission E Monograph Arnicae 
flos, except that ‘furunculosis’ and ‘rheumatic muscle and joint problems’ are absent from 
this section of the WHO Monograph Flos Arnicae. Rheumatism is, however, mentioned 
later in the traditional medicine section.  
Under the section “Uses described in traditional medicine” the WHO monograph adds these 
indications; indigestion (gastro-intest), cardiovascular disease (cardio-vasc), rheumatism 
(musc-skel; nerve), and to induce menstruation (gyn) (World Health Organization, 2007, p. 
81). These indications were collated from a database research on NAPRALERT4. A check 
on this database (accessed 30.6.2017) reveals that most of the listed articles relate to in vitro 
and animal trials. References to medical textbooks by European physicians as well as 
textbooks on the materia medica of other bioregions could not be found. Thus, a large body 
of empirical evidence from the professional medical literature was missed, meaning that 
evidence was only partially captured and is larger than shown in this monograph. 
While cardio-vascular diseases and rheumatism are listed under traditional use, 
experimental scientific research since the 1940s confirms the cardio-vascular stimulant and 
positive inotropic effects of Arnica (Erley, 1965; Gessner, 1949; Schulz, Hänsel, & Tyler, 
1998, pp. 260-262). Rheumatism as an indication is listed in the 8th commentary to the 
German pharmacopoeia based on understanding the mechanism of Arnica in the treatment 
of rheumatism (Böhme & Hartke, 1981). Two clinical trials also confirm the therapeutic 
efficacy of Arnica in treating osteoarthritis (Knuesel, Weber, & Suter, 2002; Widrig, Suter, 
Saller, & Melzer, 2007). Consequently, these indications could have been listed in the 
section ‘Uses described in pharmacopoeias and well established documents’ as well as in 
the section ‘Medicinal uses’ (see below). 
Under the section “Medicinal uses”, the WHO Monograph Flos Arnicae states that no 
clinical data on humans could be found to support specific indications (World Health 
Organization, 2007, p. 80). This contradicts the results of the database research undertaken 
 





as part of this thesis which returned for the period up to 2007 several clinical trials, 2007 
being the year the WHO monograph was published. The following clinical research studies 
on phytotherapeutic, non-homoeopathic preparations containing Arnica as the sole active 
substance and published before 2007 in German, Dutch, French or English showed positive 
clinical research findings for Arnica for the following indications (see Appendix 11): 
improvement of coronary circulation (observational study of internal use) (Erley, 1965); 
improvement of venous insufficiency (RCTs of gel, cream and bath preparation) (Brock, 
1991, 2001; Uehleke, 1996a, 1996b); improved recovery of post-training muscular pain 
with an Arnica gel (RCT) (Moog-Schulze, 1993); and reduced pain and stiffness in people 
with mild-moderate osteoarthritis of the knee (open multicentre clinical trial) (Knuesel et 
al., 2002). A further RCT published in the same year as the WHO Monograph Flos Arnicae, 
compares an Arnica gel with a NSAID (ibuprofen 5%) and demonstrated its equivalence in 
the treatment of pain and function in osteoarthritis (Widrig et al., 2007).  
The WHO monograph Flos Arnicae deliberates on three safety aspects of Arnica: in 
pregnancy and lactation, allergy potential, and internal use. Regarding the first, the text 
states that the safety of Arnica during pregnancy and nursing has not been established based 
on contemporary toxicity assessments in humans. The WHO Monograph Flos Arnicae 
quotes, however, two rodent studies which report a uterine stimulant effect from Arnica 
flower tincture (World Health Organization, 2007, p. 82). These studies do not declare the 
dosage regime applied so do not provide meaningful information in this context. Regarding 
teratogenicity, the WHO Monograph Flos Arnicae states that intraperitoneal administration 
of 6.0–20.0 mg/kg body weight (bw) of the sesquiterpene lactone helenalin, the key active 
constituent of Arnica, was not teratogenic in mice. At the upper dose this regime equates to 
1,200mg of the single component helenalin alone for a 60kg woman. This is significantly 
higher than the therapeutically recommended dosage of the whole plant extract that includes 
in its matrix numerous other constituents besides helenalin. To put these rodent studies into 
context, empirical data based on long-term regular medical care references the safe and 
effective dose range as 10 to 30 drops or 0.12ml to 1.2ml of a 1:10 Arnica tincture or a 
maximum of 2g of dried flowerhead up to 3 times per day. Within the parameter of this 
dose range, no safety issues for the use of Arnica in pregnancy and breastfeeding have been 
noted in the medical literature over the past 120 years. Arnica is, however, documented as a 
gastro-intestinal irritant when taken at high doses and as an abortifacient when taken as an 




Arnica for inducing an abortion (Bruchhausen, Danner, Baumann, & Achatz-Carmesin, 
1990; Lenz & Ardens, 1919, p. 90). In one of them (Lenz & Ardens, 1919, p. 90) a woman 
took 20g of flowerheads in one single dose. This caused severe bloody vomiting after a few 
hours combined with severe stomach pains. The abortion took place within a few days. 
Toxic effects of Arnica are reported to be temporary and transient (Spaich, 1978). Twenty 
grams is a significant overdose compared with the recommended therapeutic dose.  
Regarding the second safety issue, the WHO Monographs Flos Arnicae states that Arnica is 
contraindicated in cases of known allergy to Arnica or other members of the Asteraceae 
family. The text recounts several case reports of dermatitis of toxic or allergic origin 
following prolonged, external applications with an Arnica flower tincture, highlighting that 
Arnica is contra-indicated in those suffering from an Arnica allergy. The monograph warns 
further against all applications of Arnica on open or broken skin. This is in line with the 
ESCOP Monograph Arnicae flos but is a departure from the Commission E Monograph 
Arnicae flos and long-standing traditional use of Arnica as an antiseptic for small areas of 
skin in people with no known allergies to plants in the Asteraceae family.  
Regarding the third safety issue, the WHO Monograph Flos Arnicae recommends against 
the internal use of Arnica, which concurs with the position of the German Commission E 
and ESCOP. The quoted rodent studies on the oral median lethal dose (LD50) do not 
provide useful insights as their relevance for human consumption is unknown (World 
Health Organization, 2007, p. 82). The WHO bases its recommendation against the internal 
use of Arnica at any dose range on a historical lethal case of accidental poisoning with a 
presumed Arnica tincture (World Health Organization, 2007, p. 83). This case, which was 
originally reported in the French periodical Journal de Pharmacie et de Chimie in 1879 
(Hager, 1883c, p. 115), became the feature reference case report over the next 130 years, 
first as a caution against overdosing and then as an argument against any internal use of 
Arnica (Lewin, 1992, p. 764). The original case report recounts that a man accidently 
ingested approximately 60-80g of a presumed Arnica tincture of unknown strength. He 
developed stomach pain and later died. A review of this case questioned whether the lethal 
dose—now quoted as an average of 70g—was an Arnica preparation, as its very bitter taste 
and high alcohol content would have made it difficult to swallow (Spaich, 1978, p. 90). At 
the time of the fatality, the offending preparation was not analysed, and the botanical 
identification of the starting material not reported. The original report notes that 




blisters. This was used as the proof that the offending preparation must have been made 
with Arnica. However, there are other preparations which in high concentrations have a 
caustic effect on skin. Unequivocal causality was not established. An uncritical reference to 
this historical case report of presumed Arnica poisoning is problematic from an evidence-
based point of view because it does not satisfy basic criteria of scientific reporting such as 
adequate levels of data to establish clear causality. It is therefore surprising that it continues 
to be quoted in the WHO Monograph Flos Arnicae, and also in contemporary toxicology 
textbooks and books on clinical herbalism, without apparent awareness of the historic 
nature of the case or the issues of uncertain causality, dosage and possible misidentification. 
For example, Bone and Mills (2013) HagerROM (2003), Roth, Daunderer, and Kormann 
(2006) and Schulz et al. (1998) all quote this case report of ‘Arnica’ tincture poisoning. 
The issue of correct botanical identification aside, it is unusual that the WHO Monograph 
Flos Arnicae fails to differentiate between an adverse event and an overdose. It cannot be 
scientifically justified that misinformed use of a substance implies an inherent toxicity issue 
when that substance is used within recommended guidelines. Even if Arnica had been 
correctly identified as the offending plant drug in this case report, the alleged ingested dose 
was 70 times above the therapeutic dose recommended in long-established traditional 
European medical prescribing. In addition, internal low dose applications continue to be 
officially endorsed in the Austrian pharmacopoeia ÖAB 90 and in HAB (Blaschek et al., 
2012, pp. 12, 16). Arnica is also permitted in the USA as a food additive at a low dose (U.S. 
Food and Drug Administration (FDA), 2017). Without causality, dose and strength of the 
preparation unequivocally established, it is questionable to draw on this case report to 
prohibit the contemporary internal use of Arnica montana. Such reasoning is unfortunate, 
given that monographs published by the WHO provide a necessary and important resource 
for international decision makers. For example, the German Bundesamt für 
Verbraucherschutz und Lebensmittelsicherheit (2014, pp. 26-27), a German regulatory 
agency responsible for the safety of food and food supplements, refers to the WHO 
Monograph Flos Arnicae in its decision to limit Arnica to topical use without cross 
validating dosage considerations. Similarly, assessments published in WHO monographs 
find their way via research papers to online sources such as the WebMD5, one of the most 
widely visited databases for consumers, physicians, healthcare professionals and others with 
 





an interest in healthcare. It is noteworthy that the WebMD’s slideshow with the title Herbal 
Supplements You Shouldn’t try claims that Arnica can “bring on… death”, quoting the 
WHO Monograph Flos Arnicae  (WebMD). Because WHO monographs provide valuable 
expert information on medicinal plants to the international community, this monograph 
would benefit from an update on safety that reflects important dose considerations for this 
traditional plant. 
In conclusion, the WHO Monograph Flos Arnicae provides a comprehensive resource 
document on Arnica, predominantly reflecting legally permitted traditional uses noted in 
official and authoritative European monographs, and in experimental research. As tradition 
is bound to its relating biosphere and culture, not all regional indications may have been 
captured in this text; they should additionally be considered by a national regulator. 
Notwithstanding the unresolved issue of internal use of Arnica, this thesis recommends the 
use of the WHO Monograph Flos Arnicae as a regulatory resource for bibliographic 
evidence.  
5.2.9.3 The HagerROM. Hagers Enzyklopädie der Arzneistoffe und Drogen 
(2012)  
The monograph on Arnica in HagerROM. Hagers Enzyklopädie der Arzneistoffe und 
Drogen (also abbreviated in the literature as HagerROM), provides in-depth and up-to-date 
expertise on Arnica montana and related sub-species (Blaschek et al., 2012). The 
indications, plant parts and preparations that are discussed reflect historical and 
contemporary uses more comprehensively than any other official and authoritative 
monograph analysed in this study. This authoritative textbook is updated regularly and so 
includes the most recently published data on medicinal plants. 
As tabulated in Appendix 10, the HagerROM. Hagers Enzyklopädie der Arzneistoffe und 
Drogen covers indications relating to all five use-categories addressed in the Commission E 
Monograph Arnicae flos (card-vasc, musc-skel, nerve, respiratory, skin-mucous), but in a 
more comprehensive manner. Additionally, the text refers to traditional uses of Arnica in 
folk medicine in the areas of gynaecology, infection and as a tonic, reflecting long-
established applications in traditional European healthcare. 
With respect to plant parts, the HagerROM. Hagers Enzyklopädie der Arzneistoffe und 




mirrors clinical uses as documented in various editions of the Prussian and German 
pharmacopoeias, in their related compendiums and supplements as well as in clinical 
textbooks over the past 400 years (see Historical Database Excel spreadsheet). The various 
plant parts are to be prepared fresh or dry as tinctures, compresses, teas, gargles, creams or 
in cosmetic preparations. Most preparations are recommended as external applications, 
however ÖAB 90 (the Austrian pharmacopoeia) is referenced as permitting internal use of a 
water extraction with 0.2g of drug per cup whilst HAB permits a dry plant mother tincture 
of Arnica root at an internal dose of 5 to 10 drops 1-3x daily (Blaschek et al., 2012, pp. 12, 
16).  
5.2.10 Summary results on medicinal uses of Arnica montana listed in regulatory 
and authoritative monographs 
This section analysed two official monographs (authored by the German Ministry of Health 
and EMA respectively) and three authoritative monographs (ESCOP, WHO, HagerROM). 
As displayed in Appendix 10, all monographs list the main indications of Arnica already 
noted in the early modern period textbook authored by Tabernaemontanus, thus confirming 
the documentary relevance of this historical clinical text. The main indications of Arnica are 
recorded as the consequences of injuries and accidents such as sprains and strains, torn 
muscles and ligaments, bruises, oedema, haematoma and musculo-skeletal pain. 
The Commission E Monograph Arnicae flos published in 1984 is more reflective of clinical 
practice than the newer EU Herbal Monograph Arnicae flos published in 2014. Its 
indications relate to five use-categories; card-vasc, musc-skel, nerve, respiratory and skin-
mucous. Thus the Commission E Monograph Arnicae flos approves not only the main 
indications of Arnica, consequences of injuries and accidents, and musculo-skeletal pain, 
but further indications relevant in clinical practice: superficial phlebitis, rheumatic muscle 
and join problems, inflammation of mucous membranes of mouth and throat, inflammation 
caused by insect bites, and furunculosis.  
The EU Herbal Monograph Arnicae flos in contrast narrows approved health claims to 
complaints of the musculo-skeletal and nervous system only, which are the main indications 
for which Arnica is most known. These key indications represent a pragmatic political 
compromise rather than reflecting the totality of consistent traditional uses in various 




Of the three authoritative monographs, HagerROM. Hagers Enzyklopädie der Arzneistoffe 
und Drogen provides the most comprehensive summary of historical, contemporaneous and 
scientific data on Arnica (clinical: card-vasc, musc-skel, nerve, respiratory, skin-mucous; 
folk medicine: gyn, infection, and tonic). The clinical indications are congruent with clinical 
uses discussed by contemporaneous practising physicians. The uses listed under folk 
medicine are long-established indications previously recorded as mainstream in the 
historical medical literature. It is a recurring theme throughout this study that indications 
which are listed as folk medicine from the 1870s onwards were previously listed in the 
European medical literature as regular medicinal indications.  
The WHO Monograph Flos Arnicae lists indications across three separate sections; “Uses 
supported by clinical data” (0), “Uses described in pharmacopoeias and well established 
documents” (5: card-vasc, musc-skel, nerve, respiratory, skin-mucous) and “Uses described 
in traditional medicine” (5: card-vasc, gastro-intest, musc-skel, nerve, gyn) (World Health 
Organization, 2007, pp. 80-81). Database research of clinical trials on Arnica montana 
discovered that there were clinical data available at the time the monographs were published 
(see Appendix 11). The rheumatism indication listed under traditional use could therefore 
have been listed under “clinical data”. Therefore, while this monograph documents all main 
indications of Arnica, their listings in the different sections may benefit from updating. The 
monograph would also benefit from updates in the safety section that differentiate between 
the effects of a regular dose and an overdose. 
The ESCOP Monograph Arnicae flos published in 2003 by ESCOP is the least 
comprehensive authoritative monograph discussed in this category. It lists the long-
established main indications of Arnica relating to the musc-skel, nerve and skin-mucous 
use-category but does not fully reflect clinical uses of Arnica when compared with its 
preceding Commission E Monograph Arnicae flos or those in the medical literature (see 
Appendix 10). 
The five analysed monographs demonstrate divergence in safety assessment regarding the 
topical use of Arnica on open wounds. Whilst the Commission E Mongraph Arnicae flos, 
the WHO Monograph Flos Arnicae, and the Arnica monograph in HagerROM. Hagers 
Enzyklopädie der Arzneistoffe und Drogen permit Arnica as a disinfectant or styptic on 
small areas of skin, the ESCOP and EMA monographs advise against such use. The EMA 




pregnant adolescents and adults. EMA justifies this stance by citing a lack of scientific 
toxicity data rather than factual safety concerns for specific population groups. Concerns 
regarding the allergy potential of Arnica have been countered by recent studies which 
indicate low allergy responses in patients, although Arnica allergies have been observed and 
are troublesome for those affected (Bone & Mills, 2013, p. 378; Jeschke et al., 2009; 
Merfort, 2010, pp. 189-191).  
Four monographs endorse topical use of Arnica only. The Arnica monograph in 
HagerROM. Hagers Enzyklopädie der Arzneistoffe und Drogen references ÖAB 90 (the 
Austrian pharmacopoeia) and HAB, which both permit low dose internal use of Arnica 
preparations (Blaschek et al., 2012, pp. 12, 16). This is in line with the evaluated medical 
literature as well as the commentaries to the Prussian and German pharmacopoeias that 
documented systemic use of Arnica until the 1980s. Within the parameter of a low dose 
range, few safety issues for internal use of Arnica have been found in the researched body 
of literature, and those identified can be mitigated by appropriate use. All serious case 
reports on Arnica toxicity were noted in the literature related to overdoses (Bertin, 1864; 
Hager, 1883c, p. 115; Schoenemann, 1938; Topliff & Grande, 2000). Based on this 
analysis, it would be worth re-evaluating the stance on internal use of Arnica in official and 
authoritative monographs. The purpose would be to determine a rational differentiation 
between a safe, therapeutic dosage range and an overdose.  
The HagerROM. Hagers Enzyklopädie der Arzneistoffe und Drogen is the only monograph 
that discusses all therapeutically active plant parts of Arnica used in traditional European 
healthcare, namely flower, herb and root. The other four monographs list Arnica flower as 
the sole plant part to be used for preparations. 
In conclusion, triangulation of qualitative data established that the evaluated modern 
monographs and the medical literature concur on two clusters of indications relating to 
therapeutic usage of Arnica which are the treatment of consequences of injuries and 
accidents, and of pain related to the musculo-skeletal system and nerves. These parallel 
findings between monographs and medical textbooks validate the empirical evidence 
recorded in the medical literature. In addition, the triangulation showed that modern 
monographs cannot be taken as the sole bibliographic sources on traditional uses, as they do 




plant parts. Consequently, this thesis proposes that regulatory use of modern monographs 
occurs alongside judiciously selected medical textbooks for the validation of health claims. 
5.3 Contemporary scientific research into Arnica montana 
The following sections analyse contemporary clinical and experimental research into Arnica 
montana. Clinical trials are health interventions in humans conducted to find out whether 
there is enough evidence to support them as medical treatments. There are various models 
for clinical trials, the most prevalent being randomised-controlled trials (trial intervention 
against placebo or established therapy) or non-randomised observational outcome research 
such as cohort studies, observational studies and surveillance studies (case reports and case 
series) (Salkind, 2013). Intervention studies can be placed on a continuum, with a 
progression from efficacy trials to effectiveness trials. Efficacy can be defined as the 
performance of an intervention under ideal and controlled circumstances, whereas 
effectiveness refers to its performance under real-world conditions. Newer research 
methods such as Health Services Research and Program Evaluation are not considered here. 
Experimental research uses laboratory and basic science approaches to examine the 
mechanisms that might underlie a beneficial health intervention. Such research is conducted 
as a first step for the development of new substances, while for established therapies such as 
traditional plant medicines it is usually conducted to explain an already confirmed 
therapeutic effect (Lewith et al., 2011, pp. 9-15).  
5.3.1 Clinical research  
To cross-validate the previously established empirical evidence on Arnica montana as 
documented in medical textbooks with results from contemporary clinical research, this 
study employed a systematic method of literature searching, study selection and data 
extraction. The literature was searched using the following databases: Medline, Embase, 
AMED, Cochrane Library, Web of Science and Cinhal. In addition, the bibliographies of 
selected papers were examined for relevant studies. Searches were limited to English, 
German, French or Dutch-language material published from the inception of the databases 
to June 2014. An alert was set up when the search was concluded, and this process 
identified further literature included in this thesis. The search strategy applied is 






Figure 3. Flow diagram of database research to June 2014 of clinical trials on Arnica 
montana flower for cross-validation of clinical research with empirical science 
 
The study selection criteria were set to exclude articles outside of the scope of this review: 
 studies published in languages other than English, German, French or Dutch 
 studies on homeopathically potentised Arnica montana 
 studies on a different Arnica species other than Arnica montana 
 studies on toxicity 
 in vitro studies 
 rodent models 




 studies not declaring dose or concentration of preparation 
 papers discussing the same clinical trial 
 meta-analyses or systematic reviews (noted separately) 
 journal comments 
 narratives. 
Of the 25 clinical trials retrieved, 11 were conducted with Arnica montana as a single 
substance, three with a combination preparation that measured the additional effect of 
Arnica montana, and 11 which combined Arnica montana with other substances without 
measuring the additional effects of Arnica separately. Trials on combination remedies are 
included in this study because traditional systems of medicine commonly apply complex 
multi-component drugs, the use of a single ingredient drug being the exception rather than 
the rule. Traditional mixtures of active compounds act synergistically on a variety of targets 
affecting bioavailability, suppressing potential adverse side effects, and altering drug 
metabolism and excretion of the traditional drug (Verpoorte, 2012, p. 455). However, trials 
on complex multi-component drugs cannot be used as proof of a specific therapeutic effect 
of Arnica, rather they point to indications where a synergistic effect of Arnica was sought.  
Due to the overall high heterogeneity among the studies and indications under investigation, 
it was not possible to collate a meta-analysis (Brito, Knipschild, & Doreste-Alonso, 2014, p. 
222). This reflects the general challenge of achieving useful or valid results from meta-
analyses relating to heterogenic plant medicines (Lewith et al., 2011). Additionally, 
searching for evidence on plant medicines is not straightforward as various databases have 
shown to have incomplete listings when it comes to the retrieval of clinical studies 
conducted with specific medicinal plants (Pilkington, 2007, p. 456). 
It is outside of the scope of this study to offer a judgment on the measure of efficacy, the 
benefits and harms, of the individual studies found. An evaluation of clinical trials 
conducted until 2014 can be found, for example, in the HMPC Assessment Report on 
Arnica montana L. flos (Committee on Herbal Medicinal Products (HMPC), 2014b) and in 
the systematic reviews quoted below. The aim of this section is to provide a summary of 
indications said to be validated by contemporary science compared with indications 




5.3.1.1 Clinical research results  
A summary of scientific trials on Arnica retrieved via the systematic database research is 
displayed in Appendix 11. Clinical research on Arnica began in the mid-1950s. The first 
preparation under investigation was not a traditional remedy but a novel type of product that 
contained Arnica and Horsechestnut in combination with synthetic B vitamins for the 
treatment of elephantitis and changes to prothrombin time (Siebenhaar, 1955; Stöcker, 
1953). At that time Arnica was medically prescribed for the internal treatment of cardio-
vascular diseases for which products were available on the market, for example the test 
preparation Arnicorin (Chemiewerk Homburg, 1964). Erley (1965) provides the first 
published observational study on a traditional preparation, Arnica tincture (20 drops 3 times 
per day) but investigates it for a modern nosology, Angina pectoris. RCTs under a more 
robust scientific framework became prevalent from the 1990s onwards in response to the 
call by exponents of the EBM movement to provide modern clinical data on all therapeutic 
interventions in Western medicine (Borck, 2016).  
In total, the systematic database research returned 25 clinical trials covering 10 indications 
across four use-categories (card-vasc, musc-skel, nerve, skin-mucous). Three older clinical 
studies were conducted on the internal use of Arnica in the treatment of Angina pectoris, on 
prothrombin time, and in elephantitis, all returning positive results. Twenty-two newer 
clinical trials investigated the efficacy of Arnica in topical applications for varicose veins, 
bruises, musculo-skeletal pain, arthritis, ulcers, wounds and burns. Clinical trials on 
musculo-skeletal pain and osteoarthritis are coded to both the musc-skel and nerve use-
category as they relate to two indications each. 
Table 9 (next page) displays the summary of clinical trials on Arnica as referenced with 
author IDs established in Appendix 11 compared with similar types (but differently termed) 
historical indications documented in the medical literature. The results of the studies were 
positive unless indicated. 
Clinical trials on indications relating to the card-vasc, musc-skel, nerve and skin-mucous 
category substantiate long-standing traditional uses. Clinical research on the effect of 
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The treatment of burns with Arnica is a novel indication. While Arnica is referenced as a 
potential burn remedy in the lecture notes of the German pharmacologist Schulz (1919), this 
application is not consistently noted in other textbooks and so does not qualify under 




preparation under investigation was anthroposophical, containing mainly Nettle with a 
small proportion of Arnica as a minor adjunct drug, possibly to support circulation and for 
an antimicrobial effect in wound healing (Huber, Bross, Schempp, & Grundemann, 2010). 
Clinical trials conducted within a traditional dosage regime and treatment strategy returned 
positive results. Trials that applied a dose below traditional dosing, for example Gulick & 
Kimura’s study with a 4% Arnica cream (Gulick & Kimura, 1996), or studies that 
investigated the effect of Arnica as a one-off application (Rosenzweig et al., 2002) 
demonstrated no difference between verum and placebo. The dose correlation for achieving 
efficacy is highlighted by a systematic review on topical Arnica montana which confirms 
efficacy in preparations of 10% strength and above for the treatment of pain, swelling and 
bruises (Brito et al., 2014). Another review also confirmed substantial differences in clinical 
outcomes depending on the dosage and preparation used (Iannitti et al., 2016, pp. 1, 13). In 
2016 Iannitti et al concluded that “cumulative evidence suggests that Arnica montana may 
represent a valid alternative to non-steroidal anti-inflammatory drugs, at least when treating 
some specific conditions” (Iannitti et al., 2016, p. 1). They established further that topical 
Arnica preparations demonstrate reproducible clinical benefits, some of which are 
comparable with anti-inflammatory drugs such as diclofenac, ibuprofen and corticosteroids 
which are considered the therapeutics of choice for the treatment of osteoarthritis, 
postoperative oedema, and ecchymosis (Iannitti et al., 2016, p. 13). Their review findings 
also suggest that Arnica can be used in the context of wound healing for selected clinical 
needs, which is consistent with the therapeutic use of Arnica in conventional medicine well 
into the middle of the 20th century (Kreitmair, 1952, pp. 441-442). 
All RCTs on Arnica from the 1990s are on preparations for external use only due to a 
change in the regulatory benefit-risk assessments from the 1980s onwards, resulting in 
regulatory restrictions for the internal use of Arnica in many European countries. No RCTs 
could be found to alleviate or verify safety concerns of internal use of Arnica at the 
traditionally recommended therapeutic low dose range.  
5.3.1.2 Discussion on clinical research into Arnica montana 
Clinical trials on Arnica support long-standing historical indications for it based on clinical 
observations in patient care. Accordingly, they provide validation for the reliability of 
consistently endorsed traditional indications. At the same time, clinical trials do not 




medicinal plant (Saller et al., 2014, p. 28). Rather, they investigate a specific indication with 
a specific proprietary preparation to achieve proof of claim and/or funding for a commercial 
product. Some regulators may require clinical trials for the registration of a product, as in 
the EU for the registration of a product under the well-established use category. EMA does, 
however, not require clinical trials for the simplified registration of a product under 
traditional use (Verpoorte, 2012, p. 455). 
As illustrated in Appendix 5, Arnica has a long history of transmitted clinical uses in 
numerous pathological conditions: bruises, contusions, concussion, coronary heart diseases, 
dysmenorrhoea, partum and postpartum care and ailments of the uterus, epilepsy, fractures, 
dislocations, gout, haematoma, inflammation of the oral and throat region, hair loss, 
impaired respiration, insect bites, liver, stomach and intestinal complaints, muscle and joint 
pain from overexertion or injury, neuralgias, oedema, paralysis from accidents and strokes, 
passive bleeding from various organs, rheumatic muscle and joint pain, spasms, sprains, 
thrombosis, venous insufficiency (including varicose veins and phlebitis), skin complaints 
(boils, wounds, ulcers), systemic, respiratory and intestinal infections, and urinary 
complaints (diuretic). Many of these traditional indications have not been researched with 
modern methodologies. They could provide plausible leads for clinical research into the 
therapeutic potential of Arnica. 
5.3.2 Experimental research  
Apart from the clinical research discussed above, there is a substantial amount of 
experimental research exploring the composition of constituents in various plant parts of 
Arnica montana. Such research is not required in the EU for the registration of a product 
that qualifies under a traditional use monograph. However, experimental research provides 
insights into active constituents and mechanisms that may substantiate therapeutic uses 
documented in TEM. Arnica is one of the few traditionally used medicinal plants where 
active constituents, molecular mechanisms, pharmacokinetics, efficacy and toxicity aspects 
were established early on (Merfort, 2010, p. 188). It is plausible that this was central in 
assuring Arnica’s legal status as an ongoing essential medicine in the Prussian and German 
pharmacopoeias and thus in regular European healthcare. In vitro studies are most relevant 
to provide scientific data for topical applications. For scientific evidence on internal use, 
data obtained from bioassays should not be over-interpreted to represent clinical outcomes, 




role for enabling in vivo pharmacological effects (Gertsch, 2009). 
Experimental research identified over 150 active constituents that may explain the clinical 
treatment effects of Arnica as recorded in the European medical literature (Kriplani, 
Guarve, & Baghael, 2017, pp. 927-930; Wijnsma et al., 1995, pp. 51-54). They are 
alkaloids, amines, antioxidants, carbohydrates, coumarins, flavonoids, terpenoids, volatile 
oils, phenolic acids, resins, bitters, tannins, and carotenoids, with sesquiterpene lactones 
(SLs) and volatile oils representing the key active compounds (Blaschek et al., 2012, pp. 8-
9; Engels & Brinckmann, 2015, pp. 2-3; ESCOP, 2003a, p. 43; Kos, Lindenmeyer, Tubaro, 
Sosa, & Merfort, 2005; Kriplani et al., 2017; Wagner & Merfort, 2007; Willuhn, 1972c, 
1981; Willuhn & Herrmann, 1979; Willuhn, Rottger, & Wendisch, 1984; World Health 
Organization, 2007, p. 80). The structures of the representative constituents are presented 
below (World Health Organization, 2007, p. 80). 
 
Figure 4. Key active constituents of Arnica montana 
 
Arnica is coined a ‘phyto-cortison’ (Becker, 2005, p. 288) based on the anti-inflammatory 
properties of SLs.  Similarly to synthetic cortisone, they inhibit the transcription factors NF-
kB and NF-AT responsible for the transcription of genes that encode for inflammatory 
mediators (Ganzera, Egger, Zidorn, & Stuppner, 2008; Klaas et al., 2002). In vivo and in 
vitro studies suggest broad spectrum effects of SLs, mainly of an analgesic, anti-arthritic, 
antibacterial, anticancer, anti-ecchimotic, anti-inflammatory, antimycotic, antiplatelet, 
cholagogue, bitter tonic, immune and uterine stimulant nature (Blaschek et al., 2012, pp. 11-
12; May, 2013; Willuhn, 1981). SLs are also discussed as playing a role in the cardiotonic 
and respiratory analeptic actions of Arnica, the increase of breathing rate and strength 
(Blaschek et al., 2012, pp. 10-11). These actions are dose dependant and occur at small to 
medium doses (Gessner, 1949, pp. 825-827; Willuhn, 1981, pp. 5-6). When consumed in 




bleeding in the digestive tract and respiratory paralysis which has been scientifically 
demonstrated since the 1940s (Gessner, 1949, pp. 825-827; Šutovská et al., 2014; Willuhn, 
1981, p. 5). This dose dependant effect is confirmed in case reports as noted elsewhere 
(Merfort, 2010, p. 189) and concurs with safety observations recorded in the evaluated 
medical literature. 
Flavonoids may relate to antimicrobial, anti-inflammatory, and anti-rheumatic actions 
whilst volatile oils have shown antiseptic, anti-inflammatory and wound healing activity of 
Arnica (Roki et al., 2001; Willuhn, 1981). Phenolic and flavonoid components exhibit 
antioxidant effects (Aguilar, 2015, p. 46). The flavonoids astragalin and isoquercitrin 
improve ailments that require better systemic or local circulation (Böhme & Hartke, 1981, 
pp. 161-167). Polyacetylenes have confirmed bacteriostatic and fungicidal actions. In 
addition, procyanidins are believed to support coronary blood flow and positive inotropic 
and chronotropic actions, while chlorogenic acid and cynarine may be responsible for the 
cholagogue, choleretic and diuretic actions of Arnica (Willuhn, 1981). Its polysaccharide 
fractions are reported to show immune stimulating properties by increasing phagocytosis 
through granulocytes (Kriplani et al., 2017, pp. 931-934). Phenolic compounds isolated 
from Arnica have been related to a hepatoprotective activity (Kriplani et al., 2017, p. 934) 
Experimental evidence on Arnica’s constituents and their mechanisms of actions point to 
possible explanations of its therapeutic actions noted over the past 400 years. The scientific 
literature relates these constituents to the anti-inflammatory, anti-ecchymotic, anti-
haemorrhagic, bactericidal, bitter tonic, antineuralgic, antirheumatic, antiseptic, 
counterirritant, wound and tissue healing effects of Arnica. Additionally, in vitro and animal 
studies point to cardiotonic, circulatory stimulant, central nervous system (CNS) stimulant, 
diuretic, expectorant, hypotensive, nervine and uterine stimulant effects (Aguilar, 2015; 
Blaschek et al., 2012; Committee on Herbal Medicinal Products (HMPC), 2014a; Saller et 
al., 1995; Schulz et al., 1998; Wichtl, 2004; Willuhn, 1981; World Health Organization, 
2007, pp. 81-82).  
5.4 Summary and conclusions 
The analysis on Arnica montana comprehensively triangulated qualitative and quantitative 
data. The concept that consistent, clinically evaluated observation is a rational methodology 
which provides data that can be reproduced and validated is supported by parallel findings 




their compendia, endorsements in modern regulatory and authoritative expert monographs, 
and evidence in the form of clinical trials, and experimental laboratory research. The 
outcome of the data triangulation suggests that consistent transmissions of repeatedly 
observed and professionally evaluated treatment outcomes by professionally trained 
clinicians represent valid clinical observations. This analysis further confirmed that 
authoritative medical textbooks are the key repositories of medicinal plant knowledge on 
the European materia medica, providing a readily accessible and reliable documentary body 
of evidence relating to consistent clinical endorsements of Arnica montana over a period of 
400 years. These results strengthen confidence that empirical evidence from judiciously 
selected medical textbooks is a suitable bibliographic source of evidence which can be 
admitted alongside scientific evidence for regulatory purposes. This thesis proposes that 
such data are admissible as documentary evidence to substantiate traditional claims for the 
registration of traditional herbal preparations. 
The New vollkommen Kräuter-Buch by Tabernaemontanus and annotated by the Bauhin 
editors (4th edition, 1664) was confirmed as an appropriate starting point for this 
longitudinal textual analysis on historical clinical uses of Arnica montana in professional 
European healthcare. The triangulation confirmed that Tabernaemontanus was accurate in 
determining the pharmacological actions of Arnica, raising the possibility that he was also 
accurate about the pharmacological actions of other medicinal plants. The later expansion of 
indications for Arnica from those identified by Tabernaemontanus, to include complaints 
that benefit from circulation, came about with the discovery of blood circulation in 1628, 
illustrating that tradition is not static. The current main indications were transmitted in all 
qualitative and quantitative sources over 400 years, and many more were transmitted until 
the 1980s when the German and EU legislators restricted the internal use of Arnica as well 
as its use on broken skin, despite clinical validation for some skin infections.  
When the regulatory literature is put aside, and data is analysed across the selected 
professional literature only, then all early modern clusters of complaints were transmitted 
until at least mid-20th century, except complaints relating to the gastro-intestinal system and 
the liver-spleen. A possible explanation for the dropping of indications belonging to those 
use-categories is that firstly, Arnica root, the plant part required for the treatment of gastro-
intestinal infections, became restricted due to conservation issues—concurring with 
penicillin becoming the standard of care for infections—, and secondly, the humoral 




However, when the eight clusters of early modern indications are compared with 
experimental research, the active constituents of Arnica montana account for its therapeutic 
use in all traditional clusters of complaints.  
Longitudinal textual comparison of the medicinal uses of Arnica montana as recommended 
in authoritative medical textbooks from the 17th century to the 21st century concluded that 
despite changes in explanatory models of health and illness, the main indications for the 
therapeutic uses of Arnica has remained remarkably consistent. When comparing historic 
with present-day therapeutic uses of Arnica documented in authoritative medical textbooks, 
this body of knowledge evidences an uninterrupted medical transmission of two clusters of 
indications relating to the musculo-skeletal and nervous system: 
Table 10. Consistently endorsed indications for Arnica montana in medical 
textbooks over at least 400 years. 
Use-category Indications 
musc-skel injuries, sprains and strains, torn muscles and ligaments; bruises, oedema, haematoma 
nerve pain related to musculo-skeletal system and nerves 
 
This is the same cluster of indications that is consistently listed in the commentaries to the 
Prussian and German pharmacopoeias, and those listed in the main regulatory and 
authoritative monographs of the 20th and 21st century, namely the Commission E 
Monograph Arnicae flos, the EU Herbal Monograph Arnicae flos, the ESCOP Monograph 
Arnica flos, the WHO Monograph Flos Arnicae and the monograph on Arnica montana 
published in HagerROM. Hagers Enzyklopädie der Arzneistoffe und Drogen. 
In the 18th and 19th century, insights from physiology and experimental research expanded 
prior use of Arnica by further indications. The following historical indications meet the 
criteria of at least 30 years of continued therapeutic applications: 
Table 11. Consistently endorsed indications for Arnica montana in medical 
textbooks > 30 years. 
 
Use-category Indications 
card-vasc circulatory insufficiency (since Löseke 1790) 
varicose veins / phlebitis (topical) (since Kroeber 1948) 
respiratory breathing difficulties / catarrh (until Weiss 1974) 
sore throat (infection) (since Madaus 1938) 
skin-mucous ulcers, wounds (since Richter 1827) 
boils (since Schulz 1919) 
mouth and throat inflammation (since Strumpf 1855) 




The registration of therapeutic claims for Arnica as a tonic and as a circulatory and coronary 
stimulant, including to improve breathing, are nevertheless challenging as internal use of 
Arnica is now restricted. It might be warranted to re-evaluate these regulatory restrictions 
by the German and EU regulators in the light of consistent and uninterrupted transmission 
of traditional knowledge on internal applications within the safety parameters of traditional 
dosing.  
The remaining traditional indications which relate to the gastro-intest, gyn, head, infection, 
liver-spleen and uro use-categories show intermittent listings in the medical literature. 
Under current EU regulations these would not qualify under the traditional use criteria; 
some had also been reclassified over time from regular medicinal uses to folk medicine. 
Nonetheless, they could be analysed on a case by case basis to confirm or discount 
therapeutic rationale when considering the totality of their evidence. They could also 
provide important leads for scientific investigation of therapeutic usefulness in 
contemporary patient care. 
The results of this analysis further showed that treatments offering therapeutic benefit in 
clinical practice were maintained and transmitted by the medical profession whilst those 
which did not demonstrate practical value were dropped over time. Sometimes indications 
were discontinued due to regulatory or conservational requirements. There are various 
reasons as to why an indication may have become obsolete. The following are the most 
plausible: 
 indication was not a core traditional indication, and treatment was replaced by a 
plant drug that was seen to be more effective (e.g. Cinchona bark instead of Arnica) 
 ailment had ceased to be prevalent in the biosphere under discussion (e.g. malaria in 
Central Europe) 
 de-listing of an official plant part as an essential pharmacy item in a national 
pharmacopeia hindered easy access to that plant part, thus impeding its therapeutic 
application and related transmission of knowledge of use 
 a conservation issue prevented the use of a plant part for the treatment of an ailment 
(e.g. Arnica root for gastro-intestinal infections) 
 advances in biomedicine leading to a preferential treatment based on a biomedical 
approach (e.g. head injuries) 




applications (e.g. regulatory endorsement for external use only since the 1980s), 
hampering the legal transmission on their traditional uses. 
In addition, the current funding model for medicines in Germany and other European 
countries preferentially reimburses synthetically derived drugs. This affects the official 
access to traditional plant medicines and thus the ability to maintain tradition as part of 
conventional healthcare. The Waitangi Tribunal report on New Zealand law and policy 
affecting Māori culture and identity has come to the same conclusion when noting that 
funding levels for traditional medicines have been too low to safeguard the practice or 
ensure the transmission of knowledge about it (Legislation Direct, 2011, p. 211). For this 
reason, when traditonal medicines are investigated for the determination of their regulatory 
status and related therapeutic claims, the regulatory context with its socio-economic and 
legal framework needs to be understood alongside pharmacological and toxicological facts.  
5.4.1 Evidence from pharmacopoeias and their commentaries 
The Prussian and German pharmacopoeias provide evidence on official plant parts and their 
preparations officially approved in Germany for regular healthcare from the late 18th 
century to the present day. As such, this body of literature delivers data on the legal status 
of Arnica in a European country. It is proposed that this evidence is admissible as 
bibliographic evidence on traditional clinical uses of medicinal plants. 
Until the turn of the 20th century the official position on Arnica in the German 
pharmacopoeia and its commentaries was mostly congruent with therapeutic applications 
discussed in clinically orientated medical textbooks authored by contemporaneously 
practising physicians. The significant paradigmatic changes in medicine during the 19th 
century to a model chiefly based on natural science prompted ensuing German 
pharmacopoeia commissions to reduce the of scope of Arnica, and that of other medicinal 
plants. This is reflected in the reduction of officially endorsed plant parts of Arnica to its 
flower only, in fewer endorsed preparations and ultimately in fewer sanctioned indications 
by commentators. The commentaries from the 1st to the 10th edition of the German 
pharmacopoeia highlight the following trends: 
 reduction of permitted part parts to streamline essential pharmacy stock items 
(Arnica flower only) 




 decreased acceptance of empirical evidence by the academic community in favour 
of experimental research 
o when the complex mode of action of a plant drug could not be explained 
(yet) with new experimental science, it resulted in the discontinuation of an 
indication by some commentators (rheumatism) 
o when the mechanism of action could be explained with new experimental 
science the indication was re-listed (rheumatism) 
 reversal of benefit-risk ratio, as in discontinuation of internal use of Arnica since the 
1980s. 
While commentaries to the German pharmacopoeia continued to record the main 
therapeutic applications of Arnica for the musculo-skeletal and nervous system, and thus 
independently validate the clinical information recorded in the medical literature, they did 
not reflect its broader traditional and contemporaneous clinical uses. In the second half of 
the 20th century, commentaries re-listed some traditional indications based on insights from 
experimental research. This was, however, short lived as from the 1980s German 
regulations limited Arnica’s therapeutic applications to external use only (1986; Hartke et 
al., 1987). In contrast to evidence on harmful impacts from overdoses, overuse or allergic 
reactions to Arnica montana, no experimental or traditional evidence could be found that 
the traditional low dose regime of internal uses had caused serious harm in those not 
suffering from allergies to this particular plant species. The limitations of the commentaries 
are therefore grounded in the reproduction of the controlling regulatory paradigm of a 
national state which is guided by its legal and socio-economic framework. Since medical 
textbooks have shown to be a more comprehensive source of verifiable clinical 
endorsements for plant-based medicines compared with academic commentaries to 
pharmacopoeias, they are proposed as the primary source of evidence to substantiate claims 
for the registration of traditional herbal preparations. Commentaries are proposed as a 
complementary source of evidence to provide additional tradition-of-use (TOU) data on the 
main uses of Arnica montana.  
5.4.2 Evidence from regulatory and authoritative monographs 
Investigation of two official monographs, the Commission E Monograph Arnicae flos and 
the EU Herbal Monograph Arnicae flos (traditional use), and of three authoritative 




the Arnica montana monograph in HagerROM. Hagers Enzyklopädie der Arzneistoffe und 
Drogen highlighted consistencies as well as divergent views on therapeutic claims, the 
therapeutically active plant parts, and safety considerations depending on the legal 
framework and expert consensus at the time of their publication. All five monographs 
endorse the main indications for Arnica montana already noted by Tabernaemontanus; these 
indications are also congruent with clinical uses documented in the medical literature 
reviewed. They are consequences of injuries and accidents, and musculo-skeletal pain. 
Therefore, the triangulation of data from the five monographs and the selected medical 
literature reviewed at defined datapoints (each a generation apart) confirmed that all sources 
endorse the same indications for Arnica. This is a significant outcome and validates 
traditional clinical knowledge on Arnica montana. 
While all these sources concur on Arnica’s main therapeutic actions, there are disparities in 
the five monographs regarding further indications. As already discussed, the most striking 
change over the past 400 years is Arnica’s officially sanctioned systemic use until the mid-
1980s, after which regulators in Europe changed their benefit-risk analysis to an approval 
for external use only. This is reflected in the approved claims in the two official 
monographs and also in the type of commercial preparations now available in the market 
place, predominantly creams and gels for topical applications or homoeopathic 
preparations. The traditional use of Arnica as a tonic and as a circulatory and coronary 
stimulant has been officially impeded since the implementation of these regulatory 
restrictions, although off label use occurs (Bäumler, 2007, p. 63). 
The Commission E Monograph Arnicae flos published in 1984 is more reflective of 
indications listed in clinical textbooks compared with the newer EU Herbal Monograph 
Arnicae flos published in 2014. The EU monograph is informed by the legal framework of 
the EU Directive 2004/24/EC. The narrow legal framework and interpretation of the 
stipulations of the directive led to the exclusion of traditional water and oil extracts despite 
their long-standing documentation in the German pharmacopoeia, in the Commission E 
Monograph Arnicae flos, and in the medical literature reviewed. No evidence could be 
located in the HMPC Assessment Report (Committee on Herbal Medicinal Products 
(HMPC), 2014a) to confirm that traditional indications of Arnica had been systematically 
tracked for consistent historical uses beyond the stipulated period of 30 years. 
Consequently, the EU Herbal Monograph Arnicae flos approves three health claims for 




interpretation of the safety framework stipulated in the EU Directive 2004/24/EC restricted 
pre-approval of use to adolescents over 12 years of age, adults and elderly only. This is due 
to absence of contemporary scientific safety data rather than proof of harm.  This age 
restriction is not noted in the Commission E Monograph Arnicae flos and the medical 
literature analysed. 
Of the three authoritative monographs examined for this thesis, the Arnica monograph 
published in HagerROM. Hagers Enzyklopädie der Arzneistoffe und Drogen provides the 
most comprehensive summary of historical, contemporaneous, and scientific information. 
As tabled in Appendix 10, the indications in the Arnica monograph of HagerRom are more 
congruent with clinical uses endorsed by practising physicians compared to the ESCOP and 
WHO monographs. Furthermore, the HagerROM monograph lists all therapeutically active 
plant parts of Arnica used in traditional European healthcare, namely flower, herb and root, 
while the other two authoritative monographs only list Arnica flower as the sole plant part 
for therapeutic preparations.  
The WHO Monograph Flos Arnicae lists all the main indications of Arnica plus some 
additional traditional indications, however their listings allocated to different categories 
would benefit from updating. As with the EU Herbal Monograph Arnicae flos it may be 
advisable to re-evaluate the WHO’s stance on internal use of Arnica so that it makes a 
rational differentiation between a safe, therapeutic dose range that is underpinned by long-
standing clinical use, and an overdose. Establishing a contemporary safe internal dosage for 
Arnica is a research gap. The ESCOP Monograph Arnica flos also lists the main indications 
of Arnica pertaining to the treatment of the musculo-skeletal and nervous systems and the 
skin, but it lists the least additional historical indications compared with the other 
authoritative monographs and the analysed medical literature.  
Despite their differences in scope and safety assessments all five monographs provide 
important clinical and scientific evidence on Arnica montana which could be canvassed by 
the international community as bibliographic evidence. It is important to note though that 
these monographs reflect the particular legal and socio-economic environments in which 
they are embedded. Moreover, it is important to note that traditional uses vary in different 
regions, countries, and continents. Consequently, the scope of approved claims in regulatory 




5.4.3 Comparison of empirical evidence with scientific evidence  
When traditional medical knowledge based on empiricism as documented in the European 
medical literature is compared with clinical and experimental research on Arnica montana, 
contemporary scientific and historical evidence correspond as listed in Table 12 (next page). 
This comparison demonstrates that traditional uses of Arnica montana as transmitted by 
clinicians are scientifically well substantiated. Scientific research confirms benefits in 
ailments that require a circulatory stimulant, analgesic, anti-rheumatic, anti-inflammatory 
and skin healing action. It is noteworthy that modern clinical and experimental laboratory 
research provides few new applications for Arnica montana beyond those based on 
empirical evidence documented in traditional European medicine. Conversely, traditional 





Table 12. Comparison of historical indications of Arnica montana with clinical trials 
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6 THE MEDICINAL USES OF HYPERICUM 
PERFORATUM: THERAPEUTIC INDICATIONS FROM 
THE EARLY MODERN PERIOD (1588/1664) TO 
CONTEMPORARY PHYTOTHERAPY (2007) 
Worldwide, Hypericum perforatum (St. John’s Wort) is one of the most scientifically 
researched medicinal plants. Its remedial uses have been documented in Europe since 
classical Hippocratic times and have over 2500 years become deeply embedded in both 
formal and folk medicine (Czygan, 2003; Dell'Aica, Garbisa, & Caniato, 2007). While St. 
John’s Wort preparations are most readily known today for their efficacy in treating 
depression and somatoform disorders, there are many additional long-standing clinical 
indications. In this chapter, a botanical, etymological, and historical introduction to St. 
John’s Wort is followed by a longitudinal textual analysis on empirical knowledge as 
recorded in medical textbooks over the past 400 years. This analysis uses the same 
judiciously selected medical literature as that evaluated for Arnica. Commentaries on the 
Prussian and German pharmacopoeias are not investigated further in this chapter. The 
results from the previous chapter established that such commentaries detail the same main 
traditional uses as recorded in the medical literature but do not reflect broader clinical 
practice. Authoritative expert monographs (by ESCOP, WHO, HagerROM) are also not 
evaluated further. They were utilised as modern sources in the preceding triangulation of 
data on Arnica to cross-validate historical indications recorded in medical textbooks. As 
such they confirmed that the main historical indications of Arnica mirror current indications 
in contemporary phytotherapy. These modern monographs therefore validated historical 
textbooks as a suitable bibliographic source of verifiable traditional indications; medical 
textbooks are therefore tested further as a body of empirical evidence for regulatory 
purposes.  
In the following section the Historical Assessment Tool is applied for the systematic 
collation of traditional indications of St. John’s Wort recorded in mainstream textbooks on 
the European materia medica. This is to demonstrate how this method swiftly, summarily, 
and methodically collates traditional evidence. The analysis proceeds under the assumption 
that such summaries provide succinct bibliographic evidence for health claims once suitable 




indications is further compared with approved therapeutic indications in two European 
regulatory monographs: the Commission E Monograph Hyperici herba (Kommission E, 
1984b) and the EU Herbal Monograph Hypericum perforatum L. herba (Committee on 
Herbal Medicinal Products (HMPC), 2009b). This is to understand how comprehensively 
such regulatory monographs reflect traditional medicinal uses of St. John’s Wort and what 
role they could play as evidence on traditional plant medicines regulated in other countries 
such as New Zealand. In addition, this chapter triangulates the empirical knowledge 
documented in the medical literature with contemporary clinical and experimental research. 
The purpose of this step is to cross-validate data derived from qualitative historical sources 
with data derived from qualitative contemporary sources to strengthen conclusions drawn.  
6.1 Introduction to Hypericum perforatum in European healthcare 
6.1.1 Botanical profile 
 Hypericum perforatum is a perennial plant belonging 
to the genus Hypericum, a genus which incorporates 
about 450 species of trees, shrubs, and herbs. It is a 
member of the Clusiaceae (alternative name 
Guttiferae) family (Robson, 2003). Though native to 
Europe, it became naturalised in Asia, Africa, the 
Americas, Australia, and New Zealand (Blaschek et 
al., 2012; Dell'Aica et al., 2007, p. 109). St. John’s 
Wort has four subspecies: ssp. angustifolium (DC.) 
GAUDIN; spp. latifolium (KOCH) FRÖHLICH; spp. 
perforatum; and spp. veronense (SCHRANK) 
FRÖHLICH (Saller et al., 1995, p. 208). Hypericum 
perforatum is the official species listed in the 
European pharmacopoeia, the legally-binding 
pharmacopoeia in all EU countries. It may be 
accidentally or deliberately adulterated with other 
Hypericum species, such as H. barbatum, H. hirsutum, H. 
maculatum, H. montanum, H. tetrapterum, H. patulum, and H. 
Figure 5. Hypericum 
perforatum in Bock, 




crux-andreae, or with synthetic red dyes added to its extracts (McCutcheon, 2017, pp. 1-3). 
St. John’s Wort grows well alongside sunny paths, on the edges of woods, in gravel, in 
riverbeds, in dry pastures, and on alpine meadows at up to 1,500 meters altitude 
(Vonarburg, 1993, p. 112). It can reach a height of up to one metre. From June to July in 
European countries or from December to January in New Zealand, the opposite and paired 
branches yield intensely yellow flowers containing five petals with many protruding 
stamens. The oblong leaves are opposite, sessile, and up to two (rarely three) centimetres 
long, and they display numerous translucent glandular dots which are hypericin-containing 
oil glands. When St. John’s Wort blossoms are rubbed between the fingers, they release a 
striking blood-red juice. The fruit is a capsule containing fine seeds that are disseminated by 
the wind when the ripe capsules break open (Buch, 2016; Lauber & Wagner, 2001, p. 280; 
Pfister et al., 2014, pp. 152-155). 
Apart from Hypericum perforatum with its typical round stem, there are closely related 
species which are not official today, but which have traditionally been used for therapeutic 
purposes. It is possible that at least some of them have similar therapeutic effects to H. 
perforatum (Dall'Agnol et al., 2003; Fenner et al., 2005; Ferraz et al., 2005; Kızıl, Kızıl, 
Yavuz, Emen, & Hakimoğlu, 2008; Klejdus, Kovacik, & Babula, 2013; Pulokmukherjee, 
2001; Robson, 2003, p. 20; Zorzetto et al., 2015). These similar effects of various 
Hypericum species were already identified by ancient Greek physicians as highlighted in 
the Hypericum monograph of Tabernaemontanus (Tabernaemontanus, 1664, p. 1250), and 
echoed by 19th century physicians (Dulk, 1833b, pp. 35-36; Strumpf, 1855). The main 
contenders are H. maculatum with its four-edged stem, H. tetrapterum with its four-edged 
winged stem, H. montanum with a round stem and haired leaves, H. humifusum with a 
creeping stem up to 15 cm, H. hirsutum with haired leaves growing up to 150cm, and H. 
pulchrum with its heart shaped leaves and growth up to 50 cm. Other Hypericum species are 
grown in gardens as ground covers and are not used medicinally (e.g. H. olympicum and H. 
polyphyllum) (Vonarburg, 1993, p. 112).  
6.1.2 Historical and etymological profile 
The medical tradition and cultural significance of Hypericum perforatum in European 
medicine has been evident since antiquity. The etymology of the genus Hypericum is 
thought to link to the Greek words hyper and eikon, which translates either as ‘above’ or 




of a deity, or as ‘above apparitions’, a reference to its implied apotropaic properties against 
evil spirits (Czygan, 2003; Dell'Aica et al., 2007). During the early modern period, the 
implied apotropaic effects of St. John’s Wort were expressed in the Latin name Fuga 
daemonum (banishes demon) (Tabernaemontanus, 1664, p. 1250). The epithet perforatum 
was introduced in the medieval period to describe the translucent glands on the leaves of 
this species, which, when held against sunshine or light, appear as small black perforations.  
The Swedish botanist Carl von Linné confirmed the binominal taxonomy of St. John’s Wort 
in his seminal work Species plantarum (1753) as Hypericum perforatum (Czygan, 2003, p. 
185). The German name (Echtes) Johanniskraut, which is mirrored in the English name St. 
John’s Wort, refers to St. John the Baptist whose name day is 24 June, a time in the 
Northern Hemisphere when the plant is in full flower. In pre-Christian times, St. John’s 
Wort was an important plant during the summer solstice (21 June) and was dedicated to the 
pagan Germanic god of light, Baldur (Fischer, 1991, p. 121). Other German vernacular 
names are Herrgottsblut, Johannisblut, Sonnwendkraut, Tüpfelhartheu, Christi Wundkraut, 
Christusblut, Gottes Gnadenkraut, Dunderblume, Sonnenwendkraut, Hexenkraut, and 
Teufelsflucht (Vonarburg, 1993, pp. 111-112), many of which point to St. John’s Wort’s 
significance in Christian traditions that superseded long-standing holy pagan rituals 
(Dell'Aica et al., 2007, p. 109). The names Frauenkraut and Maria Bettstroh point to its 
importance in women’s healthcare. 
The medicinal properties of St. John’s Wort have been documented in the Hippocratic 
Corpus, around 400BC, and praised by subsequent leading Greek physicians, most notably 
by Theophrastus, Dioscorides, the historiographer Plinius (Pliny the Elder), and Galen 
(Dell'Aica et al., 2007; Jarić et al., 2017). Over the past 2500 years, it has been used 
medicinally for the treatment of burns, wounds, sciatica, urinary tract infections, stomach 
and uterine complaints, bed wetting, diarrhoea, mucosal lesions of the mouth, gout, and 
respiratory tract ailments. It has also been used as a cholagogue and anti-inflammatory in 
liver and gallbladder complaints (Mayer, 2014; Saller, Kristof, & Reichling, 1999, p. 118).  
Treatment of melancholy with Hypericum is referenced in a medical text written in the last 
decade of the 8th century, the Lorscher Arzneibuch, the oldest surviving German medieval 
monastic medical text (Mayer, 2014, p. 290). Melancholy was understood as a depressive 
state that arose from the stagnation of black bile (melas is black and kholē is bile in Greek), 




2014, p. 301). In humoralism, fear, sadness, gloom, and fright were typical symptoms of 
melancholic illnesses (Zimmermann, 1975, pp. 91-96). Such mental and emotional 
afflictions are today commonly understood and referenced as depression (Tschupp, 1998, 
pp. 44-47). In the 16th century, Paracelsus praised St. John’s Wort as a groß arcanum (a 
remedy of great mystical strength) that chases away evil influences and the mad fantasies 
that drive people to despair (Czygan, 2003, pp. 187-188), a property that was aptly captured 
in the aforementioned name Fuga daemonum. 
St. John’s Wort preparations are best known today as natural treatments for mild-to-
moderate depression because of both their equivalent efficacy to synthetic antidepressants 
and their high safety profile (Ng, Venkatanarayanan, & Ho, 2017). They are used as a cost-
effective alternative to generic antidepressants (Solomon et al., 2013).  
6.1.3 Official status 
Despite its long-standing clinical uses in alpine regions of Central Europe, including 
Germany, St. John’s Wort was not selected as an essential medicine in the first edition of 
the German pharmacopoeia (Hager, 1872). As shown in Table 13 (next page), it remained 
absent until 1986 when the Deutsches Arzneibuch DAB 9 harmonised with the 
Europäisches Arzneibuch (Ph. Europea). This pan-European pharmaceutical reference 
work provides legally binding pharmaceutical manufacturing standards for all essential 
medicines in countries of the EU and other signatory states (DAB 9, 1986, p. 3). 
While the Prussian pharmacopoeia had listed St. John’s Wort from 1799 onwards, this 
historically significant medicinal plant, its plant parts (flores, herba, sumitates), and oleum 
preparation became de-listed from its 6th edition (Gurlt, 1847). During this period, the 
committee of the Prussian pharmacopoeia was compelled to publish a pharmacopoeia that 
projected a modern image of the pharmaceutical profession by aligning themselves with 
what they perceived as the peak of natural science (Tschupp, 1998, pp. 121-122). Many 
traditional medicinal plants that could not be explained by a defining active constituent or a 
mechanism of action became de-listed, despite long-standing medicinal use (Jütte, 1996, pp. 
165-166; Schulz, 1919, pp. 2-3). The de-listing of St. John’s Wort in the Prussian 
pharmacopoeia was in line with the Swiss pharmacopoeia, where it was also absent until 
1991 (Pharmacopoeia Helvetica, 1995), but it contrasted with pharmacopoeias of other 
European countries such as France, Spain, Portugal, and the former Yugoslavia, where St. 












































































































































































































































































The de-listing of St. John’s Wort as an essential drug in Germany from mid-19th century 
onwards, despite its ongoing use in medical care, exemplifies the regulatory privileging of 
newly developed synthetic drugs over historical plant medicines during this time. Prefaces 
to commentaries for the German pharmacopoeia illustrate a new era of academic 
enthusiasm for chemistry-based medicines and a critical position towards historical plant 
medicines (Anselmino & Gilg, 1911a, p. V). Consequently, traditional medicines were 
removed in great numbers. Between its 1st and 5th editions, the German pharmacopoeia 
eliminated 258 traditional plant medicine entries, which from 896 to 638 entries was a 
reduction of 29% (Jütte, 1996, p. 166). In contrast, the 5th edition of the German 
pharmacopoeia listed 65 synthetic medicines, up from 15 in the 2nd edition (Deutsches 





In the 1970s the second, revised German drug law attempted to minimise regulatory 
inequalities of plant-based medicines; it did so by granting phytotherapy a position as a 
Besondere Therapierichtung (special therapy) (Deutscher Bundestag, 1976)). Consequently, 
the former Bundesgesundheitsamt (BGA) (German Ministry of Health) established the 
Kommission E (Commission E), a scientific advisory board providing scientific and clinical 
expertise for the evaluation of the safety and effectiveness of phytotherapy and herbal 
substances. The Commission E granted a positive monograph for St. John’s Wort 
(Kommission E, 1984b), approving a number of traditional uses. This reinstatement was 
aided by results from clinical research from the 1970s onwards which demonstrated the 
efficacy of St. John’s Wort in depressive states (Hoffmann & Kühl, 1979). Although St. 
John’s Wort was never listed in the German pharmacopoeia itself, it became represented 
after more than 100 years absence through the European pharmacopoeia with which the 
DAB harmonised in 1986.  
6.2 Hypericum perforatum in medical textbooks  
Over the past 400 years, clinical medical textbooks have consistently recorded therapeutic 
uses of Hypericum perforatum for patient care. Key indications have remained remarkably 
consistent, even though paradigmatic explanatory models of health and illness have 
changed. Table 14 (next page) provides an overview of use-categories of Hypericum 
perforatum addressed in mainstream medicine since the early modern period. 
The clinical endorsements of St. John’s Wort from the 1600s to the present can be 
summarised as follows: 
 indications relating to digestion, to the musculo-skeletal and nervous systems, to the 
skin and mucous membranes, and to somatoform disorders were consistently 
endorsed by physicians at least over 400 years 
 indications relating to complaints of the uro-genital systems and respiratory tract 
also show long-standing endorsements over 400 years, yet with some intermittent 
absences in medical textbooks 
 systemic infection fighting applications are noted by Tabernaemontanus in the 17th 
century, but are mostly absent in the literature from the end of the 18th century 
onward when the treatment of malaria became obsolete in many parts of Europe 




early modern period, mainly in folk medicine. The medical literature beyond the 17th 
century does not list this application; instead it endorses the use of St. John’s Wort 
for disorders that are referenced today as somatoform disorders. 





























































































apotrop ✓ 0 0 (✓) (✓) 0 0 0 0 0 (✓) 
card-vasc 0 0 0 0 0 ✓ ✓ ✓ ✓ ✓ ✓ 
gastro-intest ✓ ✓ (✓) ✓ (✓) (✓) ✓ ✓ ✓ ✓ ✓ 
gyn ✓ 0 0 ✓ 0 (✓) ✓ ✓ 0 ✓ ✓ 
head ✓ 0 0 0 0 0 ✓ ✓ 0 ✓ ✓ 
hormonal 0 0 0 0 0 0 0 ✓ 0 0 0 
infection ✓ 0 0 ✓ 0 0 0 (✓) 0 0 ✓ 
liver-spleen ✓ 0 0 ✓ 0 0 ✓ ✓ 0 (✓) (✓) 
musc-skel ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
nerve ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
respiratory ✓ ✓ (✓) ✓ (✓) (✓) ✓ ✓ 0 ✓ (✓) 
skin-mucous ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
somatoform ✓ 0 ✓ ✓ (✓) (✓) ✓ ✓ ✓ ✓ ✓ 
tonic 0 0 0 ✓ 0 0 ✓ 0 ✓ ✓ ✓ 
uro ✓ 0 0 ✓ 0 ✓ ✓ ✓ ✓ (✓) ✓ 
Dark green rows refer to continued use 
Light green rows refer to intermittent but present-day-use 
White rows refer to present-day discontinuation 
Indications in italics and brackets (✓) reference historical uses or folk medicine uses 
 
The 19th century brought an expansion of historical uses for St. John’s Wort as well as a 
discontinuation of some indications: 
 indications relating to the tonic use-category are first mentioned in mid-19th century 




 the use of St. John’s Wort for congestive states of the cardio-vascular system was 
introduced at the beginning of the 20th century and remains recommended for 
venous congestion (topical use) 
 St. John’s Wort was briefly used during war times for the treatment of head injuries, 
such as cerebral concussion and epilepsy from trauma (head use-category). Whilst 
such injuries are now treated with biomedical approaches as a first line treatment, 
the application of St. John’s Wort in the management of migraines, headaches, and 
meteoropathy remains 
 the use of St. John’s Wort for liver detoxification and poisoning became obsolete 
from mid-19th century onwards. 
Beneficial outcomes in patient care have been documented when St. John’s Wort was used 
in the following modes of administration: fresh or dry comminuted herb or herb powder 
extracted in water (tea), alcohol (tincture / extract), and oil (see Historical Data 
spreadsheet). These preparations were applied for both external and internal use. The 
traditional dosage range is documented from 15 drops of fresh-plant tincture (1:10 
extraction ratio) to 1g to 6.9g of drug (or fresh plant equivalent). A traditional way of 
observing this dose is by taking 1-2 cups of freshly prepared medicinal tea mornings and 
evenings (1 teaspoon of plant material per cup equates to about 1.8g of dried St. John's 
Wort) (Saller et al., 1995, pp. 208-216). The recommended dose for small children up to 
three years of age is noted as 1 cup of medicinal tea per day and 2-3 cups per day from 3 
years onwards. 
Following this overview, the analysis now turns to the detailed medicinal uses that were 
transmitted in TEM over the past 400 years. This progression will help to ascertain which 
specific indications have documentary proof of consistent therapeutic use. 
6.2.1 Hypericum perforatum in Tabernaemontanus (edition 1664) 
The 4th edition of the early modern period monograph on St. John’s Wort by 
Tabernaemontanus (1664, pp. 1249B-1252A) and which was annotated by the Bauhin 
editors provides the starting point for this longitudinal textual analysis. This clinical text 
summarises the medicinal uses of St. John’s Wort over two millennia as noted in the 
bibliographic reference list in the preface of the book. The monograph was used pars pro 




until the mid-18th century when it was last printed. The codified data were transcribed and 
translated into modern German (see Appendix 12) before being translated into English and 
allocated to pre-defined use-categories to enable further analysis on its indications (see 
Appendix 13).  
6.2.2 Hypericum perforatum in medical textbooks from 1790-2007 
Analysis of the indications listed in Tabernaemontanus with the data extracted from the 
medical literature over the ensuing centuries provides consistent evidence for numerous 
historical uses that continue to be endorsed in contemporary phytotherapeutic practice. 
Appendix 14 summarises the consistently documented therapeutic uses of Hypericum 
perforatum in the medical literature over the past 400 years. When historic and present-day 
therapeutic uses of St. John’s Wort are compared, the clinical observations by practising 
physicians provide tradition-of-use (TOU) data on five clusters of complaints, as detailed in 
Table 15. These indications meet the criteria for consistent medicinal use well beyond the 
typically required three generations or three transmission steps. 
Table 15. Consistently endorsed indications for Hypericum perforatum in medical 
textbooks over at least 400 years. 
Use-category Indications 
gastro-intest 
inflammation and catarrh of the gastro-intestinal system, gastro-enteritis, and dyspeptic 
disorders  
musc-skel 
musculo-skeletal injuries resulting in sprains, strains, bruises, and inflammation; 
rheumatic disorders 
nerve 
pain from inflammation and injuries to the nerves and musculo-skeletal system; rheumatic 
disorders  
skin-mucous burns (topical) and wounds (systemic and topical) 
somatoform 
psychovegetative disturbances such as depressive moods, anxiety, nervous unrest, and 
hormonally driven dysphoria in relation to the female menstrual cycle 
 
Historical uses were expanded on at the beginning of the 20th century when an effect of St. 
John’s Wort in congestive states was observed (Schulz, 1919, p. 229). This description led 
to its continued endorsement in the topical treatment of venous congestions, namely 
haemorrhoids and varicose veins. In this research, these two indications have been allocated 
to the card-vasc use-category. One could argue that they could also be allocated to the skin-




rationale for their use was noted as a decongestant, the card-vasc use-category is more 
fitting. Decisions on allocations must be kept in perspective: use-categories are a construct 
to help researchers group data; they have no relevance from a regulatory point of view. It is 
the indication itself that requires evidence of consistent use in the context of evidence-based 
policy.  
In addition to the cardio-vascular indications, a further indication becomes prevalent in the 
20th century, that of mental exhaustion. The tonifying effect of St. John’s Wort was first 
mentioned by Strumpf (1855). These additional indications listed in Table 16 relate to the 
card-vasc and tonic use-categories and would qualify under a traditional use criterion that 
requests at least three continuous generations of therapeutic use. 
Table 16. Consistently endorsed indications for Hypericum perforatum in medical 
textbooks throughout the 20th century. 
Use-category Indications 
card-vasc 
congestive states of the venous system; varicose veins and haemorrhoids (topical 
applications) 
tonic tonification in exhaustion and dysphoria 
 
Indications relating to the uterus and the menstrual cycle have been intermittently 
recommended since the 17th century. Additionally, there are various indications relating to 
spasms, inflammation, and catarrh of the mucous membranes of the respiratory and urinary 
tract. The following indications listed in Table 17 are the most consistently repeated: 
Table 17. Intermittent-but-persistent indications for Hypericum perforatum in 
medical textbooks over at least 400 years.  
Use-category Indications 
gyn uterine and menstrual complaints 
respiratory catarrh of the mucous membranes of the respiratory tract 
uro irritability in the urinary tract; diuresis 
 
These intermittent-but-persistent indications could be considered under a traditional use 
criterion that acknowledges the dynamic nature of tradition. The plausibility of these 
indications would be strengthened if they were backed by experimental research or clinical 




6.3 Hypericum perforatum in regulatory monographs 
Traditional indications listed in the European medical literature are now compared with two 
recent official European monographs that reflect the regulatory guidelines on therapeutic 
uses of St. John’s Wort: the Commission E Monograph Hyperici herba by the German 
Ministry of Health and the EU Herbal Monograph Hypericum perforatum L. herba by the 
European Medicine Agency (EMA). These official monographs are used as exemplars to 
compare legally permitted claims with indications consistently endorsed in the medical 
literature. 
The overview in Tables 18-20 demonstrates that the Commission E Monograph Hyperici 
herba provides an approved claim in each of the use-categories addressed by historical 
medical documentation where traditional indications persisted over 400 years. In contrast, 
the EU Herbal Monograph Hypericum perforatum L. herba provides approved claims in 
only three of these. Where indications in medical textbooks were listed intermittently or 
more recently over the past 30 years, they were not listed in either of the official 
monographs. Only indications relating to the gastro-intest, skin-mucous, and somatoform 
use-categories are consistently listed in all three sources as illustrated in Table 18. These 





Table 18. Comparison of empirically endorsed medicinal uses of Hypericum 
perforatum > 400 years with two official monographs. 
Use-
category 
Indications – medical literature 





traditional use  
gastro-
intest 
inflammation and catarrh of the 
gastro-intestinal system, gastro-
enteritis, and dyspeptic disorders 
dyspeptic complaints mild gastrointestinal 
discomfort 
musc-skel musculo-skeletal injuries resulting in 
sprains, strains, bruises, and 
inflammation; rheumatic disorders 
acute and contused 
injuries, myalgia (topical) 
0 
nerve pain from inflammation and injuries 
to the nerves and musculo-skeletal 
system; rheumatic disorders 
acute and contused 









of skin (such as in 
sunburn) and minor 
wounds 
somatoform psychovegetative disturbances such 
as depressive moods, anxiety, 
nervous unrest, and hormonally 
driven dysphoria in relation to the 
female menstrual cycle 
psychovegetative 
disturbances, depressive 
moods, anxiety and/or 





Table 19. Comparison of additional empirically endorsed medicinal uses of 
Hypericum perforatum > 30 years with two official monographs. 
Use-
category 





card-vasc congestion and inflammation in the venous 
system, e.g. varicose veins, haemorrhoids 
(topical) 
0 0 
tonic tonification in exhaustion  0 temporary mental 
exhaustion 







Table 20. Comparison of intermitted-but persistent medicinal uses of Hypericum 
perforatum with two official monographs. 
Use-
category 





EU Herbal Monograph 
2014 traditional use 
gyn uterine and menstrual complaints 0 0 
respiratory catarrh of the mucous membranes of the 
respiratory tract 
0 0 
uro irritability in the urinary tract; diuresis 0 0 
 
6.3.1 The Commission E Monograph Hypericum perforatum L. herba 
Before St. John’s Wort became one of the most scientifically studied medicinal plants in the 
world, empirical evidence was accepted by the German regulatory authority as 
demonstrating the plant’s plausible effectiveness. As already noted, scientific pluralism in 
medicine beyond natural science was explicitly mandated by the Second Medicines Act 
(Arzneimittelgesetz 1976 (AMG 76)), which went into effect in Germany on January 1, 
1978 (Deutscher Bundestag, 1976). This legal remit guided the writing of the Commission E 
Monograph Hyperici herba (Kommission E, 1984b). It is noteworthy that the monograph 
explicitly states that it approves the mild antidepressant action of the herb and its 
preparations based on its evaluation of numerous reports from physicians (Kommission E, 
1984b, para. Anwendungsgebiete).  
The approved indications relate to the following modes of administration: comminuted 
herb; herb powder; liquid and solid preparations for internal use and liquid; semi-solid 
preparations for external use; and preparations made with fatty oils for both external and 
internal use. No preparations or standardisations based on more recently developed 
pharmaceutical extraction methods are listed, apart from the option to standardise crude 
drugs to their hypericin content. The average daily dosage for internal use is recorded as 2-4 
g of herbal substance or 0.2-1 mg of total hypericin in other preparations. The monograph 
lists no contraindications for these preparations at this dosage and notes that herb-drug 
interactions are not known for the traditional preparations listed.  
The approved claims are consistent with empirical medicinal uses noted in the medical 
literature of the past 400 years. The monograph differs, however, from this body of 
literature in that it approves only external preparations for the treatment of complaints of 




systemically as well. Additionally, more recent 20th century indications, namely varicose 
veins, haemorrhoids, and tonification in exhaustion, did not pass the Commission E 
evaluation—although the latter could be a subset of ‘psychovegetative disorders.  
6.3.2 The European Community Herbal Monograph Hypericum perforatum L., 
herba 
The Committee on Herbal Medicinal Products (HMPC) of EMA released two monographs 
on St. John’s Wort, one on well-established use and one on traditional use. In this study, 
only the traditional use monograph is evaluated. Claims in the traditional use monograph 
are accepted on the basis of sufficient safety data and plausible efficacy (Europäisches 
Parlament, 2004). The EU Herbal Monograph Hypericum perforatum L. herba (traditional 
use) officially endorses therapeutic indications relating to three different areas of health 
concerns: 1) for the relief of temporary mental exhaustion; 2) for the symptomatic topical 
treatment of minor inflammations of the skin (such as sunburn) and as an aid for healing of 
minor wounds; and 3) for symptomatic relief of mild gastrointestinal discomfort. These 
indications cover the use-categories gastro-intestinal tract and skin-mucous membranes, 
whereas “temporary mental exhaustion” (Committee on Herbal Medicinal Products 
(HMPC), 2009c, p. 3) can be assigned to both the somatoform and the tonic use-categories 
depending on the cause. All approved therapeutic indications relate to the same use-
categories also addressed by long-standing empirical uses of St. John’s Wort in medical 
textbooks over 400 years. Complaints of the musculo-skeletal and nervous systems are 
absent in this monograph. 
When the health claims approved by HMPC and the Commission E are additionally 
compared to indications recorded in Tabernaemontanus 1664, it becomes evident that 
contemporary regulatory monographs have considerably narrowed clinical applications to 
fewer areas of treatment. While regular medicine in early modern Europe recommended St. 
John’s Wort in the treatment of complaints relating to 12 use-categories, the Commission E 
Monograph Hyperici herba approves indications relating to five of those and the EU Herbal 
Monograph Hypericum perforatum L. herba relating to three—with the additional use-
category of tonic first documented in the reviewed literature mid-19th century. As already 
noted in the overview in Table 18, this disparity means that only indications relating to the 
gastro-intest, skin-mucous, and somatoform use-categories are consistently listed in all 




Table 21. Indications for Hypericum perforatum listed in the early modern period 
compared with approved claims in regulatory European monographs. 
 
Use-categories  Tabernaemontanus 








apotrop ✓ 0 0 





✓ ✓ ✓ 






gyn ✓ 0 0 
 birth complications, 
menstruation, unease before 
and during menstruation, 
puerperium 
  
head ✓ 0 0 
 epilepsy, stroke   
infection ✓ 0 0 
 Malaria tertiana   
liver-spleen ✓ 0  
 liver detoxification, poison   
musc-skel ✓ ✓ 0 
 musculo-skeletal injuries 
(ligaments, tendons, facia, 
nerves, muscles) 
acute and contused injuries 
(scharfe und stumpfe 
Verletzungen) 
 
rheumatism myalgia  
(Myalgien) 
 
stiff limbs and joints; 
relaxing lame joints 
  
spasms in wounds   
nerve ✓ ✓ 0 







hip pain / sciatica   
nerve injuries   
nerve pain   
trembling, tremor   
respiratory ✓ 0 0 
 pleurisy, spitting of blood   
skin-
mucous 
✓ ✓ ✓ 
 burns 1st degree burns 
(Verbrennungen 1. Grades) 
minor 
inflammation of 
skin (such as in 
sunburn) 
wounds (deep, large, 
infected, inner, outer) 
 minor wounds 








Use-categories  Tabernaemontanus 








somatoform ✓ ✓ ✓ 










 anxiety  
(Angst) 
 





 tonic 0 0 ✓ 
   temporary mental 
exhaustion  
(also noted under 
somatoform  use-
category) 
uro ✓ 0 0 
 bladder stone, gravel, kidney 




HMPC is currently revising the EU Herbal Monograph Hypericum perforatum L. herba 
(traditional use) after a consultation period with Member States in 2018. The draft 
monograph proposes including two additional indications, namely for the supportive 
treatment of nervous restlessness (as also noted in the Commission E monograph) and sleep 
disorders (Committee on Herbal Medicinal Products  (HMPC), 2018). If accepted, these 
indications would broaden indications in the somatoform use-category. 
6.3.2.1 Areas recommended for re-assessment for approved claims  
When 17th century indications are examined from a contemporary viewpoint, it becomes 
apparent that the empirical observations recorded by Tabernaemontanus, and repeated in the 
subsequent medical literature, relate to key actions of St. John’s Wort on specific human 
body tissues present in several body systems. The pleiotropic effects of the now-confirmed 
anti-inflammatory, antimicrobial, astringent, and wound healing actions of St. John’s Wort 
(Bone & Mills, 2013, pp. 827-828) are especially beneficial on lesions of the mucous 
membranes and the skin. These effects have been historically recorded in complaints of the 
gastro-intestinal tract, the respiratory and urinary tract, the uterus, in inflammatory 




Monograph Hypericum perforatum L. herba acknowledges these pleiotropic effects for the 
mucous membranes of the gastro-intestinal system and for afflictions of the skin (wounds, 
burns), but not for mucosal lesions in the respiratory and uro-genital tracts. The results of 
this thesis suggest that historical indications relating to gynaecology, particularly uterine 
and menstrual complaints, and irritations in the respiratory and urinary tract should be re-
evaluated for regulatory approval based on St. John’s Wort’s pleiotropic actions on all 
mucous membranes throughout the body. 
Moreover, St. John’s Wort has relaxant, neuroprotective, spasmolytic, antidepressant, and 
euphoric effects (Bone & Mills, 2013, pp. 827-828), all of which may be beneficial for a 
variety of neurovegetative disturbances. These multiple pharmacological actions may 
explain St. John’s Wort’s broad historical uses for depressive moods, anxiety, nervous 
unrest, and hormonally driven dysphoria in relation to the female menstrual cycle. Since the 
20th century these pharmacological effects have additionally been applied in the treatment 
of headaches and exhaustion (see Appendix 14). Temporary mental exhaustion is currently 
the only pre-approved somatoform application in the EU Herbal Monograph Hypericum 
perforatum L. herba. This analysis suggests that the broader historical treatments of 
neurovegetative disturbances merit a re-evaluation for approval in the EU traditional use 
monograph. 
Anti-inflammatory effects are also relevant in the treatment of musculo-skeletal injuries and 
in nerve pain as recognised in the Commission E Monograph Hyperici herba. Based on 
consistent documentary evidence of clinical uses of St. John’s Wort in the treatment of 
trauma, pain, sprains, strains, bruises, and inflammation or myalgia of various origins, 
including rheumatic disorders, these could also be re-considered under Directive 
2004/24/EC. In addition, congestion and inflammation in the venous system (such as 
varicose veins and haemorrhoids) may also meet the criterion of 30 years of consistent 
medical use.  
6.3.2.2 Endorsed preparations in the EU Herbal Monograph Hypericum 
perforatum L. herba 
The EU herbal monograph on St. John’s Wort (traditional use) lists the comminuted or 
powdered herbal substance as the official drug. Approved preparations are a tea preparation, 
a 1:10, 1:5-7, or a 1:2 ethanol-water extract, and a 1:4-20 or a 1:13 vegetable oil extract. 




4-7:1 pharmaceutical extract in solid pharmaceutical form as a traditional preparation, a 
composition that was developed in the latter part of the 20th century. The text refers to the 
European pharmacopoeia for quality standards. The recommended daily dose, usually taken 
as three separate dosages, is between 600mg and 6000mg (fresh juice up to 7500mg).  
6.3.2.3 Special warnings and precautions for use 
While the Commission E Monograph Hyperici herba did not raise safety concerns with 
traditional applications and dosages, the EU Herbal Monograph Hypericum perforatum L. 
herba (traditional use) stipulates several “special warnings and precautions for use” 
(Committee on Herbal Medicinal Products (HMPC), 2009b, p. 6). As already noted in the 
analysis on Arnica, such warnings reflect an increasingly cautionary approach to risk in 
public health since the mid-1980s, a trend which became heightened in the context of the 
EU regulatory framework that is informed by not only scientific but also political 
considerations. The warnings and precautions recommend: 
 limiting UV exposure during treatment 
 not using St. John’s Wort in children and adolescents under 18 years of age because 
of the absence of sufficient scientific safety data 
 not using St. John’s Wort during pregnancy and lactation because of the absence of 
sufficient scientific safety data 
 paying attention to gastrointestinal disorders, allergic skin reactions, fatigue, and 
restlessness that may occur.  
Although these warnings and precautions in the EU Herbal Monograph Hypericum 
perforatum L. herba are not noted as contra-indications but relate to the withholding of a 
pre-approval under the simplified registration pathway, they demonstrate the challenge of 
integrating empirical safety data into a modern evidence-based healthcare model that is 
primarily set up to provide safety guidelines for novel and potentially toxic synthetic drugs. 
The precautions of not using St. John’s Wort for children under 18 years of age and for 
pregnant or lactating women is not based on evidence of harm, but on absence of 
toxicological data. This precaution is absent in the historical and contemporary medical 
literature and not raised via modern epidemiology or pharmacovigilance. For instance, 
evaluation of an open label pilot study and a multi-centre post-marketing surveillance study 
with a total of 85 patients completing the studies showed that the Hypericum perforatum 




(Hübner & Kirste, 2001), and in adolescents from 12-17 years of age (Simeon, Nixon, 
Milin, Jovanovic, & Walker, 2005).  
St. John’s Wort was historically prescribed during the puerperium (see Appendix 14) and 
continued to have relevance as a peri- and post-partum treatment during the 20th century 
(Clair & Saller, 2015; Käppeli, 2001; Stadelmann, 2005). Smeriglio, Tomaino, and 
Trombetta (2014, pp. 1113-1114) note in their overview of the literature of the most 
frequently consumed herbal remedies during pregnancy that St. John’s Wort is applied by 
some women in the treatment of mild to moderate depression instead of synthetic 
antidepressants. A prospective study comparing pregnant women taking St. John’s Wort 
preparations, pregnant women taking anti-depressive drugs, and healthy pregnant women 
not exposed to any known teratogens concluded that there are no differences in rates of live 
births, prematurity and major malformations between the three groups (Moretti, Maxson, 
Hanna, & Koren, 2009). The data were similar to the risk expected in the general 
population. Though further large-scale studies are still needed, this first published study on 
the effects of St. John’s Wort in human pregnancy provides some evidence of foetal safety. 
The current, limited clinical and experimental data on St. John’s Wort suggest no increase 
in foetal harm when exposed during pregnancy (Avila, Whitten, & Evans, 2018; Kolding, 
Pedersen, Henriksen, Olsen, & Grzeskowiak, 2015; Mills & Bone, 2005, pp. 585-593; 
Moretti et al., 2009). Overall, St. John’s Wort preparations have shown to be better tolerated 
than synthetic antidepressants, with adverse events (AEs) being mild, transient, and 
significantly lower than events recorded for synthetic antidepressants (Schulz, 2006). The 
difference in severity of AEs is clinically relevant for patients’ quality of life (QOL) and 
therefore relevant in the regulatory safety assessment of St. John’s Wort in a patient-centred 
healthcare setting. 
6.3.2.4 Herb-drug interactions  
The EU Herbal Monograph Hypericum perforatum L. herba (Committee on Herbal 
Medicinal Products (HMPC), 2009b) includes a section on herb-drug interactions. This 
traditional use monograph is mainly concerned with traditional preparations that are not 
known to induce herb-drug interactions at normal therapeutic doses (Mueller et al., 2009; 
Mueller et al., 2006; Mueller et al., 2004). However, it also includes one newer 
pharmaceutical-type dry extract (DER 4-7:1), which makes a discussion on potential herb-




Hypericum perforatum L. herba states that the daily intake of St. John’s Wort preparation is 
to be less than 1mg of hyperforin (Committee on Herbal Medicinal Products (HMPC), 
2009b, p. 9).  
Herb-drug interactions are not examined in historical medical textbooks, such interactions 
being a modern phenomenon. Until the 1990s, when some German manufacturers started to 
standardise their St. John’s Wort preparations to a higher-than-naturally occurring content 
of hyperforin, herb-drug interactions were not a topic of concern in the literature or noted 
by pharmacovigilance centres (Meier, 2001; Nahrstedt & Butterweck, 2010). However, 
research has shown that modern preparations high in hyperforin may cause interactions with 
some specific synthetic drugs (Mai et al., 2004; Mueller et al., 2009; Mueller et al., 2006). 
Clinical studies define a high-hyperforin extract as one that contains ≥ 10 mg of hyperforin 
per daily dose and a low-hyperforin extract as one that contains ≤ 4 mg hyperforin per daily 
dose (Arold et al., 2005; Whitten, Myers, Hawrelak, & Wohlmuth, 2006). Hyperforin is 
naturally unstable and traditional medicinal teas and tinctures have been shown to be low in 
or free of hyperforin, meaning that these preparations are unlikely to be relevant CAP3A 
inductors (Meier, 2001). For this reason, the Swiss Agency for Therapeutic Goods, 
Swissmedic, have exempted traditional tea preparations from safety warnings (Swissmedic, 
2002, p. 7). Medsafe (2014) in New Zealand have also highlighted the low risk of herb-drug 
preparation with low hyperforin content. 
6.4 Clinical research on Hypericum perforatum  
To cross-validate empirical evidence on Hypericum perforatum with results from 
contemporary clinical research, this study employed a systematic method of literature 
searching, study selection, and data extraction. As noted in the Material and Methods 
chapter, the literature was searched using the following databases: Medline, Embase, 
AMED, Cochrane Library, Web of Science, and CINAHL. In addition, the bibliographies of 
included papers were examined for relevant studies. Searches were limited to English, 
German, French, or Dutch language material published from the inception of the databases 
to June 2014. The search strategy applied is summarised in Appendix 1, and the results are 
displayed in the following PRISMA flow diagram. An alert was set up when the initial 





Figure 6. Flow diagram of database research to June 2014 of clinical trials on 
Hypericum perforatum flowering areal parts for cross-validation of clinical research 
with empirical evidence 
 
The study selection criteria were set to exclude articles outside the scope of this review: 
 studies published in languages other than English, German, French or Dutch 
 studies on homeopathically potentised Hypericum perforatum 
 studies on a different Hypericum species other than Hypericum perforatum 
 studies on toxicity 
 in vitro studies 
 rodent models 




 studies not declaring dose or concentration of preparation 
 papers discussing the same clinical trial (as an already-selected paper) 
 meta-analyses or systematic reviews (noted separately) 
 journal comments 
 narratives. 
The search strategy identified a total of 2320 unique articles. After consideration of title and 
abstracts using the study selection criteria, 149 full papers on unique clinical trials of St. 
John’s Wort preparations were retrieved and scrutinised. Of these, 128 clinical trials related 
to internal use and 21 to topical use. Furthermore, the search strategy identified 11 meta-
analyses and 23 systematic reviews, most of them relating to the medicinal use of St. John’s 
Wort in depressive disorders.  
Of the 149 clinical trials selected and examined, three clinical trials have been attributed to 
two use-categories. Of the total of 152 attributions, 131 are on clinical trials that were 
conducted with St. John’s Wort solely and 21 on clinical trials with a combination of St. 
John’s Wort and other substances, but without measuring the additional effects of St. John’s 
Wort separately. The clinical trials on combination remedies are included in this study 
because complex formulations are common in traditional European medicine. These trials 
cannot be used, though, as scientific proof of a specific therapeutic effect of Hypericum 
perforatum; rather, they point to indications where a synergistic effect with Hypericum 
perforatum was sought. The main substances combined with St. John’s Wort were Black 
Cohosh (Cimicifuga racemosa) for menopausal complaints, Chaste Tree berry (Vitex agnus-
castus) for PMS and menopausal complaints, and various combinations with Valerian 
(Valeriana officinalis), Lemon balm (Melissa officinalis), and Passionflower (Passiflora 
incarnata) for nervous system support. In clinical trials for topical use, St. John’s Wort was 
combined with Neem oil, Onion (Allium cepa), Calendula (Calendula officinalis or 
Calendula arvensis), and copper sulphate. 
It is outside the scope of this thesis to judge the recorded effects (benefits and harms) in 
these clinical studies. An evaluation of clinical trials conducted until 2009 can be found, for 
example, in the HMPC Assessment Report on Hypericum perforatum L., herba (Committee 
on Herbal Medicinal Products (HMPC), 2009a), and in the systematic reviews and meta-




contemporary science and compares them with historical indications that were validated by 
empirical science as in repeated clinical observations in patient care. 
6.4.1 Clinical research results 
The summary of the retrieved scientific trials on St. John’s Wort is displayed in Appendix 
15. The 149 clinical trials identified cover indications relating to nine use-categories. Unless 
marked, all studies confirmed positive results. One trial (Li, Li, Wang, & Yu, 2005) was 
allocated to both the card-vasc and the somatoform use-categories as it investigated two 
separate indications (myocardial function and depression). Another trial (Kundakovic et al., 
2012) was allocated to both the skin-mucous and card-vasc use-categories as it investigated 
venous ulcers, a condition that originates in a lack of venous flow. A third trial (Pereira, 
Pradella-Hallinan, & Alves, 2013) was allocated to both the musc-skel and nerve use-
categories, as Restless Legs Syndrome (or Willis-Ekbom’s disease) is thought in current 
aetiology to be related to nerve dysfunction. Nineteen studies (from 1979 to 2015) were 
conducted with traditional preparations, while 135 studies (from 1991 to 2014) were 
conducted with modern pharmaceutical preparations (mostly standardised tablets) (see 
Appendix 15).  
Most clinical trials (75) were set up to validate St. John’s Wort’s efficacy in treating 
depression. This significant level of research interest was in part stimulated when the 
German Commission E released a positive monograph on St. John’s Wort that officially 
approved the indications ‘psychovegetative disturbances, depressive moods, anxiety and/or 
nervous unrest’ (Kommission E, 1984b, para. Anwendungsgebiete). These indications 
became accepted claims for marketing authorisation and eligible for funding in the official 
German healthcare system. Most of the clinical trials yielded positive results, results which 
were also confirmed in 23 systematic reviews and 11 meta-analyses. Eight meta-analyses of 
RCTs established that St. John’s Wort was significantly superior to placebos in cases of 
mild to moderate depression while being equivalent to synthetic antidepressants, but with 
fewer adverse effects (Jou et al., 2005; Kim, Streltzer, & Goebert, 1999; Laakmann, Jahn, & 
Schule, 2002; Linde, Berner, Egger, & Mulrow, 2005; Linde et al., 1996; Rahimi, Nikfar, & 
Abdollahi, 2009; Röder, Schaefer, & Leucht, 2004; Whiskey, Werneke, & Taylor, 2001). 
Two meta-analyses of RCTs established that St. John’s Wort was superior to placebos for 
depressive symptoms (Kasper & Dienel, 2002; Werneke, Horn, & Taylor, 2004). 




monotherapy) was superior when compared to a placebo for the improvement of 
menopausal complaints such as hot flushes and sleep problems; Black Cohosh in 
combination with St. John’s Wort was more effective when compared to a placebo for 
controlling menopausal symptoms such as hot flushes and neurovegetative symptoms, and 
that this combination was more effective than Black Cohosh on its own; and, when 
compared with placebo, St. John’s Wort in combination with Chaste Tree berries 
significantly improved the recovery in overall PMS-like symptoms (Liu et al., 2014). The 
first updated meta-analysis published since the database research cut-off has reconfirmed 
that St. John’s Wort has comparable efficacy and better safety for patients with mild-to-
moderate depression as standard selective serotonin reuptake inhibitors (SSRIs) (Ng et al., 
2017). 
The comparison below links indications examined in the retrieved clinical trials with similar 
types of (but differently termed) historical indications documented in the medical literature, 
where applicable. The author ID is established in Appendix 15. The results of the studies 





Table 22. Historical indications compared with evidence from clinical trials. 
Use-
category 











circulatory insufficiency / 
congestive states 
(since Schulz 1919) 
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phenomenon 






























abdominal pain and colic  





(since Tab. 1664) 
 
inflammation and catarrh of 
the gastro-intestinal system; 
gastro-enteritis and 
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(since Schulz 1919) 
colic, IBS 
(1 RCTs- decrease of 
symptoms but inferior 
to placebo) 
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ulcers 
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melancholy 
(since Tab 1664) 
 
depression, nervous 
breakdown, and traumatic 
neurosis 




nervous tension and 
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(since Madaus 1938) 
 
mania  
(since Richter 1827) 
 
hysteria 
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(54 RCTs – 6 were 
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(1 observ. study;         




(1 RCT – negative;  
1 observ. study) 
 
addiction  
(4 RCTs – 2 negative; 
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58, 72**,  
111**, 143**, 150** 
 
57, 59, 60-65, 67, 69-74, 77-81, 
83, 86, 88, 90, 91, 93-98, 100, 104-
107, 112, 115-117, 120, 121, 123, 
124, 126, 127, 129, 130, 132, 133, 
135, 136, 142, 147, 149, 151 
 
76, 84, 85, 87, 89, 99, 101-103, 









































(since Strumpf 1855) 
 
mental exhaustion and 
neurasthenia 
(since Madaus 1938) 
fatigue  
(1 observ. study) 
152 
*“observ. study” relates to observational study; “RCT” relates to randomised-controlled trial; ** relates 




6.4.2 Discussion of clinical research on St. John’s Wort 
Clinical trials on St. John’s Wort conducted with EBM methods support several long-
standing traditional indications. All belong to the same use-categories as indications noted 
in the medical literature (cardio-vasc, gastro-intest, gyn, head, musc-skel, nerve, skin-
mucous, somatoform, tonic). Most trials (75) were set up to validate St. John’s Wort’s 
efficacy in the treatment of depression. Parallel findings between historical empirical 
evidence and evidence in the form of clinical trials support the concept that consistent, 
clinically evaluated observation is a rational methodology that provides data that can be 
reproduced and validated. These findings challenge the proposition that traditional 
indications are random or placebo.  
Another important finding is that humoralism and contemporary medicine are expressions 
of two separate and distinct medical paradigms, applying distinctly different descriptions 
and explanatory models of illness. Despite these differences, historical and modern 
treatments with St. John’s Wort appear to be for similar disorders. For instance, physicians 
in the early modern period targeted the elimination of ‘black bile’ (= melan-choly) and the 
banishment of a ‘demon’ (Fuga daemonum). In the ensuing period, traditional indications 
described signs and symptoms of psychovegetative disturbances such as melancholy, 
depressive moods, anxiety, nervous unrest, and hormonally-driven dysphoria in relation to 
the female menstrual cycle (see Appendix 14). Today, St. John’s Wort is used in the 
treatment of depression as defined in the International Classification of Diseases (ICD) and 
the Diagnostic and Statistical Manual of Mental Disorders (DSM).  
While traditional descriptions and modern nosological paradigms may point to similar 
disorders, there is a need to exercise caution with retrospective diagnosis (Karenberg, 2009; 
Leven, 1998). This is one of the challenges of research into historical indications where 
some subjective interpretation of historical indications is unavoidable in the codification 
process. However, not only historical but also modern classifications of diseases pose 
challenges, as they are a changing construct (Karjalainen, 1999). For example, the 
mechanisms underlying the complex illness of depression are still not well understood. The 
monoamine theory of neurotransmitter dysfunction —one of the theories—is inconsistent 
with the pharmacodynamic effects of some antidepressants that do not target this pathway 
(Davis, 2002, pp. 1139–1163). Depression has been linked to a number of other drives, 
including low-grade chronic inflammation and chronic physiological or psychological 




Alper, Najjar, & Devinsky, 2013). It is conceivable that these drivers can be linked to the 
historical nosology ‘neurasthenia’ or exhaustion where the beneficial toning effect of St. 
John’s Wort has been documented since the mid-19th century. There is a hypothesis that St. 
John’s Wort’s mechanism of action is mediated by the interrelationship between the 
immune, oxidative defence, and neuroendocrine systems (Nahrstedt & Butterweck, 2010, p. 
1017). It is a distinct feature of plant-based medicines that they exert complex effects which 
regulate multiple human receptors and over-arching processes concurrently (pleiotropic 
effect) (Chen et al., 2016; Johnson & Fahey, 2012). With their multitarget properties 
affecting molecular, genetic and cellular levels they address regulatory mechanisms that 
have a wide-reaching systemic effect (Saller et al., 2014). Such pleiotropic effects of St. 
John’s Wort in the treatment of somatoform disorders have been traditionally observed and 
documented. They are now increasingly corroborated by clinical trials (see Appendix 15) 
and by experimental research (see section below). 
There are further parallel findings between the empirically observed effectiveness of St. 
John’s Wort, and its efficacy confirmed by clinical trials. Treatment with St. John’s Wort 
for abdominal pain, colic, diarrhoea, and inflammation of the gastro-intestinal system was 
noted at least since Tabernaemontanus (1664). Some clinical research now points to the 
treatment potential of St. John’s Wort for gastro-intestinal disorders. One observational 
study found St. John’s Wort to be beneficial in treating Irritable Bowel Syndrome (IBS) 
(Wan & Chen, 2010) and one RCT found it decreased IBS symptoms; however, in the latter 
study it was inferior to placebo (Saito et al., 2010). 
Some correlations between historical indications and clinical research are also apparent in 
gynaecology (pre-menstrual tension and uterine or vaginal complaints) (see Appendix 15, 
lines 8-23) and afflictions of the nerves and muscles (trembling and pain) (Pereira et al., 
2013; Sardella et al., 2008; Sindrup, Madsen, Bach, Gram, & Jensen, 2001). In addition, 
clinical trials yielded positive results with St. John’s Wort in treating wounds, ulcers, and 
burns—either as a mono-substance or when combined with other herbal substances 
(Reichling, Weseler, & Saller, 2001; Schempp, Pelz, Wittmer, Schopf, & Simon, 1999; 
Süntar et al., 2011; Suntar, Oyardi, Akkol, & Ozcelik, 2016; Weseler, 2004). Treatment of 
wounds and ulcers with St. John’s Wort was first described in the Hippocratic Corpus (Jarić 
et al., 2017) and was extensively discussed by Tabernaemontanus (1664), and successive 
authors. Historical empirical observations agree with contemporary findings from 




of St. John’s Wort against gram-positive bacteria, with special activity towards methicillin-
resistant strains of Staphylococcus aureus (Reichling et al., 2001; Weseler, 2004).  
The use of St. John’s Wort for improving cognition is a novel application not noted under 
traditional use (Ellis, Stough, Vitetta, Heinrich, & Nathan, 2001; Johnson, Ksciuk, Woelk, 
Sauerwein-Giese, & Frauendorf, 1994; Lehrl & Woelk, 1993; Siepmann, Krause, 
Joraschky, Muck-Weymann, & Kirch, 2002; Timoshanko, Stough, Vitetta, & Nathan, 
2001). Although not all clinical studies have been able to demonstrate an improvement in 
cognition, St. John’s Wort was observed to not impair it, a known side-effect of synthetic 
anti-depressive medication.  
6.5 Experimental research  
Comprehensive experimental research on the active constituents of traditionally used plant 
medicines gives insights into their chemistry, biological activity (pharmacology and 
toxicology), and synergistic properties (Medina, Martinez-Poveda, Amores-Sanchez, & 
Quesada, 2006; Nahrstedt & Butterweck, 2010; Saller et al., 1999; Saller, Melzer, & 
Reichling, 2003). A substantial amount of experimental research has investigated the 
composition of the active constituents in St. John’s Wort which accumulate in the buds, 
blossoms, and flowerheads before or during the flowering period (Saller et al., 1999). 
Various models of experimental research have identified the following key constituents of 
St. John’s Wort (Dell'Aica et al., 2007, pp. 110-112): 
 naphthodianthrones (including hypericin and pseudohypericin) 
 flavonoids (including biapigenin, quercetin, and rutin), phenolics (including 
hyperforin, adhyperforin, xanthones, bioflavonoids, and procyanidins) 
 condensed tannins 
 essential oils 
 other constituents: various acids (including traces of amino acids), carotenoids, 
colin, nicotinamide, pectin, saturated linear hydrocarbon chains, and alcohols. 
The structures of the representative constituents are presented below (World Health 





Figure 7. Key active constituents of Hypericum perforatum 
 
The scientific literature relates these active constituents of St. John’s Wort to the following 
therapeutic actions (Bone & Mills, 2013, pp. 827-838; Dell'Aica et al., 2007; Medina et al., 
2006; Saller et al., 2003; Saller et al., 1995): 
 
antibacterial  cognitive-enhancing 
anticancer / antiangiogenic / antitumour  diuretic 
antidepressant  immune modulating 
antifungal  neuroprotective 
anti-inflammatory  photodynamic 
antioxidant  spasmolytic 
antiretroviral / anti-viral  styptic (tannins) 
anxiolytic  sedative / hypnotic 
bitter tonic  sexual function enhancer 
capillary tightening  wound healing. 
 
Not all constituents have yet been identified, and it has been suggested that numerous 
undetected active constituents and co-effectors contribute to the overall clinical efficacy of 




exert lower or different effects than those observed with whole plant preparations, so the 
entire plant extract must be considered as actively contributing to St. John’s Wort’s 
therapeutic effects. 
Experimental research points to possible mechanisms that may explain long-standing 
clinical uses of St. John’s Wort. Experimental research into traditional extracts such as hot 
water infusions (tea) and hydro-ethanolic tinctures is particularly relevant for validating 
traditional indications of St. John’s Wort. Such extracts represent the two key historical 
solvents (menstrua) while modern solvents may extract different constituents with modified 
effects. In line with St. John’s Wort’s consistent traditional usage in treating wounds, ulcers, 
and burns (see the skin-mucous use-category in Appendix14), experimental research has 
shown an antimicrobial action of traditional water and water-ethanol extracts of St. John’s 
Wort against gram-positive bacteria, with special activity towards methicillin-resistant 
strains of Staphylococcus aureus (Reichling et al., 2001). Experimental human research has 
additionally shown anti-inflammatory effects (Weseler, 2004, p. 304), with NF-kB and IL-
12 being the specific targets (Calixto, Campos, Otuki, & Santos, 2004; Kang, Chung, & 
Kim, 2001). 
When St. John’s Wort extracts are to be applied internally, experimental lab bench studies 
on isolated cells and animal models can only be taken as providing preliminary data 
because human biological systems typically work differently and complexities concerning 
absorbability and pharmacokinetics need to be additionally considered (Agrosí, Mischiatti, 
Harrasser, & Savio, 2000; Teuscher, Melzig, & Lindequist, 2004; Williamson & Clifford, 
2017). Appropriate test models are essential to avoid false positive or false negative results 
(Winterhoff, 2007, p. 3). The necessity of such cautions has also been demonstrated with in 
vitro investigations of herb-drug interactions, investigations which showed a poor in vitro-
in vivo correlation (Unger, 2014, p. 17). 
When experimental and clinical research is compared with historical empirical knowledge 
documented in the European medical literature, contemporary scientific and empirical 





Table 23. Comparison of historical indications of Hypericum perforatum with clinical 
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Parallel findings between traditional indications and results from experimental research and 
clinical trials are encouraging. They give further assurance that empirical science, when it is 
underpinned by repeated and clinically evaluated observational data, leads to valid and 
verifiable therapeutic indications. 
6.6 Summary and conclusions  
This chapter discussed the historical and therapeutic significance of Hypericum perforatum 
in Traditional European Medicine. The Historical Assessment Tool was applied to the 
medical literature to demonstrate a scientific method that systematically collates traditional-
use-evidence on traditional plant medicines. The triangulation of empirical knowledge as 
recorded in European medical textbooks that were authored by formally trained physicians 
and transmitted over the past 400 years established the following: 
 There are several consistently transmitted indications in the medical literature that 
have persisted for over 400 years. They belong to five use-categories: gastro-intest, 
musc-skel, nerve, skin-mucous, somatoform. 
 There are further indications in the medical literature which fulfil the criteria of at 
least three transmission steps (75 years of consistent medical use). They belong to 
two use-categories: card-vasc, tonic. 
 Further comparison of empirical evidence from the medical literature with approved 
health claims in European regulatory monographs showed the following:  
o the Commission E Monograph Hyperici herba approves indications 
belonging to all of the five use-categories that had empirical evidence on 
indications consistently transmitted over 400 years (gastro-intest, musc-skel, 




o the EU Herbal Monograph Hypericum perforatum L. herba provides 
approved claims belonging to three of these use-categories (gastro-intest, 
skin-mucous, somatoform) 
o indications relating to the gastro-intest, skin-mucous, and somatoform use-
categories are listed across all three sources 
o intermittent-but-persistent traditional indications listed over 400 years, nor 
those that were newly listed over the past 150 years, were approved in either 
of the regulatory monographs, except for the indication ‘temporary mental 
exhaustion’ which is approved in the EU monograph. 
 
Table 24 summarises these findings: 
Table 24. Comparison of historical indications of Hypericum perforatum with 
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Analysis relating to St. John’s Wort mirrors the results of the analysis relating to Arnica. 
The regulatory monographs authored by the Commission E and EMA (HMPC) 
independently validate and officially approve the main traditional uses of St. John’s Wort as 
recorded in authoritative medical textbooks. However, neither monograph reflects all 
consistently transmitted traditional uses and the broader clinical scope of this medicinal 
plant. Of the two monographs, the Commission E Monograph Hyperici herba approves 
more traditional uses compared to the EU Herbal Monograph Hypericum perforatum L. 
herba. Both regulatory monographs will provide important bibliographic evidence for the 
approval process for NHPs in New Zealand if the proposed list of pre-approved texts by the 
former Natural Health and Supplementary Products Bill is accepted. Yet they are unable to 
replace the broader empirical evidence of traditional uses that were consistently transmitted 
in authoritative medical textbooks. Multiple pharmacological actions (pleiotropic 
properties) may explain St. John’s Wort’s wide-ranging historical uses. 
Alongside the analysis of indications listed in medical textbooks, this chapter undertook a 
systematic appraisal of clinical and experimental research. This scientific evaluation 
demonstrated the general rationality and validity of empirical therapeutic uses of St. John’s 
Wort (Dell'Aica et al., 2007; Reichling et al., 2001). Triangulation of data derived from both 
qualitative and quantitative sources thus suggests that consistently endorsed traditional 
indications are not random but instead based on empirically observed pharmacological 
effects (see Table 23).  
A surprising discovery arising from this systematic analysis relating to St. John’s Wort is 
the significant gap that can exist between the official assessment of the therapeutic 
importance of a medicinal plant by a regulator and its assessment by practising clinicians 
authoring clinically-oriented textbooks. Despite its ongoing clinical significance, St. John’s 




(Gurlt, 1847). It was never selected for the German pharmacopoeia and only became a 
pharmacopoeia listed medicine in Germany when DAB harmonised with the European 
pharmacopoeia in 1986 (DAB 9, 1986), two years after the publication of the Commission E 
Monograph Hyperici herba (Kommission E, 1984a). In contrast, St. John’s Wort’s 
medicinal uses have been documented since classical Hippocratic times and so became 
deeply embedded in both formal and folk medicine. In the analysed medical literature St. 
John’s Wort was consistently used by physicians in patient care (see Table 15). In response 
to the publication of the 1st edition of the German pharmacopoeia, the German Apotheker-
Verein (Association of Apothecaries) released in 1889 a non-official but normative 
supplementary text for those medicinal plants that were de-listed from the German 
pharmacopoeia (Deutscher Apotheker-Verein, 1897, p. III). This supplementary text 
included a monograph for St. John’s Wort, thereby confirming that while it was no longer 
deemed an essential medicine by the German regulator, it was still deemed essential in 
clinical practice. Today, St. John’s Wort is one of the most researched medicinal plants in 
the world (Saller et al., 2003) and is said to be the most important and most frequently used 
traditional medicine in alpine regions of Central Europe (Committee on Herbal Medicinal 
Products (HMPC), 2009a, p. 75). Its efficacy has been established by almost 150 clinical 
trials (see Appendix 15).  
Different regulatory frameworks are shown to have impact on permitted health claims and 
safety requirements. The Commission E Monograph Hyperici herba echoes clinical 
considerations as deemed central to clinical practice during the 1980s and 1990s (American 
Botanical Council, n.d.). The approved indications reflect more comprehensively the body 
of therapeutic indications as validated by 400 years of consistent medical use in a 
professional setting. This monograph did not restrict therapeutic uses for children, pregnant 
or lactating women. In comparison, the EU Herbal Monograph Hypericum perforatum L., 
herba reflects the more recent regulatory situation in Europe. Alongside clinical 
assessments it was additionally influenced by a scientific and political consensus process 
involving delegates of all EU 28 Member States, resulting in the approval of a reduced body 
of traditional indications. Under the simplified registration pathway it did not pre-approve 
St. John’s Wort in any form, even as medicinal tea, for a large segment of the population 
(children under 18 years of age; pregnant and lactating women). Mainly this was due to a 
lack of availability of genotoxicity studies (Committee on Herbal Medicinal Products 




framework, there remain differences in how the regulatory EU stipulations are 
implemented. In some Member States where traditional medicines are historically used for 
the paediatric population, some traditional products were able to register for paediatric use 
under EU Directive 2004/24/EC (Austria and Germany). In countries where traditional 
medicines are less prevalent for the paediatric population they were not, such as in 
Scandinavian countries (Knöss & Chinou, 2012, p. 1315). This indicates that divergent 
views remain on the level of evidence that national authorities deem appropriate for 
substantiating the safety and effectiveness of their traditional medicines.  
Such uncertainties do not exist only geographically across the EU Member States but also 
across various EU laws. If a traditionally-used substance is regulated under drug law (EU 
Directive 2004/24/EC), proof of safety must be provided (i.e. genotoxicity studies). If the 
same traditionally-used substance is regulated as a dietary supplement under food law, no 
pre-market approval is necessary (Quintus & Schweim, 2012, p. 380). For pre-existing 
natural substances, absence of documented harm is taken as an adequate demonstration of 
probable safety. Consequently St. John’s Wort preparations in the form of dietary 
supplements continue to be readily accessible to all population segments without restriction, 
whereas they may be unavailable as a traditional medicine regulated under drug law unless 
preclinical research has been undertaken. 
Divergent views on the safety requirements for medicinal plants remain one of the biggest 
hurdles for traditional medicine to overcome in order to integrate into mainstream 
healthcare. Historical clinical safety assessments differ from safety assessments derived 
under a scientific framework where a higher level of proof is requested. This situation may 
in part stem from historical developments in European medicine. Before the advancement 
of biomedicine, plant-based medicines were the key therapeutics in clinical practice across 
all demographics and age groups, notwithstanding specific cautions noted in clinically 
oriented textbooks, such as against the use of certain medicinal plants in pregnancy or 
against strongly acting substances in children. Regarding paediatric use, not all historical 
medical textbooks provided a specific paediatric posology, but an agreed dosage range for 
children was commonly accessible to clinicians (Kahnt, 1900, pp. 67, 138). Medicinal teas, 
for example, are considered a particularly benign preparation for paediatric care and are 
endorsed by representatives of phytomedicine organisations in Europe (Reuter, 1994). 
Phytotherapeutic textbooks by clinicians also note the tolerance of St. John’s Wort in 




more recently in mood disorders such as anxiety and depression (McIntyre, 2005, pp. 265, 
227, 213, 138, 276; Mills & Bone, 2005, p. 590; Santich & Bone, 2008, p. 16). A lack of 
pharmacovigilance data on harm seems to support St. John’s Wort’s tolerance in paediatric 
care. In countries where St. John’s Wort is readily taken by all population segments, its use 
has not raised serious safety concerns. In New Zealand, for example, where the OTC sale of 
St. John’s Wort is not restricted for the paediatric population or for pregnant and 
breastfeeding women, its therapeutic use has not come to the attention of the New Zealand 
pharmacovigilance centre. In the latest report published in 2016, CARM received a total of 
3,944 reports of suspected adverse reactions to medicines. 2,522 were associated with 
synthetic drugs, 1385 were associated with vaccines, and 37 (or 1.5%) were associated with 
CAM. Twelve CAM reports (0.003%) were considered serious (Medsafe, 2017). The 
Suspected Medicine Adverse Reaction Search function on the Medsafe website does not 
disclose which CAM substances were involved in the ARD reports, nor if causality was 
established. However, a search under the term ‘Hypericum’ established that none of the 
case reports related to St. John’s Wort preparations.  
Outside New Zealand, St. John’s Wort is noted as a medicinal plant used in pregnancy 
(Smeriglio et al., 2014). Its historical names, Frauenkraut (woman’s herb) and Maria 
Bettstroh (Maria’s bedstraw) point to its historical importance in women’s healthcare. St. 
John’s Wort was prescribed during birth and the puerperium, as noted in Tabernaemontanus 
(see Appendix 13, p.11-12). It continued to be relevant as a peri- and post-partum treatment 
in midwifery during the 20th century (Clair & Saller, 2015; Käppeli, 2001; Stadelmann, 
2005). Clinical and experimental data on St. John’s Wort did not suggest increased 
frequency of malformation or of other harmful effects on the foetus when used during 
pregnancy (Kolding et al., 2015; Mills & Bone, 2005, pp. 585-593; Moretti et al., 2009). 
These findings suggest that a combination of historical safety observations and 
pharmacovigilance data could provide a way forward for regulatory safety assessments on 
pre-existing traditional therapies. 
Regarding the safety of St. John’ Wort in children and adolescents, observational data from 
long-term clinical uses have not raised concerns with traditional preparations. There is a 
small body of scientific evidence that suggests that Hypericum perforatum preparations are 
well tolerated in children under 12 years of age (Hübner & Kirste, 2001) and in adolescents 
from 12-17 years of age (Simeon et al., 2005). In contrast, a systematic re-evaluation of 




benefit-risk balance from favourable to unfavourable for several pharmaceutical drugs, 
mainly due to an increased risk of suicide (Whittington et al., 2004). Warning against the 
use of synthetic anti-depressants in treating depression in children may leave a treatment 
gap unless safer alternatives are approved and integrated into clinical care. This thesis 
argues that St. John’s Wort could play a role in filling treatment gaps due to its apparent 
safety and established efficacy.  
In conclusion, the comprehensive data analysis relating to St. John’s Wort has confirmed 
that bibliographic evidence from judiciously selected textbooks on the botanical materia 
medica, where pharmacological evaluations are consistently transmitted by clinical experts, 
generally provides reliable data on therapeutic uses. Triangulation of qualitative historical 
data with modern regulatory monographs has highlighted the congruency between the key 
historical indications of St. John’s Wort with modern approvals. A further triangulation of 
historical data with quantitative data has demonstrated efficacy of several traditional 
indications when they were investigated with clinical trials. The results of this thesis 
therefore support a conclusion that authoritative textbooks provide reliable and verifiable 
empirical evidence suitable for the regulatory registration of traditional medicines as part of 
an evidence-based healthcare system. The development of an appropriate regulatory 
framework for safety requirements remains a great challenge for the integration of 




7 EU REGULATIONS ON TRADITIONAL HERBAL 
MEDICINAL PRODUCTS (THMPS) 
One aspect that this thesis sought to document is how international regulators approached 
the challenges of regulating traditional medicines in the era of contemporary evidence-
based health policy. The most comprehensive attempt in the West to harmonise policy 
around the regulation of traditional medicines has occurred in Europe within the integrative 
processes of the European Union (EU). Harmonising policy across the EU has presented 
multiple challenges. Many of the 28 Member States had different approaches to the 
regulation of their traditional medicines. Other countries may therefore benefit from 
examining how the EU has dealt with the dilemma of integrating traditional medicines from 
various regions into a contemporary evidence-based health system.  
The Directive 2001/83/EC of the European legislative framework and its amendment 
Directive 2004/24/EC has three objectives (Knöss, 2014a, p. 30; Knöss & Chinou, 2012; 
Peschel, 2014):  
1) To ensure a future for traditional plant medicines where European citizens can 
access medicines of their choice, even if traditional uses of plant medicines have not 
yet been substantiated by clinical efficacy data according to modern requirements. 
The Directive mandates that the characteristics of plant medicines are considered 
when assessing their quality, effectiveness, and safety. 
2) To protect public health by providing a legislative framework for safe and high-
quality medicinal products containing herbal active ingredients. 
3) To harmonise legislation across the 28 EU Member States to enable the free 
movement of medicinal herbal products within Europe. 
 
This chapter will summarise key features of the legislative framework of the EU before 
discussing considerations for the development of a health policy framework on traditional 
medicines in New Zealand. 
7.1 Access to medicines of choice 
In the context of the European legislative framework, Directive 2004/24/EC was the result 




herbal medicines based on plausible levels of effectiveness, the ‘traditional use’ category, 
this legislation legally supports and protects treatment choices for consumers. Traditional 
Herbal Medicinal Products (THMPs) are regulated as medicines rather than as dietary food 
supplements, falling under the scope of pharmaceutical good manufacturing practice and 
pharmacovigilance legislation (Claeson, 2014, p. 465). Thus, they have a higher status than 
plant-based therapeutics in many other countries, including New Zealand. The separation of 
traditional plant medicines from dietary supplements is significant. It recognises that they 
transcend nutritional purpose by having a pharmacologic effect to prevent and treat 
illnesses. As such they are distinct from nutrients—whether foods, natural or synthetic 
dietary supplements—and pharmaceutical drugs. This separate regulatory framework 
enables the acknowledgment of both their specific pharmacological effects and their long-
standing role in traditional medicine of European countries. This EU approach to 
traditional medicines is noteworthy for other countries dealing with their regulations of 
traditional medicines. 
One of the key conditions for gaining simplified registration in the EU Member States is 
that a THMP has been used medicinally for at least 30 years, 15 of which must have been 
within the EU. As such the traditional use category requires bibliographic evidence of 
traditional use, but no clinical trials. Health claims are accepted on the basis of plausible 
effectiveness and sufficient safety data (European Parliamemt, 2004). EU herbal 
monographs provide information necessary for the registration of a traditional product for 
sale, namely approved indications, suitability of use, and safety information such as 
information regarding undesirable effects and interactions with other medicines. Analyses 
of the EU Herbal Monograph Arnica flos (Committee on Herbal Medicinal Products 
(HMPC), 2014b) and EU Herbal Monograph Hypericum perforatum L., herba (traditional 
use) (Committee on Herbal Medicinal Products (HMPC), 2009b) confirmed that the main 
therapeutic indications consistently recorded in the assessed medical literature are also 
approved by the monographs authored by HMPC (see Appendix 10 and Table 7). This 
ensures continued access to these traditional medicines. 
7.1.1 Impact of definition of tradition on access to THMPs 
Notwithstanding consumer access to THMPs, issues have emerged since the enactment of 
the Directive 2004/24/EC that appear to hamper the full potential of this legislative 




indications were mainly based on recent bibliographic materials even when reference to 
some historical applications was provided (Committee on Herbal Medicinal Products 
(HMPC), 2009a, 2014a). Consequently, the EU monographs did not make full use of the 
availability of consistent empirical evidence as coded in historical sources. This may have 
been one of the reasons why there are relatively few approved traditional claims in the 
evaluated EU monographs. Legally, ‘proof of tradition’ in the context of Directive 
2004/24/EC does not necessarily mean long-standing traditional use of medicinal plants. It 
means that a THMP must have been medicinally used for at least 30 years. Under this legal 
approach, medicinal plants, indications, or preparations that may have been discontinued for 
a short while, for example due to conservation issues or questions over a plant’s mechanism 
of therapeutic actions, do not qualify for the simplified ‘traditional use’ registration 
pathway. This is even when they were consistently used in TEM over long periods of time, 
sometimes for centuries. As Peschel (2014, p. 482) explains (italics by the author), “it is not 
sufficient to document that a plant has been used for several 100 years in a certain 
tradition. It is still insufficient showing that a specific preparation from a specific plant part 
has been used in certain indications, but it is required to demonstrate that a specific 
preparation from a specific plant in a specific strength and dosage had been used for more 
than 30 years in a specific indication. This stipulation is often the reason why HMPC was 
unable to include a certain indication or extract into a monograph. Therefore, this regulatory 
framework does not reference tradition in the anthropological sense of three generations or 
75 years, as applied by the World Health Organization (2013), or in the sociological sense 
of at least two transmission steps (Shils, 1981) as applied by the Canadian regulatory 
framework (Hirschkorn, 2005, p. 28).  
The 30 year stipulation means that there is no requirement to incorporate systematically the 
long-standing historical evidence of traditional medicines into the drafting of the EU 
monographs. One possible explanation for this might be that current health policies largely 
draw on the EBM model. This model does not generally consider long-standing historical 
evidence as significant or valid for an overall benefit-risk analysis (Helmstädter & Staiger, 
2014; Rawlins, 2008), although the EU Directive 2004/24/EC moderates this position by 
acknowledging 30 years of traditional evidence. The Assessment Reports for both Arnica 
montana and Hypericum perforatum exemplify the consequences of this approach. In both 
instances, a systematic historical analysis of their traditional uses as suggested with the 




(HMPC), 2009a, 2014a). As a result, several indications for Arnica (see Table 11) and for 
St. John’s Wort (see Tables 18 and 19) that may have met the criterion of consistent 
medicinal use are not listed in the final EU monographs.  
By framing regulations of THMPs from an EBM viewpoint, this approach may 
underestimate the need for traditional evidence to be systematically evaluated as part of the 
scientific enquiry. Such a thorough enquiry would fulfil a key recommendation advocated 
by the WHO Traditional Medicine Strategy 2014-2023, a strategy that seeks to “identify 
sources of evidence, whether historical, traditional or scientific, which support or invalidate 
a particular therapy (World Health Organization, 2013, p. 47). Early proponents of EBM 
also made clear that “evidence-based medicine is the conscientious, explicit, and judicious 
use of current best evidence in making decisions about the care of individual patients” 
(Sackett et al., 1996, p. 71). Extending the meaning of tradition beyond 30 years might help 
to expand the scope of traditional medicines, although the ultimate decision on accepting an 
indication lies with the assessment of the THMPC. 
7.1.2 Impact of stipulations for traditional multi-component formulations  
The regulatory concept behind EU Directive 2004/24/EC facilitates a pre-approval of 
THMPs mainly for those that contain one active ingredient. This is because EU monographs 
are monographs on individual medicinal plants and can only be referenced under this 
Directive by products containing the same or a comparable active substance as described in 
the monograph. Guideline EMEA/HMPC/104613/2005 stipulates that evidence about 
traditional use for each of the single active substances in a combination will not be 
sufficient to establish the traditional use of a multi-component formulation. Evidence for a 
multi-component combination is required in its entirety from a comparable combination 
product rather than just the parts of that product (Peschel, 2014, p. 484). In practice, most 
remedies from traditional systems of medicine are multi-component formulations rather 
than single-plant formulations. The simplified registration pathway presents difficulty for 
such multi-component remedies unless a historic formulation has been fixed for 30 years, 
which is not common. Multi-component formulations are in principle possible with the 
provision of additional scientific evidence. This does, however, appear to be challenging for 
traditional remedies, as most products registered to date under the ‘traditional use’ criteria 
are mono-component products (Peschel, 2014, p. 479). In addition, by April 2018, only two 




13). This contrasts with 72 approved multi-component formulations listed under the 
preceding German Commission E monographs6.  
7.1.3 Restrictions for THMPs from non-EU traditions 
Under the current EU legislation, the requirement to demonstrate a minimum of 15 years of 
medicinal use in the EU has shown to be an obstacle to the registration of non-EU European 
traditional herbal products for example from Switzerland, and those from traditions outside 
of Europe, such as traditional products from Ayurvedic, Chinese, Kampo Korean, 
Mongolian, Thai, Tibetan, Unani, or Vietnamese medicine. This includes products that had 
been approved in European countries previously (Qu et al., 2014; Schwabl & Vennos, 
2015). A Commission Report states that the Commission does not envisage extending the 
scope of the simplified registration procedure to traditional medicines from outside the EU, 
specifically because such medicines are based on a holistic approach to healthcare 
(Commission of the European Communities, 2008, p. 10). The Commission concludes that 
for such products a separate legal framework should be assessed. Paradoxically, the 
traditional use of European plant medicines is also underpinned by a holistic approach to 
healthcare incommensurable with the pharmaceutical model of ‘one drug, one indication’. 
Thus, an updated legislative framework may be helpful, not only for regulations of 
traditional medicines from outside the EU, but also for traditional medicines from inside the 
EU, in order to overcome “the difficulties encountered by Member States in applying the 
pharmaceutical legislation to herbal medicinal products” (Commission of the European 
Communities, 2008, p. 10).  
7.2 Protection of the public 
A key feature of regulations in Western healthcare systems is their intent to safeguard 
public health by ensuring that therapeutic interventions are high in quality, safe, and 
effective (Kelber et al., 2014, p. 448). Directive 2004/24/EC seeks to achieve this by 
integrating traditional medicines into pre-existing pharmaceutical legislation that governs 
the quality, safety and efficacy of pharmaceutical drugs. In addition, under EU Directive 
2004/24/EC traditional herbal medicinal products may be accepted under the traditional use 
criteria only if sufficient data proof demonstrates that such products are not harmful (Knöss, 
 






2018, p. 371). There are discussions by the Commission of the European Communities on 
the meaning of “proof” and what form the demonstration of “not harmful” should take 
(Commission of the European Communities, 2008, pp. 4-5). The EU Directive 2004/24/EC, 
16c (c) accepts the safety of a medicinal preparation as plausible if no risk has been 
demonstrated for a substance used commercially for 10 years (well-established use) or 30 
years (traditional use) (European Parliament, 2004, p. 87). The Directive explains: 
The long tradition of the medicinal product makes it possible to reduce the need for 
clinical trials, in so far as the efficacy of the medicinal product is plausible on the 
basis of long-standing use and experience. Pre-clinical tests do not seem necessary, 
where the medicinal product on the basis of the information on its traditional use 
proves not to be harmful in specified conditions of use. However, even a long 
tradition does not exclude the possibility that there may be concerns with regard to 
the product's safety, and therefore the competent authorities should be entitled to ask 
for all data necessary for assessing the safety. (European Parliament, 2004, p. 85, 
point 5)  
In theory, this framework could permit assessments based on the documented absence of 
harm for a proposed preparation and posology rather than proof of its safety through 
toxicological tests. The HMPC’s subsequently published guideline 
EMEA/HMPC/32116/2005 acknowledges that bibliographic safety clearance could be 
granted after a systematic and comprehensive scientific literature search of post-marketing 
safety studies and an assessment of epidemiological data of adequate power (Committee on 
Herbal Medicinal Products  (HMPC), 2006, p. 5). However, in practice, all THMPs were 
seen to require assessment of their genotoxic potential as a test of proof of no harm 
(Wiesner, 2014, p. 468). Thus, pre-approval of THMPs is currently granted based on 
demonstrated long-term safe traditional use together with negative results from 
genotoxicity, reproductive, and developmental toxicity tests. The implementation of this 
approach was seen in the Assessment Report Hypericum perforatum L., herba (Committee 
on Herbal Medicinal Products (HMPC), 2009a, p. 31) that was unable to pre-approve St. 
John’s Wort for pregnancy and lactation due to the absence of specific toxicity data. 
The absence of modern toxicology tests for most medicinal plants, the significant financial 
outlay required to generate the required scientific data, and the reluctance of phytotherapy 




standing traditional medicines that were previously considered safe and available in the 
market place (Abdel-Tawab, 2018, pp. 373, 384; Gallagher, 2013, p. 19). The absence of 
modern toxicology data is also the reason given why there are few legally binding EU List 
Entries (12 entries by April 2018) and why most EU herbal monographs do not support the 
traditional use of medicinal plants for pregnant or lactating women, or for young children 
and adolescents despite an absence of adverse drug reactions from clinical use (Knöss, 
2018, p. 386; Knöss & Wiesner, 2017, p. 13). The requirement to provide toxicology testing 
before granting marketing authorisation for children (Wiesner, 2014) resulted in the pre-
approval of only 14 medicinal plants for internal use and six for topical use for this 
demographic. Just one plant, Oats, has no age restrictions (Committee on Herbal Medicinal 
Products (HMPC), 2018).  
If a traditional medicinal product is not registered as a THMP, this same product may still 
be available in the market place as a food supplement (Nahrungsergänzungsmittel, NEM), 
as a medical device, or as a cosmetic. European food law is less strict than European drug 
law and does not request toxicity data for pre-existing and commonly used food substances 
(Quintus & Schweim, 2012, p. 380). However, few health claims can be made for 
nutritional products, requiring them to be aimed at a ‘physiological effect’ rather than a 
‘pharmacological effect’ (Steinhoff, 2013, p. 239). In practice, consumers commonly use 
herbal products for their traditonally stated pharmacological effects regardless of their 
classification by the regulator. This unsatisfactory situation was addressed in a Commission 
Report by the European Parliament: 
The introduction of the simplified registration procedure was based on the 
assumption that safety and efficacy could be adequately substantiated by long-
standing use without requiring additional testing and systematic documentation on 
all point of Annex 1 of Directive 2001/83/EC regarding safety…. In its guideline on 
non-clinical documentation for herbal medicinal products in applications for a 
marketing authorisation (bibliographic and mixed applications) and in applications 
for simplified registrations, the HMPC is of the view that the genotoxicity potential 
of herbal preparations should always be assessed…. In order to ensure the successful 
application of the Directive, the issues relating to genotoxicity demand careful 
scientific and legal consideration. As stated in the HMPC report, the systematic 




these data are generally not available. It has probably also contributed to the small 
number of applications reviewed so far. Consequently, a request for genotoxicity 
data to assess traditional herbal products should be made on a case-by case basis 
when there is a specific concern for safety, as required by the relevant provisions in 
the legislation. This ensures the protection of public health while allowing the 
registration of traditional herbal medicinal products. A more restrictive approach 
would create the risk that the products concerned will end up being marketed under 
another classification (and not as medicinal products) without the necessary quality, 
safety and efficacy controls applicable under pharmaceutical legislation. 
(Commission of the European Communities, 2008, pp. 4,5)  
Despite the concerns raised in the Commission Report, few adjustments have been made to 
date to the interpretation of the legislation, and the legislation itself has not yet been 
amended. The permission of a simplified “bracketing and matrixing” concept for the 
assessment of genotoxicity (Kelber et al., 2012, p. 1124) seems to have had only a minimal 
impact on the number of applications for THMPs or the authorisation of new List Entries.  
7.2.1 Approved levels of claims 
Restrictions on claims permitted for TMHPs are a way of safeguarding public health. The 
Directive 2004/24/EC restricts indications eligible for a simplified registration of a THMP 
to minor, self-limiting health complaints that can be treated without supervision (Gallagher, 
2013). To increase public safety further, this Directive selectively covers only traditional 
plants with undisputed innocuousness. In addition to this focused selection of medicinal 
plants eligible for a simplified registration process, monographs, as already noted, usually 
restrict usages in women during pregnancy and lactation, as well as in children and 
adolescents. Most monographs further limit the duration of usage to a defined short period, 
typically two weeks. This stipulation is to minimise the potential health risk for consumers 
who may otherwise delay seeing a physician when seriously ill by attempting to self-
medicate (Claeson, 2014, p. 465). Treating the symptoms of non-serious diseases which 
could also be symptoms of serious diseases, for example benign prostatic hyperplasia, may 
be acceptable with the disclaimer that a physician must exclude serious conditions before 
such treatment begins (Committee on Herbal Medicinal Products (HMPC), 2011).  




requirements set for a qualification under the simplified registration scheme compared to 
the limited scope of permitted health claims for THMPs may have been a contributing 
factor to the limited uptake of this regulatory pathway. Health surveys confirm that 
traditional plant medicines are an attractive option for patients and treatment providers in 
the management of chronic illnesses to improve health-related quality of life and reduce 
reliance on synthetic medications associated with risks of harmful adverse events (Cameron 
et al., 2009; Euromonitor, 2011; Institut für Demoskopie Allensbach, 2010). Phytotherapy 
is also a preferential choice for adults with multiple diseases and somatoform disorders, as 
well as for children (Kopp, 2015, p. 215; Saller et al., 2014, p. 26). Studies from Western 
countries suggest that pregnant women often resort to using traditional plant medicines that 
are familiar to them and they consider to be safe (Holst, Wright, Haavik, & Nordeng, 2009; 
Holst, Wright, Nordeng, & Haavik, 2009). The frequent use of traditional therapeutics in 
these consumer groups supports the idea that they have an urgent need for access to high-
quality, safe products. If THMPs are not officially available for these demographics, they 
might purchase the same remedies as food supplements instead, which are regulated under 
lower quality requirements. Regulators therefore have the difficult task of balancing public 
safety as well as ensuring that medicines of choice are available.  
The two-week maximum treatment period commonly mandated as a disclaimer on THMP 
labels appears to be a short timeframe for the management of many health complaints, 
particularly chronic ones, or for the use of THMPs in prophylaxis. It could be advantageous 
if mandatory labelling advice did not discourage consumers from self-care practices or from 
the management of symptoms of chronic, non-life-threatening conditions with traditional 
remedies. Patients may choose to include both herbal and pharmaceutical OTC medicines to 
deal with their needs. Clear indications on labels, including the establishment of disease-
relationship, would support patients in their choice.  
7.3 Harmonisation 
To facilitate the simplified registration of traditional plant medicines in all EU Member 
States, the HMPC at EMA was mandated to publish herbal monographs. By April 2018, 
HMPC published 154 monographs of which 13 were for well-established use (Knöss & 
Wiesner, 2017, p. 13). These monographs provide an important pathway for enabling the 
free movement of medicinal herbal products within Europe. The establishment of such 




across all 28 EU Member States. The shortness of many monographs may reflect the 
scientific and political process as laid down in the 2004 EU Directive, which mandates that 
permitted indications, modes of application, proof of effectiveness, and safety 
(innocuousness) should be reached by consensus. If consensus cannot be reached, the 
monographs must be agreed upon by the absolute majority of the members of the HMPC 
Committee (Committee on Herbal Medicinal Products (HMPC), 2013, p. 6). In the voting 
procedure, it appears that consensus was rarely reached, highlighting the divergence of 
views on clinical and scientific assessments, as well as the influence of pre-existing 
regulatory regimes, legal statuses, and practical uses of THMPs in the various Member 
States (Claeson, 2014, p. 466; Silano, De Vincenzi, De Vincenzi, & Silano, 2004).  
List Entries published by the European Commission provide, in principle, another legal 
avenue for a harmonised registration of traditional products across the EU. In contrast to the 
monographs authored by HMPC, List Entries are legally binding across all Member States 
and products that adhere to their guidelines must be registered. By April 2018, only 12 List 
Entries had been published to support the registration process. This low number has been 
linked to the absence of genotoxicity data for many medicinal plants used in traditional 
medicines (Knöss, 2018, p. 374).  
There are national differences on the status of traditional plant medicines across the EU 
Member States; regulations, classifications, definitions, and the use of traditional plant 
medicines have evolved at national levels. The implementation of Directive 2004/24/EC has 
shown that it is challenging to assimilate them under one EU-wide regulatory framework. 
To add to this challenge, the policy framework employed was initially set up for regulating 
a distinctly different class of medicines, that of pharmaceutical drugs (Commission of the 
European Communities, 2008). The implementation of the Directive has shown that on the 
one hand it legally protects the availability of traditional medicine but on the other hand it 
has been associated with an overall decrease in traditional products (Knöss, 2014b, p. 448). 
The analysis by Kazemekaitis (2010, pp. 14-15) showed that when an EU Member State 
had customary products with different indications and/or applications from those of the 
majority of the other EU Member States, those products tended to disappear from the 
market because they could not comply with the particulars of the new Directive. This 
suggests that harmonisation of local traditions across various regions of Europe requires 




7.4 Concluding observations on EU regulations 
In summary, the EU Directive 2004/24/EC is a legal commitment to pluralism in medicine 
that secured the future of traditional European therapeutics as regular medicines. Overall, 
the Directive succeeded in its objective of providing legal access to medicinal products 
originating from plants, protecting the public by implementing a legislative framework for 
safe and high-quality THMPs, and creating a framework that facilitates the harmonisation 
of free movement of medicinal herbal products within Europe. For the first time in the EU, 
a Member State can license a THMP based on pre-approved health claims and implement a 
harmonised, simplified registration process for traditional medicines. Moreover, List Entries 
by the European Commission provide an additional legal pathway for licensing THMPs. 
Unlike the EU monographs which rely on voluntary implementation, List Entries are legally 
binding for all Member States. The EU legislator has therefore legally advanced the status 
of medicinal products originating from plants. 
However, analysis of the EU health policy on traditional medicines has revealed several key 
impediments that became apparent during implementation. A relatively low uptake of the 
simplified registration pathway for THMPs by manufacturers occurred possibly because of 
low levels of permitted health claims, high and costly requirements for toxicology testing, 
and a narrow definition of the meaning of the term ‘tradition’. Consequently, for European 
citizens the potential of traditional medicines in primary healthcare and self-care remains 
untapped. A specific issue that has emerged is that EU monographs list relatively few 
traditional uses that can be referenced for health claims. While these monographs are 
regularly reviewed and updated in consultation with all 28 Member States, those currently 
approved omit a number of long-standing traditional uses and preparations which are 
customary in several Member States (Kazemekaitis, 2010). When the Historical Assessment 
Tool was applied as a systematic research tool to locate consistently transmitted indications 
of Arnica and St. John’s Wort, several long-standing indications emerged that could have 
been considered in the EU monographs. These additional indications are listed in Appendix 
10 and Tables 18-20.  
The variance between the results of the Historical Assessment Tool and the indications 
listed in the EU monographs may be explained by the narrow legal-political regulatory 
framework under which the authoring of EU monographs had to operate. For each 




consensus across 28 Member States, each with their different traditions, independently 
operating national competent authorities, and divergent stances on the legitimacy of plant 
medicines as a treatment option. In contrast, the tool applied in this thesis was unimpeded 
by such political and legal restraints and could solely focus on the triangulation and 
systematic collation of traditional indications consistently recorded across various data 
sources, datapoints and research methods. The Historical Assessment Tool may therefore 
provide a factual instrument to tabulate proof of long-standing traditional indications which 
are based on empirical observations and evaluated and transmitted by clinical experts. Once 
suitable evidence sources are established, the succinct tabulation of tradition-of-proof 
evidence may provide an accelerated pathway and practical basis for evaluating traditional 
indications in a regulatory context. This could reduce both time and cost. In addition, this 
tool could be used for translational use of traditional health claims. This is where the safety 
of a preparation has been established and such preparation is recorded as pre-approved in a 
monograph. Approval may then be extended when this preparation is associated with 
another long-standing traditional indication not yet listed in a monograph. Such an approach 
could help to update the current monographs and make them more inclusive for regional 
customs in Member States. 
7.4.1 Challenges to a comprehensive assessment of safety  
The views of HMPC at EMA on genotoxicity testing as a prerequisite for pre-marketing 
approval of all THMPs, have been seen as too restrictive by the European Commission 
(Commission of the European Communities, 2008, pp. 4,5) and as unworkable by 
phytotherapy companies (Cranz, 2010, p. 86). Thus, divergent views on sensible levels of 
proof of absence of harm have emerged as one of the biggest hurdles for registering 
traditional medicines, despite their long track record of relatively low risk and the general 
absence of severe adverse effects. Curiously, herbal formulations that encountered 
regulatory hurdles under Directive 2004/24/EC are permitted in the EU market in the food 
category without pre-market approval (Quintus & Schweim, 2012). Regarding 
implementation of the vision of the EU Directive 2004/24/EC to provide ease of access to 
traditional medicines, it remains to be seen if the European Commission clarifies its 
expectations further. 
The safety of traditional medicines is a complex topic that merits a more detailed 




standardised safety assessment framework for traditional medicines. Regulatory benefit-risk 
assessment may also change over time due to shifting views on acceptable levels of risk, as 
seen in the European regulatory history of Arnica. Safety assessments employ a qualitative 
and not a quantitative approach and therefore involve some element of subjectivity. As 
such, the safety of a therapeutic substance cannot be considered in isolation from its 
presumed benefits. Some regulators therefore acknowledge that value judgements form an 
integral part of decision making on therapeutic interventions (Culyer & Rawlins, 2004; US 
Congress Office of Technology Assessment, 1978, p. 101). Typically, the higher an 
attributed or clinically proven benefit is, the higher the tolerance for risk. Conversely, if no 
benefit is attributed then tolerance for risk tends to be low. When empirical evidence is not 
duly considered and RCT evidence is not available, these relationships affect traditional 
medicines disproportionally; the regulatory consequence might be a stipulation for proof of 
‘no risk’. Under the EU Directive 2004/24/EC, the high safety threshold set for THMPs has 
resulted in a drop in the number of traditional medicines across the EU, even for those that 
previously held market access approvals. 
To evaluate the clinical effects of traditional medicines, long-standing traditional 
knowledge is the strongest source of real-world data currently available. The WHO supports 
the inclusion of traditional observational data for the evaluation of safety and efficacy of 
traditional plant medicines (World Health Organization, 2012, p. 17; 2013). This thesis 
argues that the systematic collation of historical safety data in a large population relating to 
the traditional use of a plant part or a plant preparation should be given due consideration. 
Whereas absolute safety does not exist, it is warranted that tradition-of-use data are 
incorporated into the totality of evidence for the safe and effective use of medicinal plants 
(Anton et al., 2012a, 2012b; Cordell, 2014; Helmstädter & Staiger, 2012; Neely et al., 
2011). Such evidence was noted for acceptance in New Zealand under the formerly 
proposed Natural Health and Supplementary Products Bill7.  
Long-term beneficial use and consumer satisfaction point to plausible effectiveness and 
acceptable tolerance of plant-based drugs as commonly prescribed in European medicine 
(Benedum et al., 2000). Despite the potential for under-reporting, repeated serious events 
and side-effects occurring in a large population are unlikely to have gone unnoticed. Today, 
 





the most common risks associated with using herbal drugs arise from a lack of stringent 
quality control measures rather from the pharmacological activity of the traditionally known 
and used herbal ingredients themselves (Bowen et al., 2012).  
Quality risks affect all medicines. For traditional plant medicines, such risks relate to 
misidentification or mislabelling of herbal ingredients with an incorrect species, 
adulterations (e.g. addition of undeclared pharmaceuticals), substitutions (e.g. the fatal 
substitution of Stephania tetrandra with nephrotoxic Aristolochia fangchi), and 
contamination with heavy metals, pesticides, herbicides, and microbes (Ekar & Kreft, 2019; 
He, Ung, Hu, & Wang, 2015; Keane, Munn, Vivier, Higgins, & Taylor, 1999). In turn, lack 
of efficacy may be linked to incorrect harvesting times of the medicinal plant such as when 
active constituents are not at their prime, the collection of the wrong plant part or species, 
and incorrect processing. These risks can be minimised with proper quality control 
measures during harvesting and manufacturing. The WHO has recognised these quality 
risks with traditional plant medicines and has provided resources on good harvesting and 
good manufacturing practices (GMP) (Akerele, 1992; World Health Organization, 1994, 
2003). For those conditions which have better treatment outcomes with biomedical 
intervention than with traditional medicines, a very different risk arises from delay in 
seeking medical help. These various risks support the urgency around regulation of 
traditional plant medicines for New Zealand. 
In conclusion, it can be stated that the EU approach to the regulation of traditional plant 
medicines succeeded in guaranteeing legal access to these therapeutics. At the same time 
fulfilment of the objective of the Directive was hampered by its high level of requirements 
that resulted in an overall reduction of available traditional remedies compared to the period 
before the implementation of the Directive. This outcome is noteworthy for other regulators 
who wish to implement regulation of traditional plant medicines based on the EU approach. 




8 DISCUSSION  
8.1 Relevance and significance of results 
This thesis sought to examine how the empirical knowledge base underpinning traditional 
plant medicines can be incorporated into a contemporary regulatory framework that is 
evidence-based and appropriately accommodates long-standing traditional therapeutics. 
While many factors influence health policy decisions, evidence from health interventions is 
the central starting point (Dobrow, Goel, & Upshur, 2004). It is often implied that 
traditional therapeutics lack the modern scientific evidence to substantiate their 
effectiveness and safety and so are prevented from being formally integrated into a modern 
evidence-based healthcare system. Consequently, there is a vital need for robust information 
that can guide regulation for traditional plant medicines.  
Governments are challenged to implement health policies that are efficient, safe, 
efficacious, and cost-effective, thus meeting the healthcare needs of their citizens. These 
policies should also reflect values-based healthcare focused on patients and consumers and 
their rights to self-determination of treatment options (Code of Health and Disability 
Services Consumers' Rights Regulations 1996; Greenhalgh et al., 2015; McCarthy & Rose, 
2010). The WHO Regional Office for Europe recommends that patients play a distinct role 
in protecting their health, choosing appropriate treatments for episodes of ill health and for 
managing chronic diseases (Coulter, Parsons, & Askham, 2008, p. 2). Policy interventions 
aimed at increased patient engagement by improving health literacy, treatment decision-
making, and self-management of chronic conditions could be of benefit for the public. To 
support patients as ‘primary health care workers’, health policies should support ease of 
access and affordability to safe and efficacious interventions, but also to interventions of 
their choice. In its regional guidelines for the Western Pacific, the WHO (2012, p. v) 
highlights the important contribution of traditional systems of medicine to national and 
individual healthcare, and to the promotion of health equity. In addition, it stresses to 
governments that all people have a right to quality health services which are accessible, 
affordable, and acceptable. In its global Traditional Medicine Strategy 2014-2023 (World 
Health Organization, 2013), the WHO calls for governments to integrate traditional 
medicines into contemporary healthcare, asking that they promote, regulate and research 
them more extensively. However, despite policy gaps, many countries, including New 




their healthcare services and they do not provide regulations and formal access to them, 
including insurance coverage (Cordell, 2014, p. xxix; International Bioethics Committee 
(IBC), 2013). If traditional medicines were to become recognised under an appropriate 
regulatory framework, their potential in primary healthcare could be fully realised by 
enabling of patient access. Long-standing empirical evidence is particularly important 
where scientific evidence is wanting or completely absent, a situation common within 
traditional healing practices. 
Historical documentary sources have been permitted overseas as bibliographic evidence 
(e.g. in the EU, Canada, and Australia) (Europäisches Parlament, 2004, p. L 136/187); 
Health Canada, 2012, pp. 5-8; Therapeutic Goods Agency, 2019, pp. 15-18). Switzerland, 
similarly to the EU, accepts bibliographic evidence on traditional indications and safety for 
those plant medicines (Phytoarzneimittel) that are well-stablished (10 years) or traditionally 
used (30 years) (Swissmedic, 2018). However, as noted in sections 3.3 and 3.4 of this 
thesis, few previous studies have investigated systematic ways to record and evaluate 
traditional indications as documented in historical sources, and compared this empirical 
evidence with contemporary evidence. As illustrated in section 3.7, even fewer have 
investigated how historical research into traditional plant applications could support modern 
scientific methodologies to inform evidence-based health policies. In the Western 
regulatory context, traditional clinical knowledge is an underutilised source of data on 
health interventions. Consequently, the aim of this research was to explore a method by 
which long-standing traditional evidence on therapeutic uses of medicinal plants can be 
systematically coded and collected.  
The Historical Assessment Tool, explained in sections 4.4.1 and 4.9, was developed and 
tested as a systematic and reproducible method of organising the large amount of 
pharmacological data recorded in bibliographic sources. Longitudinal textual analysis of 
medicinal uses over 400 years triangulated data from qualitative and quantitative sources 
helped meet the objective of this thesis: to establish if clinically orientated historical sources 
within the European materia medica could provide a pathway for substantiating therapeutic 
claims for traditional plant indications in an evidence-based policy framework. This 
question is pertinent for existing traditional therapies because RCTs are seen as an 
insufficient and impractical method of validating the large volume of medicinal plants, their 





Authoritative medical textbooks were methodically surveyed as key repositories of clinical 
knowledge on the European materia medica. The results provided a reliable body of 
documentary evidence relating to the consistent clinical endorsements of traditional 
indications of Arnica montana and Hypericum perforatum over 400 years. The New 
vollkommen Kräuter-Buch by the German physician, apothecary, and botanist 
Tabernaemontanus (first published in 1588) and annotated by the Bauhin editors (4th 
edition, 1664) was confirmed as a suitable starting point for such a longitudinal textual 
analysis on historical clinical uses. Triangulation of data confirmed that the 16th century 
physician was accurate in determining therapeutic uses of Arnica and St. John’s Wort, 
raising the possibility that he was also accurate in determining therapeutic uses of other 
medicinal plants. The results from the evaluation of these two exemplars suggest that the 
clinical conclusions from repeated empirical observations have withstood the test of time 
due to the frequency, consistency, and extent of the treatment effects reported. 
By way of illustration, evaluation of Arnica in the selected qualitative and quantitative 
sources demonstrates uninterrupted medical transmission of two clusters of indications over 
a 400-year period; its therapeutic use in the treatment of consequences of injuries and 
accidents, and its use for pain related to the musculo-skeletal system and nerves (see Table 
10). These two clusters of indications are consistently listed in the historical medical 
literature and contemporary textbooks reviewed at the defined datapoints (each a generation 
apart), in the commentaries of the Prussian and German pharmacopoeias, in the main 
European regulatory monographs of the 20th and 21st century authored by the German 
Commission E and the European Medicine Agency, and in the authoritative monographs 
authored by ESCOP, the WHO, and the publishers of HagerROM. Where clinical trials 
have been conducted on traditional indications, they have also returned positive results 
confirming benefits for ailments listed in traditional sources, namely for those that require 
circulatory stimulant, analgesic, antirheumatic, anti-inflammatory, and skin healing actions 
(see Appendix 11). In addition, experimental research points to Arnica’s mechanisms of 
therapeutic actions (Kriplani et al., 2017; Merfort, 2010; Wijnsma et al., 1995).  
Similarly, the analysis of data on St. John’s Wort also showed congruency between 
indications already noted by Tabernaemontanus, albeit in different terminology, and the 
subsequent qualitative and quantitative data sources that were evaluated. Consistent 
indications are recorded in all medical textbooks as well as the two evaluated regulatory 




of the gastro-intestinal system (gastro-enteritis, dyspeptic disorders); to burns (topical) and 
wounds (systemic and topical); and to psychovegetative disorders (depressive moods, 
anxiety, nervous unrest, and hormonally driven dysphoria in relation to the female 
menstrual cycle). The validity of these traditional indications was further supported when 
cross-checked with outcomes from clinical trials. Data from experimental research provided 
insights into active constituents and possible mechanisms related to the empirically 
observed effects of St John’s Wort, most importantly (in modern terminology) its 
antidepressant, anxiolytic, antiviral, antimicrobial, anti-inflammatory, nervine tonic, 
spasmolytic, and vulnerary actions (Dell'Aica et al., 2007; Reichling et al., 2001).  
These results of the systematic analysis of Arnica and St. John’s Wort confirm the WHO’s 
assessment (2012, p. 17) that traditional medicines administered over long periods lead to 
the empirical evolution of dosages and formulations that maximise therapeutic effectiveness 
and minimise risk. The undertaken analysis infers that clinical knowledge transmitted over 
several generations of clinicians provides a reliable form of empirical evidence which aligns 
with modern assessments for the ailments investigated. This conclusion is further 
strengthened by clinical trials consistent with traditional dosage and treatment strategies, 
returning positive results on efficacy as seen with Arnica (see Appendix 11). However, 
trials applying a dose below traditional dosing as recorded in medical textbooks, or trials 
that investigated the effect of Arnica as a one-off application, demonstrated no difference 
between verum and placebo. Continuous clinical recommendations by clinicians do not 
appear to be random but based on therapeutic effects as empirically observed in patient care 
over long periods.  
The analysed data also suggest that traditional knowledge is comprehensive. Recent clinical 
research has provided only one new application (burns) for Arnica montana beyond those 
based on traditional use already noted over at least 150 years (see Table 9). This lack of 
innovation is also true for Hypericum perforatum where contemporary investigations for 
traditional indications already noted in the early modern era by Tabernaemontanus returned 
positive results. These include gastro-intestinal inflammation, menstrual complaints, pain 
and injuries of the musculo-skeletal system, wound care, and psychovegetative disturbances 
such as melancholy (today attributed to depression), and discomfort around menstruation 
(today attributed to hormonally driven dysphoria in relation to the female menstrual cycle). 
In contrast, new indications for addiction, social phobia, Obsessive-Compulsive Disorder 




(see Appendix 15). Based on the results of these analyses, this thesis argues that the method 
of empiricism used in traditional medicine delivers a comprehensive and reliable body of 
evidence on traditional plant medicines that can be canvassed for evidence-based policy. 
8.2 Traditional knowledge as empirical evidence in the context of evidence-
based policy 
The findings of this thesis suggest that a reliable pathway exists for addressing gaps of 
evidence for traditional medicines. Contemporary professional use of medicinal plants relies 
on long-standing clinical expertise because it represents reliable observations of treatment 
outcomes (Mills, 2011; Wiese, 2016). It is suggested that these empirical data could also be 
an important source of evidence for regulators. Consequently, and once suitable sources are 
identified, summaries of traditional-use-evidence could provide succinct bibliographic data 
for regulatory purposes. It is the distinct advantage of literary sources that they can be 
critiqued, challenged, and corrected if they contain inconsistencies. This minimises 
erroneous information. Traditional clinical knowledge was recorded according to the 
medical theory under which it operated. This may now seem quaint or antiquated. For 
example, St. John’s Wort was variably thought to eliminate evil spirits, black bile, or 
melancholy before it was attributed as a treatment for depression. Despite such disparities in 
medical theories and their explanatory models, applications grounded in observational 
clinical outcomes continued. In other words, the observed treatment effects persist even if 
what is believed it to be curing has changed.  
British anthropologist Gregory Bateson (1979) provides a useful metaphor when describing 
various representations of knowledge. He compares knowledge of the material world to a 
map which describes a terrain. The map itself is not the terrain, only a representation of it. 
Many different maps can describe the same terrain. Data recorded in the medical literature 
can extend the typologies of evidence, metaphorically the map, by integrating long-standing 
clinical uses as validated and empirically informed sources. Currently, such evidence is 
neglected in EBM, as proponents of this movement have created a hierarchy of knowledge 
where evidence from RCTs, as conducted on highly selected groups of patients, is elevated 
above clinical expertise, as drawn from observations on average patients treated in real life 
clinical practice. Traditional knowledge, the transmitted clinical expertise over several 
generations of clinicians, is entirely absent in the various EBM pyramids of evidence. The 




Numerous issues arise from privileging statistical analysis from RCTs as evidence for 
decisions on health policies (Bensing, 2000; Kahlert, 2012; Rawlins, 2008; Speller et al., 
1997). In the context of this thesis, the most problematic is the limiting of the evidence base 
(Holmes et al., 2006; Lewith et al., 2009; Traynor, 2002, p. 165). Moreover, those clinical 
trials that are undertaken are often not representative of how a medicinal plant is used in 
clinical practice or by consumers (Mills, 2011; Veal, 2004). As Khan et al. (2018, p. 247) 
note, an assessment of efficacy in a clinical trial is not principally designed to inform the 
real-life efficacy of an intervention, but to clear regulatory hurdles. For health policies on 
traditional plant medicines, RCTs are useful but limiting sources of data on the overall 
scope of such medicines (Witt, 2013). Hence health policy makers should exercise great 
caution when using RCTs as the sole policy evaluation tool, and instead should extend the 
overall methodological repertoire (Grice et al., 2017; Kahlert, 2012, p. 7). 
Scientific evidence is not a substitute for traditional knowledge (Evans, 2006, p. 95). As the 
International Council for Science (2002) explains, each makes different contributions. 
Critically evaluated observational data are now established as a central tenet of medical 
science and regulatory practice in German speaking countries as demonstrated by the 
legislative mandate of the German Commission E, the EU Directive 2004/24/EC, and Swiss 
regulations (Deutscher Bundestag, 1976; European Parliament, 2004; Swissmedic, 2018). 
The results of triangulating clinical data on Arnica and St. John’s Wort confirm that long-
standing empirical observations as recorded in clinically oriented medical textbooks are 
reliable upon testing. This thesis suggests that both traditional and scientific evidence be 
recognised in a regulatory framework, especially because delineating biomedicine as the 
only medical system underpinned by ‘true science’ does not reflect clinical reality. When 
the evidence base of biomedicine has been assessed, questions have arisen about how much 
of medical practice can be based on “best evidence” (RCTs) because empirical evidence 
remains vital to biomedical practice (Coulter, 1998; Hufford, 2003; Imrie & Ramey, 2000; 
Smith, 1991; US Congress Office of Technology Assessment, 1978, 1983). The majority of 
clinical decisions require some other form of evidence (Djulbegovic et al., 2000, p. 103). 
Most notably, modalities such as surgery are almost exclusively based on empirical 
expertise and expert opinions. There appears to be a growing understanding of the inherent 
complexity of real-world healthcare interventions and of the need to find new ways to 
evaluate these interventions as they are actually practiced (Boon et al., 2007). This thesis 




traditional clinical knowledge should be incorporated as an integral part of the evidence 
base. 
8.2.1 Traditional management of risks of medicinal plants 
Historical medical textbooks are also repositories of observational data on side-effects and 
serious adverse events. Traditional systems of medicines managed risks of therapeutics well 
before the development of modern analytical methods (Etkin, 1993, p. 97). As medicinal 
plants have been widely used throughout human history, including by those frequently 
deemed vulnerable such as children, the elderly, pregnant, and breastfeeding women, these 
risks needed to be managed broadly. They continue to be managed in traditional systems of 
medicine because the majority of the world population still treats some or all aspects of its 
health with traditional medicines (International Bioethics Committee (IBC), 2013).  
Pre-modern systems of medicine (i.e. TEM, TCM, and Ayurveda) have been formally 
codified through repeated trial and error, clinical judgement, pattern recognition, tacit 
knowledge, and inspiration. In European medicine, experimentation on human physiology 
also played a role, influencing compounding rules of medicines and safety considerations 
(Saad & Said, 2011, pp. 107-109). As early as the 1st century AD, risks with medicinal 
plants such as adulteration, substitution, and toxic effects were extensively discussed by 
Dioscorides (Heinrich et al., 2017; Riddle, 1985, p. 1111). Analysis of medical textbooks 
evaluated for this thesis showed that historical sources either warn against the use of certain 
toxic plants, offering advice on risk mitigation by suggesting the synergistic use of plants 
that moderate irritating or toxic herbs (for example combining Arnica with mucilage drugs 
to mitigate stomach irritation), or else they recommend a specific extraction method that 
guards against extracting potentially toxic substances such as alkaloids. Textbooks on the 
European materia medica demonstrate that different therapeutic effects with different 
extraction methods were known, as exemplified in the Arnica and St. John’s Wort 
monographs by Tabernaemontanus (Appendices 3, 4, 12, and 13). This clinical expertise 
mirrors records in other textbooks of the early modern era (Schanz, 2009, p. 143).  
Typical historically noted risks are: primary toxic effects such as Teucrium spp. being 
unsafe unless extracted as a traditional water infusion; undesirable side-effects as in bitter 
herbs possibly causing nausea; allergic reactions such as contact allergy to Arnica montana; 
reproductive toxicity (e.g. abortifacients, toxicity of berberine containing herbs to the 




infants and children are administered mostly the same herbs as adults, albeit at lower doses. 
Powerful laxatives and strongly tasting bitters and spices, as well as those with potentially 
toxic compounds, are not recommended in traditional paediatric care (Santich & Bone, 
2008).  
In addition, each system of medicine uses theory to formulate effective and safe therapeutic 
strategies. The early modern textbook by Tabernaemontanus illustrated that humoralism 
categorised all pharmakons into the four qualities of hot, cold, moist, and dry, each with 
their respective degrees of one to four, their organoleptic properties of sweet, sour, bitter, 
and salty, and their specific actions such as anodyne, laxative, or anti-diarrhoeal (Tobyn, 
1997, 2013, pp. 224-243). The degrees refer to intensity of action (Madaus, 1938b, pp. 3-4; 
Salmon, 1710, pp. x-xv). Traditional plants classified at an intensity level of one or two are 
unlikely to cause harm when used appropriately, those classified at an intensity level of 
three are likely to require some risk mitigation strategy, and those classified at an intensity 
level of four are not suitable for use without supervision and can cause injury if used 
incorrectly or for too long. This suggests that historical clinical judgement is noteworthy. 
8.2.2 Limitations to safety information recorded in historical medical textbooks 
There are limitations to the safety information that can be gained from historical medical 
literature. They relate to herb-drug interactions and safety issues with accumulative poisons. 
Interaction data are not available from historical sources because many synthetic drugs are a 
recent discovery. Modern herb-drug interaction research is an emerging field that is 
challenged to distinguish between theoretically deducted interaction and real interaction in 
order that assessments are relevant for real-life applications. This is necessary because 
plants are made up of complex substances; thus the conflation of risk of an isolated or 
purified compound with that of a whole plant, where such a compound occurs in the 
presence of a complex matrix, is problematic (Huang et al., 2016; Jacob, Khan, & Lee, 
2017; Shirakami & Shimizu, 2018). For this reason, some regulators, for instance Health 
Canada (2012, p. 9), do not consider theoretical safety concerns in the absence of clinical 
data.  
The type of preparation also determines the likelihood of herb-drug interactions. This can 
be illustrated with traditional plant preparations of St. John’s Wort, which contain low 
levels of hyperforin and are unlikely to cause herb-drug interactions; in contrast modern 




shown to induce herb-drug interactions (Mai et al., 2004; Medsafe, 2014; Mueller et al., 
2009; Nahrstedt & Butterweck, 2010; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 
2017; Swissmedic, 2002, pp. 7-8; Whitten et al., 2006). 
Herb-drug interactions are most likely to take place when synthetic medicines with a narrow 
therapeutic range are co-administered with plant-based medicines (Shi & Klotz, 2012). 
Other potential herb-drug issues relate to parallel interactions where a herb and a drug with 
similar effects are combined without modification of the drug dose, opposing interactions 
where the action of a herb counters the desired effect of a drug, or adverse interactions 
where a herb reinforces the adverse reaction of a pharmaceutical drug or vice-versa.  
The assessed historical medical literature records safety concerns for immediate toxic 
effects on the skin as well as systemic irritations but is uncertain regarding accumulative 
poisons. For Arnica, potential toxic effects have been noted at least since the 19th century. 
They relate to overdose, overuse, and allergic reactions. These risks were historically 
mitigated by recommendations on dosage (a low average daily dose of 1g per day), 
restrictions on usage to small areas when applied to open surfaces, and contra-indication of 
use in allergies. In contrast, the detection of hepatotoxicity, carcinogenicity, and 
reproductive and developmental toxicity (teratogenic potential) due to long-term use or 
accumulative poisons relies on newer methods of detection. This limitation means that 
accumulative poisons were traditionally less well understood than those immediately acting, 
and their side-effects less recognised and recorded (Moreira, Teixeira, Monteiro, De-
Oliveira, & Paumgartten, 2014, p. 254; Reuter, 1994, p. 152). Today, medicinal plants with 
potential high-risk profiles are usually excluded as OTC medicines and more appropriately 
classified in a practitioner-only category. They are not permitted as OTC medicines under 
the EU Directive 2004/24/EC. For those traditional plant medicines which are currently 
accessible over the counter, adverse reaction reporting data suggest that when correctly 
selected, compounded and administered, traditional plant medicines are unlikely to cause 
toxic effects such as liver injury, notwithstanding idiosyncratic reactions (Frenzel & 
Teschke, 2016). Even when considering potential underreporting and compared with their 
prevalence of use, plant-based medicines appear to have a very low probability worldwide 
of an ADR, including those investigated as exemplars in this thesis (Abdel-Tawab, 2018, 
pp. 377-381; Wegener, Deitelhoff, & Silber-Mankowsky, 2015, pp. 247-248).  




affects all medicines. EBM relies on clinical trials to ascertain safety risks. RCTs have, 
however, been shown to be an inadequate tool for measuring safety, in particular in relation 
to infrequent and uncommon adverse effects of drugs (Rawlins, 2008; Stephens, Talbot, & 
Waller, 2004). RCTs are usually designed to evaluate efficacy of a therapeutic intervention 
rather than harm (Chou et al., 2010, p. 503). This approach is reflected in the limitations of 
study size, short observational periods, and patient selection criteria that are not 
representative of the general population. This affects their ability to evaluate risks in 
populations not included in the study and long-term harm (Bodeker, 2000, p. 2; 
Vandenbroucke, 2004, p. 2).  
Systematic collation of historical safety assessments could be used together with 
observational data collated with epidemiological methods from contemporary clinical use, 
for example from outpatient clinics via the databank PhytoVIS8 or the European Network 
for Centres for Pharmacoepidemiology and Pharmacovigilance9, as well as state sponsored 
pharmacovigilance data. Evaluating safety data from various angles will improve the 
availability of bibliographic safety data on many traditional medicines and may support 
their pre-marketing approval. Toxicology studies may not be necessary for therapeutic 
substances with established use and data on effectiveness and safety. They are not always 
seen as mandatory, for example in Switzerland (Swissmedic, 2018).  
8.3 Limitations of pharmacopoeias and commentaries as bibliographic 
evidence 
Pharmacopoeias and their compendia provide important bibliographic proof of the official 
use of a medicinal plant and its recommended therapeutic applications. However, 
triangulation of data provided reasons why they cannot replace historical textbooks on the 
European materia medica as an essential documentary body of evidence on the clinical uses 
of traditional plant medicines. Analysis of data showed that a significant gap can exist 
between clinically oriented textbooks and a regulator’s official assessment of the 
therapeutic importance or non-importance of a medicinal plant. For instance, despite its 
ongoing clinical significance in medical patient care over more than two millennia, St. 
John’s Wort was entirely absent in all German pharmacopoeia editions until 1986 when the 







(DAB 9, 1986). The regulatory view of St. John’s Wort changed only when strong research 
interest into the therapeutic potential of St. John’s Wort began to establish its efficacy in the 
1970, resulting in over 150 clinical trials. This delay highlights how non-listing in a 
pharmacopoeia does not necessarily imply the lack of effectiveness of a medicinal plant. 
Such a delay may reflect the judgment of the majority of a pharmacopoeia committee at a 
given time, and this judgement may differ from clinical assessments by those providing 
patient care. The results of this thesis demonstrated that pharmacopoeias and their 
commentaries do not incorporate the full spectrum of clinical applications. The regulatory 
fate of St. John’s Wort over the past 150 years is a cautionary tale for traditional medicines 
that now co-exist under the framework of a modern biomedical healthcare system. Unlike 
St. John’s Wort and regardless of their clinical effectiveness, not all traditional medicines 
became re-selected as official medicines and thus are not yet integrated into the official 
healthcare systems of European countries.  
Arnica, too, was affected by divergent assessments between the German pharmacopoeia 
committees and practising physicians, most noticeably after the end of the 19th century. 
While Arnica’s legal status as an essential medicine was assured in both the Prussian and 
German pharmacopoeias, an analysis of its official plant parts revealed that Arnica root was 
de-listed in the 2nd edition of the German pharmacopoeia (1882). This de-listing contrasts 
with the full range of plant parts, namely aerial parts, flowers, and root, as used by 
Tabernaemontanus and succeeding physicians. The reason for discontinuing Arnica root as 
a listed medicine is unclear, but it may have been due to conservation issues or re-
assessment of treatment options for diarrhoea and gastro-intestinal infections, the key 
indications for Arnica root. Consequently, indications related to the gastro-intestinal tract 
were also absent in the commentaries to the German pharmacopoeia from the second 
edition onwards (Hager, 1883a). This absence was reversed only when the different active 
constituent profiles of Arnica root and flower became recognised in the 1st edition of the 
compendium to the DAB (HAB 1, 1978).  
Comparison of clinical uses and regulatory assessments suggests that contemporary 
evaluations of traditional use need to cover sufficiently long timeframes. Official approvals 
can be affected by factors independent of the pharmacological actions of medicinal plants. 
Analysis of therapeutic recommendations on Arnica showed that commentaries of the 
Prussian and German pharmacopoeias were initially closely aligned with indications listed 




medicinal plants in pharmacopoeias and indications listed in commentaries are noticeably 
fewer than in the analysed medical literature. This reduction coincided with regulatory 
changes to the attributed scope and safety of Arnica stemming from new benefit-risk 
assessment. During this time, non-clinical technical experts increasingly displaced 
physicians from the regulatory domain of medicine (Schneider, 1966, p. 192). While 
commentaries continued to list the main therapeutic uses of Arnica, they did not continue to 
reflect the broader clinical applications. In the last commentary, the only remaining 
indications of Arnica pertained to external uses (Hartke, 1993, A54 p.4). This decrease in 
indications demonstrates that commentaries mirror the controlling regulatory framework of 
a nation state, rather than the pluralistic clinical strands of phytotherapy. While clinically 
oriented textbooks on the materia medica are affected by regulatory directives too, they 
nonetheless have been shown to reflect actual clinical practice more comprehensively. 
Consequently, they are more encompassing sources of traditional evidence for plant 
medicines.  
8.3.1 Limitations of regulatory monographs as bibliographic evidence 
Analysis of data showed that a gap can also exist between indications endorsed in 
regulatory monographs and by those providing patient care. Based on their assessments, the 
two respective committees of the reviewed European regulatory monographs approved the 
main traditional indications of Arnica and St. John’s Wort but did not consider other 
indications with an equally long-standing tradition. For instance, medical textbooks 
continuously recorded the use of St. John’s Wort for musculo-skeletal pain from sprains, 
strains, bruises, and rheumatic disorders at least since the early modern period (see 
Appendix 14). These traditional indications are absent in the official monographs. Equally, 
intermittent but persistent indications listed by physicians over an entire 400 years or those 
that were listed more recently over at least the past 150 years were also not considered in 
either of the official monographs, except for the indication “temporary mental exhaustion” 
which is approved in the EU monograph (Committee on Herbal Medicinal Products 
(HMPC), 2009b, p. 3). With Arnica, the variance between regulatory and clinical 
assessments arose in the 1980s when European regulators were compelled into a new 
approach to healthcare based on preventative measures of health and safety. Due to 
mounting concerns about side-effects and severe adverse events caused by pharmaceutical 




Traditional medicines became part of this regulatory review which increased the focus on 
plant toxicology, potential risks, and side-effects. While no additional risks were noted in 
the 1980s for Arnica other than those already clinically identified and mitigated via dosage 
limits and cautions, regulators moved to restrict usage of Arnica to external applications 
only. This recent regulatory-driven reduction of the official therapeutic scope of Arnica 
montana has caused the biggest variance of historical and contemporary uses over the past 
400 years. It might warrant a re-evaluation of the regulatory restrictions by the German and 
EU regulators, with emphasis on the consistent clinical internal applications within the 
safety parameters of traditional dosing.  
Discrepancies in assessments between regulators and clinicians make it clear that official 
monographs reflect their specific legal-political framework, one set by the German 
regulator during the 1980s and 1990s and the other by EMA under the Directive 
2004/24/EC, rather than the entirety of long-standing clinical uses. Of the two official 
monographs, the Commission E monographs provide approvals for more traditional uses 
than do the more recent EU herbal monographs, reflecting the respective eras in which they 
were published. Consequently, the strengths and limitations of both sets of monographs 
need to be considered. It could be unjustified to rule out a priori traditional indications 
which are not listed in these two official monographs, because some additional traditional 
uses have long been accepted and continue to be applied in clinical practice. For instance, 
St. John’s Wort continues to be recommended in treating varicose veins, respiratory tract 
infections, and rheumatic disorders (see Table 14). Other historical indications are 
supported by pharmacological research and clinical reasoning, such as the treatment of 
biliary disorders, bedwetting in children, or distress during childbirth. Lastly, a small, 
preliminary body of clinical research has shown the efficacy of a further traditional 
indication, that of relieving premenstrual tension (Pakgohar, Mehran, Salehi, Akhondzadeh, 
& Ahmadi, 2004; Stevinson & Ernst, 2000).  
In the absence of mechanistic studies or clinical trials, multiple traditional applications for a 
medicinal plant may at first appear as a “lengthy and indiscriminate laundry lists of effects” 
(Johnson & Fahey, 2012, p. 778). However, such appraisals might unjustifiably dismiss 
potentially sound scientific bases for many of these traditional uses. This potential exists 
because medicinal plants inherently exert complex effects due to their multiple independent 
mechanisms (Chen et al., 2016; Rezadoost et al., 2016; Schwabel et al., 2014; van der Greef 




plant’s multiple constituents (HemaIswarya & Doble, 2006; Herranz-Lopez et al., 2012; 
Ulrich-Merzenich, Panek, Zeitler, Wagner, & Vetter, 2009). Thus, an evaluation of a 
traditional indication should take into consideration the polyvalent nature of medicinal 
plants that result in their broad therapeutic effects. These effects are most comprehensively 
noted in the historical medical literature and are increasingly also confirmed and explained 
by modern scientific research methodologies.  
8.4 Non-pharmacological reasons influencing the scope of traditional plant 
medicines in the regulatory literature  
There are further cautions against using pharmacopoeias and regulatory monographs as the 
sole body of qualitative evidence for traditional plant medicines. These official texts are 
embedded in their wider socio-economic and legal-political environment and reflect the 
state-sponsored approach to healthcare at the time of their publishing. They may not 
necessarily represent the pluralistic strands of medicine in clinical practice. Today’s 
Western science-based medical system is not culturally neutral but rooted in the European 
scientific revolution (Wartmann, 1993). It is beyond the scope of this present research to 
detail how the current state-sponsored medical system developed over the past 150 years 
while progressively aligning with the industrial worldview and its economic market model 
(Huisman, 2010) or how the increased commercialisation of medicine in the late 19th 
century and the emergence of academic medicine and related professional medical 
associations advanced the prevalence of new synthetic drugs which gradually displaced 
traditional medicines (Hionidou, 2016, p. 494; Ijaz & Boon, 2018; MacLennan & Pendry, 
2011, pp. 7,11). However, it is important to note that such factors can influence the type of 
medicines which regulators endorse. Such factors also influence the type of evidence that a 
state mandates to sponsor a medicine.  
Following the 19th century shift in clinical reasoning from humoralism to organ- and cell-
related thinking in medicine (Uehleke et al., 2012, p. 189), academia increasingly favoured 
evidence related to pathophysiological explanatory models deducted from experimental 
science over evidence acquired through empiricism, the repeated and evaluated 
observations of therapeutic uses in patient care. In a regulatory context, this preference was 
most noticeably exercised by the committee of the Prussian pharmacopoeia which aligned 
itself with what it perceived as the peak of natural science (Tschupp, 1998, pp. 121-122). 




medical repertoire for three key reasons: an initial lack of molecular biological evidence for 
broadly acting traditional plant medicines, a preference for potent but potentially toxic 
medicinal plants with their rapid onset of actions, and the increased favouring of new 
pharmaceutical drugs (Jütte, 1996, p. 166; Rezadoost et al., 2016, pp. 2-3; Schulz, 1919). 
Accordingly, commentators on the German pharmacopoeia distanced themselves from 
empirical uses of medicinal plants during this time (Anselmino & Gilg, 1911a, pp. VI-VII; 
1911b, pp. 537-539; 1928, pp. 604-607). They championed a new approach to the European 
materia medica, one that was critical of ‘dated’ medical textbooks. These, they alleged, 
might contain more ‘harmful than useful’ information and represent an embarrassment to 
modern medicine (Anselmino & Gilg, 1911a, pp. VI-VII). Consequently, 20th century 
annotations to the German pharmacopoeia increasingly reflect an academic rather than a 
clinical approach to traditional plant medicines.  
Preclinical plausibility as a prerequisite for the continued acceptance of the traditional 
materia medica was not, however, an approach approved by all scientists. Dutch 
pharmacologist Vogelenzang (1967, pp. 351-352) criticised the 20th century trend to 
modernise pharmacopoeias by deleting those medicinal plants for which the mechanism 
was unknown. He considered such rationale for de-listings as non-scientific, since 
‘obsolete’ meant not sufficiently researched according to modern science rather than not 
proven to be effective. This analysis showed that St. John’s Wort, a medicinal plant with 
actions that could initially not be explained via experimental scientific methods, was 
eliminated from the Prussian pharmacopoeia and not considered in the German 
pharmacopoeia, yet it continued to be listed in medical textbooks and was later validated via 
experimental research and clinical trials.  
Today, experimental proof of the mechanism of action has been superseded by the EBM 
principle’s demand of proof of efficacy from clinical trials. From a social science 
perspective, divergent views on what constitutes evidence reflect paradigmatic preferences 
rather than validity based on objective rules of science (Cassidy, 1995, p. 19; Churchill, 
1999; Evans, 2006, 2008). Ultimately, scientific discourse cannot be divorced from its 
cultural context or the associated legal-political and economic agenda of an era (Coulter, 
2007; Kim A. Jobst, 1998, p. 125). What this thesis has demonstrated is that traditional 
therapeutics have continued to be used in clinical practice regardless of the various 




8.5 Implications for New Zealand 
Current regulations neither adequately address the place of traditional plant medicines in 
New Zealand’s healthcare system nor protect public health. Therefore, they fail to provide a 
health policy framework that maximises the contribution of safe and effective traditional 
medicines to meet primary healthcare needs of New Zealand citizens. This thesis argues 
that given the important contribution of traditional systems of medicine to national and 
individual healthcare and the high prevalence of use of traditional plant medicines in New 
Zealand (Barnes et al., 2016), progress on such regulations should be a matter of urgency.  
Bowen and Zwi (2005) argue that the policymaking context is highly political and depends 
on numerous factors, inputs, and relationships. After the identification of a policy gap, the 
political agenda of an incumbent government affects the timing of such policy and its 
implementation. Milio (1985, pp. 273-274) emphasises that timeliness is a key principle for 
policy success, as improvements in health through primary healthcare interventions take 
time to become apparent. However, successive New Zealand governments have not made 
recognisable progress on regulating therapies from traditional systems of medicine over the 
past decades despite advice from their own Ministerial Advisory Committee on 
Complementary and Alternative Health (2004) and from the WHO Traditional Medicine 
Strategy 2014-2023, one to which New Zealand is a signatory (World Health Organization, 
2013).  
Under the current New Zealand healthcare system, pharmaceutical drugs and dietary 
supplements, the category in which traditional medicines are currently allocated, are divided 
into two distinct groups, the former being government funded through Pharmac, and the 
latter privately funded. This system presents an obstacle for patients wishing to use 
traditional medicines due to out-of-pocket costs, a lack of quality and safety assurance, and 
the uncertainty of the scope of non-pharmaceutical remedies due to a lack of permitted 
health claims on labels. The current New Zealand regime contrasts with health policies in 
European countries where the EU proceeded to protect the status of traditional medicines 
legally. Under Directive 2004/24/EC, traditional medicines obtained their own regulatory 
classification as Traditional Herbal Medicinal Products. Switzerland has gone a step further 
in that since the binding constitutional referendum in 2009, phytotherapy is a treatment 
option that must be adequately integrated into healthcare services for citizens. This 




provides patient-centred and cost effective treatment options (Saller, 2009; Schweizerischer 
Bundesrat, 2017; Wolf et al., 2005).  
The exclusion of traditional remedies from New Zealand mainstream medicine since the 
early 20th century is therefore out of step with developments in other countries which have 
now proceeded to grant citizens legal rights to pluralism in medicine. The marginalisation 
of traditional medicines is perpetuated in the current New Zealand Medicines Act 1981 and 
the Dietary Supplements Regulations 1985, both of which require updating to accommodate 
modernisation in New Zealand healthcare. To that end, the replacement of the Medicines 
Act 1981 is currently under consultation and is an opportunity to address the legal void 
currently existing around traditional therapeutics, including plant-based medicines. 
In its formerly proposed domestic Natural Health and Supplementary Products Bill, New 
Zealand had moved towards legal acknowledgement of traditional plant medicines by 
drafting a large list of pre-approved plant species that the Ministry of Health had classified 
as low risk substances (Ministry of Health, 2017; "Natural Health Products Bill 2011 (2012 
No 324-2),"). In the policy advice that preceded this draft, Medsafe issued the following 
risk considerations for plant-based medicines: 
 intrinsic risk – risk arising from ingredients themselves, for example aristolochia 
 extrinsic risk – risk arising from the way goods are manufactured, for example 
spiking with pharmaceuticals 
 inappropriate use – risk arising from misuse or abuse (Jessamine, 2004, slide 8).  
The risk management strategy by Medsafe proposed addressing minimum quality standards, 
ingredient safety requirements, adverse reaction monitoring in the form of post-market 
monitoring and surveillance, and appropriate therapeutic claims. If these four key points 
were integrated into a risk minimising strategy, such a strategy would support the beneficial 
use of traditional plant medicines and minimise many of the avoidable harms that could 
arise from it. Assessments for the proposed Permitted Substances List were undertaken in 
consultation with herbal experts, toxicologists, and pharmacologists who are trained in the 
intrinsic quality and safety features of plant medicines (Medsafe, n.d., p. 3). 
There are some important legacy issues which new regulations on traditional plant 
medicines will need to address. Schedule 1 of the current Medicines Regulations prevents 




plant species currently regulated as pharmaceutical substances. Pharmacists and physicians 
are the only professions to have legal access to these medicinal plants even though they are 
usually not trained in their clinical use. The creation of a practitioner-only category for 
professionally trained herbal experts, as undertaken in other countries, such as the UK 
(Linnenbrink, 1990; "The Medicines (Retail Sale or Supply of Herbal Remedies) Order 
1977," 1970), would address the misappropriation of traditionally used medicinal plants and 
provide a legislative framework to put them back into traditional context. This category 
would be appropriate for more potent medicinal plants (in their whole plant format) that 
have higher risk profiles than medicinal plants which are milder acting and suitable as 
OTCs. This recommendation aligns with the WHO policy approach that traditional plant 
medicines and traditional medicine practitioners should be regulated together (World Health 
Organization, 2013). As such, Medical Herbalists should be prioritised for admission under 
statutory regulation.  
Another critical issue that needs addressing is how to deal with evidence on traditional 
medicines. A consultation document relating to the formerly proposed Natural Health and 
Supplementary Products Bill suggested that health claims for natural health products 
(NHPs) may be made based on evidence of traditional use (Ministry of Health, 2015, p. 9). 
The Bill proposed establishing pre-approved bibliographic sources that could be used as 
evidence for health claims. However, the list did not specify authoritative clinical textbooks 
on the traditional materia medica as sources to be permitted, even though they are—based 
on this analysis—the most comprehensive and clinically relevant repository of traditional 
evidence. The findings of this thesis on two traditionally used medicinal plants support the 
admission of evidence from authoritative textbooks as primary evidence sources.  
8.6 Strengths, limitations, and research implications of the thesis  
This thesis explored a method to widen the evidence base of traditional plant medicines to 
support their regulation in the era of contemporary evidence-based health policy. The 
Historical Assessment Tool was developed to tabulate proof of long-standing indications 
which are based on empirical observations and evaluated and transmitted by clinical 
experts. Once clinically oriented and authoritative sources of evidence for a medical 
tradition are established, the concise tabulation of tradition-of-proof evidence may provide 
an accelerated pathway for evaluating traditional indications in a regulatory context. The 




both time and cost for regulators.  
The historical research design of this study with its method of systematically triangulating 
empirical and scientific data is an extension of previous approaches to evaluating traditional 
knowledge on the European materia medica in order to make such data operational in a 
regulatory context. In a preliminary step, considerable time was spent in archives and 
libraries to locate historical medical textbooks on the European materia medica as well as 
official pharmacopoeias of Prussia, Germany, and Switzerland, including their 
commentaries and supplements. This was in addition to authoritative and regulatory 
monographs, and modern textbooks on European phytotherapy. Such a broad approach was 
necessary for the selection of sources appropriate for health policy purposes. Additionally, 
systematic database research was undertaken to locate scientific clinical trials as 
quantitative sources to cross-validate the qualitative tradition-of-use data.  
The comprehensive nature of evaluation of the first exemplar, Arnica montana, was 
required to cross-validate historical medical textbooks as reliable sources of empirical 
evidence on traditional indications. The simplified approach applied in the evaluation of 
Hypericum perforatum helped to fine tune the method so that it can be recommended as a 
policy tool to collate proof of traditional evidence for regulatory purposes. By going 
through the stages of methodically cross-validating various independent data sources, this 
research sought to develop a reliable framework that could swiftly, summarily, and 
methodically collate traditional-use-evidence. The results of the data analyses demonstrated 
that historical and contemporary clinical textbooks are a central bibliographic source of 
empirical evidence. For the exemplars evaluated, they provided reliable and verifiable data 
on traditional therapeutic use. The resultant consolidated method may therefore offer a 
pathway to provide empirical evidence for regulatory purposes.  
Aside from its practical use as a health policy tool, the Historical Assessment Tool has 
further applications. It may provide a research framework for the discovery of potential 
drug leads, thus helping to save research time and money. It could also be used to validate 
contemporary phytotherapeutic practice by elevating long-standing clinical knowledge as a 
reliable form of empirical evidence.  
There are several limitations with the research design employed in this thesis. First, the 




research be undertaken on other exemplars to verify that the outcomes of this research can 
be replicated. Such broadening of evaluation would strengthen the validity of the method. 
Second, this thesis evaluated the German language materia medica and collated traditional 
evidence on long-standing clinical use of therapeutics from Traditional European Medicine. 
More research is required to determine the suitability of the tested method for traditional-
use-evidence pertaining to other written medical traditions of societies prevalent in New 
Zealand and around the world such as TCM, Ayurveda, Kampo, Traditional Tibetan 
Medicine, Korean medicine, and other systems of traditional medicine. 
Third, there are linguistic and conceptual challenges that need to be addressed so that 
historical research can reach its potential as a tool for bibliographic substantiation of 
traditional plant medicines. More work needs to be done to bridge the gap between 
traditional nosology and the biomedical classification of diseases. Traditional descriptions 
of diseases prior to the 19th century are conceptually different from contemporary Western 
classifications, and such differences must be considered so that traditional indications can 
be understood. For the European medical tradition, a study could systematically evaluate 
the full pharmacological and pharmaceutical content of the New vollkommen Kräuter-Buch 
(Tabernaemontanus, 1664). This early-modern textbook is particularly suited to such an 
undertaking because the results of this thesis confirmed that the author was accurate in 
determining the pharmacological actions of Arnica and St. John’s Wort, raising the 
possibility that he was also accurate about the pharmacological actions of other medicinal 
plants.  
Fourth, the Historical Assessment Tool is only suitable for the coding of data from written 
medical traditions. Future research could therefore develop a data gathering framework for 
traditional evidence pertaining to traditional uses of medicinal plants in oral traditions. This 
is urgently needed in New Zealand to progress appropriate regulations that apply to Rongoā 
Māori (traditional Māori medicine), a system of healing that was and is transmitted orally. 
Such a framework could potentially also support empirical evidence of other oral medical 
traditions.  
Fifth, one objection that proponents of EBM have raised about the experiential nature of 
medical practice is that experience can be a repetition of mistakes (Djulbegovic et al., 2000, 
p. 101). Moreover, traditional knowledge is seen by some as being at risk of bias, and 




present-day practice (Leach, 2016, p. 148). Sackett (1989) proposed a logical, deductive 
framework for the interpretation of evidence to reduce the impact of un-controlled 
experience. While eliminating the subjective interpretation of evidence is unrealistic and 
may not even be desirable (Rawlins, 2008), this thesis employed triangulation of data from 
various sources to reduce the risk of bias and to strengthen conclusions drawn from 
historical sources. Assessments on Arnica and St. John’s Wort have shown that historical 
data are reliable and verifiable if such data includes proof of inter-generational records in 
clinically evaluated textbooks.  
Sixth, the premise of triangulation of data is to provide different angles for looking at the 
same phenomenon, thus adding credibility by strengthening confidence in conclusions 
drawn (Patton, 2014, p. 661). For this purpose, this thesis triangulated traditional-use-data 
documented in historical sources on the materia medica and contrasted these data with 
indications on the same exemplars documented in distinctly separate sources such as 
contemporaneous regulatory pharmacopoeias, their commentaries, regulatory and 
authoritative herbal monographs, and clinical and experimental research. Such triangulation 
showed parallel findings between the medical literature and these independent qualitative 
and quantitative sources. However, some information in the medical textbooks may not 
have been independent as it is the nature of tradition to be informed by previous 
evaluations. To reduce the likelihood of including un-evaluated data on the materia medica 
recorded in the medical literature, a selection criterion determined that authors needed to be 
clinicians who applied plant-based medicines in patient care. The independence of these 
data could, however, have been further strengthened if clinical records on the same 
medicinal plants over distinct cultures and languages had also been included. This step was, 
however, beyond the scope of this thesis.  
Seventh, there are unsolved challenges pertaining to safety evaluations of traditional 
medicines. While the Historical Assessment Tool corroborates reports on observed and 
documented individual adverse reactions or adverse events from clinical use on a large 
population over time, these data are incomplete for a contemporary evidence-based 
healthcare system. More research is required to show how benefit-risk assessments of 
traditional plant medicines could be approached. Research on safety of traditional 
medicines would need to consider their actual use in traditional format and posology in 
order to deliver clinically relevant information. Such investigations are of clinical and 




scope of Arnica and St. John’s Wort listed in the two European regulatory monographs 
could be a starting point for such research. In addition, it would be worthwhile re-evaluating 
the current stance on internal use of Arnica in official monographs to determine a rational 
differentiation between a safe, therapeutic dosage range and an overdose. 
Eighth, complementing bibliographic evidence, research using modern observational 
studies, or pragmatic trials would address knowledge gaps on the effectiveness and safety of 
traditional plant medicines when used under real-world conditions. External validity of 
relevance is highly important not only for healthcare professionals but also for policy 
makers (Rothwell, 2005). Observational research on existing practices also allows for data 
to be collected without the ethical difficulties of assigning patients to novel, unproven 
treatments or placebos. While the EBM model considers qualitative research to be a lower 
level of evidence than clinical trials, an investigation into the estimates of treatment effects 
in observational studies suggests that they are neither consistently larger nor qualitatively 
different from those obtained in RCTs (Benson & Hartz, 2000). As noted before, 
observational studies are also a necessary method to adequately determine risks with an 
intervention. Such real-world studies would further support the integration of traditional 
medicines into contemporary healthcare. 
Ninth, some researchers assert that desktop research for the development of evidence-based 
policy is incomplete and needs to be supplemented by expert knowledge and personal 
contacts (Joffe & Mindell, 2002, p. 137). Some organisations such as the US National 
Institutes of Health, the US Institute of Medicine, and RAND Corporation view scientific 
evidence on conventional interventions as insufficient for the decision-making process of an 
evidence-based healthcare system. It can be argued that this insufficiency also applies to 
traditional evidence. Any treatment recommendation has to take into consideration 
appropriateness and necessity (Coulter, Shekelle, Mootz, & Hansen, 1999). Consequently, 
research organisations propose the vetting of evidence by using expert panels that provide 
clinical guidance to policy makers, clinicians, and patients (Coulter, Elfenbaum, Jain, & 
Jonas, 2016; O'Donnell et al., 2017). This is congruent with the approach of the 
Commission E and of HMPC, and was proposed in New Zealand (Medsafe, n.d., p. 3). It 
also concurs with the opinion of the former Chairman of the UK National Institute for 
Health and Clinical Excellence (NICE), who notes that judgments and contextual 
considerations are an essential component of the health policy decision-making process 




this thesis—and how evidence is used in the decision-making process on health policies are 
both important (Dobrow et al., 2004). Further reviews regarding the utilisation of traditional 
knowledge at health policy level would be worthwhile (Stephens et al., 2004). 
Tenth, long-standing traditional use of plant-based medicines reflects a high level of 
cultural acceptance and regulations on traditional medicines therefore deal with practices 
that have established cultural authority.  Regulators of traditional systems of medicine 
should therefore consider regulations that are sensitive to established cultural practice. To 
support this proposition, a research angle could be to evaluate cost savings in secondary and 
tertiary healthcare when preventative and primary healthcare with traditional remedies are 
actively supported. Such research could be extended to quantify the loss of quality of life or 
life expectancy that occurs when New Zealanders are prevented from fully practicing their 
traditional medical customs and addressing health issues which are treatable with traditional 
plant medicines.  
Finally, the WHO guidelines on herbal medicines recommend that “each country should 
seek to identify ten major public health problems amenable to herbal treatment and ten 
single plants used locally to treat these conditions. The results can usefully be exchanged 
between countries” (Akerele, 1992, p. 104). New Zealand has a rich biodiversity of 
medicinal plants—both indigenous and naturalised—which have been shown to possess 
highly active bio-compounds that could be commercialised (McCallion, 1982; Morgan, 
1989; Muir, 1982). This richness has already been demonstrated with Mānuka 
(Leptosperum scoparium) (Cooke & Cooke, 1991; Maddocks-Jennings, Wilkinson, 
Shillington, & Cavanagh, 2005), now a significant export earner for New Zealand. 
Therefore, the support of research into traditional plant medicines could help to meet not 
only local but also global health needs and be commercially beneficial for New Zealand.  
The next and final chapter presents the conclusions and policy recommendations arising 




9 CONCLUSIONS AND RECOMMENDATIONS 
Evidence of the effectiveness and safety of therapeutic interventions is paramount to the 
regulatory integration of traditional medicine into a contemporary evidence-based 
healthcare system. A presumed lack of evidence is one reason why New Zealand is yet to 
make progress in regulating traditional plant medicines, despite their prevalent use by its 
indigenous and immigrant populations. Without adequate regulation, their formal 
contribution to preventive and primary healthcare cannot be determined, which limits 
access to medicines of choice. This legal void may also pose a public safety concern, as 
lack of regulation does not prevent their use. 
The findings of this thesis have several implications for the development of health policies. 
The results of systematic analysis of evidence sources on the European materia medica 
indicate that a body of evidence is available that may help resolve the regulatory difficulty 
of deciding if there is sufficient proof available to support traditional health claims. The 
comparison of findings from triangulation of inter-generational clinical expert consensus on 
two widely used medicinal plants recorded in authoritative medical textbooks and evidence 
from modern phytotherapeutic use and clinical and experimental research, led to the 
conclusion that traditional medical knowledge represents a reliable and verifiable source of 
evidence. It is based on the method of empiricism, a deductive approach to knowledge 
generation that is central to both traditional and contemporary systems of medicine. In 
written medical traditions, clinically evaluated observational data are recorded in the 
clinically orientated professional literature on the materia medica. Compared with the 
official Prussian and German pharmacopoeias, their normative commentaries, modern 
herbal monographs (i.e. by the Commission E, EMA, WHO, ESCOP, and HagerROM), and 
scientific research, this body of evidence has shown to be the most comprehensive 
repository of consistent therapeutic applications, including information on safe use. The 
analysis infers that empirical knowledge transmitted over several generations of clinicians is 
reliable and harmonises with modern assessments for the ailments investigated.  
Notwithstanding the small number of exemplars analysed—Arnica montana and Hypericum 
perforatum—the results of this thesis imply that clinically orientated historical and 
contemporary textbooks on the European materia medica could be admitted as an empirical 
evidence source for substantiating traditional plant indications. This thesis proposes the 




evidence for traditional health claims. This would enable tradition-of-use data to be duly 
incorporated into a comprehensive system of evidence in an evidence-based policy 
framework and make this body of evidence operational.  
9.1 Health policy recommendations 
The following key recommendations are drawn from the conclusions of this thesis. The 
recommendations are to support regulation of traditional plant medicines in New Zealand 
but may also be relevant for other countries who seek to address regulation on traditional 
therapeutics. 
9.1.1 Recommendation to advance regulation on traditional plant medicines 
It is recommended that the New Zealand Government addresses the existing health policy 
gap in relation to traditional medicine. The analysis of the EU approach to regulation of 
traditional medicine has found that this area of regulation is complex and so may require the 
establishment of a dedicated authority that includes subject matter experts on all aspects of 
traditional medicine, namely its products, practices, and professions. Regarding regulation 
of traditional plant-based products, health policies should include their empirical evidence 
base, in particular their traditional indications, their traditional guidelines about conditions 
of use, and safety aspects in the context of traditional knowledge. This evidence base has 
been recognised by other regulators (European Parliament, 2004; Health Canada, 2012; 
Swissmedic, 2018; Therapeutic Goods Agency, 2019). A regulatory framework for long-
established plant medicines should be appropriate, feasible, practical, and affordable. 
9.1.2 Recommendation to define traditional plant medicines 
In line with the EU approach for Traditional Herbal Medicinal Products (THMPs), 
traditional plant medicines should be defined for regulatory clarity (Europäisches 
Parlament, 2004). It is recommended that traditional plant medicines are classified and 
regulated in a separate category, reflecting their distinct features and pharmacological 
purpose. They have distinctly different characteristics from synthetic pharmaceutical drugs. 
They also have a distinctly different composition and purpose compared to modern dietary 
supplements that are administered to address nutritional needs. Based on the EU approach 
to Traditional Herbal Medicinal Products (THMPs), Appendix 16 suggests a definition for 




considered for regulations. The proposed definition is built on the EU definition of THMPs, 
and provides additional clarifications drawn from extensive analysis of traditional plant 
medicines. This definition does not include other traditional, non-herbal remedies, modern 
natural health products, or dietary supplements. 
9.1.3 Recommendation to implement a systematic framework for data collection 
of bibliographic empirical evidence  
Based on advice of the Ministerial Advisory Committee on Complementary and Alternative 
Health (2004) systematic systems for the collation of evidence on CAM interventions have 
previously been used in New Zealand to provide assistance for regulatory frameworks and 
health policy processes. New Zealand Health Technology Assessment (NZHTA), operating 
from 1997 to 2007, and the New Zealand Centre for Evidence-based Research into 
Complementary and Alternative Medicine (ENZCAM), operating from 2005 to 2013, 
produced university based and independent evidence summaries on natural medicine 
interventions10. With a re-establishment of funding, such centres could be contracted to 
assist the collation of evidence on traditional plant medicines used by consumers in New 
Zealand. 
As a future structure for data collection and evaluation, the Historical Assessment Tool has 
been developed to summarily and methodically collate bibliographic traditional-use-
evidence of inter-generational clinical knowledge on medicinal plants. The systematic 
process of searching the literature for empirical evidence is similar to the process of 
undertaking reviews of the best available evidence using PICO (University of Canberra, 
2018) or GRADE (Schünemann, Brożek, Guyatt, & Oxman, 2013). This thesis has 
demonstrated the tool to be feasible, practical and efficient for the corroboration of 
bibliographic evidence. It is recommended that the tool be admitted by policy makers for 
submitting evidence on traditional health claims.  
However, the selection of appropriate sources is key for the successful implementation of 
the tool. The following criteria for data collection of empirical evidence are suggested: 
 






1) selected historical and contemporary textbooks on traditional plant medicines have 
been authored by formally trained and qualified experts with long-standing clinical 
experience in patient care 
2) selected sources reflect authoritative mainstream clinical texts as determined by 
their use in professional education, or proof of multiple print editions, or peer 
recognition via citations by other authoritative authors 
3) selected sources triangulate independent textbooks at data points about 25 years 
apart to capture clinical use data for each successive generation of formally trained 
clinicians 
4) selected sources represent a minimum dataset in order to comprehensively cover 
long-standing traditional uses (see Appendix 17 for a template to assist the 
organisation of these data) 
5) specific data are collated so that a bibliographic source is admissible. Most 
importantly, it is a prerequisite for the admission of tradition-of-use data that a 
medicinal plant is unequivocally identified in the written source (see Appendix 17). 
 
To ensure that the bibliographic data collection on traditional plant medicines meets the 
policy criteria of feasibility, practicality, and affordability, this thesis recommends that 
future work need not require as extensive a period as investigated herein to collate data. 
Results from evaluating exemplars of the German language materia medica highlighted that 
a foundational historical medical textbook from the early modern period, together with 
authoritative clinical textbooks on phytotherapy from the turn of the 20th century onwards, 
comprehensively cover long-standing traditional uses.  
It is suggested that the following authors (listed below) are used as sources of bibliographic 
evidence for the German language materia medica. These clinical textbooks are not the 
only bibliographic evidence sources on the European materia medica that fulfil the 
proposed selection criteria; rather, they are suggestions of validated options. Each medical 
tradition would need to agree on its own body of authoritative textbooks that represent 
regular applications of their traditional medicines. Since the Historical Assessment Tools is 
only suitable for written traditions, the development of a data gathering framework for oral 






Author Reason for selection 
Tabernaemontanus (1664) and re-
prints to this edition (last released in 
1731) 
Practising physician and enduring influential medical author of the 
early modern period 
Schulz (1919) Practising pharmacologist and university lecturer; evaluated 
traditional materia medica from a scientific viewpoint in 
conjunction with clinical use 
Madaus 1938a, 1938b, 1938c Practising physician; evaluated traditional materia medica based on 
traditional uses in conjunction with contemporaneous clinical uses 
and scientific studies; remains in print 
Weiss (1985) Practising physician and post-graduate education lecturer; 1985 
edition remains in print. 
Saller et al. (1995) Practising physicians and pharmacists covering expertise in plant 
medicine, pharmacology, and pharmacy; university lecturers. 
 
It is recommended that regulators approve a traditional indication as a health claim on the 
basis of traditional evidence if systematic collation of data from authoritative sources 
demonstrates that the indication meets one of the following two conditions: first, that a 
traditional plant indication has been consistently recommended over at least two 
transmission steps (three independent clinically oriented evidence sources); or second, that 
a traditional indication was intermittently recommended and is clinically plausible today 
based on contemporary phytotherapeutic use, clinical trials, or relevant experimental 
research. 
9.2 Recommendation on safety aspects of traditional plant medicines 
It is recommended that regulatory safety assessments of traditional plant medicines relate to 
their actual clinical uses, traditional types of preparations, and dosage range because 
historical safety information only relates to these specifications. It becomes problematic if 
regulatory risk assessments relate to different types of preparations or to synthetic 
analogues of plant substances. Traditional whole plant preparations have different effects to 
synthetic isolates and therefore different safety parameters. Similarly, in vitro studies need 
to be carefully analysed for their relevance for traditional in vivo applications. It is further 
suggested that the comparison of the benefits and risks between a plant-based and synthetic 
drug treatment option is considered in overall regulatory safety assessments.  
It is recommended that regulatory safety assessments evaluate history-of-safe-use 




and international databases (e.g. CARM, WHO) in order to meet requirements of a 
contemporary evidence-based healthcare system (Abel et al., 2012). Traditional plant 
medicines permitted as OTC therapeutics should not exceed low to medium risk when used 
correctly. In line with an approach to protect public health, it is further recommended that 
manufacturers of traditional plant medicines are subject to reporting obligations for adverse 
reactions of their products. 
It is further recommended that a special practitioner-only category be created for medicinal 
plants (in their whole-plant format) that are not suitable as OTC remedies but are required 
by herbal experts in clinical practice. Practitioner access to these stronger traditional 
therapeutics would help preserve the integrity of traditional systems of medicine. In New 
Zealand, Schedule 1 of the Medicines Regulations currently prevents registered Medical 
Herbalists and Tohunga from legally accessing these traditional plant medicines. They are 
regulated as pharmaceutical substances in conjunction with their synthetic isolates, 
regardless of their distinctly different risk profiles. The creation of a practitioner-only 
category would address the misappropriation of medicinal plants and provide a legislative 
framework to put them back into traditional context. As such, Medical Herbalists should be 
prioritised for statutory regulation to optimise the accessible delivery of safe and effective 
traditional medicines for patients, while supporting such traditional treatment options in a 
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APPENDIX 1: DATABASE RESEARCH STRATEGIES 
Database search strategies for literature on history of plant medicine and traditional 
knowledge (TK) 
Database: Embase <1974 to 2013 May 01> 
Search Strategy: 
1     Tabernaemontanus.af. (6) 
2     traditional medicine/ or herbal medicine/ (30160) 
3     ((folk or traditional) adj3 (medicine or remed* or herbal)).tw. (26424) 
4     materia medica/ (1220) 
5     Traditional knowledge.tw. (509) 
6     Ethnopharmacology/ (1373) 
7     Ethnobotany/ (1101) 
8     Pharmacognosy/ (1771) 
9     Plant preparations/ (7691) 
10     Phytotherapy/ (14765) 
11     plants, medicinal/ (62512) 
12     (Western adj3 (herbal* or phytotherapy)).tw. (135) 
13     or/2-12 (120805) 
14     exp Europe/ (1156936) 
15     "history of medicine"/ (44881) 
16     history/ (282713) 
17     century.tw. (68191) 
18     paradigm.tw. (72656) 
19     Chinese medicine/ (20875) 
20     Chinese.tw. (134054) 
21     homeopathy/ (8139) 
22     homoeopath*.tw. (985) 
23     Ayurveda.tw. (1434) 
24     19 or 20 or 21 or 22 or 23 (151449) 
25     15 or 16 or 17 or 18 (429884) 
26     13 and 14 and 25 (1421) 
27     26 not 24 (1345) 






Database: Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) 1946 to Present with 
Daily Update 
Search Strategy: 
1     Tabernaemontanus.af. (3) 
2     Medicine, Traditional/ (8200) 
3     ethnobotany/ or pharmacognosy/ or herbal medicine/ (2925) 
4     Materia Medica/ (1579) 
5     Ethnopharmacology/ (515) 
6     plant preparations/ (5961) 
7     phytotherapy/ or eclecticism, historical/ (26841) 
8     Plants, Medicinal/ (50342) 
9     ((folk or traditional) adj2 (medicine or remed* or herbal)).tw. (15145) 
10     (Western adj2 (herbal* or phytotherapy)).tw. (47) 
11     Traditional knowledge.tw. (316) 
12     2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (93680) 
13     exp Europe/ (1050915) 
14     history/ or "history of medicine"/ (46296) 
15     century.tw. (53810) 
16     paradigm.tw. (56149) 
17     or/14-16 (154736) 
18     12 and 13 and 17 (335) 
19     Drugs, Chinese Herbal/ or Medicine, Chinese Traditional/ or Acupuncture Therapy/ or Medicine, East 
Asian Traditional/ (44415) 
20     Chinese.tw. (95121) 
21     homeopathy/ or mesotherapy/ or mind-body therapies/ or reflexotherapy/ or rejuvenation/ or    sensory 
art therapies/ or speleotherapy/ or spiritual therapies/ (6727) 
22     homoeopath*.tw. (610) 
 23     medicine, ayurvedic/ or medicine, east asian traditional/ or shamanism/ (5051) 
24     19 or 20 or 21 or 22 or 23 (134057) 






Database search strategy for Arnica (Arnica montana) to cross-validate empirical evidence 
with contemporary clinical research  
Arnica in database: Embase <1974 to 2014 June 20> 
Search Strategy: 
1     Arnica montana/ or Arnica/ or Arnica montana extract/ (616) 
2     arnica.tw. (425) 
3     1 or 2 (756) 
4     meta analysis/ (69811) 
5     ((meta adj analy$) or metaanalys$).tw. (66246) 
6     (systematic adj (review$ or overview$)).tw. (51546) 
7     clinical trial/ (880742) 
8     Randomized controlled trial/ (341721) 
9     Clinical study/ (90524) 
10   Longitudinal study/ (59078) 
11   Retrospective study/ (311872) 
12   Prospective study/ (228817) 
13   Cohort study/ (142723) 
14   or/4-13 (1673812) 
15   3 and 14 (132) 
16   exp history/ or "history of medicine"/ (310826) 
17   3 and 16 (9) 
18   to.fs. (450593) 
19   pd.fs. (1892437) 
20   18 or 19 (2242080) 
21   3 and 20 (170) 
22   15 or 17 or 21 (271) 
*************************** 
 
Arnica in database: Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R) <1946 
to June 2014> 
Search Strategy: 
1     Arnica/ (138) 
2     arnica montana.tw. (124) 
3     arnica.tw. (275) 
4     1 or 2 or 3 (296) 
*************************** 
 
And so on for: 





Database search strategy for St. John’s Wort (Hypericum perforatum) to cross-validate 
empirical evidence with contemporary clinical research  
St. John’s Wort in database: Embase <1974 to 2014 June> 
 
Search Strategy: 
1     Hypericum perforatum/ (2324) 
2     St John's Wort.tw. (1956) 
3     Hypericum perforatum extract/ (3194) 
4     1 or 2 or 3 (5112) 
5     meta analysis/ (70589) 
6     ((meta adj analy$) or metaanalys$).tw. (67373) 
7     (systematic adj (review$ or overview$)).tw. (52592) 
8     clinical trial/ (881449) 
9     Randomized controlled trial/ (343904) 
10   Clinical study/ (91065) 
11   Longitudinal study/ (59775) 
12   Retrospective study/ (316001) 
13   Prospective study/ (231918) 
14   Cohort study/ (145124) 
15   case control.tw. (83763) 
16   longitudinal.tw. (154223) 
17   retrospective.tw. (341171) 
18   observational.tw. (89883) 
19   or/5-18 (2041463) 
20    4 and 19 (1372) 
21    exp history/ or "history of medicine"/ (311305) 
22    4 and 21 (35) 
23    Hypericum perforatum/to, pd [Drug Toxicity, Pharmacology] (164) 
24    23 or 22 or 20 (1514) 
25    letter.pt. (821333) 







St. John’s Wort in database: Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & 
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R) 
<1946 to June 2014> 
Search Strategy: 
 
1     Hypericum/ (1625) 
2     St John's Wort.tw. (1355) 
3     1 or 2 (2119) 
4     Meta-Analysis as Topic/ (12527) 
5     meta analy$.tw. (49637) 
6     metaanaly$.tw. (1213) 
7     Meta-Analysis/ (38469) 
8     (systematic adj (review$ or overview$)).tw. (41815) 
9     exp Review Literature as Topic/ (6609) 
10   Randomized controlled trial/ (344493) 
11   Randomized controlled trials as topic/ (84173) 
12     exp clinical trial/ (708782) 
13     controlled clinical trial.pt. (85528) 
14     Randomized controlled trial.pt. (344493) 
15     multicenter study.pt. (153386) 
16     Clinical trial.pt. (475515) 
17     epidemiologic studies/ (5601) 
18     exp case control studies/ (591698) 
19     exp cohort studies/ (1237501) 
20     case control.tw. (68374) 
21     longitudinal.tw. (125516) 
22     retrospective.tw. (242806) 
23     observational.tw. (63831) 
24     or/4-23 (2175900) 
25     3 and 24 (366) 
26     exp history/ (330847) 
27     exp history of medicine/ (16302) 
28     hi.fs. (255045) 
29     td.fs. (262841) 
30     26 or 27 or 28 or 29 (592411) 
31     3 and 30 (31) 
32     exp Pharmacology/ (142441) 
33     3 and 32 (58) 




And so on for: 





APPENDIX 2: PHARMACOPOEIAS, COMMENTARIES, 
MONOGRAPHS, MEDICAL TEXTBOOKS, HAGER: 
PRELIMINARY AND FINAL SELECTION 
Pharmacopoeias and commentaries 
Notes Title Edition Reference 
 




Germanica, the official 
pharmacopoeia of the 




Germanica / Deutsches 
Arzneibuch of 
Germany 




Extractum Arnicae e toto: 
100 
 






 Pharmacopoea Borussica 1804 
2. ed. 
Not found 
 Pharmacopoea Borussica 
 
Pharmacopoea Borussica. 
Die Preussische Pharmakopoea, 
übersetzt und erläutert von Friedrich 
Philipp Dulk. 
 
Professor Dr. Dulk was apothecary and 
pharmaceutical lecturer at Albertus 











comment on 2nd 












 Pharmacopoea Borussica 
 
Pharmacopoea Borussica. 
Die Preussische Pharmakopoea, 
übersetzt und erläutert von Friedrich 
Philipp Dulk. 
 
Professor Dr. Dulk was apothecary and 
pharmaceutical lecturer at Albertus 












comment on 2nd 
edition of            
Ph. Borussica 
Arnica  
Extractum (radicis): 377 
 











Notes Title Edition Reference 
 Pharmacopoea Borussica. 
Die Preussische Pharmakopoea, 
übersetzt und erläutert von Carl Wilhelm 
Juch. 
 
Professor Dr. Carl Wilhelm Juch was a 
Bavarian “Hofrat” and Professor of 
Chemistry, Natural History and 












Extractum (e toto): 246 
 
St. John’s Wort 
Oleum coctum hyperici: 
316-317 
 
 Pharmacopoea Borussica. 
Die Preussische Pharmakopoea, 
übersetzt und erläutert von Friedrich 
Philipp Dulk 
 
Professor Dr. Dulk was apothecary and 
pharmaceutical lecturer at Albertus 
















St. John’s Wort 
Herba: 567-568 
Oleum: 568 






Extractum (radicis): 165 
Tinctura (flores): 244 
 
St. John’s Wort 
Herba: 268-269 
Oleum: 304 – adulteration 
with Arkanna root 
officially recommended! 
 Pharmacopoea Borussica. 
Die Preussische Pharmakopoea, 
übersetzt und erläutert von Friedrich 
Philipp Dulk 
 
Professor Dr. Dulk was apothecary and 
pharmaceutical lecturer at Albertus 
University, Königsberg (East Prussia) 
1827 












St. John’s Wort 
Herba: 488, 907 
Oleum: 488 
 Pharmacopoea Borussica. 
Die Preussische Pharmakopoea, 
übersetzt und erläutert von Friedrich 
Philipp Dulk 
 
Professor Dr. Dulk was apothecary and 
pharmaceutical lecturer at Albertus 
University, Königsberg (East Prussia) 
1827 





Vol. 2  
(zubereitete und 
zusammengesetzte)  
No entries for Arnica 





Notes Title Edition Reference 
 Pharmacopoea Borussica oder 
Preussische Pharmakopoe. Lateinisch 
und deutsch mit Anmerkungen und 
Zusätzen. Vierte, völlig umgearbeitete 
Auflage.  
 
Carl Wilhelm Juch 
Wilhelm Raab 
 
Professor Dr. Carl Wilhelm Juch was a 
Bavarian “Hofrat” and Professor of 
Chemistry, Natural History and 
Nutrition at the Hohe Schule in 
München. 
 
Mr Raab was apothecary in Bayreuth.  
 
Further comments were made by 






The translation of the 4th 
edition of the Ph. 
Borussica does not add 
further information. 
Therefore, this edition 
was not entered into the 
Historical Data excel 
spreadsheet 
 Preussische Pharmakopöe. Übersetzung 
aus der lateinischen Urschrift von H. 
Straberoh. 
 









St. John’s Wort 
Herba: 277-278 





Die Preussische Pharmakopoea, 
übersetzt und erläutert von Friedrich 
Philipp Dulk 
 
Professor Dr. Dulk was apothecary and 
pharmaceutical lecturer at Albertus 














Vol. 2, 1848 




 Preussische Pharmakopöe. Nach der 
sechsten Ausgabe der Pharmacopoea 
Borussica übersetzt von Professor Dr. 
Gurlt 
 
Professor Dr. Ernst Julius Gurlt was a 
surgeon and associate professor at the 












St. John’s Wort 
Herba: not listed 
Oleum: not listed 
 Commentar zur Preußischen 
Pharmacopoe nebst Übersetzung des 
Textes. Nach der sechsten Auflage der 
Pharmacopoea Borussica bearbeitet von 
Dr. Friedrich Mohr für Apotheker, 
Aerzte und Medicinal-Beamte. 
 
Dr. Mohr was an apothecary and 
pharmaceutical assessor at the Royal 




6. ed.  
 
Commentary 













Notes Title Edition Reference 
  1847 
6. ed.  
 
Commentary 
Vol. 2, 1849 
Arnica 
Radix: 245 
Tinctura: 411 (made with 
flowers) 
 
 Preussische Pharmakopöe. 







St. John’s Wort  
Not listed 
 Friedrich Mohr 
Commentar zur preussischen 
Pharmacopoe nebst Übersetzung des 
Textes. Dritte umgearbeitete Auflage. 
 
Dr. Mohr was an apothecary and 
pharmaceutical assessor at the Royal 




Very short – no added insights  
 
1862 












 Hermann Hager 
Kommentar zu der siebenten Ausgabe 
der Pharmacopea Borussica mit 
besonderer Berücksichtigung der 
neusten Pharmakopöen des Königreichs 
Hannover und des Kurfürstenthums 
Hessen. 
 
Dr. Hermann Hager, was a Prussian 
apothecary, pharmacist, chemist, 
pharmacologist and writer of 
pharmaceutical commentaries and 
textbooks. 
1862 






Flores: 691-692  
(re Arnica fly/irritating 




Florum:  582 (Ph. Hann.) 
Extractum Arnicae 
radicis: 582-583 (Ph. 
Hann et Ph. Hass.) 
Radix: 1133-1134 (Ph. 
Hann et Ph. Hass.)  
 
St. John’s Wort 
Not listed 
 




preparation of the 
unification of the 
German Reich 
Pharmacopoea Germaniae 1865 
 
Arnica 
110, 224, 289 
 




pharmacopoeias of the 








Übersetzt von Hermann Hager 
1872 






Tinctura flori: 350 
 







Notes Title Edition Reference 
 Commentar zur Pharmacopoea 
Germanica.  
 
Herausgegeben von Dr. Hermann Hager 
 
Dr. Hermann Hager, was a Prussian 
apothecary, pharmacist, chemist, 
pharmacologist and writer of 
pharmaceutical commentaries and 
textbooks. 
1872 
1. ed.  
 
Commentary 








  1872 
1. ed.  
 
Commentary 






St. John’s Wort 
Not listed 
 Commentar zur Pharmacopoea 
Germanica.  
 
Professor Dr. Ludwig Andreas Buchner 
und Professor Dr. Herman von Boeck. 
 
Professor Dr. Buchner was a physician, 
professor of pharmacy and doctor of 
philosophy 
 
Professor Dr. von Boeck was a 
professor of pharmacology 
1872 
1. ed.  
 
Commentary 




St. John’s Wort 
Not listed 
 
 Commentar zur Pharmacopoea 
Germanica.  
 
Professor Dr. Ludwig Andreas Buchner 
und Professor Dr. Herman von Boeck. 
 
Professor Dr. Buchner was a physician, 
professor of pharmacy and doctor of 
philosophy 
 
Professor Dr. von Boeck was a 
professor of pharmacology 
1872 
1. ed.  
 
Commentary 
Vol. 2, 1884 
Arnica 
Radix: 530-532  
(prevalence of Arnica 
popular in folk medicine 








 Pharmacopoea Germanica. Editio altera. 
Deutscher, der lateinischen Ausgabe zu 
Grunde liegender Entwurf 
1882 
2. ed.  
Arnica 
Flores: 107-108 
Radix: not listed anymore 
for first time. 
Consequently, not listed 
in commentaries either 
Tinctura: 272 
St. John’s Wort  
Not listed 
 Commentar zur Pharmacopoea 
Germanica. Herausgegeben von Dr. 
Hermann Hager 
 
Dr. Hermann Hager, was a Prussian 
apothecary, pharmacist, chemist, 
pharmacologist and writer of 
pharmaceutical commentaries and 
textbooks. 
1882 




Vol. 1, 1883 
 
Arnica 
Flores: 750-752       
 




 Commentar zur Pharmacopoea 
Germanica. Herausgegeben von Dr. 
Hermann Hager 
 
Dr. Hermann Hager, was a Prussian 
apothecary, pharmacist, chemist, 
1882 














Notes Title Edition Reference 
pharmacologist and writer of 
pharmaceutical commentaries and 
textbooks. 
  
 Kommentar zur zweiten Auflage der 
Pharmacopoea Germanica.  
 
O. Schlickum was a German apothecary 
and writer of pharmaceutical 
commentaries and textbooks 
1882 








St. John’s Wort 
Not listed 








St. John’s Wort 
Not listed 
 Commentar zum Arzneibuch für das 
Deutsche Reich (Pharmacopoea 
Germanica, editio III.) : mit 
vergleichender Berücksichtigung der 
früheren deutschen u.a. Pharmakopöen 
von Dr. Bruno Hirsch und Dr. Alfred 
Schneider 
 
Dr. B. Hirsch was apothecary in Berlin 













(=gleicher Geruch und 
Geschmack = gleiche 
Inhaltsstoffe wie Blüthen) 
Flores Arnicae cum 
receptaculis (calicibus) 
Tinctura: 650  
keine Änderungen 
 
St. John’s Wort 
Not listed 
 Kommentar zum Arzneibuch für das 
Deutsche Reich, Dritte Ausgabe 
(Pharmacopoea Germanica, editio III.). 
Herausgegeben von H. Hager, B. 
Fischer und C. Hartwich. 
 
Drs. H. Hager, H. (Frankfurt am Main), 
B. Fischer (Breslau), C. Hartwich 
(Zürich) were apothecaries and writers 
of pharmaceutical commentaries and 
textbooks 
1890 




Vol. 1, 1891 
Arnica 
Flores: 635, 662-664,  
 
St. John’s Wort 
Not listed 
(“Johannisblume” 
referred to Arnica not to 
St. John’s Wort) 
 
 








St. John’s Wort 
Not listed 
 Arzneimittel, welche in dem Arzneibuch 
für das Deutsche Reich, 3. Ausg., 
(Pharmacopoea Germania, editio 3) 
nicht enthalten sind.  
Deutscher Apotheker-Verein. 
 
Supplement complementing the official 
Ph. Germanica. Not a commentary and 









Not listed under poison 
 
St. John’s Wort 
Herba: 145 
Not listed under poison 
 
 
 Arzneimittel, welche in dem Arzneibuch 
für das Deutsche Reich, 3. Ausg., 
(Pharmacopoea Germania, editio 3), 
Neudruck 1895 nicht enthalten sind.  
Deutscher Apotheker-Verein. 
 
Supplement complementing the Ph. 
Germanica. Not a commentary and no 









Not listed under poison 
 
St. John’s Wort 
Herba: 160 





Notes Title Edition Reference 
 Arzneibuch für das Deutsche Reich. 
Vierte Ausgabe.  
1900 





St. John’s Wort 
Not listed 
 Kommentar zum Arzneibuch für das 
Deutsche Reich, 4. Ausgabe 
(Pharmacopoea Germanica, editio IV.): 
Ergänzungsband zum Kommentar für 
die III. Ausgabe des Arzneibuchs, 
enthaltend Nachträge und die 
Veränderungen der IV. Ausgabe des 
Arzneibuchs, herausgegeben von B. 
Fischer und C. Hartwich. 
 
Drs. B. Fischer (Breslau) and C. 
Hartwich (Zürich) were apothecaries 
and writers of pharmaceutical 














 Kommentar zum Arzneibuch für das 
Deutsche Reich. Mit Zugrundelegung 
des amtlichen Textes, sowie einer 
Anleitung zur Massanalyse im 
Anschluss an den Schlickumschen 
Kommentar. Bearbeitet von Dr. C Jehn 
und Dr. E. Crato. 











St. John’s Wort 
Not listed 
 
 Handkommentar zum Arzneibuch für 
das Deutsche Reich, vierte Ausgabe ‚ 
Pharmacopoea Germanica, editio IV. 3. 
Auflage des Hirsch’Schneider’schen 
Kommentars zum Deutschen 
Arzneibuch. Mit vergleichender 
Berücksichtigung der früheren 
deutschen und anderen Pharmakopöen 
bearbeitet von Dr. Alfred Schneider und 
Dr. Paul Süss. 
 
Dr. A. Schneider was military 
apothecary („Korps-Stabsapotheker“) 
and Dr. P. Süss was apothecary and 
Assistant at the „Hygienisches Institut 
der Technischen Hochschule“ 
1900 












 Ergänzungsbuch zum Arzneibuch für 
das Deutsche Reich. (Arzneimittel, 
welche in dem Arzneibuch für das 
Deutsche Reich nicht enthalten sind). 
Dritte Ausgabe. 
 
Deutscher Apotheker-Verein (editor). 
1906 
 







St. John’s Wort 
Herba: 182 
 Arzneibuch für das Deutsche Reich. 5. 
Ausgabe. 
1910 










Notes Title Edition Reference 
 Kommentar zum Deutschen Arzneibuch. 
5. Ausgabe 1910. Auf Grundlage der 
Hager-Fischer-Hartwichschen 
Kommentare der früheren Arzneibücher 
in 2 Bänden. Herausgegeben von Dr. O. 
Anselmino und Dr. Ernst Gilg. 
 
Dr. O. Anselmino was private lecturer at 
the University of Greifswald and Dr. E. 
Gilg was professor of botany and 
pharmacognosy at the University of 
Berlin and „Kustos“ at the „Königiches 













 Kommentar zum Deutschen Arzneibuch. 
5. Ausgabe 1910. Auf Grundlage der 
Hager-Fischer-Hartwichschen 
Kommentare der früheren Arzneibücher 
in 2 Bänden. Herausgegeben von Dr. O. 
Anselmino und Dr. Ernst Gilg. 
 
Dr. O. Anselmino was private lecturer at 
the University of Greifswald and Dr. E. 
Gilg was professor of botany and 
pharmacognosy at the University of 
Berlin and „Kustos“ at the „Königiches 













 Ergänzungsbuch zum Arzneibuch für 
das Deutsche Reich. (Arzneimittel, 
welche in dem Arzneibuch für das 






4th Supplement to 




St. John’s Wort 
Herba: 194 
 
 Arzneibuch für das Deutsche Reich. 6. 
Ausgabe. 
 
With index for first time! 
1926        





St. John’s Wort 
Not listed 
 Arzneibuch für das Deutsche Reich. 6. 
Ausgabe. 
 
With index for first time! 
1926        







St. John’s Wort Not 
listed 
 Kommentar zum Deutschen Arzneibuch 
6. Ausgabe, Erster Band, 1926. 
Herausgegeben von Dr. O. Anselmino 
und Dr. Ernst Gilg. 
 
Dr. O. Anselmino was private lecturer at 
the University of Greifswald and Dr. E. 
Gilg was professor of botany and 
pharmacognosy at the University of 
Berlin and „Kustos“ at the „Königiches 
















Notes Title Edition Reference 
 Kommentar zum Deutschen Arzneibuch 
6. Ausgabe, Zweiter Band, 1926. 
Herausgegeben von Dr. O. Anselmino 
und Dr. Ernst Gilg. 
 
Dr. O. Anselmino was private lecturer at 
the University of Greifswald and Dr. E. 
Gilg was professor of botany and 
pharmacognosy at the University of 
Berlin and „Kustos“ at the „Königiches 














 Ergänzungsbuch zum Deutschen 
Arzneibuch (Arzneimittel, die im 
Deutschen Arzneibuch nicht enthalten 
sind). Fünfte Ausgabe (Erg.-B. 5). 
 
Deutscher Apotheker-Verein (editor) 
1930 
 







St. John’s Wort 
Herba: 225 
 Ergänzungsbuch zum Deutschen 
Arzneibuch (Arzneimittel, die im 
Deutschen Arzneibuch nicht enthalten 
sind). Sechste Ausgabe (Erg.-B. 6) 
 





6th Supplement to 
DAB 
 
Reprint of first 
edition from 1941  
 
Arnica 
Tinctura destillata: 482 
Radix: discontinued 
 
St. John’s Wort 
Flores recentes: 170 
(new) 
Herba: 254-255 
Oleum: 366-367 (new) 




345                               
(not flores anymore) 
Tinctura: 346 
 
St John’s Wort 
Not listed 
 Deutsches Arzneibuch. 7. Ausgabe. 
Kommentar von Prof. Dr. Dr. h.c. H. 
Böhme und Prof. Dr. K. Hartke, 
Universität Marburg. 
 
Prof. Dr. Horst Böhme was a German 
pharmacist and chemist and professor of 
pharmaceutical chemistry and rector at 
the University of Marburg. Prof. Dr. K. 







512                                 
(not flores anymore) 
Tinctura: 513 
 
St John’s Wort 
Not listed 
 








St John’s Wort 
Not listed 
 Deutsches Arzneibuch. 8. Ausgabe. 
Kommentar. Kommentar von Prof. Dr. 
Dr. h.c. H. Böhme und Prof. Dr. K. 
Hartke, Universität Marburg. 
 
Prof. Dr. Horst Böhme was a 
pharmacist and chemist and professor of 
pharmaceutical chemistry and rector at 
the University of Marburg, Germany. 
Prof. Dr. K. Hartke was a pharmacist 





















Notes Title Edition Reference 








Planta tota: 205-210 
 









St. John’s Wort 
No addition 
 Homöopathisches Arzneibuch 1983 
2. Nachtrag  
Arnica 
Planta tota: 47  
 
St. John’s Wort 
Planta tota: 109-110 
 Homöopathisches Arzneibuch 1985 





St. John’s Wort 
Flores, herba 
(summitates): 237-238 






St. John’s Wort 
Not listed 
 DAB 9-Kommentar. Deutsches 
Arzneibuch, 9. Ausgabe 1986, mit 
wissenschaftlichen Erläuterungen. Prof. 
Dr. K. Hartke, Universität Marburg 
(Gesamtherausgeber) und Prof. Dr. Dr. 
E. Mutschler (Herausgeber des 
Pharmakologischen Teils). 
 
Prof. Dr. K. Hartke was a pharmacist 
and professor at the University of 
Marburg, Germany. Prof. 
Dr.Dr.E.Mutschler was a 













St. John’s Wort 
Not listed 
 






Flores: A (no page 
numbers) 
Tinctura: A (no page 
numbers) 
 DAB 10-Kommentar für Studierende. 
Wissenschaftliche Erläuterungen zum 
Deutschen Arzneibuch, 10. Ausgabe 




Prof. Dr. K. Hartke was a pharmacist 
and professor at the University of 
Marburg, Germany. 
1993 





Flores: A 54 
Tinctura: A 55 
 





Notes Title Edition Reference 




Flores: not listed 
Tinctura: A 
 
St. John’s Wort 
Not listed 
 Deutsches Arzneibuch 2012. 
 
Covers the period from 1999-2012.  
 
All regular entries are in Ph. Europea. 
The regional pharmacopoeiae now only 
list amendments to these officially 
binding European entries. 
2012 








 DAB 2012 was at the cutoff date for 
data collection (June 2014) the latest 
available regional pharmacopoeia. This 
data was subsequently checked against 




European Community (EU) – Pharmacopoeia Europea 
 
































Praefatus est Albertus de Haller 
 
The author, Dr. Albrecht von Haller, 
was a Swiss physician, anatomist, 
physiologist, natural scientist and writer 





St. John’s Wort 
(I)85-86 
 
(II) 38, 39, 40, 67, 106-
107, 108, 110, 111, 150, 
151, 155, 201, 203, 235, 





Notes Title Edition Reference 











Scafhusiae (ex officina Brodtmanniana). 






St. John’s Wort  
Not listed 
 
(but exotic medicinal 
plants such as Ginger, 
Ipecacuanha, Myrrh, 
Lobelia are listed) 
 








St. John’s Wort 
Not listed 









St. John’s Wort 
Not listed 






St. John’s Wort 
Not listed 
 Commentar zur Pharmacopoea 
Helvetica. Editio Tertia  
 
Dr. Carl Dünnenberger, Pharmacist 
1893 






St. John’s Wort 
Not listed 
 Pharmacopoea Helveticae. Editio 
Quarta. Deutsche Ausgabe 
 








St. John’s Wort 
Not listed 
 Kommentar zur Pharmacopoea 
Helvetica. Editio Quarta. 
 
Dr. Eugen Beuttner (1860 – 1950) was a 
Swiss apothecary, pharmaceutical 










St. John’s Wort 
Not listed 
 






Tinctura: 938  
 





Notes Title Edition Reference 
 Kommentar zur Pharmacopoea 
Helvetica, Editio Quinta.  
 
Prof. Robert Eder, pharmaceutical 
Chemistry 
 
Prof. Jackob Büchi, pharmaceutical 
Chemistry and galenical chemistry 
 
Prof. Hans Flück, Pharmacognosy 
 















 Kommentar zur Pharmacopoea 






No comments listed for 
Arnica and St. John’s 
Wort  
 Kommentar zur Pharmacopoea 





No comments listed for 
Arnica and St. John’s 
Wort  
 Pharmacopoea Helvetica  
Editio Sexta. Deutsche Ausgabe. 
 
Edited by Prof. Jackob Büchi, 









St. John’s Wort 
Not listed  






 Kommentar zur Pharmacopoea 
Helvetica Editio Sexta 
 
Prof. Jackob Büchi, pharmaceutical 
Chemistry and galenical chemistry 
 
Prof. Hans Flück, Pharmacognosy 
 
Prof. Hans Mühlemann 
Galenical pharmacy 
 
Prof. André Mirimanoff 














 Pharmacopoea Helvetica Editio 






Flores: no page number 
Tinctura: no page number 
  1992 
D-K 
St. John’s Wort 
Herba: no page number - 
newly listed! 







Monograph totally revised 
based on DAB 10 
 





Notes Title Edition Reference 







Flores: e1220 – Ph Eur. 4 
 
St. John’s Wort 
Summitates cum floribus 
recentes: 259 
(for immediate processing 
into oil) 
Herba: e2157 - Ph Eur. 4 
Oleum: 260 





Flores: Ph. Europea 5th 
ed. e1426 
Tinctura: Ph. Europea 
e5.1 ed. 3836 
 
St. John’s Wort 
Hyperici sumitates cum 
floribus recentes: 251 
Herba: Ph. Europea 5th 
ed. 2481 
Oleum: 252 
 Pharmacopoea Helveticae 
11. Ausgabe 
2012 Arnica 
Flores: Ph. Europea 7th 
ed. e1626 
Tinctura: Ph. Europea 7th. 
ed. 1628 
 
St. John’s Wort 





Europea 7th. ed. e1757  
Hyperici sumitates cum 
floribus recentes: 311 
Oleum: 312 
 Ph. Helvetica 11 (2012) was at the 
cutoff date for data collection (June 
2014) the latest available regional 
pharmacopoeia. This data was 
subsequently checked against the two 

















Flores (no page number) 
 
St. John’s Wort 
Herba (no page number) 
28 Member States of the 




























Authored by governing 




















WHO Monographs on 







WHO Monographs on 
selected medicinal plants. 
Volume 2 






Hagers Enzyklopädie der 











Medical and modern phytotherapeutic textbooks 
Final selected was based on authors with therapeutic experience. The selection reflects 
approximately one textbook every 25 years (one for every generation). Textbooks by 
authors without therapeutic patient experience were excluded. Data were entered into 
Historical Data Excel spreadsheet for final analysis. The Neu vollkommen Kräuterbuch by 
Tabernaemontanus was used as pars pro toto for medical practice in the early modern 
period. The last reprint of this textbook was in 1731. For this reason, the data collection on 
successive medical textbooks started in the last third of the 18th century. This coincides with 
the start of the data collection of the Prussian and Swiss pharmacopoeias (only the 
Prussian pharmacopoeia was used in the final analysis). 








Personal physician to Philip 
II, Count of Nassau-
Saarbrücken 
and to Marquard von 
Hattstein, bishop of Speyer. 
"Stadtphysicus" (town 
physician) to the free 
imperial city of Worms, 
Germany 
Yes Neu vollkommen Kräuterbuch: 
darinnen uber 3000 Kräuter, mit 
schönen und kunstlichen Figuren, 
auch deren Unterscheid und 
Wirckung, sampt ihren Namen in 
mancherley Spraachen 
beschrieben: Deßgleichen auch, 
wie dieselbige in allerhand 
Kranckheiten, beyde der 
Menschen und des Viehs, sollen 
angewendet und gebraucht 
werden, angezeigt wird. 
1664 
 

















proponent against heroic 
medicines. Chair of medicine 
at the University of Halle, 
president of Collegium-
Medicum in Berlin. Personal 
physician to Duke Johann 
Ernst of Sachsen-Weimar 
and King Friedrich Wilhelm 
I. of Prussia  
 
Made transition from 
alchemy to chemistry 
No Materia medica: das ist: 
Zubereitung, Krafft und 
Würckung, derer sonderlich durch 
chymische Kunst erfundenen 
Artzneyen 
 
1744 1659-1734 Arnica   


















dermatologist and surgeon. 
Appointed by Maria 
Theresia, archduchess of 
Austria and Queen of 
Hungary, as Professor for 
Surgery and Obstetrics to the 
University of 
Tyrnau (Slovakia. Professor 
of Chemistry and Botany at 
the Military-Medical 
Academy of Wien. 
No Joseph Jacob Plenks Chirurgische 
Pharmakologie: oder Lehre von 
den Arzneymitteln, welche zur 
Heilung äußerer Krankheiten 
pflegen angewendet zu werden 









  Icones plantarum medicinalium 
 













Vol. 6: 57  
Löseke  
Johann Ludwig Leberecht 
 
Physician; practising in 







Physician, chemist, natural 
scientist (Germany) 
Yes Materia medica oder Abhandlung 
von den auserlesenen 
Arzneymitteln: nach derselben 
Ursprung, Güte, Bestandtheilen, 
Maße und Art zu wirken nebst 
Vorschriften wie dieselben aus 






















Physician, Professor of 
Medicine, University of Jena, 
Director of Medical Hospital 
Charité, Berlin 
"Hofarzt" (personal 
physician) of Friedrich 
Wilhelm III of Prussia and 
personal physician of Johann 
Wolfgang Goethe, German 
poet and natural scientist, as 
well as of other celebrities 









1762-1836 Arnica  
81,118,128, 








  System der praktischen 
Heilkunde. Spezielle Therapeutik 
 






  Conspectus Materiae medicae 
secundum Ordines naturales in 
Usum Auditorium 















Military physician. Professor 
of Practical Medicine 
(„praktische Heilkunde“), 
University of Königsberg 
Yes Ausführliche Arzneimittellehre. 
Handbuch für praktische Aerzte  
1827 
Vol. 2 

















pharmazeutische Flora: enthaltend 
die systematische Aufzählung und 
Beschreibung sämmtlicher bis 
jetzt bekannt gewordenen 
Gewächse aller Welttheile in ihrer 
Beziehung auf Diätetik, Therapie 
und Pharmazie, nach den 




















obstetrician, Lecturer of 
Medicine, University of 
Rostock, Doctor of 
Philosophy 
 
No Ausführliche Encyklopädie der 
gesammten Staatsarzneikunde: für 
Gesetzgeber, Rechtsgelehrte, 
Polizeibeamte, Militärärzte, 
gerichtliche Ärzte, Wundärzte, 









1794-1832 Arnica / 














Physician, Professor of 
Medicine and Coroner, City 
of Berlin 
No Wochenschrift für die gesamte 
Heilkunde 
1841 1796-1864 Book on 
constitutiona




Carl Johann Alexander 
 
Physician, translator of 
French medical textbooks  
 
No Grundriss der medicinischen 
Receptierkunst und der 
systematisch-practischen 
Arzneimittlelehre 














Physician, student of 
Hufeland. Stadtphysicus 
(town physician) of Goch 
 
No Rechtfertigung der von den 
Gelehrten misskannten, 
verstandesrechten 
Erfahrungsheillehre der alten 
scheidekünstigen Geheimärzte 
und treue Mittheilung des 
Ergebnisses einer 25jährigen 
Erprobung dieser Lehre am 
Krankenbette 
 
Contains many case studies 
1848 























Physician. Practising in 
Berlin (since 1840), 
previously "Stadtphysicus" 
(town physician) of Stassfurt. 
Prussian “Hofrath” (civil 
service title) since 1835 
 
Descendent of renowned 
Professor of Chemistry and 
Botany in Halle, Karl 
Christoph Strumpf, to whom 
Linnaeus dedicated the 
genus “Strumpfia”. 
 


















Physician in Berlin, surgeon. 
“Geheimer Hofrath” 
(honorary member of 
academia). Published a three 
book series on Paracelsus’s 
life and work and medical 
textbook for students  
No Handbuch der speciellen 
praktischen Arzneimittellehre 








  Kurzer Abriss der Materia 
Medica. Ein Repetitorium 
 











Apothecary, chemist and 
pharmacologist and writer of 
pharmaceutical 
commentaries and textbooks 
Yes Handbuch der pharmaceutischen 
Praxis: für Apotheker, Ärzte, 
Droguisten und Medicinalbeamte. 
1876 (1) 








   1878 (2) 
 
2. ed. 
 St. John’s 
Wort 
170-172  















extraordinary Professor of 
Pharmacology 
 
No Grundriss der Materia medica für 
praktische Ärzte und Studierende: 
mit besonderer Rücksichtnahme 
auf die Pharmacopoea Germanica  
 
Editor. G. Pabst 










Author(s) Selected Title Edition Biographical 
data 
Reference 
  Köhler’s Medizinal-Pflanzen.  
Atlas zur Pharmacopoeia 
germanica, austriaca, belgica, 
danica, helvetica, hungarica, 
rossica, suecica, Neerlandica, 
British Pharmacopoeia, zum 
Codex medicamentarius, sowie 
zur Pharmacopoiea of the United 
States of America. 
 
This book belonged to Insel 





















Professor of Pharmacy and 
Pharmacognosy University 
of Bern; Professor of 


































Physician and military 
physician. Professor of 
Theoretical Medicine at the 
"Institut für  feldärztliche 
Zöglinge", Vienna. Profesor 
of Pharmacology 
(Arzneimittellehre) and 
Pathology at the Josef 
Academy (Josephinum), 









Professor of Pharmacology 
and Pharmacognosy, 
University of Vienna. 
"Hofrath" (honorary member 
of academia) 
No Lehrbuch der Arzneimittellehre. 
Mit gleichmässiger 
Berücksichtigung der 
österrreichischen und deutschen 
Pharmacopoe.  
 
Zweite, vermehrte und mit 
Rücksicht auf die neue 
österreichische Pharmacopoe vom 
Jahr 1889 (Edit. VII) 




































Physician. Professor of 
Medicine and 
Pharmacology, University of 
Göttingen 
No Handbuch der Arzneimittellehre. 
Mit besonderer Rücksichtnahme 
auf die neuesten Pharmakopöen 





















pharmacologist. Professor of 
Pharmacy University of 
Dorpat 
No Die Heilpflanzen verschiedener 
Völker und Zeiten. 
 













Curator at "Königliches 
pflanzenphysiologisches 
Institut", München. Co-
editor of Hager’s Handbuch 
No Arzneidrogen: als 
Nachschlagebuch für den 
Gebrauch der Apotheker, Ärzte, 
Veterinärärzte, Drogisten und 
Studierenden der Pharmazie. Die 
in Deutschland, Österreich und 
der Schweiz offizinellen Drogen. 

























Professor of Chemistry, 
University of Oslo 









Apothecary, Pharmacist and 
pharmacognosist. Professor 
of Pharmacy and 
Pharmacognosy, University 
of Berne 






34, 67, 70 
 
St. John’s 
Wort   70, 
96, 100-102 






   Vol. 2.1  Arnica 
523 
   Vol. 2.2  Arnica 
1174-1184, 
1560 












and toxicologist. Professor 
of Pharmacology, University 
of Greifswald 
Yes Vorlesungen über Wirkung und 
Anwendung der deutschen 
Arzneipflanzen  















Physician. Professor of 
Medicine, University of Bonn 
No Arzneimittel der heutigen 
Medizin: mit therapeutischen 
Notizen. Zusammengestellt für 




















Chemist. “Studientrat” in 
München (honorary 





Chemist. Author of textbooks 
on chemistry. Owner of a 
drugstore (“Drogerie”) in 
Charlottenburg. Politician 




 Drogenkunde.  Ein Hilfsbuch für 
den Unterricht and den 
Drogeisten-Fachschulen und zum 
Selbstunterricht, sowie ein 
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APPENDIX 3: TRANSCRIPT OF ARNICA MONTANA 
MONOGRAPH IN TABERNAEMONTANUS 
This appendix is the German language transcript of Tabernaemontanus’ monograph on 
Arnica montana (1664). The pharmaceutical and pharmacological data is translated into 
English in Appendix 4. 
 
Das XXII. Capitel. 
VON MUTTERWURTZ. 
Mutterkraut Chalta [Caltha] alpina. 
 




<Buch 2, Sektion 1, Kapitel 22, S. 714E-715A> 





Djeses Kraut beschreibet LOBELIUS in seinen 
OBSERVATIONIBUS und ADVERSARIIS 
NOVIS / daß es ein schönes Gewächs sey / seine Wurtzel vergleicht 
sich der Wurtzel des grossen Baldrians / außgenommen daß sie 
kleiner ist / und mit vielen Faseln behencket / bey nahe dem 
DORONICO gleich / eines räsen / scharffen / durchtringenden / 
bittern / und doch wurtzigen Geschmacks / dem NARDO gantz 
gleich / auß welcher Wurtzel ein Stengel herfür tritt / einer elen hoch 
/ bißweilen auch nidriger / an welches Gipfel ein gestirnte goldgelbe 
Blum herfür kommt / gantz lustig und schön anzusehen / der 
Rindsaugblumen oder Johannsblumen fast gleich. Seine blätter sind 
lang / breit und bleichgelb / mit vielen Aederlein durchzogen / der 
Entzian so gleich und ähnlich / daß sie in der erst vor die Entzian 
möchte angesehen werden. GESNERUS und DODONEUS 
vergleichet sie den Wegrichsblättern / mit welchen sie auch gar 
übereinkommen. LOBELIUS schreibet / daß er es in AGRO 
Über diese Pflanze schreibt Lobelius11 in seinen OBSERVATIONES 
und ADVERSARIA NOVA, dass sie schön sei. Ihre Wurzel ähnelt 
der des großen Baldrians12. Allerdings ist sie kleiner und hat 
zahlreiche Seitenwurzeln, ähnlich wie die Gemswurz13. Sie 
schmeckt rösch14, scharf, durchdringend, bitter und dabei doch 
würzig wie die Narde15. 
Aus ihrer Wurzel wächst ein Stengel hervor, der ungefähr 54 cm16 
hoch, manchmal aber auch niedriger sein kann. An der Spitze des 
Stengels erscheint jeweils eine sternförmig strahlende17 goldgelbe 
Blüte, die sehr anmutig18 und schön aussieht und eine starke 
Ähnlichkeit mit der Blüte der Färberkamille19 oder der 
Wucherblume20 besitzt. Die Blätter der Pflanze sind lang, breit und 
blass, mit vielen Gefäßen durchzogen. Sie ähneln denen des 
Enzians21 so sehr, dass man sie zunächst leicht für Enzianblätter 
halten könnte.  
 
11 Matthias Lobelius, eigtl. M. de l’Obel (1538 - 1616), niederländischer Botaniker 
12 „grosser Baldrian“: großer Baldrian - Valeriana phu L., aus dem Kaukasus; MARZELL, IV, Sp. 1000 
13 „Doronicum“: Gemswurz - Doronicum L.; MARZELL, II, Sp. 153f 
14 „räsen“: zu rösch, ‚frisch’; KLUGE, S. 770b 
15 „Nardus“: als Narde wurden verschiedene aromatisch riechende Pflanzen bezeichnet (u.a. Deutsche Narde - Lavandula latifolia Medic., Römische 
Narde - Valeriana celtica L., Speik - Nardostachys jatamansi (Jones) DC. = Valeriana spica (L.) Vahl.) ; vgl. MILDENBERGER (1997), III, S. 1288 - 
1290, und siehe auch MARZELL, III, Sp.  291 
16 eine Elle entspricht ungefähr 54 cm; MULSOW (1910), S. 33; MEYER III, Sp. 804: Frankfurter Elle 
17 „gestirnt“: mit einem Blütenstern versehen; DWB, IV / I / II = 5, Sp. 4241 
18 „lustig“: anmutig; DWB VI = 12, Sp. 1340-1342 
19 „Rindsaugblume“: Färberkamille - Anthemis tinctoria L.; MARZELL, I, Sp. 324 
20 „Johannsblume“: Wucherblume - Chrysanthemum leucanthemum L.; MARZELL, I, Sp. 964 




 Originaltext Moderne Übersetzung 
NARBONENSI habe angetroffen / es wächßt auch in den feuchten 
Wiesen / auff den hohen Gebirgen. [In Schweitzerland und Elsaß] 
Gessner22 und Dodoens23 vergleichen sie mit den Blättern des 
Wegerichs24, mit denen sie ebenfalls große Ähnlichkeit besitzen. 
Lobelius schreibt, dass er die Pflanze im südlichen Languedoc25 
gefunden habe. Sie wächst auch auf hochgelegenen feuchten 
Wiesen. [so auch in der Schweiz und im Elsass] 
 Von den Namen.  
Mutterwurtz wird [von Pnegellern in den Bürden wilder Wegerich] 
Lateinisch genennt CALTHA ALPINA, dieweil es für ein Art der 
Ringelblumen gehalten wird: 
RONDELETIUS hält es für ein Geschlecht des NARDI 
GALLICAE, andere sagen / es sey ein SPECIES des NARDI 
CELTICAE, GESNERUS nennet es CALTHAM ALPINAM. 
Von den Namen. 
 
Arnika wird [von Pnegellern in den Bürden wilder Wegerich26] 
lateinisch als Caltha alpina bezeichnet, weil man sie für eine Art der 
Ringelblumen hält.27  
Rondelet28 ordnet sie der Gallischen Narde zu, andere der Keltischen 
Narde.29 Gessner nennt sie Caltha alpina. 
 [Bey den Sachsen und Seestätten wird es Wolveley geheissen bey 
dem gemeinen Mann: aber 
von den MEDICIS, ARNICA, DORONICUM PLANTAGINIS 
FOLIO ALTERUM, C.B. 5. GERMANICUM & 6. 
[Die Sachsen und die Küstenbewohner nennen sie volkstümlich 
Wolveley30. Die Ärzte dagegen verwenden die Namen ARNICA, 
DORONICUM PLANTAGINIS FOLIO ALTERUM, C.B. 5. 
GERMANICUM & 6. PANNONICUM, CLUS.31 HIST. ALISMA, 
 
22 Konrad Gessner (1516 - 1565), eidgenössischer Naturforscher und Arzt 
23 Rembert Dodoens (1516 - 1585), kaiserlicher Leibarzt flämischer Herkunft in Wien, Internist in Leiden, erhielt den Reichsadel 
24 „Wegrich“: großer Wegerich - Plantago major L.; MARZELL, III, Sp. 815 
25 „Narbonensis“: ehemals römische Provinz im jenseits der Alpen gelegenen Gallien (GEORGES [1913], II, 1090); zur territorialen Verflechtung von 
Stadt, Erzbistum und Grafschaft Narbonne siehe LexMA VI, Sp. 1020-1023 
26 „wilder Wegerich“: MARZELL, I, Sp. 407 hat nur „Welscher Wegerich“; „Pregeller“ bleibt zunächst ungedeutet; für „Bürde“ liegt die Deutung 
‚Bündel’ nahe, vgl. FrnhdWb IV, Sp. 1406; vielleicht verballhornt aus „von den Bergellern in den <Grauen> Bünden“ 
27 „Ringelblume“: vgl. MARZELL, I, Sp. 400: Caltha alpina als alter Name für Arnica montana L.;  
 sowie MARZELL, I, Sp. 715: Caltha für Calendula officinalis L. 
28 Guillaume Rondelet (1507 - 1566), französischer Naturforscher 
29 „Nardus celtica“: vgl. MARZELL, IV, Sp. 986, Nardus gallica bzw. Nardus celtica als alte Namen für den Echten Speik (Valeriana celtica L.) 
30 „Wolveley“: verballhornt aus ´Wohlverleih`, zusammengesetzt aus ´Wohl` und ´Verleih, ‚Wellness-Spender’; MARZELL, I, Sp. 400f;  zur 
Wortbildung KEIL / MÜLLER (1997) 




 Originaltext Moderne Übersetzung 
PANNONICUM, CLUS. HIST. ALISMA, MATTH. CAST. CAM. 
EYST. ALPINUM, GES. HORT, THAL. CALTHA ALPINA, GES. 
HORR. CALENDULA ALPINA, GER. NARDUS CELTICA 
ALTERA, AD. LOB. LUGD. CHRYSANTHEMUM LATIFOL. 
DOD. LUGD. GER. DAMASONIUM 
SIVE ALISMA, LUGD. PTARMICA MONTANA, LUGD.] 
MATTH.32 CAST. CAM. EYST. ALPINUM, GES. HORT, THAL. 
CALTHA ALPINA, GES. HORR. CALENDULA ALPINA, GER. 
NARDUS CELTICA ALTERA, AD. LOB. LUGD. 
CHRYSANTHEMUM LATIFOL. DOD. LUGD. GER. 
DAMASONIUM SIVE ALISMA, LUGD. PTARMICA 
MONTANA, LUGD.]  
Harn 
treiben 
Von der Natur und Wirckung. 
 
LOBELIUS schreibet / daß es den Harn sehr und gewaltig forttreibe 
/ was sein Complexion sey / ist zuvor angezeiget. 
Von der Natur und Wirkung  
 
Lobelius schreibt, dass die Pflanze stark harntreibend wirke. Ihre 






[GESNERUS meldet / daß die Wurtzel niessen mache. 
Bey den Sachsen braucht es das gemein Volck / denen so hoch 
hinunder gefallen / oder so sich sonst etwan mit Arbeit verletzt 
haben: Nemmen ein Handvoll / sieden es in Bier / trincken des 
Morgens einen Trunck warm davon / decken sich zu / und 
schwitzen: Wo sie sich dann verletzt haben / empfinden sie an dem 
verletzten Ort großen Schmertzen / auff zwo oder drey Stund / und 
werden also curiert: Haben sie 
sich aber nicht verletzt / empfinden sie keine Veränderung.  
[Nach Gessner löst die Wurzel Niesreiz aus. 
Die Sachsen verwenden die Pflanze volkstümlich zur Behandlung 
von Sturzverletzungen oder sonstigen Arbeitsunfällen.  
Dazu wird eine Handvoll davon in Bier gekocht. Diesen Absud 
trinkt man morgens warm. Anschließend deckt man sich warm zu, 
um die Schweißbildung zu fördern. Verletzte spüren an den 
betroffenen Körperstellen während der folgenden 2 oder 3 Stunden 
zunächst starke Schmerzen, danach setzt die Heilung ein. Dagegen 
nehmen Personen ohne Verletzungen keine Veränderung wahr.   
 Auch zu Dantzig in Preussen ist es sehr in grossem Brauch / und 
obwol bey ihnen es nicht wächst / wird es doch auß Nider Sachsen in 
Fässern dahin gebracht.] 
Auch zu Danzig in Westpreußen wird die Pflanze oft verwendet, 
obwohl sie dort nicht wächst. Sie wird deshalb in Fässern aus 
Niedersachsen dorthin geliefert.] 
 
Rembert Dodoens’, wirkte bzw. wurde ausgebildet in Montpellier, Marburg, Wittenberg, Frankfurt a. M., Leiden, kaiserlicher Leibarzt in Wien, richtete 
den Wiener botanischen Garten ein, wurde berühmt durch seine Beschreibung der österreichisch-ungarischen Flora. 
32 Pietro Andrea Mattioli (1501-1577), kaiserlicher Leibarzt in Prag, stammte aus Siena, wirkte seit 1527 als Arzt zu Cles in Nonsberg / Sulzberg 




 Originaltext Moderne Übersetzung 
 [Von diesem Kraut wird auch gehandelt unden in der 11. Section am 
20. Cap. under dem Namen: groß Lucians Kraut / das erste / welches 
nichts anders dann diß Mutterwurtz.]  
[Diese Pflanze wird auch weiter unten in der 11. Abteilung des 20. 
Kapitels33 unter dem Namen ´Groß Lucians Kraut`34 (erster 





33 Dies ist ein Druckfehler. Die Beschreibung des „Groß Lucians Kraut“ befindet sich im Kapitel 23. 




APPENDIX 4: APPROXIMATION TO THE PHARMACEUTICAL AND PHARMACOLOGICAL 
PROFILE OF ARNICA MONTANA, TABERNAEMONTANUS 1664  
Label Contemporary English  
 
Contemporary German  Original Text Use-categories 
Contemporary name Arnica   
Botanical name Arnica montana Arnica montana Caltha alpina, Chalta alpina, 
Arnica, Doronicum plantaginis 
folio alterum, Alisma, 
Calendula alpina, Nardus 
celtica altera, Chrysanthemum 
latifol., Damasonium sive 
alisma, Ptarmica montana 
 
Historical names n.a. Arnica Mutterwurz, Mutterkraut, 
Wilder Wegerich, Wolveley 
 
Constitutional effect warm and dry                                   
(listed in contemporaneous 
literature (Gerard, 1633 
(1975), p. 740). 
   
Organoleptic properties it tastes fresh, sharp, 
penetrating, bitter, 
aromatic 
sie schmeckt rösch, scharf, 
durchdringend, bitter und dabei doch 
würzig 
eines räsen, scharffen, 
durchtringenden, bittern und 
doch wurzigen Geschmacks 
 




Label Contemporary English  
 




not defined decoction 
(used as a diuretic) 
 
beer decoction of root 
 
Absud: 
Absud (als Diuretikum gebraucht – 
nicht näher definiert) 
 
Bierabsud der Wurzel 
 
„es“35 (den Harn…fortreibe) 
 
 










Wurtzel niessen mache 
 
 
Actions internally diuretic 
 
 































daß es den Harn sehr und 
gewaltig forttreibe 
 
denen so hoch hinunder 
gefallen oder so sonts etwann 
mit Arbeit verletzt haben...und 
werden also curiert 
 
empfinden sie an dem 
verletzten Ort großen 
Schmertzen...und werden also 
curiert 
 
dienet auch wider den 




















35 The extraction method is not defined here. Since this preparation was used for diuresis it is most likely that it was a water extraction. The authoritative 
German apothecary textbook from 1783, printed a little more than 50 years after the last edition of Tabernaemontanus’ textbook (1731), provides guidelines 
for a water extraction of Arnica with the whole plant (herb, flowers, root): “…man giebt gemeiniglich die ganze Pflanze, als Blumen, Wurzeln und Kraut in 
einen Absud…” (one usually uses the whole plant including flowers, roots, and herb and makes a decoction) (Pfingsten, 1783, p. 99).  




Label Contemporary English  
 












treibt die Monzeit37 
 
stopffet den Stulgang38 
 
Es meldet Camerarius, daß die 
Bauern dem Viehe gesotten zu 
trinken geben / wann sie 
vermeinen  daß sie etwas 







Actions externally sneezing effect (drainage, 
tonic) 
Niesreiz auslösend (reinigend, 
Tonikum) 
 
daß die Wurtzel niessen mache tonic 
cleanse 
 
37 Inserted by the Bauhin editors (Tabernaemontanus, 1664, p. 1116). 
38 Insert by the Bauhin editors (Tabernaemontanus, 1664, p. 1116). 




Label Contemporary English  
 
Contemporary German  Original Text Use-categories 
Medicinal uses 
Internally 
































treibt die Monzeit 
 
 
daß es den Harn sehr und 
gewaltig forttreibe 
 
stopft den Stulgang 
 
mit Arbeit verletzt haben...und 




etwas vergifftes gessen 
 



























Dosage internal use Extractions: 
plant extract; dose 
unknown 
 
Beer extraction:  
a handful [of root] boiled 
in beer; drink warm each 
morning, cover up and 
sweat 
 
Extraktion:                    
Pflanzenextrakt. Dosis unbekannt 
 
Bier Extrakt:                                
eine Handvoll [der Wurzel] in Bier 
sieden; davon warm morgens trinken, 






Nemmen ein Handvoll / sieden 
es in Bier / trincken des 
Morgens einen Trunck warm 






Label Contemporary English  
 
Contemporary German  Original Text Use-categories 
Dosage external use Snuff  
(usually dosage to fill 
cavity of the nose) 
Schnupftabak  
(üblicherweise Dosis um ein 
Nasenloch zu füllen) 
 
  
Contraindications None mentioned Keine genannt   
Warnings and Precautions None mentioned Keine genannt   
Pregnancy and Lactation No contraindication 
mentioned explicitly for 
use during pregnancy or 
breastfeeding or in the 
section “uterus tonic” 
Keine Kontraindikation genannt 
expressis verbis für Gebrauch während 
Schwangerschaft oder Stillen oder in 
der Sektion „Uterus stärkend“ 
  
Side effects None mentioned Keine genannt   
 
 





APPENDIX 5: INDICATIONS FOR ARNICA MONTANA IN MEDICAL TEXTBOOKS 
Use-
























card-vasc 0 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 







































































































































   




































































































   
gyn ✓ ✓ ✓ ✓ 0 (✓) ✓ 0 0 (✓) (✓) 
 to bring on 
menstruation 
(amenorrhoea) 
to bring on 
menstruation 
(amenorrhoea) 








































   uterus 
complaints 
 
 knots in 
breasts 
         
head 0 
 

















inner / outer 
eye bleeding 
   































   
  after stroke   after stroke after stroke     
      nosebleed     
      tooth pain     
 hair colouring 
 





























infection 0 ✓ ✓ ✓ ✓ 0 ✓ 0 0 (✓) ✓ 
  malaria malaria malaria        















































         
musc-skel ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 









inner and outer 
injuries 
 




inner and outer 
injuries 
 















































































 torn muscles, 
ligaments 






  gout, 
rheumatism 







 stiffness of 
joints 








  sciatica 
 
 





























     strained 
vocal cords 
     
      contusions 
after passing of 
kidney stones 






















nerve ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
 pain pain due to 
injuries 
 
pain due to 
injuries 
pain due to 
injuries 
pain due to 
injuries 
 











pain due to 























     neuralgias neuralgias  neuralgias   
 nerve injuries 
/ function 
 nerve injury; 
inflammation 























    
  epilepsy  epilepsy  epilepsy     
respira-
tory 
0 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 


































































































      sore throat  sore throat sore throat sore throat 












✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
























    
  ulcers 
 







ulcers  ulcers ulcer ulcer  ulcer 
    infected lesions wounds wounds wounds 
bleeding 
wounds 
wounds wounds wounds 








      infections              
(viral - herpes) 
    
     burns 
 
     




































tonic ✓ ✓ ✓ ✓ (✓) ✓ ✓ ✓ ✓ (✓) ✓ 










 for sneezing 
(tonic) 





























     smoking  smoking     
      cardiac 
stimulant 




      fortifying 






















        shock recovery    
uro ✓ ✓ ✓ 0 ✓ 0 ✓ 0 0 0 0 
 diuresis 
 
diuresis diuresis  
 
diuresis       
  gravel     kidney stones 
(recovery from 
passing) 
    
 
Dark green rows refer to continued use 
Light green rows refer to intermittent but present-day-use 
Grey rows refer to present-day discontinuation 







APPENDIX 6: DETAILED ANALYSIS OF THERAPEUTIC 
INDICATIONS FOR ARNICA MONTANA RECORDED IN 
HISTORICAL MEDICAL TEXTBOOKS 
This appendix provides a detailed discussion on the recommended medicinal uses of Arnica 
over the past 400 years. For an overview, the indications are tabulated in Appendix 5. 
Documented indications for using Arnica montana have been identified in the treatment of 
12 different body systems: 
 Musculo-skeletal and nervous system  
The treatments of complaints of the musculo-skeletal and nervous systems involving 
various types of injuries and pain syndromes have been consistently listed in the 
medical literature since at least the early modern period. 
Main indications in the musc-skel use-category are as follows: 
o inner and outer injuries (noted since Tabernaemontanus 1664) 
o haematoma (noted since Löseke 1799) 
o sprains and strains (noted since Richter 1827) 
o torn muscles and ligaments (noted since Schulz 1919) 
o gout and rheumatism (intermittent since Löseke 1799) 
o stiffness of joints (intermittent since Löseke 1799). 
 
Main indications in the nerve use-category are as follows: 
o pain related to musculo-skeletal complaints (noted variously since 
Tabernaemontanus 1664) 
o nerve injuries (intermittently noted since Löseke 1799 until Saller et al 
1995). 
 
Treatment of paralysis with Arnica as noted from Löseke 1799 until Madaus 1938 was 
discontinued after WW2, most likely due to better treatment options. This discontinuation 








While indications belonging to the tonic use-category have been consistently listed 
across the past 400 years, Arnica was applied in different ways to achieve the 
stimulant effect. From the mid-17th to the beginning of the 20th century the tonic 
effect was achieved by either habitual snuffing or smoking of Arnica, whereas from 
the turn of the 20th century onwards the tonic effect in debility and exhaustion from 
various sources was achieved by ingesting a tincture, distillate (Schnapps 
preparation), powder, or water extract. 
Main indications in the tonic use-category are as follows: 
o as a stimulating snuff or tobacco (noted from Tabernaemontanus 1664 until 
Hager 1876) 
o in debility due to exhaustion or heart complaints (since Schulz 1919). 
 
 Cardio-vascular and respiratory systems  
Indications relating to cardio-vascular and respiratory use-categories have been 
noted consistently since the end of the 18th century. Awareness of the circulatory 
stimulant action of Arnica was raised with the conclusive confirmation of blood 
circulation by the English physician William Harvey in 1628. Subsequently, new 
physiological understandings expanded on prior traditional uses of Arnica to include 
indications that benefit from a stimulation of circulation and lymph flow. Continued 
research into Arnica’s sympathicotonic, vasodilating, spasmolytic, and circulatory 
stimulant properties led to the inclusion of Arnica’s medicinal use in coronary 
insufficiency, varicose veins, and phlebitis from the middle of the 20th century 
onwards.  
Main indications in the card-vasc use-category are as follows: 
o circulatory insufficiency (noted since Löseke 1799) 
o congestion, swelling, paralysis, and respiratory tract infections (noted since 
Löseke 1799) 
o bleeding (noted since Richter 1827 until Kroeber 1948) 
o varicose veins (noted since Kroeber 1948) 





Main indications in the respiratory use-category are as follows: 
o lower respiratory tract infections (noted since Löseke 1799 until Kroeber 
1948) 
o breathing difficulties (noted since Löseke 1799 until Kroeber 1948) 
o cough of various origins (noted since Löseke 1799 until Weiss 1974) 
o sore throat (noted since Madaus 1938). 
 
 Skin-mucous membranes 
Indications relating to the skin-mucous membranes category have shown 
consistency since the middle of the 19th century. These indications were confirmed 
by experimental research conducted since the 19th century, providing scientific proof 
of Arnica’s antiseptic properties.  
Main indications in the skin-mucous use-category are as follows: 
o ulcers (noted since Richter 1827)  
o wounds (noted since Hager 1876) 
o boils (noted since Schulz 1919) 
o inflammation of the mouth and throat (noted since Strumpf 1855). 
 
Additionally, Arnica snuffs were noted from Tabernaemontanus (1664) until Hager 
(1876). The purpose of Arnica snuffs was not only a stimulating effect, but also the 
cleansing of the mucous membranes in the nasal cavity.  
 
 Infection 
The treatment of non-specific systemic infections resulting in fever with Arnica 
montana preparations was listed from the end of the 18th century until WW2. The 
co-treatment of infections with Arnica was discussed once again by Bäumler (2007). 
From a contemporary perspective, there are at least two different mechanisms that 
may support this traditional application. In vitro assays have demonstrated Arnica’s 
topical antimicrobial actions against several gram-positive and gram-negative 
bacteria as well as fungi (ESCOP, 2003a, p. 44). It is possible that these 
antimicrobial properties also come to effect with internal use. In addition, infections 




established that Arnica improves cardiac output and oxygenation (Erley, 1965, p. 
236).  
Within this infection use-category, there are some interesting shifts to note. Arnica 
came to prominence in the 18th century when it was tried as a European malaria 
treatment in place of imported Cinchona bark (Cinchona officinalis), an alkaloid rich 
medicine from the tropical Andean forests. Malaria, caused by protozoal parasites 
transmitted by mosquitos that thrive in wetlands, was widespread in swampy areas 
of Central Europe from antiquity to the 20th century (Adams, Alther, et al., 2011, pp. 
278-288). The most likely explanation for the discontinuation of Arnica in the 
treatment of malaria by the mid-1800s is that Arnica was an experimental stand-in 
drug only when Cinchona was either unavailable or became unaffordable. Cinchona 
bark or its alkaloid quinine, which was first isolated in 1820 (Willcox, Bodeker, 
Rasoanaivo, & Addae-Kyereme, 2004), is more effective than Arnica in the 
treatment of malaria and remained first choice. In addition, during the 19th century, 
Central European wetlands were drained, thus reducing or eliminating the habitat for 
the malaria vector. The reduction of malaria decreased the need for experimentation 
with local treatment options, such as with Arnica. This example illustrates that the 
therapeutic use of Arnica was not randomly transmitted but came through a process 
of trial and error where effective treatments were passed on whilst ineffective or 
unnecessary treatments were eliminated. 
 
 Gastro-intestinal system  
Several factors may explain why indications relating to the gastro-intestinal system 
were consistently recommended in medical textbooks until the middle of the 20th 
century at which point the use of Arnica for such conditions was discontinued. 
Arnica root, the plant part used for the treatment of gastro-intestinal infections, was 
de-listed as an official plant part from the 2nd edition of the German pharmacopoeia 
(Pharmacopoea Germanica, 1882) onwards, possibly due to a conservation issue. 
This de-listing made access to Arnica root for the treatment of gastro-intestinal 
infections and diarrhoea more difficult. When Arnica became a protected species 
due to overharvesting, the root (the plant part used for the treatment of such 




the availability of synthetic antibiotics, which became the drug of choice for the 
treatment of bacterial infections.  
Main indications in the gastro-intest use-category are as follows: 
o diarrhoea (noted since Tabernaemontanus 1664 until Kroeber 1948) 
o ‘putrefaction’ (Faulfieber), typhus, dysentery, and other gastro-intestinal 
infections (noted since Löseke 1799 until Kroeber 1948). 
 
 Head 
Arnica was used for treating head injuries, cerebral concussion, bleeding in the 
brain, and paralysis after concussion from the first quarter of the 19th century 
onwards. It enjoyed renewed fame during 20th century war periods. With advances 
in trauma care, Arnica became redundant for treating haematoma and bleeding in the 
brain in the latter part of the 20th century; this is reflected in the discontinuation of 
Arnica’s specific recommendation in the treatment of head injuries. However, this 
did not affect the general recommendation of use of Arnica for injury recovery after 
traumatic events. 
Main indications in the head use-category are as follows: 
o eye complaints such as reduced vision, injury to the eye, or bleeding (noted 
since Löseke 1799 until Kroeber 1948) 
o cerebral concussion (noted since Richter 1827 until Kroeber 1948) 
o post stroke (noted since Richter 1827 until Madaus 1938). 
 
 Gynaecology  
Arnica was used medicinally as a uterine remedy at least since the 17th century to the 
middle of the 19th century after which such use was mainly continued in lay care. 
Main indications in the gyn use-category are as follows: 
o to promote menstruation in amenorrhoea and infertility (noted since 
Tabernaemontanus 1664 until Strumpf 1855) 
o to cleanse the uterus after birth (noted since Tabernaemontanus 1664 until 





Overdoses of Arnica were also noted for the induction of abortion; however, this 
was a folk medicine use rather than a clinical use. 
 
 Liver-spleen  
The use of Arnica as a liver-spleen remedy was permanently discontinued by the 
end of the 18th century. This coincided with paradigmatic changes to the 
understanding of the human body from a humoral perspective to a 
pathophysiological view of illness. The remedial treatment of poisoning with Arnica 
most likely related to the concept of humoral detoxification. 
The main indications in the liver-spleen category are as follows: 
o poisoning (noted since Tabernaemontanus 1664 until Löseke 1799) 
o bitter tonic (noted since Tabernaemontanus 1664 until Löseke 1799). 
 
 Urinary tract 
Arnica was noted by Tabernaemontanus (1664) to promote diuresis and was also 
used in formulations to treat urinary calculi (Löseke 1799). However, this use 
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Ph. Borussica 
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Dulk 1829 
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comm. to 7th ed. of 
Ph. Borussica 
card-vasc 0 0 0 0 0  ✓ 
       circulatory stimulant 
to treat paralysis from 
injuries to the head 
and bone marrow, 
cerebral concussion, 
epilepsy 
       circulatory 
insufficiency 
       diaphoretic 
gastro-
intest 
✓ ✓ ✓ ✓ ✓  0 
 diarrhoea diarrhoea diarrhoea diarrhoea diarrhoea   
gyn ✓ 0 0 0 0  0 
 to bring on 
menstruation 
(amenorrhoea) 
      
 uterus complaints       
head 0 0 0 0 0  ✓ 
       cerebral concussion 
infection 0 ✓ ✓ ✓ ✓  ✓ 
  antiseptic remedy antiseptic remedy antiseptic remedy antiseptic remedy  infections resulting in 
fever or putrefaction 
liver-
spleen 
✓ 0 0 0 0  0 
 poisoning       
musc-skel ✓ ✓ ✓ ✓ ✓  ✓ 
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comm. to 7th ed. of 
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  bruises bruises bruises bruises  bruises, haematomas 
  rheumatism rheumatism rheumatism rheumatism   
nerve ✓ ✓ ✓ ✓ ✓  ✓ 
 pain       
  nerve stimulation nerve stimulation nerve stimulation nerve stimulation  nerve stimulation after 
cerebral concussion, 
brain or bone marrow 
injuries, epilepsy, in 
putrefaction 
(septicaemia) 
  paralysis paralysis paralysis paralysis  paralysis 
  rheumatism rheumatism rheumatism rheumatism   
respiratory 0 0 0 0 0  ✓ 
       breathing difficulties 
skin-
mucous 
✓ ✓ ✓ ✓ ✓  ✓ 
 for sneezing 
(cleansing of mucous 
membranes) 
for sneezing 
(cleansing of mucous 
membranes) 
for sneezing 
(cleansing of mucous 
membranes) 
for sneezing 
(cleansing of mucous 
membranes) 
for sneezing 
(cleansing of mucous 
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 for sneezing 
(cleansing of mucous 
membranes) 
  wounds wounds wounds wounds   
       ulcers 
tonic ✓ ✓ ✓ ✓ ✓  (✓) 
 for sneezing (tonic) for sneezing (tonic) for sneezing (tonic) for sneezing (tonic) for sneezing (tonic)  for sneezing (tonic) 
       for smoking 
uro ✓ 0 0 0 0  ✓ 
 diuresis 
 






APPENDIX 8: INDICATIONS FOR ARNICA MONTANA IN THE COMMENTARIES TO THE 




















































































































































































































































































































































   shock  shock shock         





            bleeding   
gastro-
intest 















































































































































































































































            




























             
 uterine 
complaints 
          abortive   
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        tonic tonic / 
exci-tant 
tonic / (excitant     
uro ✓ ✓ ✓ 0 ✓ ✓ 0 ✓ 0 0 0 0 0 0 
 diuresis 
 




APPENDIX 9: EVALUATION OF INDICATIONS LISTED IN 
THE COMMENTARIES TO THE GERMAN 
PHARMACOPOEIA 
Commentaries to the German pharmacopoeia are used as an independent source to 
triangulate therapeutic use data recorded in medical textbooks. This body of literature is 
also a potential source of bibliographic evidence for verifying claims on traditional clinical 
applications of medicinal plants. Alongside Appendix 8 which tabulates the indications of 
Arnica as endorsed in the commentaries to the German pharmacopoeia, this appendix 
provides a comprehensive evaluation of these indications in the context in which they were 
embedded. 
The 19th century commentaries provide evidence of congruency between the normative but 
not legally binding commentaries to the German pharmacopoeia and contemporaneous 
clinically based medical textbooks. Apart from the gastro-intest use-category, both bodies 
of literature list indications in nine use-categories (card-vasc, head, infection, musc-skel, 
nerve, respiratory system, skin-mucous, tonic, and urinary tract) as displayed in Appendices 
5 and 8. These nine use-categories expand on body systems addressed by 
Tabernaemontanus in the following areas; the stimulating effect of Arnica on the cardio-
vascular and respiratory system, its benefits in trauma to the head, and its anti-infective 
effects on systemic and topical infections.  
The various commentaries reveal considerable differences in depth of therapeutic 
information offered. While some commentaries are extensive (Hager, 1874, 1883a; Hager et 
al., 1891), another of the same period is short (Schlickum, 1883, pp. 178-179) and one does 
not offer therapeutic guidance at all (Hirsch & Schneider, 1891). Since Hager (1865) was 
the commentator of the last edition of the Prussian pharmacopoeia, a text which became the 
founding text for the Ph. Germania, his commentaries mirror initially the same indications. 
The 2nd commentary by Hager (1883a) demonstrates that tradition is not static but expands 
when new insights are gained. This commentary lists three new indications; rheumatic 
complaints, cardiovascular weakness, and shock. For the last, it recommends a preparation 
with ½ teaspoon of a 1:10 Arnica tincture in ½ a glass of sugar water, drunk at once for the 




2nd commentary does not list the treatment of gastro-intestinal infections with Arnica root 
because the German pharmacopoeia de-listed this plant part as an official drug.  
By the turn of the 20th century, divergent views between academic scholars and clinicians 
become apparent. Compared with the clinician authored medical literature, annotations to 
the German pharmacopoeia now display a reductionist trend in their endorsements of 
indications of Arnica montana (Anselmino & Gilg, 1911c, 1911d, 1928). It is beyond the 
scope of this research to discuss how the privileging of the new natural-science based 
medical paradigm, commercial competition, and politically enforced regulatory 
requirements shaped the development of drug approvals, licensing guidelines, and funding. 
It is, however, important to understand that the evaluations of the therapeutic value of 
Arnica and other drugs reflect broader contextual factors within their time. They cannot be 
considered as an assessment purely based on a neutral scientific position. Rapid changes in 
pharmaceutical manufacturing captivated European healthcare during this time, and almost 
all newly developed and registered medicines became chemically synthesised (Müller-
Jahncke & Friedrich, 1996). The rapid rise of industrial pharmaceutical manufacturing 
threatened the commercial viability of local compounding pharmacists, their image as 
traditionalists, and their skill base (Anselmino & Gilg, 1911a, p. VI). By the turn of the 20th 
century, long-standing, traditional plant drugs that were mainstream medicines until then 
became a target of commercial rivalry. In response to intense competition from industrially 
mass-produced pharmaceutical drugs and in an attempt to gain legitimacy and a greater 
share of the market, local pharmacists developed a strategy to frame their image as that of 
modern scientists (Huisman, 1999; Quirke & Slinn, 2010, p. 21). Over time, a focused 
narrative framed traditional plant medicines and other non-pharmaceutical approaches to 
health as ‘unscientific’ or ‘quackery’, a situation that persists to this day (Holmes et al., 
2006; Schwager, 2012; Walach, 2009).  
It is in this context that the commentators on the 5th German pharmacopoeia distance 
themselves from the broader, empirically-based use of Arnica applied by contemporaneous 
physicians. They reduce the indications of Arnica to its use as a circulatory stimulant, as a 
treatment for bruises, haematoma, sprains and strains, as a topical disinfectant in wounds, 
and as an internal tonic (use-categories card-vasc, musc-skel, nerve, skin-mucous, and 
tonic) (Anselmino & Gilg, 1911d, pp. 537-539; 1928, pp. 604-607). As non-clinicians, the 
commentators omit all traditional indications relating to Arnica’s nerve and respiratory 




infections, and to its diuretic effects. The authors acknowledge Arnica’s essential oil and 
bitter principles but are unaware of other complex mechanisms involved in the diverse 
therapeutic effects of Arnica. 
Even though indications were reduced in the commentaries to the German pharmacopoeia 
during the first decades of the 20th century, Arnica continued to be used in patient care and 
attracted scientific curiosity. Experimental in vitro and animal studies in chemistry, 
pharmacology, and toxicology from the 1930s onwards contributed to an increasing 
evidence base for the clinical use of Arnica (Faber, 1953a; Kreitmair, 1952; Kroeber, 
1949a; Labadie, 1968; Stirnadel, 1959). This increase is reflected in the partial re-
introduction to the German pharmacopoeia of traditional indications in the 7th and 8th 
commentary by two professors of pharmacy, H. Böhme and K. Hartke from the University 
of Marburg (1969, 1981).  
In their commentary to DAB 7, Böhme and Hartke (1969, pp. 509-512) discuss Arnica as a 
circulatory stimulant based on the presence of distinct active constituents in Arnica flower; 
these had been scientifically shown to activate blood circulation in skin and mucous 
membranes. This stimulant effect had previously been recorded in the medical literature 
based on empirical observations. The authors further endorse topical uses of Arnica 
preparations with a 2% infusion or with a 20-25% cream (prepared with a 1:10 tincture) to 
recover from injury, bruises and haematomas, to decrease fluid in oedema, to support the 
healing of sprains, and to accelerate wound healing. These are long-standing historical 
indications. Based on pharmacological evidence, the authors further recommend a gargle or 
paint with either a 2% Arnica infusion or a 1:10 Arnica tincture (diluted five to ten times 
with water) for the treatment of inflammation of the mucous membranes in the mouth, 
another clinical indication previously noted in the medical literature (Fischer, 1941, p. 59; 
Schulz, 1919, p. 298).  
The authors claim, however, that the use of Arnica in cardio-vascular weakness and asthma 
is not defensible with modern pharmacology (Böhme & Hartke, 1969, p. 512). This 
comment highlights divergent views between an academic approach to the European 
materia medica and clinical practice at the time (Weiss, 1974, p. 177). In contrast to the 
1969 commentary, post WW2 medical textbooks continued to list clinical uses of Arnica 
preparations for conditions such as coronary heart insufficiency, Angina pectoris, asthma, 




In the commentary to DAB 8, Böhme and Hartke (1981, pp. 161-167) come to accept the 
empirically observed systemic circulatory stimulant effect of Arnica on the cardio-vascular 
system and the brain as well as its local stimulant action. Their re-assessment is informed by 
new experimental research into the active constituent profile of Arnica, which discovered 
the flavonoids astragalin and isoquercitrin with plausible systemic or local circulation 
actions. The 8th commentary (1981) also re-lists the traditional indication of rheumatism, an 
indication that was recorded in the 1st and 2nd commentary to the German pharmacopoeia 
(Hager, 1873, 1874; 1883a, p. 752) but that became de-listed when the mechanism of 
therapeutic action could not be explained by modern science methodologies. By the 1980s, 
research into the molecular mode of actions of Arnica elucidated its mechanism of 
inhibition on the transcription factors NF-κB and NF-AT at micromolar concentrations. 
Both transcription factors regulate how genes encode many inflammatory mediators 
(Merfort, 2003). The anti-inflammatory effect of this mechanism in rheumatism is now also 
established with clinical trials (Cameron et al., 2009; Knuesel et al., 2002; Widrig et al., 
2007).  
Parallel to the re-introduction of traditional clinical indications, the commentary to DAB 8 
(1981) highlights the risk profile of Arnica montana. The commentators caution against 
excessive doses of Arnica preparations, both internally and externally. Excessive external 
doses are said to lead to significant inflammation, including blisters and even necrosis, 
whilst excessive internal doses are said to irritate the mucous membranes of the 
gastrointestinal system, which can cause nausea, vomiting, and diarrhoea. Such toxic side-
effects based on overdoses had been previously noted in medical textbooks. The 
commentators to DAB 8 confirm symptoms of transient central nervous system dysfunction 
such as significant irritability and paralysis when Arnica is taken at extreme high doses for 
abortive purposes. The commentary lists the safe internal dose as 0.3-0.5g (20-30 drops) of 
tincture or an infusion of 200mg of flowers in 200ml hot water, taken by tablespoon full 
10ml at a time. A 2% Arnica flower infusion is recorded as a safe external application 
(Böhme & Hartke, 1981, p. 165). 
While the commentary to the 8th German pharmacopoeia continues to endorse the internal 
use of Arnica within a safe therapeutic dosage range, German commentaries beyond the 
1980s depart from such a favourable benefit-risk assessment. This departure reflects a 
period when official risk assessments of plant medicines changed overall (Zepernick et al., 




commentaries consistently endorsed both the internal and external use of Arnica 
preparations as exemplified in the German (DAB 8, 2. AB-DDR), Swiss (Ph. Helv. VI.), 
Austrian (ÖAB), and French (FP 56) pharmacopoeias (Blaschek et al., 2012; Zepernick et 
al., 1983, pp. 56-59). Research during the 1980s did not add new information regarding 
Arnica’s constituents, its proposed modes of actions, or its therapeutic effects, but a new 
approach to risk prompted some national regulators to recommend against most Arnica 
preparations for internal use (Wijnsma et al., 1995, p. 54; Zepernick et al., 1983, pp. 56-59). 
Since the 1980s, the only approved internal preparations are listed in HAB 1 (1981), the 
homoeopathic compendium to the German pharmacopoeia. These preparations are 
traditional mother tinctures (strength 1:10) of various plant parts which are applied either 
undiluted as phytotherapeutic preparations or diluted as homoeopathic preparations.  
The commentary to the Arnica monograph in DAB 9, written by toxicologist Schäfer-
Korting (Hartke et al., 1987, p. 876), signals an unprecedented departure from previous 
expert consensus. She sees the therapeutic action of Arnica as ungewiss (doubtful). Despite 
the availability of consistent empirical evidence that was noted in medical and 
pharmaceutical textbooks (see Appendix 5) and evidence from experimental research and 
clinical patient research (see Appendix 11), Schäfer-Korting drastically reduces the 
indications for Arnica tincture to two areas of topical treatment: sprains and muscular pain. 
Without elaborating on dosage, she advises against internal use of Arnica due to 
‘intoxication’ (Hartke et al., 1987, p. 876). Contradicting the assessment of the Commission 
E on Arnica montana which permitted Arnica’s use as a disinfectant on small wounds of the 
skin, Schäfer-Korting recommends the use of Arnica preparations for unbroken skin only.  
The commentary to DAB 10 (1993) reverses some of the narrowing of indications noted in 
the commentary to DAB 9. However, without elaborating on dosage, it recommends that 
systemic, internal applications are to be excluded from clinical practice. Therefore, by the 
end of the 20th century, indications relating to the external use of Arnica in the treatment of 
musculo-skeletal injury and pain remained the only indications endorsed in the commentary 
to the German pharmacopoeia. There are no amendments for Arnica noted in DAB 2012.  
In conclusion, commentaries to the German pharmacopoeia independently validate the main 
indications of Arnica recorded in the mainstream medical literature. They could be used as 
an additional source of bibliographic evidence for traditional health claims. Their 




regulator. Therefore, they should not be used as the sole source of evidence on traditional 





APPENDIX 10: INDICATIONS FOR ARNICA MONTANA IN OFFICIAL AND AUTHORITATIVE 
MONOGRAPHS COMPARED WITH THE MEDICAL LITERATURE 
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Dark green rows refer to continued use 
Light green rows refer to intermittent but present-day-use 
Grey rows refer to present-day discontinuation 
Indications in italics and brackets (✓) reference historical uses or folk medicine uses 
 
The Kommission E Monografie (Commission E Monograph) is a regulatory monograph by the former German Bundesgesundheitsamt (BGA) (German Ministry of Health) that provided 
approved claims for sale of plant-based medicines based on empirical and scientific evidence. 
 
The European Union Herbal Monograph is a regulatory monograph authored by the Committee on Herbal Medicinal Products (HMPC) of the European Medicines Agency (EMA) based on 
consensus of 28 EU Member States. The Arnica monograph evaluated was a ‘traditional use’ monograph. 
 






APPENDIX 11: ARNICA MONTANA DATABASE RESEARCH EXCEL SPREADSHEET 




APPENDIX 12: TRANSCRIPT OF HYPERICUM PERFORATUM MONOGRAPH IN 
TABERNAEMONTANUS (1664) 
This appendix is the German language transcript of Tabernaemontanus’ monograph on Hypericum spp. The pharmaceutical and pharmacological 
data is translated into English in Appendix 13.  
Das CXL III. Capitel. 
VON SANCT JOHANNESKRAUT 
1. Sanct Johanneskraut. 
Hypericon. 
 






<Buch 2, Sektion 11, Kapitel 143, S.1249B-1252A> 
 






Sanct Johanneskraut (I.) hat ein harte holtzechte Wurtzel / 
welche sich hin und wider im Land weit außbreitet / auß 
der Wurtzel entstehen viel runde / holtzechte / braunrothe 
Stengel / welche einer Elen hoch wachsen / mit andern 
Nebenästlein besetzet / an welches Giepffel kleine 
Blümlein erscheinen / mit fünff gelben Blättlein geziehret 
/ mit härichten Fäsichen / wenn man diese Blumen 
zwischen den Fingern zerreibet / wie auch seine Blätter / 
so geben sie / wie DODONÆUS schreibet / einen 
schwartzrothen / oder vielmehr einen braunroten Safft / 
wie ein Blut. Die Blätter seyn etwas breyt / auch länger 
dann rund / den Dostenblättern oder Gauchheyl bey nahe 
gleich / und so man sie gegen dem Tag oder das Liecht 
helt / sihet man viel kleiner Löchlein darinn / als wären 
sie mit Nadeln durchstochen. Nach den Blumen wachsen 
kleine Schörtlein / welche forn spitzig seyn / und an dem 
Stiel runde und etwas weit einem Gerstenkorn ähnlich / in 
welchen sehr kleiner Saame verschlossen ist / welcher 
I. Sankt Johanniskraut besitzt eine zum Verholzen neigende 
Wurzel, die sich gelegentlich weitflächig ausbreitet; aus der 
Wurzel sprießen mehrere runde, verholzende rotbraune 
Stengel, die bis zu einer Höhe von 60 bis 70 Zentimetern 
aufwachsen, sich astig verzweigen, am Ende kleine Blüten mit 
fünf gelben Kronblättern tragen, die mit haarigen Fäserchen 
besetzt sind. Wenn man diese Blüten, wie auch die Blätter, 
zwischen den Fingern zerreibt, dann geben sie, wie Rembert 
Dodoens schreibt, einen dunkelroten oder braunroten Saft wie 
Blut. Die Blätter sind breit und eher länglich als rund, den 
Blättern des Thymiandostes40 oder Ackergauchheils41 nahezu 
gleich, und wenn man sie gegen das Tages- oder Kerzenlicht 
hält, sieht man in ihnen viele kleine Löchlein, als wären sie 
mit Nadeln perforiert worden42. Aus den Blüten wachsen 
kleine Schoten, die spitz zulaufen, am Stiel breiter sind und 
einem Gerstenkorn ähnlich sehen; sie umschließen winzig 
 
40 Origanum vulgare L.; MARZELL (2000), III, 449ff. 
41 Anagallis arvensis L.; MARZELL (2000), I, 253ff.  
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erstlich roht / darnach schwartz wird / am Geschmack 
dem Hartz gleich / wie DODONÆUS vermeldet. 
kleinen Samen, der zunächst rot ist, dann schwarz wird und 




   II. Von dem andern Geschlecht schreibt LOBELIUS, 
daß seine Blätter viel kleiner seyen / dann am ersten 
Geschlecht / sonst sey es mit seinen gelben Blümlein 
demselbigen durchauß gleich. 
II. Von der anderen Art schreibt Matthias Lobelius van 
Rijssel44, dass ihre Blätter erheblich kleiner seien; ansonsten 




    III Das dritte Geschlecht HYPERICON 
TOMENTOSUM, genennt / hat ein hartes holtzechtes 
Würtzlein / mit viel Zaseln / deren sich etliche uber die 
Erden außbreyten / uber die Wurtzel kommen viel rauhe 
Zweiglein / welche sich uber die Erden außbreiten / mit 
viel kleinen Blettlein besetzet / wie an dem gemeinen 
Sanct Johanskraut / außgenommen daß sie graw und 
wollecht seyn: Seine blümlein seyn von Farben gelb / 
doch etwas bleicher dann am andern Geschlecht. 
III. Die dritte Art, die sich Hypericum tomentosum nennt46, 
verfügt über eine kleine, harte, verholzende Wurzel mit 
zahlreichen Wurzelfäserchen47, von denen einige über dem 
Boden verlaufen. Die Stengel sind zahlreich, niederliegend 
und rauh; sie zeigen einen Besatz mit vielen kleinen Blättern 
wie beim echten Sankt Johanniskraut, mit dem Unterschied 
allerdings, dass sie grau und wollig erscheinen. Die Blüten 
sind zwar ebenfalls gelb, wirken aber blasser als bei der 
anderen Art. 
 Dem Johannskraut werden noch zwey andere Geschlecht 
zugeschrieben / so von dem Authore noch nit seyn / 
nemlich Hartheuw und Conradskraut / von welchen man 
Unter „Johanniskraut“ werden noch zwei weitere Arten 
aufgelistet, die dem Autor48 noch nicht bekannt sind, nämlich 
 
43 “het welcke ghewreven zijnde nae den Harst schijnt te riecken”, DODOENS (1644), S. 101b. Dies wurde bereits bei Dioskurides vermerkt, DIOSCURIDES (1610) III, 
S.242. 
44 In seiner Plantarum seu stirpium historia von 1576. 
45 Das hier als andere, sehr ähnliche Art geführte (und in der Bild-Beischrift als „Hypericum Alexandrinum“) ausgewiesene Hypericum quadrangulum L. = Hypericum 
maculatum GRANTZ wurde in der Volksbotanik vom Sankt Johanniskraut Hypericum perforatum L. nicht unterschieden; vgl. MARZELL (2000), II, 937f.  
46 Vermutlich Hypericum elodes L. (= Elodes palustris SPACH.) oder Hypericum humifusum L. „Tomentosum“ bezieht sich auf den ‚wollig’- filzigen Besatz der Stengel und 
Blätter; vgl. GEORGES (1879/80), II, Sp. 2824; Dfg. 587a „tomentum“, und sieh auch DRAGENDORFF (1898), S. 437f. 
47 Zur Bedeutung der ‚kleinen Fasern an der Pflanzenwurzel’ sieh DWB, XV = 31, Sp. 314. 
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bey dem DIOSCORIDE und DODONÆO lesen kan / sie 
seyn aber diesem Johanskraut fast gleich / allein daß das 
Harthew ständlechter ist / auch grösser Stengel und Aest 
hat / welche braunrot seyn. In dem Conradskraut kommen 
/ als neben den grossen Blättern / andere kleine Blättlein 
herfür. 
Hartheu49 und Konradskraut50, über die man indessen bei 
Dioskurides51 und Dodoens52 etwas nachlesen kann; sie sind 
freilich mit dem echten Sankt Johanniskraut nahezu identisch, 
ausgenommen dass das Hartheu stabiler53 ist und höher 
aufragende Stengel und Seitentriebe besitzt, die rotbraun 
gefärbt sind. Beim Konradskraut sprießen neben den großen 





IV. [Das Hartheuw hat ein weißlecht Wurtzeln / in viel 
Zaseln zertheilet / so nicht tieff in der Erden stecken / auß 
welcher die Stengel herfür schiessen / so braunrot und 
grösser dann am St. Johannskraut: die Blätter sind dünn / 
mit Striemlein nach der länge durchzogen / so viel breiter 
und länger dann am St. Johannskraut: die Blumen sind 
Dottergelb: Der Saamen klein und schwartzlecht am 
Geruch wie Hartz / welcher zwischen den Fingern 
zerrieben / dieselbige färben / als wann sie mit Blut 
angestrichen wären. 
IV.54 [Das Hartheu besitzt eine helle, weißliche Wurzel, die 
sich fasrig verästelt und nicht tief in die Erde reicht; aus ihr 
sprießen zahlreiche Stengel, braunrot gefärbt und höher 
aufragend als die des Sankt Johanniskrauts; die Blätter sind 
dünn, der Länge nach von Nerven durchzogen, im übrigen 
breiter und länger als beim Sankt Johanniskraut; die Blüten 
erscheinen dottergelb. Die kleinen, schwärzlichen Samen 
riechen nach (Koniferen-)Harz und färben, wenn sie zerrieben 
werden, die Finger dunkelrot, wie mit Blut bestrichen. 
V. Conrads kraut V. Conradskraut aber ist ein standechtes Kraut / mit 
schmalen rothen Aestlein / die Blätter sind länger und 
spitziger dann deß Harthew / allwegen ein par beysamen / 
V. Das Konradskraut oder Mannsblut zeigt dagegen einen 
stabilen, aufrechten Wuchs, besitzt schmale, rot-stenglige 
Verästelungen; seine Blätter sind länger und spitzer als beim 
 
49 In der Tat bezeichnet „Hartheu“ üblicherweise das Sankt Johanneskraut, also die erstgenannte Art vgl. MARZELL (2000), II, S. 939-940.  
50 Dies bezieht sich auf „Mannsblut“, Hypericum androsaemum L., das von den Botanikern des 16. Jahrhunderts allerdings auch als Hypericum perforatum gedeutet wurde; 
vgl. MARZELL (2000), II, S. 937. 
51 DIOSCURIDES (1610), III, S.243; BERENDES (1902), S. 362f. 
52 DODENS (1664), S. 102a. 
53 Zur Bedeutung „ständlich“ ‚stabilis’ sieh DWB, X/II/I = 17, Sp. 778. 
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zwischen jedem par wachsen andere kleine blättlein: am 
obern theil deß Stengels / bringet es viel Nebenzweigle / 
wie Flügel außgespreitet / umb welche kleine gelbe 
Blümlein wachsen: Der Saamen ligt in Hülsen / dem 
schwartzen Magsamen ähnlich. Diese beyde Kräuter 
wachsen an feuchten Orthen.] 
Hartheu, sie wachsen gegenständig, und zwischen jedem 
Blattpaar sprießen kleine Nebenblätter; der obere Stengel 
verzweigt sich und breitet seine Seitenstengel wie Flügel aus, 
auf denen kleine gelbe Blüten wachsen. Die Samen liegen in 
Hülsen wie der schwarze Samen des Schlafmohns. Diese 
beiden Kräuter55 bevorzugen feuchte Standorte.] 
 St. Johannskraut wächst allenthalben in den Hecken / an 
den Reinen und in den Wiesen / blühet im Julio. 
Das Sankt Johanniskraut ist verbreitet und wächst in Hecken, 
auf Rainen und Wiesen; im Juli blüht es. 
 
 Von den Namen. 
Sanct Johannskraut heißt Griechisch ύπέριϰον, Leteinisch 
HYPERICUM, PERFORATA, FUGA DÆMONUM. [I. 
HYPERICUM VULGARE, C.B. HYPERICOUM, 
BRUNF. MATT. FUCH. ANG. TUR. LAC. LON. DOD. 
AD. LOB. CÆS. LUGD. CAST. CAM. GER. EYST. 
HERBA PERFORATA & HYPERICUM VULGARE, 
TRAG. ASCYRON. DOD. GAL. CORD. IN DIOSC. 
ANDROSÆMON MINUS, GER. COL. II. 
HYPERICUM FOLIO BREVIORE, C.B. SYRIACUM & 
ALEXANDRINUM, LOB. SYRIACUM, LUGD GER. 
Von den Namen. 
Sankt Johanniskraut heißt auf Griechisch „hypérikon“, auf 
Lateinisch „Hypericum“, „(Herba) Perforata“, „Fuga 
daemonum“56 [...]57. Auf Arabisch „ Rejo. fricon.“ Auf 
Italienisch58 „Hiperico.“ „Herba rossa“, auf Französisch 
„Mille pertuis“, auf Englisch „G(reat). Johannes woorte“, auf 
Tschechisch59 „Zwoncek cerweny“, [auf Niederländisch „Sint 
Janscruyt“], auf Spanisch „concillo“60 - „Hartheu“, auch als 
„Waldhopfen“ bezeichnet, wird „Ascyron“ genannt und heißt 
auf Niederländisch „Herthooy“, auf Englisch „St. Peterswoort 
 
55 Nämlich Hartheu und Konradskraut. 
56 Weil es die ‚bösen Geister’ in die Flucht schlägt; vgl. HWdAgl. (1927-1942), III, 1486f., und IV, 743; RGA (1973-2008), XVI, S. 68ab. 
57 Der terminologische Einschub der Bauhin Redaktion wird in der Übersetzung ausgelassen. 
58 „Welsch“ hier bezogen auf das ‚Italienische’ (wie in „Welsch Tirol“ oder in „Welsch Bern“ = ‚Verona’ [im Gegensatz zu „Deutsch Bern“ = ‚Bern’]). 
59 Im Sinne der Bohemistik ‚das Tschech[oslowak]ische’. 
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III. HYPERICUM SUPINUM TOMENTOSUM VEL 
MONSPELIACUM, G.B. SUPINUM, DOD. 
TOMENTOSUM LOB. LUGD. GER. ALTERUM 
TOMENTOSUM, AD. TOMENTOSUM FECUNDUM. 
CLUS. HIST. ANDROSÆMUM ALBUM DALECH. 
LUGD. IV. ASCYRUM SIVE HYPERICUM 
BIFOLIUM GLABRUM NON PERFORATUM, C.B. 
ANDROSAEMON, MATTH. FUCH. TUR. LAC. 
CORD. IN DIOSC. CAST. GES. COL. HYPERICUM 
ALIUD. DOD. GAL. V. ANDROSÆMON ALTERUM 
FOLIIS HYPERICI, C.B. ANDROSÆMON, LOB. 
ALTERUM, AD. RUTA SYL. HYPERICOIDES, DOD.] 
Arabisch Refo. fricon.  Welsch Hiperico, herba rossa. 
Frantzösisch Mille pertuis. Englisch G. Johannes woorte. 
Böhmisch Zwoncek cerweny. [Niderländisch St.  
Janscruydt: Spanisch concillo. Hartheuw aber so auch 
Waldthoff / wird ASCYRON genannt / Niderländisch 
Herthooy: Englisch St. Peterswoort square great St. 
Johanns grasse: Welsch asciro.  
square great“ oder „St. Johanns grasse.“ Auf Italienisch heisst 
er „asciro“. 
 Conradsdraut wird gemeiniglich ANDROSÆMUM, und 
auff Welsch ANDROSÆMON genannt.] 
[Das Konradskraut wird üblicherweise Androsaemum genannt 
oder auf Italienisch Androsaemon.] 
 Von der Natur / Krafft und Eygenschafft des St. 
Johannskrauts. 
AETIUS schreibet / das Kraut sey warm und trucken und 
einer subtilen Substantz. [Die Geschlecht der Hartheuw / 
oder St. Johannskräuter / sind warmer und trucknender 
Von der Natur, Kraft und Wirkung des Sankt 
Johanniskrauts  
Aëtius von Amida schreibt, Sankt Johanniskraut sei warm 
und trocken und zusammengesetzt aus einer feinen, zarten 
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Natur im andern / oder wie etliche wöllen im dritten 
Grad: haben auch gleiche Würckung.] 
warmer und trockener Natur im zweiten Grad und werden 
von manchen Autoren sogar als warm und trocken im dritten 









Wiewol diese Kräuter heylsame Wundkräuter sind / wie 
die lange und tägliche Erfahrnuß gnugsam beweißt / wird 
dieses von den Alten nicht gemeldet / dann sie ihnen 
nicht weiters zugeben / dann daß sie das Blut in den 
Wunden stillen / und dieselbigen sonderlich was verbrant 
ist / heylen. Aber dieser zeit werden sie nicht allein 
innerlichen zu Wundträncken / sonderen auch eusserlich / 
Oel und darvon gesottene Brühen / in grossen / tieffen 
Wunden / Verletzung deß Geäders / nutzlichen gebraucht 
/ solche zu reinigen / und von grund auß zu heylen.] 
Innerliche Anwendung 
[61Obwohl all diese Arten von Johanniskräutern überaus 
wirksame Heilpflanzen sind, was aus der Langzeiterfahrung 
bekannt ist und sich durch den täglichen Gebrauch aufs neue 
erweist, werden die entsprechendem Heilwirkungen von den 
antiken Autoren nicht erwähnt, insofern als sie den 
Johanniskräutern lediglich eine blutstillende und 
wundheilende Wirkung zugestehen, besonders bei 
Verbrennungen. Heutzutage werden indessen die 
Johanniskräuter nicht nur innerlich als wundheilende 
Getränke verwendet, sondern auch äußerlich angewandt als Öl 
und Absude, die bei großflächigen, tiefen Wunden und 
Verletzungen von Sehnen, Nerven und Muskeln62 wirksam 
sind; solche Präparate haben einen reinigenden Effekt, was 
eine Heilung vom Wundgrund her ermöglicht.] 
Harn treiben PAULUS ÆGINETA schreibt / daß das gantze Gewächs 
ein Natur und Krafft habe den Harn fort zu treiben: Darzu 
Paulus von Agina schreibt, dass die gesamte Pflanze in ihrer 
Natur die Heilkraft habe, den Harn zu treiben, wenn man das 
 
61 Diesen Einschub der Bauhin Redaktion in den Originaltext lässt sich leicht entkräften durch eine Überprüfung des Johanniskraut Kapitels von Dioskurides [wie Anm. 12]; 
vgl. auch die Vielzahl von mittelalterlichen Indikationen (menstruationsfördernd, diuretisch, gefäßerweiternd, leber-protektiv, antidotisch, traumatologisch, gegen Arthralgien 
bei Rufinus Bl. 59rbf., THORNDIKE/BENJAMIN (1945), S. 152f. 
62 Zur Bedeutung von frühneuhochdeutsch „Ader“ = ‚strangartiges Gebilde’ sieh MILDENBERGER (1997), I, S. 38-40, S. 665: Sehnen, Nerven, Muskel(strang), auch 




 Originaltext Moderne Übersetzung 
Gifft 
Weiberzeit 
man dann Kraut / Blumen und Saamen in Wein sieden 
kan und darvon trincken / [welches auch das Gifft außjagt 
/ und der Weiber Blödigkeit treibt.] 
Kraut mit Blüten und Früchten63 in Wein siedet und den 
Absud davon trinkt. [Die gleiche Abkochung wirkt auch als 
Antidot, indem sie Gift ausleitet, und den Frauen als 
menstruationsförderndes Mittel ihr Unwohlsein nimmt64.]  
 
Hufftweh 
GALENUS schreibet / daß etliche das Kraut oder den 
Saamen eingeben wider die Schmertzen und Wehethumb 
der Hüfft. DIOSCORIDES schreibet / man soll den 
Saamen viertzig Tag langdarzu gebrauchen. 
Galen schreibt, dass viele das Kraut oder den Samen bei 
Hüftweh, also bei Ischialgien65 und diesbezügliche 
Schmerzen verordnen, wobei Dioskurides meint, dass der 
Samen zur Schmerzlinderung 40 Tage lang eingenommen 
werden sollte. 
Harn und Griess 
treiben. 
Blasenstein. 
PLINIUS schreibet / der Saame [gesotten und 
getruncken] habe ein Art den Leib zu stopffen / dargegen 
aber treibe er den Harn und den Grieß. [Ist treffenlich gut 
dem Blasenstein. 
Bei Plinius steht geschrieben, dass der Samen [abgekocht und 
das Dekokt getrunken] stopfend wirke; im Gegensatz dazu 
treibe er den Harn und schwemme Grieß aus. [Er hilft auch 
gegen den Blasenstein. 
 
63 Hier handelt es sich in der modernen botanischen Terminologie um die sich formenden Früchte, die an einer blühenden Pflanze zusammen mit den Knospen und Blüten 
vorhanden sein können. Die effektiven Samen bilden sich zu einem späteren Zeitpunkt, wenn keine Blüten mehr vorhanden sind. Brunfels 1532 (Kapitel CCLI) verwendet, 
genauer als Tabernaemontanus, sowohl den Begriff “Frucht” wie auch als separate Droge “Somen”. 
64 „der Weiber Blödigkeit“ bezieht sich auf die Menstruation, siehe FrnhdWb (1986) IV, Sp. 636. Brunfels 1532 (Kapitel CCLI) bestätigt: “…das sye den Frawen ire zeit”. 
Tabernaemontanus scheint hier aber nicht nur von der physiologischen Monatsblutung zu sprechen, wie etwa bei der „Kammille“ (1664, Buch I, Sektion 1, Kapitel 13, S.65) 
„fürdert die weibliche Monatsblum“, sondern benennt mit dem Begriff „Weiber Blödigkeit“ einen umfassenderen Komplex des Unwohlseins, der auch psychologische 
Aspekte miteinschliessen kann. Heute wird Johanniskraut nach wie vor zur Behandlung von Stimmungsschwankungen und Depression beim prämenstruellen Syndrom, 
während der Peri-Menopause und im Klimakterium verwendet. 
65 Bock (1577, S.28) erläutert, dass es sich bei Hüftweh um Ischias handelt: “Vertreibt…beschwerlich hüfftwehe, Ischia genant...”. ‘Ischi-‘ bedeutet auf Griechisch 
Hüftgelenk und Hüfte. Sieh auch Rufinus, Bl. 59va, THORNDIKE/BENJAMIN (1945), S. 153, Z. 7, wo es vom Johanniskraut heißt: „Herba sancti Iohannis... femorum 
dolorem auffert.“. PSCHYREMBEL (1977), S. 572 bestätigt die Synonymität von Hüftweh und Ischias: “Ischias, Ischialgie (…Schmerz): Hüftweh, Neuralgie des Nervus 
ischiadicus, Neuritis ischiadica, Malum Cotuunii” und erläutert, dass die Kompression des Nerves unter anderem bei latenten Bandscheibenvorfällen, Bandscheibenschäden 
und Erkrankungen der Wirbelsäule und des Hüftgelenks vorkommt. Siehe auch Pschyrembel (1993), S. 739. Die empfohlene Anwendung bezieht sich also wahrscheinlich 
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Blutspeyen Der Same zerstossen mit Wegrichsafft oder Wasser 
getruncken / dienet wider das Blutspeyen.] 
Wenn man Blut speit, sollte Johanniskraut-Samen mit 
Wegerichsaft oder -wasser getrunken werden.] 
Dreytägig Fieber DIOSCORIDES schreibet / wann man das Kraut mit 
Wein trincke / so vertreibe es das dreytägige Fieber. 
Bei Malaria tertiana solle man laut Dioskurides das Kraut in 





Das Kraut mit dem Saamen gedörrt und gepülveret / mit 
Wein getruncken / dienet fürs Gesicht an Füssen / 
[reiniget Nieren und Leber. 
Bei rheumatischen Beschwerden66 an den Füßen hilft 
Johanniskraut, wenn man das Kraut samt dem Samen 
trocknet, zerstößt und das Pulver in Wein trinkt; [das reinigt 
auch die Nieren und die Leber. 
 In Polen pfleget man den jenigen / so jhnen von wegen 
schwerer Last weh gethan haben / diese Blumen in einem 
warmen Bier mit Butter und Saltz warm einzugeben.] 
In Polen ist es üblich, diejenigen, die sich an schweren 
Lasten verhoben haben und über Schmerzen klagen, mit 
Johanniskrautblüten zu heilen: Man legt die Blüten in warmes 
Bier, fügt Butter und Salz hinzu und gibt das dem Patienten 







Es schreibet AETIUS, wann man das grüne Kraut 
zerknitsche / und wie ein Pflaster überlege / so heffte es 
die Wunden und die offene Geschwär widerumb 
zusammen / und sonderlich was von Brand ist / welches 
auch GALENUS bezeuget. 
Äußerliche Anwendung 
Für Wunden und offene Geschwüre—insbesondere für 
solche, die von Verbrennungen stammen – empfiehlt Aëtius 
von Amida, dass man die Frischpflanze zerdrücke67 und als 
Pflaster68 aufbringe; dann schließe es die Wunden sich heile 
das offene Geschwür. Galen kann das bezeugen. 
 
66 „Gesicht“ entspricht mittelhochdeutsch „gesühte“ (‚Krankheit’), ‚rheumatische Übel’, LEXER (1872-1878), I, 936; vgl. HÖFLER (1899), S.707a: „Polyarthritis 
rheumatica“. 
67 Die Bedeutung von „zerknitschen“ ist ‚zermalmen’, auch ‚zerstoßen’ und ‚zerdrücken’; vgl. MILDENBERGER (1997), V, S.2353. 
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Verstopfte69  
Nerven     
FERNELIUS meldet / daß diß Kraut gar nutzlich zu 
gebrauchen sey zu den zerknitschten und zerstossenen 
Nerven. 
Fernalius meldet, dass dieses Kraut sehr nützlich sei bei 
zerquetschten und verletzten Nerven.  
Zittern. [Die Glieder mit dem Kraut gerieben / deß Tags zwey 
mal vor dem Essen / ist gut fürs Zittern und Beben.] 
[Wenn man die Extremitäten zweimal täglich mit frischem 
Johanniskraut einreibt, so wirkt sich dies günstig bei Zittern 
und Tremor aus.] 
 
Unreine Wunden 
PAULUS ÆGINETA saget LIB. 7. DE RE MEDICA; 
wann man das dürre Pulver in die unreine feuchte 
Wunden sträuwe / so verzehre es die Feuchtigkeit / und 
heyle die Wunden / und auch dergleichen Geschwär. 
Was unreine und nässende Wunden betrifft, so empfiehlt 
Paulus von Aegina im siebten Buch seiner ‚De re medica’, 
dass man die Trockendroge zerstoßen und das Johanniskraut-
Pulver in die Wunden streuen soll, dann höre das Nässen auf 
und es könne solche Wunden und Geschwüre zur Heilung 
bringen. 
Kindsnöht. Wenn ein Weib in schweren Kindsnöhten ligt / soll man 
sie mit dem dürren Kraut beräuchen. [Etliche beräuchen 
die sechswöchige Weiber darmit / derohalben nennet man 
es an etlichen Orten unser Frawenwurtz.] 
Wenn eine Frau in schweren Kindsnöten liegt, soll man sie 
mit getrocknetem Johanniskraut beräuchern70. [Manche 
beräuchern auch die Mütter nach deren Niederkunft in den 
sechs Wochen71 ihres Wochenbetts mit getrocknetem 
Johanniskraut. Derartige (obstetrische) Verwendung hat der 
Pflanze in einigen Regionen72 den Namen „Frauenwurz“ 
eingebracht.] 
 
69 Reizleitende Nerven, die als Hohlorgan gedeutet wurden, galten als „verstopft“ („oppilati“), wenn sie ihren Dienst verweigerten; EnzMedGesch (2005), II, S. 1039a. 
70 Die Beräucherung erfolgte in der Regel genital. Zu den beim Beräuchern verwendeten Trichtern und Röhren sieh DELVA (1983), S. 172-178; auf S. 176, Z. 14 (= Bl. 7v1) 
lies „onder eenen stoel“ statt „up eenen stoel“ und vgl. entsprechend KUSCHE (1990), S. 192, Bl. XXIIr4-6: „ende sedt den pot al heet onder hare dat die heete lucht jn haren 
lichaeme slaen mach van onder op“, ebd. S. 200, XXVr2-5: „onder enen stoel met enen gate“, ferner S. 208, XXIXrf, und KEIL (2009), S. 174f. mit Abb.1. 
71 Zur Dauer des Wochenbetts siehe RGA (2007), XXXIV, S. 174a-180a.  
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Rote Ruhr. 
 
MATTHIOLUS schreibt / wenn jemandts die rote Ruhr 
hat / dem soll man ein Fußbad auß diesem Kraut machen 
/ und jhn darein setzen / und die Füß waschen / so stopffe 
es den Durchlauff. 
Für Patienten, die an der roten Ruhr73 erkrankt sind, 
empfiehlt Matthioli, dass man ihnen aus Johanniskraut ein 
Fußbad bereite, sie in den Badezuber setze und ihnen die Füße 
darin wasche. Das wirke stopfend auf den Durchfall. 
Gespengst. Die alte Weiber sagen / daß diß Kraut sey für Gespengst / 
wann man es bey sich trägt / daher es auch FUGA 
DÆMONUM soll genennt werden. 
Alte Frauen sagen, dass man mit Johanniskraut Gespenster in 
die Flucht schlagen könne, indem man es als Amulett trage; 
deswegen würde es auch „Fuga daemonum“74 genannt. 
 Von dem Safft des Johanneskrauts. 
Auß den Blättern und Blumen kan man auch einen Safft 
außpressen / wie bey dem Wermuhtsafft ist angezeigt 
worden. 
Vom Presssaft des Johanniskrautes 
Aus den Blättern und Blumen des frischen Johanniskrauts 
kann man auch einen Saft auspressen, und zwar auf die 




Dieser Safft mit Wegrich oder Wegtrittwasser getruncken 
/ hilfft wider das Durchlauffen und Bauchflüß / und ist 
auch gut wider das Blutspeyen. 
Wenn dieser Saft mit Wegerichwasser oder Wegetrittwasser76 
gemischt und getrunken wird, wirkt dies gegen (akuten) 
 
73 Die Ruhr löst blutig-schleimigen Stuhlgang aus. 
74 Erstbeleg in einer Salerner Drogenliste des 13. Jahrhunderts: RGA (2000), XVI, S. 68b. Brunfels schreibt ebenso 1532 (Kapitel CCLI) “…Fuga demonum genennt. 
Darumb das man meynete, wo solchs kraut behalten würt, da komm der teuffel nicht bey. Möge auch kein gespenst bleiben und darumb berüchet man in etlichen landen die 
kindtbetterin damit. Lass es aber vorsegnen uff unßer frawen offarttag und haben also ire kurzweil damit”. In alten Kräuterbüchern findet man eine Vielzahl von Ausdrücken 
für Symptome, die man heute auch als depressive Verstimmung und Angstzustände bezeichnen würde, und wo Johanniskraut nicht alleiniglich als Schutzmassnahme 
eingesetzt wurde, so bei Paracelsus (1525) der Johanniskraut gegen die Geister und tollen Fantasien, die den Menschen in Verzweiflung bringen, verschrieb; bei Carl (1719), 
der die Heilpflanze als „gute Nervenstärkung und wider die Zauberey“ rühmte; bei Zedler (1732), der Johanniskraut als das heilkräftigste bei Zauberei (= Depression) 
bezeichnete und bei Krünitz (1784-1836), der es als wirksam beschrieb “bey allen Nervenkrankheiten, bey hypochondrischen, hysterischen und melanchonlischen Zufällen; 
vgl. TSCHUPP (1998), S. 44-46. Siehe auch Bäumeler (2007), S. 223. 
75 Vgl. Tabernaemontanus (1664), Buch 1, Kapitel, 1, S.10 C bis I. 
76 Es handelt sich hier um wässrige Destillate, vgl. Anm. 39. „Wegerich“ und „Wegtritt“ sind trotz ähnlicher Namen keine Synonyme; während „Wegerich“ für ‚Plantago 




 Originaltext Moderne Übersetzung 
Durchfall und (chronische) Diarrhöe und hilft auch bei 
Blutspucken77. 
                     
Wunden. Brand. 
Der Safft eusserlich in Wunden gethan / reiniget 
dieselbige und heylet sie: Ist auch gar gut zum Brand 
eusserlich auffgestrichen. 
Wenn man den Saft äußerlich in Wunden träufelt, reinigt er 
sie und lässt sie heilen. Er wirkt auch ausgezeichnet bei 
Verbrennungen, wenn man ihn äußerlich aufstreicht. 
Würm der Ross [Diesen Safft gibt man mit Odermenig den Rossen ein für 
die Würm.] 
[Diesen Saft verabreicht man den Pferden zusammen mit 
Odermennigkraut gegen Wurmbefall.] 
 Von Johanneskrautwasser.  Vom Johanniskrautwasser78 
 
(1993), Nr. 358, 166 u.ö. WILL (2009), Nr. 49 -51, 257, 287; WELKER (1988), S. 233: „Weggras wasser jst gůtt für den rotten durchgang“; SCHILD (2007), S. 13: Weggras 
Wasser … ist gut fur dy Rurre“. 
77 Hamoptoë und auch Hämoptyse, welche bei verschiedenen Krankheiten, so der Lungenturberkulose und Lungeninfarkt aber auch bei Tumoren, Abszess, Bronchitis, 
Pilzerkrankungen und Gefäßveränderungen wie Aneurysmen vorkommen kann. 
78 Der Begriff “Pflanzenwasser” ist im Unterschied zu anderen Zubereitungen wie Sirupen oder Weinabsuden keine genaue Angabe, um welche Art der 
Arzneimittelverarbeitung es sich handeln soll. Heute beschreibt ein „gebranntes Wasser“ eindeutig ein alkoholisches Destillat (siehe auch Anm. 40). In der frühen Neuzeit 
konnte sich der Begriff „Pflanzenwasser“ jedoch sowohl auf ein wässriges wie auch (selten) auf ein alkoholisches Destillat beziehen oder auch auf eine Art wässrigen 
Dekokt. Eine Aussage über die Herstellungsweise und dem verwendeten Menstuum war in der frühen Neuzeit autoren- und rezeptspezifisch; siehe MÜLLER-GRZENDA 
(1996), S. 95. Tabernaemontanus erläutert an dieser Stelle nicht die Zubereitungsart des Johanniskrautwassers. Eine Überprüfung der Zubereitungsart anderer Pflanzenwässer 
in seiner materia medica, zum Beispiel beim „Gedestilliert Grasswasser“ offenbart jedoch, dass Tabernaemontanus unter „Pflanzenwasser“ - wenn er keine weiteren 
Angaben macht – einen Auszug des frischen und zerkleinerten Pflanzenguts über einem Balneo Mariae  (Doppeltopf-Methode) meint; vgl TABERNAEMONTANUS (1664) 
Buch I, Sektion 6, Kapitel 1, S. 524. Dies ist also eine Art Trockendestillation der gewaschenen Pflanzen, die er “ohn allen Zusatz” ausziehen lässt: ebenda S. 106, G. Eine 
Variante dieses Auszugs über dem Balneo Mariae, bei der eine Weiterverarbeitung mittels Sonnendestillation erfolgt, ist unter “Chamillenwasser. Aqua Chamaemeli 
stillatitia“ zu finden: …soll man Kraut und Blumen miteinander hacken/ und sänfftiglich in Balena Mariae abziehen, folgendes ein Zeitlang wol vermacht zu rectificieren in 
die Sonne setzen / und zum Gebrauch verwahren.” Eine andere Destillationsvariante, gezielt eingesetzt zum Auszug pflanzenspezifischer Wirkstoffe, beschreibt er im 
Dillkrautwasser Kapitel. Hier setzt der Autor erst den „blinden Helm“ (Alembicu coecum) auf das Balneo Mariae, den er nach 24 Stunden mit einem „Helm mit Schnabel“ 
ersetzt, der die Flüssigkeit nach abgeschlossener Destillation abfließen lässt: ebenda, Buch I, Sektion 2, Kapitel 16, S. 169, D-E. Bezüglich der verwendeten Gerätschaften 
findet sich beim Erdrauch Kapitel ein Hinweis, dass das frische, gewaschene und zerkleinerte Pflanzengut in ein Gefäß, dem Cucurbit, eingeschlossen, und so im Balneo 
Mariae ausgezogen werden soll, also eine Art Vakuumdestillation: ebenda, Buch 1, Sektion 1, Kapitel 21, S. 89. Der Cucurbit scheint jedoch keine obligatorische Gerätschaft 
zum Destillieren mittels Balneo Mariae zu sein, da er nicht überall erwähnt wird – oder war so selbstverständlich, dass dessen Beschreibung weggelassen wurde. Die 
Pflanzenwasser beziehen sich bei Tabernaemontanus also in der Regel auf eine Destillation mittels Doppeltopf-Methode ohne Wasser- oder Alkoholmenstruum. Diese 




 Originaltext Moderne Übersetzung 
Im Ende deß Brachmonats soll man das Kraut und 
Blumen von den Stengeln abstreiffen und ein Wasser 
darauß brennen. 
Ende Juli soll man Blüten und Blätter von den Stengeln 
abstreifen und einen wässrigen Auszug herstellen79. 
 
herstellte. Im Gegensatz zu Tabernaemontanus besprengte dieser die Medizinalpflanzen vor dem Ausziehen manchmal mit einer kleinen Menge Wein oder Essig: 
LONICERUS (1679), S.11-27; vgl. auch Will (2009) zu den Destillationsvorschriften des Straßburger Chirurgen und Wundarztes Hieronymus Braunschwig. Zusätzlich zu 
den Trockendestillationen, beschreibt Tabernaemontanus auch Destillationen mit Zusatz von Wasser, die letztlich nichts Anderes als Spielarten von Dekokten sind. Im 
Kapitel „Wegwarten gedistillirt Wasser“, beschreibt er eine wässerige Destillation, welche er spezifisch für alle kühlenden Pflanzenwasser empfiehlt: „Die beste Zeit das 
Wegwartenwasser zu distilliren ist mitten in dem Mayen / Kraut und Wurzeln mit einander klein gehackt / und darvon genommen zwölf Krämerpfund / darüber geschüttet 5 
oder 6 Maß frisch und kalt Brunnenwasser / solches mit einander in ein Vesicam gethan / und davon abgezogen 2 maß / so halten ein sehr kräftiges Wasser...“: ebenda, Buch 
1, Sektion 5, Kapitel 22 S. 474 I. Beim „gesottenen Fenchelwasser“ geht er folgendermassen vor: „Man nimbt schönes ausserlesen gesäuberten Fenchel / 3 Loth, guten feinen 
Zucker / 4 Loth / frisch Brunnenwasser / 2 Mass. Die Stück thut man zusammen in eine grosse glatte Flaesch, die oben ein breite Schraube hat / und verschraubt sie gar geheb 
zu / stellt die in ein Kessel mit sidendem Wasser / und lässt sie 4 Stund in steter Hitz darin sieden / darnach thut manns heraus / und seihets durch ein Claretsack / und setzts 
darnach in ein kühlen Keller“: ebenda: Buch I, Sektion 2, Kapitel 12, S. 159 D. Der Autor beschreibt auch die Doppeldestillation, so im Frauenmantelkapitel (ebenda, Buch 
1, Sektion 3, Kapitel 20, S. 250 K), und eine Wasserdestillation mit getrocknetem, gepulvertem Pflanzenmaterial mittels eines Perkolators (Kolben), so beim „Gedistilliert 
Engelwurtz oder Angelickwaasser (ebenda, Buch 1, Sektion 3, Kapitel 12 S. 235 B).  
79 Im Gegensatz zu der heutigen Verwendung des Begriffs “brennen” als Synonym für „destillieren“ von alkoholischen Destillaten, untermauern die deutsch-lateinischen 
Wörterbücher des 15./16. Jahrhunderts, dass sich der Begriff „brennen“ in erster Linie darauf bezog, eine Substanz mittels Hitze auszuziehen. Hierbei bezeichnet ‚brennen’ 
einen Oberbegriff, der alle Tätigkeiten miteinbezieht, die mit starkem Erhitzen und Aufwallen von Flüssigkeiten zu tun hatten. Dies konnte sieden, kochen, brauen und auch 
destillieren (mit Wasser oder Alkohol) sein; vgl. MÜLLER-GRZENDA (1996), S. 44-46. Die terminologischen Bezeichnungen verschiedener Extraktionsmethoden wie 
Destillat, Dekokt, Mazeration und Infusion waren in dieser Zeitperiode noch fließend. Deren Bedeutung müssen deshalb von Autor zu Autor neu ermittelt werden; vgl. 
ebenda, S. 92-94. Bei einer Analyse verschiedener Tabernaemontanus Rezepturen wird offensichtlich, dass der Autor den Begriff „sieden“ und den Begriff „brennen“ auf 
zwei verschiedene Zubereitungsarten anwendet. Seine Anleitungen „...Wermuth in Wein und Wasser gesotten/ und darmit die frischen Wunden gewäschen...“, (ebenda, 
S.10A ) bezieht sich auf ein Dekokt im heutigen Sinne, welches mit Wein oder Wasser als Auszugsflüssigkeit hergestellt wurde. Im Gegensatz dazu beschreibt der Begriff 
„brennen“ – wenn nicht näher erläutert – eine Art Trockendestillation ohne Zusatz von Wasser oder Alkohol mittels eines Balneo Mariae, so auch beim Johanniskrautwasser: 
„... soll man das Kraut und Blumen von den Stengeln abstreiffen und ein Wasser darauß brennen“, siehe auch Anm. 37. Weiter verwendet Tabernaemontanus in den 
verschiedenen Pflanzenwasserparagraphen synonym zu “brennen” auch die Begriffe „abziehen“ und „destillieren“, zum Beispiel: „Fenchelwasser. Foeniculi aqua stillatitia. 
Von dem Fenchel wird auch ein heylsames und köstliches Wasser gedistilliert / zu vielen innerlichen und äusserlichen Leibesgebrechen dienlich. Die beste Zeit seiner 
Distillirung ist im Brachmonat/ Kraut und die Gipffel der Blumen / mit einander klein gehackt / und sänftiglich in Balneo Mariae abgezogen / darnach an der Sonne 
rectificiert.“, S. 157 C. Ein Pflanzenwasser ist bei Tabernaemontanus also nicht eine alkoholische Destillation im heutigen Sinne, sondern entweder ein Dekokt oder eine Art 
Trockendestillation; vgl. Anm. 39. Absude, Dekokte und wässrige „Destillationen“ waren in der frühen Neuzeit einfache und erschwingliche Arzneiformen, die besonders in 
der Selbstmedikation des „gemeinen Mannes“ einen zentralen Platz einnahm, da sie jedermann ohne großen apparativen Aufwand durchführen konnte; vgl. MÜLLER-









Diß Wasser ist gut und heylet alle innerliche und 
eusserliche Wunden / davon [Morgens und Abendts] 
getruncken / [damit gewaschen] und das Wasser 
eusserlich auffgeschlagen. Das Wasser mit 
Päonienwasser getruncken / alle Tag zwey oder drey mal 
/ jedes mahl zwey oder drey loth / ist gut für die 
Fallendesucht / [und den Schlag.] 
Johanniskrautwasser ist hochwirksam und heilt alle 
innerlichen und äußerlichen Wunden, wenn man davon 
[morgens und abends] trinkt [bzw. sich damit wäscht] und das 
Wasser in feuchten Umschlägen auflegt. Johanniskrautwasser 
mit Pfingstrosenwasser gemischt und täglich zwei oder 
dreimal eingenommen je in der Menge von 30g-45g ist gut 
gegen Epilepsie [und Schlaganfall80]. 
 
Bauchflüß. 
Das Wasser mit rotem Wein vermischet / und davon 
getruncken / stopffet die Bauchflüß und rohte Ruhr / [wie 
dann auch mit einem Tuch auff den bauch gelegt.] 
Trinkt man Johanniskrautwasser gemischt mit Rotwein, so 
wirkt dies stopfend bei Diarrhöe und der roten Ruhr. [Es ist 









Die Apothecker und auch die Wundärtzte pflegen ein 
köstlich Oel auß dieses Krauts Blumen zu machen: 
welches man aber auff ein schlechte weiß also præpariren 
soll: Nimb der frischen Blumen so viel du wilt / thu sie in 
ein Glaß / geuß Baumöl darüber / stopffs oben zu / und 
stelle es an die Sonne etliche Tag darnach seige das Oel 
ab / truck die Blumen wol auß / und thu andere frische 
darein / setze es widerumb an die Sonn / darnach trucke 
Vom Johanniskrautöl 
Sowohl die Apotheker wie auch die Wundärzte81 sind in der 
Lage, ein köstliches82 Öl aus den Blüten des Johanniskrauts 
herzustellen, das man freilich auch in einem schlichteren 
Verfahren gewinnen kann: Nimm von den frischen Blüten in 
beliebiger Menge, tu sie in ein Glas und gieß Olivenöl 
darüber, verschließ das Glas mit einem Stöpsel und lass es 
mehrere Tage an der Sonne stehen; dann seihe das Öl ab, 
drücke den Blütenrückstand gut aus, fülle mit frischen Blüten 
 
80 Aus humoralpathologischer Sicht waren beide Krankheitsbilder, Epilepsie und Schlaganfall, eng miteinander verwandt; vgl. KEIL (1997), S. 54f. – Die Pfingstrose 
(Paeonia officinalis L. EMEND. WILLD.) galt als eines der wichtigsten Anti-Epileptika; vgl. MILDENBERGER (1997), III, S. 1461f.: „Mittel gegen mehrere, vor allem für 
unheilbar gehaltene Krankheiten, darunter auch Apoplexie“. 
81 Zur Destillation von Öl durch Chirurgen siehe die Abbildungen von Ölöfen in der ‚Ulmer Wundarznei’ (um 1485), MARTIN (1991), S. 203, Bl 97r, sowie S. 60: „Also 
mach ainen oelofen / darinn du die oeler brennen wollist... Sant Johanns krut oel ofen...“ (mit Balneum Mariae) – ; sieh auch CRONE (2002). 
82 „köstlich“ verweist auf die ätherischen bzw. Balsamöle, die durch Destillation gewonnen wurden; das Verfahren schonenden Destillierens (= Brennens) beschreibt die 









es auß wie zuvor / solches thue etlich mal nacheinander / 
zu letzt stoß die Hülsen sampt dem Saamen / und lege sie 
auch in das Oel / so wird das Oel schön Blutroht: Dieses 
Oel schreibet MATTHIOLUS, heylet die Wunden gar 
wol / sonderlich aber die verwundten Sennadern. [Dieses 
Oel wird viel kräfftiger / wann man Myrrhen / Aloe / 
Mastix und Terpentin darzu thut] Ist auch dienstlich zu 
allen kalten Gebrechen der Glieder und Gewerben. 
nach und stelle es wiederum an die Sonne. Danach presse es 
ab wie zuvor und wiederhole das ganze etliche Male. Zuletzt 
nimm auch die Samen in den Schoten, zerstoß sie und fülle sie 
ihrerseits ins Öl, das (wiederum an die Sonne gestellt und 
dann abgeseiht) sich wunderschön blutrot färbt: Dieses Öl – 
so schriebt Matthioli – heilt die Wunden bestens und 
insbesondere die verletzten Sehnen, Bänder und Nerven83. 
[Wenn man Myrrhe84, Aloe85, Mastix86 und Terpentin87 
hinzufügt, lässt sich die Wirkung des Öls noch steigern.] Das 
Öl hilft (als warm und trocken) auch bei allen kalten 
Arthrosen der Glieder88 und Gelenke89. 
Brand Ist auch gut zu dem Brand vom Fewer / leget und miltert 
die Schmertzen der Hüfft. 
Das Öl hilft darüber hinaus bei Verbrennungen und heilt 
oder mildert die Schmerzen und Ischialgien der Hüfte90. 
 
83 Zur weitgespannten Begrifflichkeit von frühneuhochdeutsch „Sehnader“ sieh DWB, X/I = 16, Sp. 148: ‚Flechsen’ = ‚Faszien’ und ‚Gefäße’ waren mit inbegriffen. Siehe 
auch Anm. 23 bezüglich Geäder.  
84 ‚Myrrhenharz’ von Commiphora myrrha (NEES) ENGL. und andern Commiphora spec., vgl. MILDENBERGER (1997), III, S. 1231-1233. 
85 Eingedickter Saft unterschiedlicher Aloë-Arten wie Aloe sucotrina LAM. (der Natal-Aloe), Aloe ferox MILL. (der Kapland-Aloe) oder Aloe perryi BAK., Liliaceae; vgl. 
MILDENBERGER (1997), I, S. 72-75. 
86 Gummiharz des Mastixstrauches Pistacia lentiscus L.  
87 Rohbalsam oder Harz unterschiedlicher Kiefernarten, insbesondere Pinus palustris MILL., Pinus pinaster Soland, Pinus halepensis MILL, Pinus nigra aber auch Pinus 
sylvestris L., Pinus cembra L. und andere; vgl.  (TEUSCHER, MELZIG & LINDEQUIST 2004), S. 401-402. Nach MILDENBERGER (1997), IV, S. 1951-1953 wurde 
Terpentin auch aus anderen Holzarten gewonnen: ‚Lärchenharz’, ,Venetianisches Terpentin’ von Larix decidua MILL. = Larix europaea L., Harz der Terpentinpistazie 
Pistacia terebinthus L., ‚Zyprisches Terpentin’, ‚Straßburger Terpentin’ und ‚Tannblatterpech’, was sich auf Flüssigharz aus Harzkammern unter der Weißtannenrinde 
bezieht.  
88 Zu „Glied“ als beweglichem Teil einer Extremität vgl. MILDENBERGER (1997), II, S. 679f. 
89 Zur Gleichung „Gewerbe“ ‚Articulatio’ = ,Gelenk’ sieh DWB, IV/I/III = 6, Sp. 5489. 




 Originaltext Moderne Übersetzung 
Rote Ruhr Es ist dieses Oel auch gut wider die rote Ruhr / so man 
den Bauch warm damit schmieret / dann es leget den 
Schmertzen und stopffet das Durchlauffen. 
Johanniskrautöl ist des weiteren wirksam bei der roten Ruhr, 
wenn es warm auf den Bauch aufgetragen wird: es wirkt 
schmerzlindernd und stopft den Durchfall. 
 [Wider gemeldte rohte Ruhr ein Experiment: Nimb ein 
Stück Netze von einem Schaff / zerschneid es / und röste 
es in das Oel / legs also warm auff den Bauch / es lindert 
die Schmertzen / und verstillet die Stulgäng.] 
[Experimentell lässt sich die Wirkung gegen die rote Ruhr 
wie folgt bestätigen: Nimm das Bauchnetz91 eines Schafes, 
schneide es in Stücke und röste es in Johanniskrautöl, lege es 
warm auf den Bauch, so lindert es die Schmerzen und 
beseitigt den Durchfall.] 
Krimmen92. Es wird auch gebrauchet wider die COLICAM, wenn 
man sich umb den Nabel damit schmieret / welches aber 
kräfftiger wird /wann man Dillöl darzu thut / und mit 
Wachs zu einem Sälblein machet. 
Eine zusätzliche Heilanzeige fürs Johanniskrautöl ergibt sich 
gegen die Kolik, wenn man sich den Nabel damit salbt. Das 
Oel wirkt noch stärker, wenn man dem Johanniskrautöl 
zusätzlich Dillöl93 beimengt und das Gemisch mit Wachs zu 
einer Salbe94 verarbeitet. 
 [In Welschland pfleget mans den Kindern / die Grimmen 
haben / über den Nabel zu legen / daher es viel HERBAM 
UMBILICAREM nennen. 
[In Italien pflegt man den Nabel95 der Kinder, die an 
Bauchgrimmen leiden, mit einer solchen Salbe einzureiben; 
deshalb wird Johanniskraut auch oft auch Herbam 
umbilicarem oder ‚Nabelkraut’ genannt96. 
 
91 Das Netz bezeichnet das Bauchnetz oder Omentum von Ovis ammon f. aries L.; zum Terminus siehe PSCHYREMBEL (2007).  
92 HÖFLER (1899), S. 202a: Krimmen ist synonym zu „Darmgrimmen“. Die Lokalität der Schmerzen bezieht sich auf den Kolon, den ‚Grimmdarm’: ebd. S. 91ab . 
93 Öliger Auszug von Dill (Anetum graveolens L.) auf Olivenöl-Basis oder auf Keimöl-Grundlage, Oleum anetinum germinale, vgl. CRONE (2002), S.7, 13, 16, 20; Dill galt 
als warm und trocken im zweiten Grade und wurde gezielt gegen die Bildung von Darmgasen eingesetzt, e.g. gegen „lienae conflatae“, so bereits im ‚Herbar’ des Rufinus, 
Bl. 23rbf., THORNDIKE/BENJAMIN [1945], S. 26f. und gegen „venae inflatae“ in WÖLFEL (1939), S. 18. 
94 Unguentum leniens, entsprechend Galens Konzept; vgl. FEHLMANN (1983). 
95 Der Nabel galt als eine Ein- bzw. Austrittspforte in Bezug auf die Bauchorgane, insbesondere die Därme; sieh KEIL (1961), S. 251; und vgl. auch HWdAgl (1927-1942), 
IX, S. 855: Nabelwurm, sowie zum Konzept BARGHEER (1931). 
96 Herbarum umbilicarem ist eine Bezeichnung, die MARZELL (2000), II, Sp 954ff. fürs Johanniskraut nicht notiert. Wohl aber belegt er in Bezug auf die hier besprochene 











Dieses wird für das allerbest und nützlichst gehalten. 
Nimb unzeitig Baumöl zwölff loth / Mastix zwey loth / 
Terpentinöl anderthalb loth / Rosenöl / lauter Terpentinöl 
jedes vier loth / Mastix und Weyrauchkörnle jedes ein 
halb loth / frischer Mirrhen / Aloes / jedes iii. Quintlein / 
Gummi Elemnij / Griechisch Bech / jedes dritthalb 
Quintlein / Tausentgüldenkrautsafft / S. Johannskrautsafft 
/ breiten oder spitzigen Wegrichsafft / Katzenwadelsafft / 
jedes ij. loth / Schaaffgarben j. halb loth / 
Diese Johanniskrautöl-Variante wird für die wirksamste und 
nützlichste Zubereitung gehalten: Nimm 180g97 grünes, von 
unreifen Oliven gepresstes Baumöl, 30 g Mastix(-Öl)98, 22,5 g 
Terpentinöl99, je 60g Rosenöl100 und geläutertes 
Terpentinöl101, je 7,5g Mastix-Gummiharz und 
Weihrauchharz-Körner102, je 11,25g frisches Myrrhen-Harz 
und eingedickten Aloë-Saft, je 9,4g103 Elemi-Harz104 und 
Griechisches Pech105, je 30g Saft vom Tausendgüldenkraut106, 
 
97 Zur Umrechnung siehe MILDENBERGER (1997), II, S. 1104, der bei der Gleichung 1 Lot(h) = (etwa) 15g das in der Oberrheinebene gängige Basler Apothekergewicht 
zugrunde legt. Ein Lot(h) ist die Gewichtsheinheit einer halben Unze, was 14.9075g entspricht. 
98 „Oleum masticinum“ ist bei CRONE (2002), S. 42, erfasst und wurde als Auszug auf Baumölbasis hergestellt. 
99 Terpentinöl wird aus dem Kiefernrohbalsam verschiedener Kiefer-Arten (Pinus-Arten, Pinaceae) gewonnen (siehe Anm. 48). 
100 Der Rosenblütenblätter-Auszug wurde auf Olivenölbasis hergestellt und bezieht sich nicht auf das heute gebräuchlichere ätherische Rosenöl. Tabernaemontanus (1664), 
Buch 3, Sektion 2, Kapitel 100, S. 1500E beschreibt zwei verschiedene Auszugsarten für die Herstellung des Rosenöls. Die erste schreibt vor, einen Auszug aus frischen, 
noch geschlossenen roten Rosenköpfen herzustellen, die geschnitten und in Olivenöl während 14 Tagen an der Sonne ausgezogen werden. Die zweite schreibt einen Absud 
derselben über Hitze vor. Eine Variante davon ist, dass nach einem solchen Absud das Gemisch in einem Glasbehälter während 50 Tagen zusätzlich an der Sonne ausgezogen 
wird. Siehe auch die zeitlich vorangegangenen, mittelalterlichen Olivenöl Vorschrift des Circa instans, WÖLFEL (1939), S. 100 und diejenige des Breslauer Arzneibuch 
(1270/80), Bl. 147v, welche ebenfalls die Sonnen-Digestion beschreibt: KÜLZ & KÜLZ-TROSSE (1908), S. 182f. 
101 Lauteres oder Gereinigtes Terpentinöl ist eine durch Wassserdampf gewonnenen klare, flüchtige Flüssigkeit. Dieses ätherische Öl wird aus dem Rohbalsam (Terpentin) 
verschiedener Kiefer-Arten (Pinus-Arten, Pinaceae) gewonnen (siehe Anm. 46). Die bei 155 bis 170 Grad übergehende Fraktion ist farblos und wurde entsprechend als 
„lauter“ bezeichnet. Gereinigtes Terpentinöl wird auch heute noch äußerlich zur Behandlung rheumatischer und neuralgischer Beschwerden sowie von Bronchitiden 
eingesetzt; vgl. TEUSCHER, MELZIG & LINDEQUIST (2004), S. 401-402; CRONE (2002), S. 44, Z.2f. Zeitgenössische Untersuchungen bestätigen die antimikrobische 
Wirkung von Pinus spp.. Pinus elliottii, zum Beispiel ist wirksam gegen Antibiotika resistente Bakterien wie Staphylococcus epidermidis: LEANDRO, CARDOSO, SILVA, 
SOUZA, VENEZIANI, ABMROSIO, MARTINS (2014). 
102 Erstarrte Harztropfen des Weihrauchbaums Boswellia carteri Birdw., synonym zu Boswellia sacra FLUECKIGER und anderer harzausscheidender Gehölze der 
Balsambaum-Gewächse Boswellia spec.; MILDENBERGER (1997) V, S. 2292ff; MARTINEZ, LOHS & JANTZEN (1989), S. 81, Abb. 6.8. 
103 „dritthalb“ = ‚zweieinhalb’; ein Quentchen ist ein Viertellot und wiegt 3,75g. 
104 „Resina elemi“ von Boswellia spec., Burseraceae; DRESSENDÖRFER (1978), S. 229; STAHNKE (1983), S. 573: „Elemi (Ölbaum-)Harz“. 
105 Destillationsrückstand nach Abdampfen des Terpentins: Kolophonium, Geigenharz, von Pinus sylvestris L., der Gemeinen Kiefer oder Föhre; vgl. MILDENBERGER 
(1997), II, S. 1000.  














Tormentillwurtzel / weissen Diptamwurtzel / 
Cardenbenedicten / jedes ein Quint. Ferberröte / 
Scharlachfarbsaamen / jedes ein halb loth /und ein halb 
quintlein /Saffran ein halb Quint. frischer Regenwürmer 
gewaschen und bereit iiij. loth /  Eschenbaumlaub und 
Rinden von der Wurtzel / jedes ein halbe Handvoll / 
guten weissen Wein zwey Pfund. Von obgemelten 
Stücken / stoß groblecht was sich stossen laßt / seuds 
dann mit dem Wein und Saffran / biß sich die Feuchte 
verzehre: dann trucke das uberblieben Oel wol darauß 
durch ein hänffen Tuch / thu es in ein Glaß / und thu 
darzu die frischen Blumen von St. Johannskraut / 
Roßmarinblumen / jedes ein wenig / laß es fünffzehen 
vom Sankt Johanniskraut, vom Breit- oder Spitzwegerich107 
und vom Ackerschachtelhalm108, 7,5g Schafgarbe109, je 3,75 g 
Blutwurz110, Diptamwurzel111 und 
Kardobenedikten(wurzel)112, je 7.5g Färberröte113 und 
Muskatellersalbeisamen114, 1.9 g Safran115, 60g frische 
Regenwürmer116, gewaschen und zubereitet117, je eine halbe 
Handvoll Eschenlaub und Wurzelrinde von der Esche118 
sowie 715,5g119guten Weißwein. Was sich von dem 
genannten Ingredienzien zerstoßen lässt, stoß im Mörser leicht 
an, sied es dann mit Wein und Safran, bis der wässrige Anteil 
verdampft ist; presse das zurückgebliebene Öl sorgfältig aus, 
filtriere durch ein Seihtuch aus Hanf, fülle es in ein Glas, füge 
je ein wenig frische Johanniskraut- und Rosmarin- Blüten 
 
107 Plantago major L., Plantago lanceolata L.; vgl. oben Anm. 35. 
108 „Katzenwadel“ ist im Alemannischen die Bezeichnung für Equisetum arvense L.; MARZELL (2000), II, Sp. 247. 
109 Achillea millefolium L., DAEMS (1993), Nr. 316, 637. 
110 Rhizom von Potentilla erecta (L.) RAEUSCH. Synonyme sind Potentilla tormentilla, Tormentilla erecta und Potentilla laeta. Blutwurz wird auch „Rotwurz“ oder 
„Braunwurz“ genannt.  
111 Das Rhizom von Dictammus albus L., dem Brennenden Busch; vgl. MARZELL (2000), II, Sp. 124. 
112 Das Rhizom von Cnicus benedictus L.; MARZELL (2000), I, Sp. 1062f.; VL (2002), XI, Sp. 826-829. 
113 Rubia tinctorum L.; MARZELL (2000), III, Sp. 1447: Krapp. 
114 Samen von Salvia sclarea L., dem Muskateller-Salbei; vgl. MARZELL (2000), IV, Sp. 53-55: „Die Oberlippe der Blütenkrone ist hellila bis rosa“, „Gartenscharlach“. 
115 ‚Gewürzsafran’, ‚Griffel von Crocus sativus L.’ bzw. ‚das aus den getrockneten Blütennarben von Crocus sativus L. (= Crocus orientalis) gewonnene Pulver’; 
MILDENBERGER (1997), III, S. 1636f. 
116 Rötliche Vertreter der Lumbricus-Gruppe, die Carl von Linné unter der Sammelbezeichnung Lumbricus terrestris L. zusammenfasste und die bis Ende des 18. 
Jahrhunderts offizinell waren; SCHNEIDER (1968/75), I, S. 48. 
117 „zubereitet“ bzw. „präpariert“ bezieht sich auf die Droge „Lumbrici praeparati“: Lebende Regenwürmer wurden gewaschen, in Weißwein mazeriert und dann getrocknet; 
SCHNEIDER, I, S. 49.  
118 Fraxinus excelsior L., Gewöhnliche  Esche. 
119 Zur Umrechnung siehe MILDENBERGER (1997), III, S. 1453, der bei der Gleichung 1 Pfund = (etwa) 358g das in der Oberrheinebene gängige Basler Apothekergewicht 




 Originaltext Moderne Übersetzung 
Tag an der Sonnen erbeitzen / dann ändere einmal solche 
nach gethane Blumen / laß widerumb so lang an der 
Sonnen erbeitzen / so hast ein kostbarlich Oel an statt deß 
gerechten Balsams zu gebrauchen / in alle Wunden / 
außgenommen so von harter Zerknitschung verursacht / 
oder sonst vom Lufft zerstört weren: lindert allen 
Schmertzen der Wunden / deßgleichen der Glieder / 
sonderlich nach den bösen Frantzosen: erweichet das 
Geäder in erlambden Gliedern: wehret dem Krampff / so 
von Wunden / und offnen Schäden verursacht worden. 
hinzu, lass das ganze zwei Wochen an der Sonne digerieren, 
verwirf die eingelegten Blüten und fülle neue nach und lass 
den Ansatz noch einmal vierzehn Tage120 an der Sonne 
mazerieren121, so hast Du ein kostbares Öl, das dem echten 
Balsam122 in den Heilanzeigen entspricht und ihm an 
Wirkkraft gleichkommt. Es ist indiziert bei allen Wunden, 
ausgenommen bei solchen, die durch eine schwere 
Zermalmung123 verursacht worden sind oder wo Gasbrand124 
die Ursache der Gewerbszerstörung ist. Es lindert bei allen 
übrigen Wunden die Schmerzen, sowie auch Schmerzen der 
Gelenken, insbesondere solche Gelenkschmerzen, die sich 
nach Infektion mit der Frambösie125 einzustellen pflegen: 
hier lindert es die Kontrakturen und darüber hinaus schützt 
es vor den Krämpfen, die sich infolge der Wunden126 und 
offenen Geschwüre127 ergeben. 
 
120 Der Text spricht von „fünfzehn“ Tagen, wobei sich die Differenz dadurch ergibt, dass (wie bei der Malaria tertiana und quartana) sowohl der erste wie auch der letzte 
Tag mitgezählt wurde; vgl. französisch „une quinzaine“ = ‚zwei Wochen’, ‚Zeit von vierzehn Tagen’, SACHS/VILLATTE (1907), I, S. 670c. 
121 „erbeitzen“ bezieht sich auf ‘digerieren’ respektive ‘mazerieren’; vgl. DWB III = 3, Sp. 715, mit Beleg aus Tabernaemontanus. Vgl. zur Sache DAEMS (1983). 
122 Der „echte Balsam“ – ein Commiphoren-Harz namens Opo balsamum – galt im 16. Jahrhundert als nicht verfügbar. Valerius Cordus empfahl 1646 entsprechend, ihn 
durch destillierte Öle zu ersetzen. Ein solches „opobalsamum“-Ersatzöl wird durch Tabernaemontanus in Gestalt seines „köstlich Öls“ bereitgestellt. Andere „opobalsamum“-
Surrogate verzeichnet CRONE (2002), S. 43-46. Vgl. zur Sache SCHNEIDER (1968/75), V/1, S. 355ff.; MILDENBERGER (1997), I, S. 174f.: Schlangen-Öl als Balsam-
Ersatz. 
123 Zur „harten Zerknitschung“ sieh oben Anm. 28. 
124 Folge der „harten Zerknitschung“ ist die Ablederung (Exkoriation) bzw. Gewebszerstörung mit sich anschließendem Gasbrand, bei dem die „Luft“ – dokumentiert durch 
die Gasblasen – Ursache der Zersetzung zu sein schien. 
125 „böse Frantzosen“ korrespondieren mit der „grôzen“ oder „bösen blâter“ der Frambösie-Infektion, dem ulzerierenden Primäraffekt einer Spirochaetose, die den Namen 
„Franzosen“ trug und den Formenkreis der Syphilis nach Europa (bzw. zum Exazerbieren) brachte. Charakteristisch für sie sind die nächtlichen Schmerz-Sensationen, die 
Arthralgien, Kontrakturen und Ankylosen. Vgl. KEIL/DAEMS (1977), S. 112f. und 118f.  
126 Wundstarrkrampf einschließlich Narbentetanus. 










Auff viel andere weiß wird diß Oel gemacht / also daß 
schier ein jedweder Wundartzet sein eigen Wundöl hat 
von diesem Kraut. Under andern ist nachfolgendes sehr 
nutzlich: Nimm alt Baumöl iiij. Pfundt: weissen guten 
Wein j. Pf. frische St. Johannsblumen und Saamen vier 
Handvoll / laß durch einander in einem wolvermachten 
Geschirr zwen Taglang stehen / siede es in BALNEO 
MARIÆ, trucks wol auß / zu dem außgetruckten thue 
andere frische Blumen / und das zum drittenmal: seihe es 
dann durch / und thu darzu ein Terpentin xij. Loth / 
Wermuthöl vj. Loth / Diptam / Entzian / 
Cardenbenedicten / Tormentill / Eberwurtz / Kalmuß / 
jedes ein halb loth / Regenwürm zum offtern in Wein 
gewaschen iiij. loth / zerstoß alles undereinander / stells 
Es gibt noch zahlreiche andere Verfahren, Johanniskrautöl 
herzustellen, und es sieht so aus, als ob nahezu jeder 
Wundarzt über seine eigene Johanniskrautöl-Spezialität 
verfüge128. Neben anderen Zubereitungen ist folgende 
Wundöl-Spezialität überaus hilfreich: Nimm 1432g altes 
Baumöl129, 358g guten Weißwein, vier Handvoll frische Sankt 
Johanniskrautblüten und Johanniskrautsamen, vermische das 
und lass es in einem dicht verschlossenen130 Gefäß zwei Tage 
lang stehn , dann siede es im Balneum Mariae131 , drücke es 
aus; zum ausgepressten Ansatz gib erneut frische 
Johanniskrautblüten hinzu, koche abermals schonend im 
Wasserbad, und tu das zu drei Malen; seihe es dann ab und 
füge hinzu: 180g Terpentin, 90g Wermutöl132, je 7,5 g, 
 
MILDENBERGER (1997), 1, S. 1687f. 
128 Die früheste bisher nachgewiesene magistrale Formel für eine derartige wundheilende Johanniskrautöl-Spezialität chirurgischer Provenienz findet sich im Kapitel 107 der 
‚Ulmer Wundarznei’, für die um 1485 der Wundarzt Magnus Bengger zeichnete; vgl. MARTIN (1991), S. 59. Die Formel steht auf den Blättern 95r-96r, vgl. VL IX (1995), 
Sp. 343, und 1238f. 
129 Während das frische Baumöl – insbesondere das grüne, aus unreifen Oliven gepresste – als besonders geeignet für gesunde Menschen galt, wurde das gealterte bevorzugt 
für die Arzneimittelherstellung herangezogen, so erläutert in der Renaissance Übersetzung des Dioskurides: „so ælter und frischer es ist, so nuezer vnnd bequemer es wirdt zu 
den Kranckheiten in der Artzney zu gebrauchen“, DIOSKURIDES (1610), S. 19; Siehe auch MILDENBERGER (1997), I, S. 250f. s.v. „boum-öle’; BERENDES (1902), S. 
56, I, 29f. Für einen mittelalterlichen Beleg siehe Rufinus, Bl,. 75va in THORNKIKE/BENJAMIN (1945), S. 210: „Oleum de olivis [d.i. ‘Baumöl], si multo magis 
inveteraverit, ut saporis fiat asperioris ac horribilioris, inconveniens erit esui, medicine tamen utile“. 
130 “vol... vermachen“ ‚dicht verschließen’; MILDENBERGER (1997), IV, S. 2127f. 
131 ,Balneum Mariae’, ist die technische Bezeichnung für Wasserbad, ein Verfahren, das zum schonenden Sieden einer Flüssigkeit bei einer gleichmäßigen Temperatur von 
100°C über einem kleinen (Holzkohlen)feuer eingesetzt wurde; vgl. auch den „Sant Johanns krut œl ofen“, MARTIN (1991), S. 60 und 303 (mit Abbildung). 
132 Ölauszug von Artemisia absinthium L. Zur Herstellung siehe das Wermutkapitel, TABERNAEMONTANUS (1664), Buch 1, Sektion 1, Kap 1, S.15, D-G, welches in 
Anm. 59 näher beschrieben wird. Vgl. auch das Olmützer ‚Öl-Salben-, Pulver- und Pflasterbuch’ (15. Jh., Bl. 131r), publiziert in Mähren: „Oleum absinthei ist von wermut 
gemacht: Nu nym wermut saf... und gist ol daron und seczit is an dy sonne...“; CRONE (2002), S. 19f., vgl. ebd. S. 13 das „Oleum Absinthii“ süddeutscher Arzneitaxen des 




 Originaltext Moderne Übersetzung 
an die Sonn dreissig oder viertzig Tag: setz es dann wol 
verdeckt an einen sauberen Ort.] 
Diptam133, Enzian134, Kardobendikten(wurzel)135, 
Blutwurz136, Eberwurz137 und Kalmus-Wurzel138, 60 g 
(frische) Regenwürmer, mehrfach in Wein gewaschen und 
präpariert139; vermenge diese Zutaten alle miteinander, 
zerstoß sie im Mörser und stell das ganze dreißig bis vierzig 
Tage an die Sonne; (nach dem Digerieren seihe es ab und) 
verwahre es dann gut zugedeckt an einem sauberen, 
geeigneten Platz.] 
 Von Johannskrautsaltz SAL HYPERICI genennt. 
Von dem Johannskraut kan man auch ein Saltz 
præpariren, wie aber dasselbige zu machen / darvon kan 
man lesen bey dem Wermuth saltz. 
Vom Johanniskraut-Salz, dem „Sal hyperici“ 
Mit Johanniskraut läßt sich auch eine mineralische Asche 
herstellen, deren Herstellungsweise im Wermut-Kapitel140 mit 
Bezug auf das Wermut-Salz141 beschrieben ist142.  
 Was aber dieses Saltzes besondere Tugende seyn ist noch 
nicht offenbar / allein sagt man für gewiß / daß dieses 
Welche Wirkungen es im Einzelnen hat, ist noch nicht 
festgestellt worden; als sicher kann indessen gelten, dass es 
 
133 Vgl. Anm. 70. 
134 Offizinell war Gentiana lutea L.; vgl. DRESSENDÖRFER (1978), S. 226; MILDENBERGER (1997), II, S. 552f. und 688f. 
135 Vgl. Anm. 73. 
136 Vgl. Anm. 74. 
137 Eberwurz, Carlina acaulis L., MARZELL (2000), I, Sp. 840-844; SCHÜTZEICHEL (2004), II, S. 352b-354b; EIS (1966). 
138 Das aromatische Rhizom von Calamus aromaticus oder synonym Acorus calamus L., dem Gewürzkalmus. DRESSENDÖRFER (1978), S. 198; MILDENBERGER 
(1997), I, S. 33f., 289f., II, S. 945f.; STOLL (1992). Zu historischen Indikationen von Kalamus siehe MADAUS (1932). 
139 Vgl. zum Verfahren oben Anm. 77 und 78. 
140 TABERNAEMONTANUS (1664), Buch 1, Sektion 1, Kap 1, S. 14K-15B. 
141 Von Tabernaemontanus werden zwei Herstellungsverfahren beschrieben, die beide auf das thermische Extrahieren der mineralischen Bestandteile hinauslaufen, die nach 
Verdunstungs-, Lösungs- und Filtrationsvorgängen als „weiβes Saltz“ beim letzten Verdampfen in Gestalt eines kalzinierten (nicht kristallinen) Bodensatzes zurückbleiben. 
Ein solches Verfahren ist eine Veraschung und wird auch heute noch in der Spagyrik eingesetzt. 
142 Das Verfahren wird im Wermutsalz-Abschnitt als allgemeingültig ausgewiesen und als grundsätzlich für alle Heilkräuter anwendbar deklariert: „Und auf solche Weiβ kan 




 Originaltext Moderne Übersetzung 
Seitenkräncke Saltz wider die Seitenkräncke / PLEURITIS genennt / ein 
sehr köstliche Artzney sey / wie zu lesen ist IN 
TRACTATU DE RE- MED. SECRET. CONRADI 
GESNERI. 
als vorzügliches Arzneimittel gegen das Seitenstechen bei 
Rippenfellentzündungen143, die man Pleuritis nennt, 
eingesetzt werden kann; Konrad Geßner berichtet darüber in 
seinem Tractatu de remediis secretis. 
Harn und Sand 
treiben 
  
Es hat auch ohn zweiffel diß Saltz ein Krafft den Harn 
und den Sand zu treiben / sonderlich da man es im 
Hauwhechelwasser einnimpt. 
Zweifellos ist das Salz auch in der Lage, den Harnfluss 
anzuregen und Harn-Grieß auszuschwemmen, und diese 
(lithotriptische) Wirkung wird noch gesteigert, wenn man es 
mit Hauhechel-Wasser 144 einnimmt. 
 
 
Brandt.               
Blutstillen.             
[Von der Natur / Krafft / und Wirckung deß Harthew 
oder Cunrads. 
Das Kraut zerstossen und wie ein Pflaster ubergelegt 
heylet den Brandt und gebrandte Schäden: stopfft das 
Blut der Wunden. 
[Von der Natur, Kraft und Wirkungen des Hartheus bzw. 
des Konradskrauts 
Das (frische) Kraut von Hartheu wie auch Mannsblut heilt 
Verbrennungen und deren Geschwüre, und stillt 
Blutungen, wenn man es zerstößt und als Kataplasma auflegt. 
Gall ausstreiben 
Hufftweh. 
Der Samen ein halb loth / in einem warmen trunck Meth 
früh eingenommen / treibt die uberflüssige Gallen durch 
den Stulgang: und so man diß Trancks viel Tag nach 
Nimmt man den Samen des Hartheus bzw. Konradskrauts 
allmorgens je 7,5g in einem Trunk warmen Mets145 ein, dann 
treibt das die überschüssige (schwarze) Galle mit dem 
Stuhlgang aus und beseitigt somit die Melancholie146. 
 
143 „Seitenkränke“ von HÖFLER (1899), S. 322b, in der angegebenen Bedeutung ab dem 18. Jahrhundert gebucht; das DWB, X/I = 16, Sp. 395, hat die vorliegende Referenz 
als einzigen erfasst. 
144 Wässriges Destillat von Ononis spinosa L., eine Medizinalpflanze, die rezent „zur Durchspülung... der ableitenden Harnwege und zur Vorbeugung gegen Nierengrieß“ 
verordnet wird; die moderne Indikation schließt „entzündliche“ Harnwegserkrankungen mit ein; HILLER/MELZIG (2003), II, S. 109b; bereits bei Dioskurides beschrieben: 
„treibt den Harn, zertrümmert den Stein“; vgl. BERENDES (1902), S. 273f. 
145 Ältestes gegorenes Getränk Mittel- und Südeuropas, nach unterschiedlichen Verfahren aus Honig und Wasser hergestellt, bis zu 15% alkoholhaltig, verabreicht mit 
mehreren Zusätzen; RGA (1973-2008), XIX, 618a-622a; GOETTLER (1958), S. 310ab: „auf einen Teil Honig dürfen nicht mehr als zwei Teile Wasser kommen“. 
146 Galle bezieht sich hier auf eine der vier humoralen Säfte, wie ein Vergleich mit Textstellen aus medizinischen Büchern derselben Zeitperiode zu belegen ist. Der Arzt und 
Universitätsprofessor Leonhart Fuchs schreibt 1543 (unter Harthaw, Kapitel XXIIII): “…treib auß die cholerische überflüssigkeit. Man muss aber solchs offt und so lang tun 
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einander gebrauchet dienet es wider das Wehthumb der 
Hüfft.] 
Außerdem, wenn man diesen Trank über viele Tage 
nacheinander einnimmt, dann hilft das gegen die Schmerzen 
und Ischialgien der Hüfte147. 
  
 
taken continually, till the patient be whole.”; vgl. CHAPMAN & TWEDDLE (1989), S. 245. Sein Lehrmeister Bock, schreibt 1577 (S. 28): “…füret auß Choleram”. In der 
Humoralpathologie bezieht sich die schwarze (mela) Galle (chole) auf den melancholischen Gemütstypus. In dieser Art der medizinischen Diagnostik führt ein Überschuss an 
schwarzer Galle zu psychischen Krankheiten und mentalen Zuständen wie der Melancholie, unter der wir heute Depression verstehen; vgl. Francia & Stobart 2014, P.301.  




APPENDIX 13: APPROXIMATION TO THE PHARMACEUTICAL AND PHARMACOLOGICAL 
PROFILE OF HYPERICUM PERFORATUM, TABERNAEMONTANUS 1664 




St. John’s Wort Johanniskraut 
 
  
Botanical name Hypericum perforatum Hypericum perforatum Hypericum, (Herba) Perforata, Fuga daemonum  
Historical names St. Peterswoort square 
great / St. Johanns 
grasse 
Sankt Johanniskraut Sanct Johannskraut heißt Griechisch ύπέριϰον, 
Leteinisch HYPERICUM, PERFORATA, FUGA 
DÆMONUM. [I. HYPERICUM VULGARE, C.B. 
HYPERICOUM, BRUNF. MATT. FUCH. ANG. 
TUR. LAC. LON. DOD. AD. LOB. CÆS. LUGD. 
CAST. CAM. GER. EYST. HERBA PERFORATA & 
HYPERICUM VULGARE, TRAG. ASCYRON. 
DOD. GAL. CORD. IN DIOSC. ANDROSÆMON 
MINUS, GER. COL. II. HYPERICUM FOLIO 
BREVIORE, C.B. SYRIACUM & 
ALEXANDRINUM, LOB. SYRIACUM, LUGD 
GER. III. HYPERICUM SUPINUM 
TOMENTOSUM VEL MONSPELIACUM, G.B. 
SUPINUM, DOD. TOMENTOSUM LOB. LUGD. 
GER. ALTERUM TOMENTOSUM, AD. 
TOMENTOSUM FECUNDUM. CLUS. HIST. 
ANDROSÆMUM ALBUM DALECH. LUGD. IV. 
ASCYRUM SIVE HYPERICUM BIFOLIUM 
GLABRUM NON PERFORATUM, C.B. 
ANDROSAEMON, MATTH. FUCH. TUR. LAC. 
CORD. IN DIOSC. CAST. GES. COL. HYPERICUM 
ALIUD. DOD. GAL. V. ANDROSÆMON 





Label Contemporary English Contemporary German  Original Text Use-
categories 
ANDROSÆMON, LOB. ALTERUM, AD. RUTA 
SYL. HYPERICOIDES, DOD.] Arabisch Refo. 
fricon.  Welsch Hiperico, herba rossa. Frantzösisch 
Mille pertuis. Englisch G. Johannes woorte. Böhmisch 
Zwoncek cerweny. [Niderländisch St.  Janscruydt: 
Spanisch concillo. Hartheuw aber so auch Waldthoff / 
wird ASCYRON genannt / Niderländisch Herthooy: 
Englisch St. Peterswoort square great, St. Johanns 




warm and dry in the 
second or third degree 
warm und trocken im zweiten 
oder dritten Grad 
sei warm und trucken und einer subtilen Substantz; 
sind warmer und trucknender Natur im anderen oder 
wie etliche wöllen im dritten Grad 
 
 
Organoleptics n.a. n.a. n.a.  
Plant part used aerial parts with flowers 
and fruits during 
flowering period; seeds 
 
Kraut mit Blüten und Früchten; 
Samen 







hot water decoction of 
herb 
 
hot water decoction of 
seeds 
 
wine decoction with 
fresh, flowering parts, 
incl. fruits 
Absud 
Wasserabsud des Krauts 
 
 
Wasserabsud der Samen 
 
 
Weinabsud des (frischen149) 
blühenden Krauts, inkl. Früchte 
 
Absud 
Wässriger Absud; davon gesottene Brühen [Kraut] 
 
 
der Saame gesotten und getruncken 
 
 





148 In contemporary botany, this refers to forming fruits which can appear together with buds and flowers on a flowering plant. The true seeds form after the flowering stage.  
149 It is likely, that this refers to a preparation made with fresh plants, as in other passages the author specifically refers to “gedörrt” (dry) when he discusses a preparation 




Label Contemporary English Contemporary German  Original Text Use-
categories 
warm beer extraction of 




fresh plant juice of 
leaves and flowerheads 
 
Hydrosol: 
St. John’s Wort water          
(hydrosol of fresh 
flowers, leaves) 
 
mixture of St. John’s 




flowering plant with 
fruits 
 
herb taken with wine  
 
 
warmer Bierauszug der 




frischer Pflanzensaft aus den 
Blättern und Blütenständen 
 
Hydrolat 
Johanniskrautwasser                








blühendes Kraut mit Früchten 
 
 
Kraut mit Wein einnehmen 
 
 









Kraut und Blumen von den Stengeln abstreiffen und 
ein Wasser darauß brennen150; davon getrunken 
 
 





das gantze Gewächs - Kraut / Blumen / Früchte 
 
 




150 The term “Wasser brennen” (burning water) (Tabernaemontanus, 1664, p. 1251G) refers today to an alcohol distillation. However, during the early modern period this 
term was not conclusively defined and could, depending on author and book, refer to an extraction with water or more rarely with alcohol. Encyclopaedias of the 15th  and 
16th  century define the term “brennen” (burning) as the extraction of a substance with heat without specifying the medium (Müller-Grzenda, 1996, pp. 44-46). Based on 
Tabernaemontanus’ descriptions of “Wasser brennen” in various plant monographs (e.g. St. John’s Wort, Fennel, Dill, Wormwood, Chamomile and others), the author 
appears to reference a type of steam distillation where the medicinal plants were first decocted for 24 hours via a Balneo Mariae (water bath) that was covered with an 
Alembicu coecum (blind helmet), before the saturated fluid was drained off with a helmet with beak (Tabernaemontanus, 1664, p. 169). The sizable dosage of 30-45g of this 
’burnt water’ of St. John’s Wort to be taken 2-3x per day adds to the plausibility that Tabernaemontanus references a water steam distillate and not an alcohol distillate 




Label Contemporary English Contemporary German  Original Text Use-
categories 
Crude drug 
powder of dried herb 
and fruit taken with 
wine 
 




sees taken with warm 
mead  
 
Combustion of plant 
ash (salt) 
Droge 
Pulver aus getrocknetem Kraut 
mit Früchten mit Wein 
einnehmen 
 









Kraut mit dem Saamen gedörrt 




Saamen eingeben; Saamen gebrauchen; der Samen 
zerstossen mit Wegerichsafft151 oder Wasser 
getrunken 
 









































151 Some recipes in this monograph consist of complex formulations. This hinders a direct correlation of St. John’s Wort with an indication. Nonetheless, its use in complex 









poultice (cataplasm) of 
fresh herb 
 
rub with fresh herb 
 




St. John’s Wort water          
(hydrosol of fresh herb 
and flowerheads)  
 
Specialties: 
gauze compress with a 
mixture of St. John’s 
Wort hydrosol and wine 
 
plaster from peritoneum 
of sheep roasted in St. 
John’s Wort oil 
 
ointment with St. John’s 
Wort oil and wax 
 




Breiumschlag (Kataplasma) aus 





frischer Pflanzensaft aus den 
Blättern und Blütenständen 
 
Hydrolat: 
Johanniskrautwasser           




Umschlag aus einer Mixtur aus 
Johanniskrauthydrolat und Wein 
 
 
Pflaster aus dem Bauchnetz 
eines Schafes geröstet in 
Johnanniskrautöl 
 
Salbe aus Johanniskrautöl und 
Wachs 
 








Glieder mit dem (grünen) Kraut gerieben 
 




Kraut und Blumen von den Stengeln abstreiffen und 




das Wasser mit rotem Wein vermischt...mit einem 
Tuch auff den bauch gelegt 
 
 
ein Stück Netze von einem Schaff, zerschneide es und 
röste es in Öl, legs also warm auff den Bauch 
 
 
Oel ...und mit Wachs zu einem Sälblein machtet 
 
 








Label Contemporary English Contemporary German  Original Text Use-
categories 
fumigation with dry 
herb 
 
talisman made with herb 
 
foot bath with herb 
 
a wash with St. John’s 
Wort water of herb and 
flowerheads (hydrosol) 
 
wet compress with St. 
John’s Wort hydrosol 
Beräucherung mit getrocknetem 
Kraut 
 
Talisman aus Kraut 
 




aus Kraut und   Blütenständen   
 
Feuchter Umschlag mit 
Johanniskrautwasser (Hydrosol) 
mit dürrem Kraut beräuchen 
 
 
Kraut sey für Gespengst wann man es bey sich trägt 
 
Fussbad auß diesem Kraut 
 
Kraut und Blumen von den Stengeln abstreiffen und 
ein Wasser darauß brennen; damit gewaschen 
 
 
das Wasser eusserlich auffgeschlagen 
 






























wider die Schmerzen und Wehethumb der Hüfft; so 
ihnen von wegen schwerer Last weh gethan haben; 
mildert die Schmertzen der Hüfft; wider das 
Wehthumb der Hüfft   
 
treibt die uberflüssige Gallen153 
 
habe ein Art den Leib zu stopffen; hilfft wider das 
Durchlauffen und Bauchflüß; stopffet die Bauchflüß 
und rothe Ruhr; stopffet das Durchlauffen; verstillet 
die Stulgäng  
 
ist gut für die Fallendesucht  
 

















153 See Francia & Stobart (2014, p. 301). To ‘chase excess (black) bile’ references a humoral concept and relates to the elimination of melancholy. Melas is Greek for black 
and kholē is bile. In humoralism, fear, sadness, gloom and fright were seen as typical symptoms of melancholic illnesses (Zimmermann, 1975, pp. 91-96). Such mental and 
emotional afflictions are today commonly referenced as depression (Tschupp, 1998, pp. 44-47).  






















































diesen Saft gibt man mit Odermenig den Rossen ein 
für die Würm 
 
so vertreibe es das dreytägige Fieber (Malaria 
tertiana) 
 
dienet fürs Gesicht155 an Füssen  
 
ist gut für ... den Schlag 
 
welches auch das Gifft außjagt 
 
ein Natur und Krafft habe den Harn fort zu treiben; 




treibe ... den Grieß; ist treffenlich gut dem 
Blasenstein; ein Krafft ... den Sand zu treiben 
sonderlich da man es im Hauwhechelwasser…  
 
reiniget ... Leber 
 


























symptoms of tuberculosis, an illness known and described by 16th century authors (Ackerknecht, 1967, p. 89). 
155 „Gesicht“ relates to the  Middle High German word „gesühte“ which references „rheumatisches Übel“ (rheumatic complaint) (Lexer, 1872-1878, pp. I, 936). See also 
reference „Polyarthritis rheumatica“ in Höfler (1899, p. 707a). 
156 „der Weiber Blödigkeit“ broadly refers to menstruation (FrnhdWb, 1986-, pp. IV, Sp. 636). However, in the St. John’s Wort monograph of Tabernaemontanus this term 
seems to cover more than the physiological process of bleeding since the author uses elsewhere a different term for this: „…fürdert die weibliche Monatsblum“ 
(Tabernaemontanus, 1664, p. 65). Thus, the term „Weiber Blödigkeit“ may refer to broader physical and psychological aspects of menstruation. Today, St. John’s Wort is 
used for the treatment of pre-menstrual syndrome (PMT), mood changes and dysphoria in connection with the menstrual cycle. It is assumed here, that the term „Weiber 












tissue healing                       
(in burns) 
vulnerary                         
(in wounds and ulcers) 
 
 









gewebeheilend                          
(in Verbrennungen) 
wundheilend                                     










daß sie das Blut in den Wunden stillen 
 
was verbrannt ist heylen; so hefte es wiederum 
zusammen ... sonderlich was von Brand ist 
innerlich zu Wundtränken; heylet alle innerliche und 
eusserliche Wunden; so hefte es die Wunden und 
offene Geschwär wiederum zusammen 
 
in grossen, tieffen Wunden, Verletzungen deß 















Actions externally analgesic  

























mildert die Schmerzten der Hüfft ; legs also warm auff 
den Bauch es lindert die Schmertzen; gut wider die 
rote Ruhr so man den Bauch warm damit schmieret 
dann es leget den Schmerzten; legs also warm auff 
den Bauch es lindert die Schmertzen; wider die 
COLICAM; lindert allen Schmertzen der Wunden 
deßgleichen der Glieder ... sonderlich nach den bösen 
Frantzosen157 
 
legs also warm auff den Bauch es ... verstillet die 
Stulgäng; stopffet die Bauchflüß und rothe Ruhr 















157 The term „böse Frantzosen“ corresponds with „grôzen“ or „bösen blâter“, a sexually transmitted infection which presented with chancres, sores and neurological 
symptoms (Keil & Daems, 1977, pp. 112-113, 118-119). It is presumed that this illness references the spectrum disorder of syphillis. This infection was named after the 


























tissue healing  
 
 































gelegt; wenn jemandts die rote Ruhr hat ... so stopffe 
es den Durchlauff 
 
Die Glieder mit dem Kraut gerieben / ist gut fürs 
Zittern und Beben… 
 
sey für Gespengst / wann man es bey sich trägt / 
FUGA DAEMONUM soll genennt werden158 
 
wenn ein Weib in schweren Kindsnöthen ligt 
 
zu den zerknitschten und zerstossenen Nerven 
 
wehret dem Krampff so von Wunden und offnen 
Schäden verursacht; gebraucht ... die COLICAM; den 
Kindern die Grimmen haben über den Nabel zu legen;  
erweichet das Geäder in erlambden Gliedern; 
 
stofft das Blut der Wunden 
 
heylet ... sonderlich aber die verwundeten 
Sennadern159  
 
so heffte es die Wunden und die offene Geschwär  
widerumb zusammen ... sonderlich was von Brand ist; 
gar gut zum Brand eusserlich aufgestichen; gut zu 





























158 This term has been first noted in the 13th century in a catalogue of drugs from Salerno (Italy) (Reallexikon der Germanischen Altertumskunde, 1973-2008, pp. XVI, 68b). 
In herbals of the early modern period there are a number of expressions for symptoms which would be referenced today as states of anxiety or depressive mood disorders 
(Tschupp, 1998, pp. 44-46). 
159 The term „Ader“, references here “strangförmiges Gebilde” (strand-like formation) (Mildenberger, 1997, p. 38). „Ader“, „Sehnader“, „Sennader“ or „Geäder“ may include 



























































heylet den Brandt und gebrandte Schäden 
 
so heffte es ... die offene Geschwär widerumb 
zusammen; Pulver in die unreine feuchte Wunden 
sträuwe so verzeher es die Feuchtigkeut und heyle … 
auch dergleichen Geschwär; 
 
heylet alle …eusserliche Wunden; der Wunden 
deßgliechen der Glieder; zu Wundtränken ... auch 
eusserlich; in grossen, tieffen Wunden, Verletzungen 
deß Geäders nutzlichen gebraucht...von grund auß zu 
heylen; so heffte es die Wunden … widerumb 
zusammen; eusserlich in Wunden gethan ... heylet sie; 
eusserliche Wunde ... damit gewaschen und das 
Wasser eusserlich auffgeschlagen;  Pulver in die 
unreine feuchte Wunden sträuwe so verzeher es die 
Feuchtigkeut und heyle die Wunden; heylet die 
Wunden gar wol in allen Wunden außgenommen so 
von harter Zerknitschung verursacht oder sonst von 
Lufft zerstört;  
 
ist auch dienstlich zu allen kalten160 Gebrechen der 
Glieder und Gewerben 
 
in grossen, tieffen Wunden, Verletzungen deß 
Geäders nutzlichen gebraucht solche zu reinigen; 






























160 In humoralism, St. John’s Wort was classified as warm and dry in the second or third degree. The plant was therefore applied to warm up cold or stiff areas as experienced 






















gravel (in urinary tract) 
 
 









































trefflich gut dem Blasenstein 
 
das Blut in den Wunden stillen  
 
wider das Blutspeyen 
 
was verbrant ist heylen 
 
stopffet die Bauchflüße und rohte Ruhr; ein Art den 
Leib zu stopffen; wider das Durchlauffen und Bauch 
Flüß  
 
ist gut für die Fallendesucht 
 
treibe... den Grieß; den Sand zu treiben... sonderlich 
da man es im Hauwhechelwasser einnimpt 
 
Wehethumb der Hüfft 161 
 
reinigt Nieren; Gifft außjag 
 
reinigt ... Leber; Gifft außjag 
 
vertreibe das dreytägige Fieber 
 
treibt die überflüssige [schwarze] Galle 
 
































161 Bock (1577, S.28) explains, that „Hüftweh“ (hip pain) referrs to „Ischias“ (sciatica): “Vertreibt…beschwerlich hüfftwehe, Ischia genant...”. “Ischi-“ is Greek for hip, hip 












tendons, facia, nerves 
and muscles) 
 
pain (in the musculo-
skeletal system) from 














urine voiding                               







Verletzungen von Gewebe des 
Bewegungsapparats (Bänder, 
Faszie, Nerven, Muskeln) 
 
 
























Verletzungen des Geäders; heylet ... sonderlich aber 








Gesicht an Füssen  
 
 
wider die Seitenkränke PLEURITIS genennt 
 
dienstlich zu allen kalten Gebrechen der Glieder162 
und Gewerben163 
 




Harn .. zu treiben ... sonderlich da man es im 
Hauwhechelwasser einnimpt 
 































162 The term „Glied“ refers here to the mobile part of an extremity or a limb (Mildenberger, 1997, pp. II, 679-680). 




Label Contemporary English Contemporary German  Original Text Use-
categories 
wounds                                           
(deep,  infected, large) 
Wunden                                        
(großflächige, infizierte, tiefe) 
innerlich zu Wundtränken .. grossen, tieffen 
Wunden... solche zu  
reinigen und von grund auß zu heylen; heylsame 
Wundkräuter; heylet alle innerliche und eusserliche 



























hip pain, sciatica 
 
 













Bauchkolik, Kolic in Kindern 
 
 











lahme Glieder erweichen  
So man den Bauch warm damit schmieret dann es 
leget den Schmertzen; legs also warm auff den Bauch 
es lindert die Schmertzen 
 
in schweren Kindsnöhten 
 
Stopfft das Blut der Wunden 
 
was vom Brand ist; gar gut zum Brand; gut zu dem 
Brand vom Fewer; heylet den Brandt und gebrandte 
Schäden   
 
wider die COLICAM; Krimmen; den Kindern die 
Grimmen haben 
 
sey für Gespengst...FUGA DAEMONUM soll 
genennt werden 
 
stopffet die Bauchflüße und rohte Ruhr wie dann auch 
mit einem Tuch auff den bauch gelegt; rote Ruhr ... so 
stopffe es den Durchlauff; wider die rote Ruhr; 
verstillet die Stulgäng 
 
leget und miltert die Schmertzen der Hüfft 
 
 



































tendons, muscles, facia, 





nerve pain  
 
 









spasms in wounds 
 
 






Verletzungen vom Gewebe des 
Bewegungsapparats (Bänder, 






(Nerven) Schmerzen nach 
Syphilis 
 
Schmerzen                              
(Abdomen, Glieder, 
Bewegungsapparat,  weiblicher 




















zerknitschten und zerestossenen Nerven; verstopfte 
Nerven 
 
Schmerzen...nach den bösen Frantzosen 
 
 
alle Schmerzen der Wunden, deßgleichen der Glieder; 








Krampff so von Wunden und offnen Schäden 
verursacht165  
 
dienstlich zu allen kalten Gebrechen der Glieder und 
Gewerben 
 
sey für Gespengst / wann man es bey sich trägt  
Die Glieder mit dem Kraut gerieben / deß Tags zwey 































164 For the period of post-birth confinement see Reallexikon der Germanischen Altertumskunde (1973-2008, pp. XXXIV, 174a-180a). 









wounds                                            







Wunden                               




die offene Geschwär widerumb zusammen; unreine, 
feuchte…Geschwär 
 
grossen tieffen Wunden; so heffte es die Wunden; in 
Wunden gethan reiniget dieselbigen und heylet sie; 
unreine Wunden; heylet all … eusserliche Wunden ... 
damit gewaschen und das Wasser eusserlich 
auffgeschlagen; heylet die Wunden gar wol; stopft das 
Blut der Wunden; in allen Wunden aussgenommen so 
von harter Zerknitschung verursacht oder sonst vom 





















Absude:                                             
Dosis unbekannt 
 




(Hydrolat):                    30-
45ml; 2-3x pro Tag 
 



















compresses, foot baths: 
dose unknown 
Fresh juice: 
drip into wound 
 
Absud: 
für Waschungen, Umschläge, 
Fußbad:                   
Dosis unbekannt 
Presssaft:                                          













Label Contemporary English Contemporary German  Original Text Use-
categories 






covering surface with 
fresh, pounded plant 
 
Oil: 
sufficient for massage 
 
Ointment: 





(Hydrolat) für feuchte 
Umschläge:                                       
Dosis unbekannt 
 
Pflaster:                           
flächendeckend mit zerdrückten 
Pflanze 
 
Öl:                                              
genügend für Massage 
 





















Contraindications None mentioned Keine genannt   
Warnings and 
Precautions 




mentioned for use 
during pregnancy or 
breastfeeding 
 
Fumigations for six 
weeks after birth 
(coincides with 
breastfeeding) 
Keine Kontraindikation genannt 
für Gebrauch während 
Schwangerschaft oder Stillzeit 
 
 
Beräucherung während sechs 
Wochen nach Geburt (fällt 







[Etliche beräuchen die sechswöchige Weiber darmit / 
derohalben nennet man es an etlichen Orten unser 
Frawenwurtz.] 
 











































card-vasc 0 0 0 0 0 ✓ ✓ ✓ ✓ ✓ ✓ 














varicose veins varicose 
veins 
 







      cardiac 
neurosis 
   heart 
strengthe-
ning 
        anaemia    
gastro-
intest 
✓ ✓ (✓) ✓ (✓) (✓) ✓ ✓ ✓ ✓ ✓ 
 abdominal 
pain, colic 



























diarrhoea dysentery dysentery 
bloody 
diarrhoea 



































       dyspepsia, 





       lack of 
appetite 




worms worms worms    worms   worms 
gyn ✓ 0 0 ✓ 0 (✓) ✓ ✓ 0 ✓ ✓ 
 birth 
complications 























































    




    
          fertility 































 epilepsy      epilepsy 
(from 









to the head) 
   
stroke          stroke 




brain bleeds  
   















hormonal 0 0 0 0 0 0 0 ✓ 0 0 0 
        metabolic 
disorders 
   
infection ✓ 0 0 ✓ 0 0 0 (✓) 0 0 ✓ 
 Malaria 
tertiana 




       
   chronic 
infections 
       







































✓ 0 0 ✓ 0 0 ✓ ✓ 0 (✓) (✓) 
 liver 
detoxification 
      liver diseases  liver diseases liver tonic 
poison   poison             
(snake bite) 
catalepsy 
      detoxification 
of poison 
   bile 
stagnancy 














musc-skel ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 




 hip pain / 
sciatica 
  sciatica hip pain / 
sciatica 
























































































   












   
   haematoma  bruises haematoma bruises, 
contusions, 
swelling 





         myalgia myalgia 




nerve ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 




 hip pain / 
sciatica 
  sciatica hip pain / 
sciatica 
   




nerve injuries    
nerve pain     neuralgias 



















































































































dysfunction   
 
      neurofibro-
matosis 
    




paralysis    
respiratory ✓ ✓ (✓) ✓ (✓) (✓) ✓ ✓ 0 ✓ (✓) 



























   
   chest and 
lung 
infections 




















       asthma    
skin-
mucous 




  bleeding 
(wounds:   
styptic 
action) 
   bleeding 
(wounds) 
  bleeding  
(wounds          
styptic 
action) 




















































































wounds, wounds wounds; 
wounds 
(infected) 
   mouth and 
throat 









         inflammation inflam-
mation 









✓ 0 ✓ ✓ (✓) (✓) ✓ ✓ ✓ ✓ ✓ 
 demons 
(banish) 


















       anxiety 
 



























































depression  depressive 
moods  
depression 
  mania mania   mania     
     enuresis in 
children 
enuresis enuresis in 
children 
enuresis   







dystonia    







      insomnia insomnia  insomnia, 
insomnia 
insomnia 














































   mental 
afflictions 


















tonic 0 0 0 ✓ 0 0 ✓ 0 ✓ ✓ ✓ 
    for 
tonification  







        dystonia   
uro ✓ 0 0 ✓ 0 ✓ ✓ ✓ ✓ (✓) ✓ 
 bladder stone,  
gravel 
      bladder 
stone; gravel 





















   kidney stones    






   
     enuresis in 
children 





   blood in 
urine 




  irritable 
bladder 
 
Dark green rows refer to continued use 
Light green rows refer to intermittent but present-day-use 
Grey rows refer to present-day discontinuation 





APPENDIX 15: HYPERICUM PERFORATUM DATABASE 
RESEARCH EXCEL SPREADSHEET 




APPENDIX 16: DEFINITION AND SPECIAL 
CHARACTERISTICS OF TRADITIONAL PLANT 
MEDICINES  
1. Definition of a traditional plant medicine 
A traditional plant medicine is a health product that is intended for a therapeutic application 
rather than for nutritional support as intended for a dietary supplement. It contains extracts 
of plants (as opposed to individual phytochemicals, vitamins, or other active compounds) 
as the only claimed active ingredient(s).  
A traditional plant medicine contains: 
 herbs, seeds, berries, roots, leaves, bark, flowers, algae, lichens, certain exudates, 
fossilised remains of marine phytoplankton, and macroscopic fungi. 
 
A traditional plant medicine does not contain: 
 pharmaceutical drug material 
 individual synthetic or isolated chemical compounds 
 isolated plant constituents (e.g. menthol, thymol etc.) 
 animal products (except propolis and honey) 
 added amino acids  
 added minerals or vitamins, or other non-plant ingredients, unless these are 
excipients only 
 organisms listed in Schedule 1 of the Convention on the International Trade in 
Endangered Species (CITES) or locally endangered plants. 
 
Representative traditional preparations are: 
 fresh or dry plant tinctures 
 fresh-plant and its juice 
 alcohol extracts (traditional extraction ratio up to 2:1) 
 dried extracts 
 comminuted dried herbs and powders 




 oil, vinegar, glycerine, wine or spirit extracts  
 essential oils and hydrosols 
 mels, and oxymels. 
 
Traditional plant medicines are applied orally, externally, or through inhalation. The main 
meaning of external use relates to topical applications to the skin. However, if the 
traditional use of a herbal medicinal product relates to oral, nasal, rectal, vaginal mucosae, 
ocular, or auricular delivery, such delivery is also accepted if no safety concerns exist. 
Delivery formats include:  
 oral liquid, spray, syrup, pressed powder, tablet, capsule, lozenge, cream, liniment, 
gel, oil, compress, poultice, pessary, suppository, enema, eye drop, inhalation, 
gargle. 
 
Long-standing effectiveness of traditional plant medicines relates to unadulterated, 
traditional preparations only. The potential inhibitory effects of modern additives on 
absorption and bioavailability of therapeutic plant compounds is poorly understood. It is 
therefore recommended that the classification of a ‘traditional plant medicine’ pertains to a 
product that has a natural composition and does not contain modern artificial colours, 
flavours, synthetic sweeteners, monosaccharides, and GMO ingredients or substances 
derived from GMO manufacturing processes. 
 
 
2. Quality standards 
The safety and effectiveness of a traditional plant medicine directly relate to the quality of 
the raw herbal drug(s) and the manufacturing process of the remedy. It is therefore 
recommended that quality standards for traditional plant medicines are developed to ensure 
their quality, safety and effectiveness, thus protecting consumer health. The most common 
risks with herbal drugs are due to a lack of stringent quality control measures rather than to 
the pharmacological activity of traditionally known and used herbal ingredients themselves 
(Bowen et al., 2012). Risks can be minimised with proper quality control measures during 
harvesting and manufacturing. The most common quality risks of traditional plant 
medicines relate to misidentification or mislabelling of herbal ingredients with an incorrect 




herbicides and toxic microbes (Ekar & Kreft, 2019; He, Ung, Hu, & Wang, 2015; Keane, 
Munn, Vivier, Higgins, & Taylor, 1999). In turn, lack of efficacy may be linked to incorrect 
harvesting times of the medicinal plant (when active constituents are not at their prime), the 
collection of the wrong plant part or species, and incorrect processing.  
This makes it imperative that the quality control process for traditional plant medicines 
starts in the field. Protocols should require full supply chain traceability, including 
authentication details for the raw plant, plant part used, location and time of harvest, 
growing conditions (wild, cultivated), vegetation stage, as well as processing techniques 
applied (i.e. drying method, extraction ratio, solvent used in extraction), and storage. 
Medicinal plants should be harvested according to WHO Good Agricultural Practice (GAP) 
or similar guidelines to yield a defined raw material of high quality. Medicinal plants should 
not be exposed to pesticides, herbicides, heavy metals, and toxic microbes.  
 
3. Special characteristics of traditional plant medicines 
There are special characteristics of traditional plant medicines that should be considered for 
their regulation. They relate to their compounding and scope of claims. 
 
3.1 Multi-component formulations 
Traditional plant medicines either contain a single ingredient, or more commonly a 
combination of ingredients. To enable traditional prescribing that is based on empirical 
knowledge of effectiveness and safety, it is recommended that a daily therapeutic dose may 
be made up with several plant ingredients. If regulations specify that the dosage for each 
individual ingredient is to be in line with the dosage used in a clinical trial where a 
medicinal plant was investigated in isolation, then a traditional multi-component 
formulation may not be able to be registered. This is because in a multi-component 
formulation the total dose is made up of several ingredients. Each single component might 
therefore fall below the mono dosage applied in a clinical trial or suggested in monographs 








3.2.Traditional health claims 
Permitted health claims for traditional medicines sold over the counter should be 
appropriate for use without supervision. Consistent with documented traditional use it is 
recommended that approved indications relate to health supporting claims, structure-
function claims, risk-reduction claims, treatment claims, and to the complementary use of 
traditional medicines in the management of symptoms of chronic, non-life-threatening 
illnesses, including the easing of treatment side-effects.  
It is recommended that communication of health claims relating to traditional plant 
medicines is consumer friendly. Permitting claims solely in relation to modern biomedical 
nosolgies as indexed in the International Disease Classification (IDC) is unsuitable and too 
narrow for the communication of traditional indications. Moreover, terms described in the 
IDC are often too technical to be understood by consumers not trained in medical sciences, 
and therefore it is recommended that equivalent vernacular terms for such indications also 
be permitted. In addition, it seems appropriate to approve traditional health claims based on 






APPENDIX 17: HISTORICAL ASSESSMENT TOOL: A 
DATA COLLECTION FRAMEWORK 
Use-categories  Foundational 
historical 
textbook of a 
written medical 
tradition 
Author 1 Author 2 Author 3 
apotrop 
 
    
cancer 
 
    
card-vasc 
 
    
gastro-intest 
 
    
hormonal 
 
    
gyn 
 





   
infection 
 
    
liver-spleen 
 
    
musc-skel 
 
    
nerve 
 
    
respiratory 
 
    
sex 
 
    
skin-mucous 
 
    
somatoform 
 
    
tonic 
 






For the independent verification of data, it is recommended that the following information   
from the selected sources is recorded: 
Data Record 
conclusive identification of data source: author, title 
of source, year of publication, reference pages 
 
conclusive identification of botanical and 
vernacular name(s) 
 
plant part(s) used  
indication(s)  




posology (if noted): dosage, frequency, duration  
external / internal application  
safety considerations: cautions, warnings, contra-
indications (if noted) 
 
age range (if noted)  




*A purely analytical approach towards characterisation of medicinal plants does not 
necessarily capture quality requirements because it is often not known which components or 
combinations of components are responsible for the therapeutic effects. 
 
